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ABSTRACT
A major route of detoxification for many halogenated xenobiotics is by conjugation to the 
tripeptide glutathione. Subsequent metabolic processing of the glutathione conjugate yields 
the corresponding cysteine conjugate of the xenobiotic, which may then serve as a substrate 
for enzymes which express p-lyase activity. Kidney cysteine conjugate (3-lyase [glutamine 
transaminase K (GTK), kynurenine aminotransferase (KAT)] is an enzyme which 
metabolises cysteine conjugates of certain halogenated alkenes and alkanes to form reactive 
metabolites. Such metabolites produce nephrotoxicity in experimental animals, 
neurotoxicity in rabbits, and may produce subtle kidney changes and neurotoxicity in man.
Although the role of kidney cysteine conjugate p-lyase in the production of nephrotoxic 
thiols from cysteine conjugates of xenobiotics has been well established, the factors 
controlling the cellular distribution and substrate specificity of the enzyme have yet to be 
elucidated. Additionally, the recent finding by other researchers that the rat brain p-lyase 
enzyme also possesses KAT activity raises the possibility that it may play a role in 
neurotransmission via modulation of the NMDA receptor.
As an approach to understanding the species specific differences in halogenated alkene 
nephrotoxicity, the full-length cDNAs for both rat and human kidney cysteine conjugate p- 
lyase have been isolated using a combination of hybridisation screening, 5' RACE and RT- 
PCR technologies. The cDNAs were sequenced and their identities confirmed by deduced 
molecular weight, deduced amino acid composition, the presence of a consensus pyridoxal 
phosphate binding site in their deduced amino acid sequences, and expression of the 
cDNAs in tissue culture cells. The rat and human cDNAs coded for proteins of 47.8 kDa 
and 47.9 kDa respectively, consistent with the published values for the purified p-lyase 
proteins. Cytosolic extracts of COS-1 cells, transfected with the rat and human cDNAs 
demonstrated significant increases in both p-lyase and GTK activity, with approximately 
similar Km values for the rat and human enzymes. Western blot analysis using the purified
antibody to rat kidney cytosolic p-lyase, was performed on cytosolic extract from COS-1 
cells transfected with the rat cDNA and demonstrated a protein band identical in its position 
to that of authentic rat kidney p-lyase. Comparison of the human deduced amino acid 
sequence with that of the rat enzyme indicated an 82% overall similarity, with 90% 
similarity either side of the pyridoxal phosphate binding site (residues 187-289), many of 
the changes being conservative in nature. Preliminary mapping of the gene for human 
cysteine conjugate p-lyase, using PCR analysis of genomic DNA from human-rodent 
hybrid cells, indicated that it is located on human chromosome 9. The use of the rat and 
human p-lyase cDNAs for the elucidation of the mechanism of action, substrate specificity, 
localisation and potential toxicity of these enzymes is discussed in this thesis.
The work presented here, has given rise to a number of poster presentations, oral 
communications and refereed publications (see appendix II).
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CHAPTER 1 
INTRODUCTION
1.1 GENERAL INTRODUCTION
The living organism is equipped with an efficient defence mechanism able to deal with 
drugs, pesticides and environmental pollutants, J>/converting them to polar metabolites 
which have greater solubility and can be readily excreted. While ionic polar compounds are 
dealt with very efficiently, the kidney is considerably less competent when eliminating lipid 
soluble compounds. The majority of drugs are lipid soluble and therefore, without 
mechanisms for disposal, would remain in the body indefinitely. Extensive study over the 
last 30 years has revealed a wide range of chemical reactions involved in the conversion of 
lipid soluble compounds to polar metabolites. This metabolism is divided into two major 
processes, namely phase I (functionalisation) and phase II (conjugative) reactions.
Phase I metabolism modifies the xenobiotic by the introduction of a functional group, a 
typical phase I reaction is hydroxylation. The primary function of phase I metabolism is not 
to make the compounds more polar, but to prepare them for subsequent conjugation in 
phase II reactions to highly polar moieties, thus facilitating excretion in the urine or the bile. 
Phase II reactions involve conjugation of the phase I product to endogenous groups, which 
include moieties such as glucuronic acid, sulphate and glutathione. Good reviews of phase 
I and phase II metabolism are given in Gibson & Skett (1994) and Timbrell (1991).
More recently a third phase of xenobiotic metabolism has been postulated, wherein a 
compound conjugated in a phase II reaction is further metabolised, after excretion in the 
bile, by gut microflora. The compound is subsequently re-absorbed and metabolised. This 
is seen particularly with glutathione conjugates and their further metabolism to cysteine 
conjugates and mercapturic acids (Figure 1.1) is now recognised as a third phase of 
metabolism (Gibson and Skett 1994). All phases of xenobiotic metabolism may result in 
the production of toxic intermediates from a parent compound.
1
Generally the liver is considered to be the most important organ in the biotransformation of 
absorbed xenobiotics due to the very high levels of drug metabolising enzymes, a relatively 
high blood flow and because it is the first organ to which the blood and therefore orally 
absorbed xenobiotics are transported. Drug metabolising enzymes are also found in extra- 
hepatic tissues, and although they may only contribute to a small percentage of the overall 
metabolism of a compound may have potential toxicological significance. Reactive 
intermediates (electrophilic species, radicals and activated oxygen species) formed in 
biotransformation reactions, may be produced in target organs and tissues or may be 
formed in the liver and subsequently transported to the target organ. Alternatively some 
chemicals are activated in multistep reactions in which a stable proximate toxic metabolite 
may be formed in one organ with subsequent transport to and bioactivation in the target 
organ. This is true for some of the halogenated hydrocarbons eg., hexachloro-1,3- 
butadiene (HCBD), which have been implicated in rodent nephrotoxicity and 
carcinogenicity. Kidney cysteine conjugate p-lyase is the enzyme of particular interest in the 
bioactivation of these compounds and is the subject of further study in this thesis. Attention 
has been directed towards the toxicological importance of this enzyme since its activity can 
yield metabolites which are selectively toxic to the P3  segment of the kidney proximal 
tubule.
2
1.2. MERCAPTURIC ACID SYNTHESIS
In drug and chemical detoxification the endogenous peptide glutathione (y-glu-cys-gly), 
present in all mammalian cells, is known to play a major role in protection against toxic 
compounds. Glutathione S-conjugate biosynthesis (Figure 1.1, Step 1) is an important 
mechanism of xenobiotic detoxification and provides cellular defence against a wide variety 
of strong electrophiles such as epoxides, haloalkanes, nitroalkanes, alkenes and aromatic 
nitro- and halo- compounds. These electrophilic compounds react with the nucleophilic 
sulphur atom of the cysteine moiety of glutathione to form, in general, non-toxic 
conjugates. The glutathione conjugate formed is usually further processed to an N-acetyl-L- 
cysteine conjugate, also known as a mercapturic acid, which is usually excreted in the urine 
or bile. For this reason, metabolism via glutathione conjugation is referred to as the 
mercapturic acid pathway.
1.2.1. Glutathione conjugation
S-haloalkyl and S-haloalkenyl glutathione conjugates are the products of cytosolic and 
microsomal glutathione S-transferases (GST, EC 2.5.1.18.) present in several tissues 
(Chasseaud 1979). However, highly electrophilic substrates undergo substantial non- 
enzymic conjugate formation.
Cytosolic glutathione S-transferases are a family of homo and heterodimeric proteins. Their 
subunit monomeric molecular weights range from 25,000 to 29,000 with broad and 
overlapping substrate specificities (Mannervik and Danielson 1988), which catalyse the 
reaction of the thiolate of glutathione with electronegative atoms. Microsomal glutathione S- 
transferases are membrane bound, and different from the cytosolic transferases in both 
molecular weight and immunological reactivity (Morgenstem et al., 1985). Quantitatively, 
the most important site of glutathione S-conjugate formation in the body is the liver. Within 
the liver, the microsomal glutathione S-transferases are more effective in catalysing 
glutathione S-conjugate formation with haloalkenes than are the hepatic cytosolic enzymes 
(Elfarra, 1993).
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Figure 1.1: Mercapturic acid synthesis
1.2.2. Hydrolysis of the glutathione y -glutamyl group
The first step in the metabolism of glutathione conjugates to mercapturic acids is the 
hydrolytic transfer of the y-glutamyl group of the conjugate onto an appropriate acceptor 
(Figure 1.1, Step 2). The enzyme y-glutamyl transpeptidase (y-gt) catalyses this reaction 
(Meister and Tate, 1976), with the formation of a cysteinyl glycine S-conjugate of the 
xenobiotic.
With the exception of muscle, y -gt is found in all mammalian cells and also in serum. The 
majority of enzyme activity is membrane bound although some y -gt activity is observed in 
the cytosol. The membrane bound enzyme is orientated so that its active site is on the 
luminal side of the renal tubule cell (Horiuchi et al., 1978).
The kidney has the highest y-gt activity, followed by the pancreas which displays 
approximately 20% of the renal activity (Goldbarg et al., 1960). Other tissues contain less 
than 1 % of the renal y-gt activity, y-gt activity is found in specific, localised areas of the 
proximal convoluted kidney tubule. The most notable are the luminal (brush border), and 
basolateral membranes in the P3  region of the proximal kidney tubule. A much lower 
activity is found in the remainder of the proximal convoluted tubule (Spater et al., 1982). It 
is also found on the brush border membrane of the villus cells in the small intestine 
(Curthoys and Shapiro, 1975) and in the biliary tree (Ballatori etal., 1988).
1.2.3. The removal of glycine by peptidases
Two enzymes responsible for the removal of glycine from cysteinylglycine S-conjugates 
(Figure 1.1, Step 3) are cysteinylglycine dipeptidase (CGD, EC 3.4.13.6) and 
aminopeptidase M (APM, EC 3.4.11.2) (Kozak and Tate, 1982). The former is the most 
active. Dipeptidase activity is highest in the kidney, followed by the liver (Hinchman and 
Ballatori, 1990), with lower activities in the small intestine (Grafstrom et al., 1979). 
Kidney peptidase activity is present in the luminal (Hughey et al., 1978) and basolateral 
membranes of the proximal tubule cells (Dass et al., 1981). In the liver APM is located in
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the luminal membrane of the biliary epithelium and in the canalicular membrane of 
hepatocytes (Inoue et al., 1983).
1.2.4. N-acetylation of cysteine S-conjugates to mercapturic acids.
As already stated, mercapturic acids are N-acetylcysteine conjugates and are end products 
of a pathway involved in the detoxification of potentially harmful electrophilic compounds 
(Duffel and Jakoby 1982). N-acetylation, the final reaction of the mercapturic acid pathway 
(Figure 1.1, step 4 ) , is catalysed by cysteine S-conjugate N-acetyl transferase (NAT, EC 
2.3.1.8) (Green and Elce 1975). As with other enzymes involved in mercapturic acid 
synthesis, NATs are present in their highest activities in the liver and kidney, although they 
are present at lower activities in many other tissues. They require acetyl coenzyme A as a 
co-substrate, and are found in the endoplasmic reticulum of both kidney and liver cells with 
their active sites facing the cytoplasm (Okajima et al., 1984). NAT activity is thought to be 
primarily located in the cells of the straight proximal tubule (Hughey et ah, 1978). The 
reaction of N-acetylation is reversible by enzymatic deacetylation and regeneration of the 
cysteine S-conjugate by the enzyme deacetylase (Suzuki and Tateishi, 1981).
1 .3  BIOACTIVATION AND NEPHROTOXICITY: THE ROLE OF 
GLUTATHIONE
Although mercapturic acid synthesis via glutathione conjugation plays an important role in 
detoxification of xenobiotics, glutathione conjugation has been the subject of much research 
since the discovery that this ‘protective’ mechanism may also play an important role in the 
bioactivation of some xenobiotics to toxic metabolites (van Bladeren, 1988). Toxic 
glutathione conjugates can be divided into three groups (figure 1 .2 ), namely:
1. Reactive, direct acting glutathione conjugates;
2. Glutathione conjugates in which glutathione reversibly binds and serves as a transporter 
molecule, and
3. Glutathione conjugates which require further bioactivation.
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1.3.1 Direct acting glutathione conjugates
Two well studied dihaloalkanes, 1,2-dichloroethane and 1,2-dibromoethane, conjugate 
with glutathione to form 2-chloro and 2-bromoethyl glutathione (Hill et al., 1978; van 
Bladeren et al., 1979). These half sulphur mustards may undergo internal displacement of 
the second halogen atom by the sulphur atom, giving rise to highly reactive episulphonium 
ions. These strong electrophiles may play an important role in the mutagenicity and 
nephrotoxicity of 1,2-dihaloalkanes and in the formation of DNA-adducts (Hill et al., 
1978).
Dichloromethane is metabolised by glutathione S-transferase to form the reactive 
electrophile S-(chloromethyl)glutathione, which is rapidly hydrolysed to S-(hydroxy- 
methyl)glutathione, which finally decomposes to formaldehyde and glutathione. Both S- 
(chloromethyl)glutathione and formaldehyde are reactive intermediates and may be 
responsible for the dichloromethane-induced tumourigenesis in sensitive species (Dekant 
and Vamvakas, 1993).
1.3.2 Glutathione as a transporter of electrophiles
Bruggeman et al., (1986) investigated the conjugation reaction between equimolar amounts 
of glutathione and allyl isothiocyanates. They demonstrated that at equilibrium, 15-20% of 
the isothiocyanate was still in the unconjugated form and that by changing the concentration 
of the reactants and adjusting the pH, they could alter the position of equilibrium. The 
possible implications of this finding are that after initial in vivo detoxification the 
isothiocyanates may be released at different sites where the glutathione concentrations are 
lower or the conditions of pH are different. An interesting finding with respect to this is 
that allyl isothiocyanate gives rise to bladder carcinoma in the rat (Dunnick et al., 1982), the 
acidic environment favouring release of the isothiocyanate in the bladder.
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1.3.3 Glutathione S-conjugates requiring further metabolism
Several nephrotoxic and/or nephrocarcinogenic halogenated alkenes undergo activation 
subsequent to glutathione conjugation. The glutathione conjugates undergo metabolism to 
cysteine conjugates which are finally N-acetylated to form readily excretable mercapturic 
acids (section 1.1). However, thioethers of cysteine with electronegative and/or unsaturated 
substituents are also substrates for the enzyme cysteine conjugate p-lyase in the kidney 
proximal tubule cells, which cleaves the conjugate to pyruvate, ammonia and reactive 
sulphur containing fragments which are selectively toxic to the P3  segment (straight 
portion) of the kidney proximal tubule cells (Lock and Ishmael, 1979).
The glutathione S-conjugates of hydroquinones (eg., bromoquinone, benzoquinone 
menadione and chloroquinones) and aminophenol are nephrotoxic in rat and cytotoxic to 
kidney cells, p-lyase mediated cleavage does not play a role in the toxicity of these 
glutathione S-conjugates, however, their toxicity is dependent on y -gt (Monks and Lau 
1990; Klos etal., 1992). The glutathione conjugates of hydroquinones and quinones may 
serve as transport forms to y-gt rich organs to be accumulated there eg., the kidney. 
Hydrolysis catalysed by y -gt results in the formation of the corresponding hydroquinone 
cysteine S-conjugate, which is more readily oxidised to toxic quinone metabolites than the 
parent hydroquinone (Monks and Lau 1990).
Thus, it is now recognised that glutathione conjugation and the mercapturic acid pathway 
do not function solely as detoxification routes for the excretion of xenobiotics, but that 
xenobiotics may form biologically active glutathione derived adducts which may be further 
metabolised to sulphur containing products with alkylating/mutagenic potential.
With regard to the halogenated alkene compounds, the major factors determining the toxic 
potential of this group of glutathione conjugates are thus, ( 1 ) their suitability as substrate 
for the cysteine conjugate p-lyase(s) and (2 ) the reactivity of their thiol products.
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1.4. INTERORGAN TRANSPORT OF GLUTATHIONE CONJUGATES AND THEIR 
METABOLITES
Figure 1.3, illustrates the proposed routes for glutathione conjugates and their metabolites. 
Glutathione conjugates are synthesised in the liver, most pass across the canalicular 
membrane into the bile, however, when the bile is saturated with glutathione conjugates 
some pass into the plasma via the hepatic sinusoidal membrane (Chasseaud, 1976). The 
glutathione conjugates released into the bile may be degraded to their appropriate cysteine 
S-conjugates by y -gt and peptidases present in the luminal membrane of the biliary 
epithelium and in the bile canalicular membranes, (Inoue et al., 1983). A transport system 
in canalicular membranes may function in the biliary secretion of glutathione S-conjugates 
(Inoue et al., 1984). Those glutathione conjugates which reach the small intestine 
undegraded may be metabolised here to their cysteine S-conjugates by y gt and CGD/APM.
From the small intestine or the bile duct, cysteine S-conjugates are absorbed into the blood 
and transported to the liver via the hepatic portal vein. In the liver some cysteine S- 
conjugates are converted to mercapturic acids by N-acetyl transferase (Green and Elce, 
1975), from here both the mercapturic acids and remaining cysteine S-conjugates are 
transported to the kidney, along with the glutathione conjugates which passed directly from 
the liver into the plasma. The kidney is the primary organ for the handling of plasma 
glutathione and cysteine S-conjugates. Once in the renal circulation they are either filtered 
into the tubular lumen or pass into the peritubular circulation. The glutathione S-conjugates 
may be metabolised by renal brush border y gt and CGD to cysteine S-conjugates (Hughey 
et al., 1978; Elfarra and Anders, 1984) followed by uptake across the brush border 
membrane, y gt, and peptidases present in the peritubular vasculature (Sochor et al., 1980, 
Dass et al., 1981) or basolateral membrane (Spater et al., 1982), are thought to be 
responsible for cysteine S-conjugate synthesis in the peritubular circulation. It is thought 
that intact glutathione conjugates may pass into the proximal tubule epithelial cell, across 
the basolateral membrane, from the peritubular circulation (Rankin and Curthoys 1982; 
Rankin et al., 1985). It has been suggested that the renal clearance of glutathione S-
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conjugates may also include transport from the blood through epithelial cells into the lumen 
by a sodium-dependent organic anion transport mechanism that is inhibited by probenecid 
but not by cysteine S-conjugates (Lash and Jones 1984; 1985). A membrane potential 
sensitive transport system in the brush border membrane may transport the glutathione 
conjugates into the tubular lumen, where ygt and CGD/APM may subsequently metabolise 
these glutathione conjugates to cysteine S-conjugates (Inoue and Morino, 1985). Once in 
the peritubular circulation or renal tubular lumen, the cysteine S-conjugates pass into the 
tubular cells. Here they have four possible fates:
1. They may be N-acetylated by NAT in the tubular cells to their corresponding mercapturic 
acids (Duffel and Jakoby, 1982), the majority of these pass into the urine via a specific 
renal active transport system (Smith and Francis, 1983).
2. They may be secreted into the plasma and transported to the liver via the renal hepatic 
circulation, where they may be subsequently N-acetylated to mercapturic acids and excreted 
as above.
1  and 2  above result in detoxification and elimination of potentially toxic species, however, 
detoxification via the mercapturic acid pathway is not always the case. As mentioned 
above, studies have also implicated glutathione S-conjugate formation as the initial step in 
the bioactivation of nephrotoxic halogenated alkenes. Here the cysteine S-conjugates 
undergo fate 3.
3. The cysteine S-conjugates may undergo an activation mechanism catalysed by the kidney 
(3-lyase enzyme.
4. Mercapturic acids may undergo enzymatic deacetylation to regenerate the cysteine S- 
conjugates (Suzuki andTateishi, 1981).
5. Some cysteine S-conjugates are direct acting nephrotoxins, by the spontaneous, 
non-enzymatic formation of episulphonium ions from sulphur mustards.
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1.5. THE THIOMETHYL SHUNT
Cysteine S-conjugates are N-acetylated to mercapturic acids in preparation for excretion, 
however, the mercapturic acids and cysteine S-conjugates can be shunted away from the 
direction of detoxification by the enzymes deacetylase (Suzuki and Tateishi, 1981) and 
cysteine conjugate p-lyase (figure 1.4), with the formation of a toxic thiol. The thiol is then 
methylated by the microsomal enzyme thiol-S-methyl transferase (Weisiger and Jakoby, 
1979) to a thiomethyl group, a less water soluble derivative. This alternative pathway has 
been termed the thiomethyl shunt (Jakoby et al., 1984).
The activity of the deacetylases may be a crucial factor in the observed nephrotoxicity of a 
number of mercapturic acids both in vivo (Commandeur et al., 1988) and in vitro 
(Boogaard et al., 1989). A limited availability of acetyl coenzyme A, the cofactor for the 
deactivating N-acetylation step, also might direct biotransformation of the haloalkenes 
towards the bioactivation step (Commandeur et al., 1989)
Thus mercapturic acid synthesis, a pathway which was thought to be responsible for 
detoxification, produces a group of toxic thiol compounds which after methylation are less 
excretable due to decreased water solubility. However, although the thiomethyl metabolites 
are less excretable, they are also less toxic than the thiol metabolites produced by (3-lyase 
metabolism. The role of thiol-S-methyl transferase may therefore be detoxication of thiols 
to thiomethyl derivatives, which may be further metabolised by cytochrome P450 or flavin 
monooxygenase to excretable products.
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1.6. HALOGENATED ALKENE TOXICITY
Numerous toxicology studies have shown various halogenated alkenes to be nephrotoxic to 
experimental animals, mainly rats and mice, with minimal or no liver damage. Their 
metabolism occurring mainly via glutathione conjugation. The well known environmental 
contaminant HCBD, a chlorinated aliphatic unsaturated hydrocarbon, is of high 
toxicological interest. Its toxicity is directed almost exclusively toward the kidney (Lock 
and Ishmael, 1979). This widely used solvent is extensively formed as a by-product in the 
manufacture of trichloroethylene and tetrachloroethylene (metal degreasing solvents and dry 
cleaning solvents) and carbon tetrachloride. It is also used in small quantities as a vineyard 
fumigant and in the removal of chlorine gas in the manufacture of HC1. Changes in renal 
function were observed after administration of HCBD to male rats. A dose of 200 mg/kg 
resulted in a fall in urine concentrating abilities, glucosuria, proteinuria, increased urinary 
excretion of alkaline phosphatase and N-acetyl-a-D-glucosamidase. A significant reduction 
in renal clearance of inulin, urea, p-aminohippuric acid (PAH) and tetraethyl ammonium 
bromide (TEA) have been demonstrated with a concurrent rise in plasma urea (Lock and 
Ishmael, 1979).
24 hours after intraperitoneal administration of HCBD to the rat, necrosis, confined to the 
straight portion of the proximal renal tubule (pars recta, S3  or P3  segment) was observed, 
giving rise to a distinct band of damage in the outer stripe of the outer medulla (Lock and 
Ishmael, 1979; Ishmael et al., 1982). This necrosis was similar to that observed in acute 
renal failure. When rats were dosed intraperitonealy with 200mg HCBD/kg body weight, 
morphological changes in several proximal tubules were detectable by light microscopy 
after eight hours. On administration of 300mg/kg, ultrastructural changes were seen as 
early as one hour after dosing, however, marked necrosis was not observed until eight 
hours, by which time the pathological changes consisted of loss of brush border, 
mitochondrial swelling and cellular necrosis, which were largely confined to the S3  
segment (Ishmael et al., 1982). Additionally, the widely used solvents tetrachloroethene
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and trichloroethene induced carcinomas of the proximal tubules in rat after high doses were 
administered (NCI 1986a, b).
The fluoroalkenes are also implicated in halogenated alkene toxicity. Chlorotri- 
fluoroethylene (CTFE) (Dohn et al., 1985), used in the production of fluoropolymers and 
tetrafluoroethylene (TFE) (Odum and Green, 1984), used in the production of 
polytetrafluoroethylene (PTFE), are commercially important monomers which have been 
produced in large quantities since the 1960s. CTFE and TFE induced specific S3  segment 
renal injury in the rat, whereas it has been reported that hexafluoropropene (HFP) causes a 
more widespread injury additionally involving the Si and S2  segments (Potter et al., 1981).
The potential toxicity of halogenated hydrocarbons to man due to occupational and 
environmental exposure, has resulted in an increasing concern and subsequent research to 
evaluate their toxicological effects and to understand the mechanisms underlying these 
effects. Presented below is experimental evidence in rodents, for the metabolism and 
resulting toxicity of these compounds via glutathione conjugation and the mercapturic acid 
pathway.
1.6.1 Toxicity of halogenated alkene glutathione conjugates
1.6.1.1 Studies demonstrating glutathione conjugation
Chlorinated alkenes: HCBD administration causes depletion of hepatic glutathione 
levels in the rat (Lock and Ishmael, 1981). Female rats are approximately four times more 
susceptible to the toxic effects of HCBD and its metabolites than are male rats (Ishmael and 
Lock, 1986). This may be explained by observations that after administration of HCBD, 
there was depletion of the glutathione pool in the liver and kidney of female rats, and 
glutathione depletion only in the male rat liver (Lock and Ishmael, 1981; Hook et al., 
1983). Glutathione depletion is due to direct conjugation of HCBD with glutathione, 
mediated primarily by a microsomal glutathione transferase (Wolf et al., 1984). Due to 
significantly lower levels of cytosolic and microsomal glutathione S-transferases in the
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kidney (Wolf et al., 1984), it is thought that conjugates formed in the liver may initially be 
responsible for the extra-hepatic effects (Elfarra and Anders, 1984).
When rats were treated with 1 4 C-HCBD, a number of radiolabelled metabolites were 
identified in the bile. The major metabolites were S-( 1,2,3,4,4-pentachloro-1,3- 
butadienyl)glutathione, (PCBDG), and S-(l,2,3,4,4-pentachloro-l,3-butadienyl) cysteinyl 
glycine (Nash et al., 1984). These studies were confirmed by Jones and co-workers 
(1985). They identified the mono- and di-substituted glutathione conjugates of HCBD in 
bile in addition to a number of unidentified metabolites. This was followed by in vitro 
studies by Dekant et al., (1988) which demonstrate that in the presence of glutathione, 
liver microsomes and cytosol, HCBD is transformed to PCBDG. From these and other 
experiments they put forward the view that after conjugation of the parent compound to 
glutathione in liver, subsequent metabolism to the cysteine S-conjugate, gives rise to 
formation of reactive intermediates in the kidney which may be the cause of HCBD induced 
nephrotoxicity and carcinogenicity.
On administration of tetrachloroethylene to rats, S-(l,2,2-trichlorovinyl)glutathione 
(TCVG) was demonstrated in bile, whilst its further metabolite S-(l,2,2-trichlorovinyl)N- 
acetylcysteine was detected in the urine, (Odum and Green, 1987). Administration of 
chemically synthesised haloalkene glutathione conjugates to experimental animals, gave rise 
to toxicity similar to that caused by exposure to the parent compound. Examples of these 
are; the HCBD glutathione conjugate, PCBDG (Ishmael and Lock, 1986) and the 
trichloroethene glutathione conjugate S-(l,2-dichlorovinyl)glutathione (DCVG) (Lash and 
Anders, 1986). The observation that chlorinated alkenes give rise to S-chloroalkenyl 
glutathione conjugates, indicates that an addition-elimination mechanism is involved. The 
conjugation reaction of trichloroethene with glutathione is illustrated in figure 1.5.
17
Fluorinated alkenes
In contrast to the vinylic S-conjugates formed from chloroalkenes, fluoroalkenes are 
generally metabolised by glutathione S-transferases to S-(fluoroalkyl)glutathione 
conjugates (figure 1.6), eg., tetrafluoroethene (TFE) is metabolised by glutathione S- 
transferasetoS-(l,l,2,2-tetrafluoroethyl)glutathionem vitro (Odum and Green ,1984). In 
vivo studies in which rats were exposed to TFE (Odum and Green, 1984), demonstrated 
glutathione conjugation by the presence of a cysteine conjugate of TFE (S -(l,l,2 ,2 ,- 
tetrafluoroethyl)-cysteine) in the bile. On exposure to the chemically synthesised S-(2- 
chloro-1,1,2-trifluoroethyl)glutathione, the glutathione conjugate of CTFE, (Dohn et al., 
1985) to experimental animals, toxicity similar to that caused by exposure to the parent 
compound was observed. CTFE and TFE form glutathione conjugates when rat hepatic 
glutathione S-transferases catalyse the addition of glutathione across their double bonds 
(Dohn and Anders, 1982; Odum and Green, 1984) (figure 1.6). From the studies 
described above it is evident that the metabolic processing of haloalkene glutathione 
conjugates is important in glutathione conjugate-induced nephrotoxicity.
1.6.2. Experimental data to support further metabolism of glutathione 
conjugates.
The glutathione conjugate of HCBD is toxic to isolated rat renal cells (Earl et al., 1984; 
Jones et al., 1986). However, inhibition of y -glutamyl transferase with anthglutin (Minato, 
1979), gave rise to complete protection against toxicity. This provided evidence that further 
metabolism of the glutathione conjugate was required for toxicity. S-(2-chloro-1,1,2- 
trifluoroethyl)glutathione was demonstrated to be cytotoxic to isolated rat renal proximal 
tubular cells. Incubation of renal tubule suspensions with CTFE resulted in a progressive 
decrease in CTFE concentration and a concomitant appearance of S-( 1,1,2-trifluoro-2- 
chloroethyl)glutathione (CTFG) in the suspension medium (Hassall et al., 1984). The 
toxicity of CTFG and that of DCVG, could be reduced by the y-glutamyl transferase 
inhibitor AT-125 [L-(aS,5S)a-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid] (Dohn 
etal., 1985; Hassall et al., 1984).
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Figure 1.5: Conjugation of trichloroethene and glutathione (GSH) to form the 
glutathione conjugate S-(l,2-dichloroethyl)glutathione (DCVG)
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Figure 1.6: Conjugation of tetrafluoroethene (TFE) and glutathione (GSH) to form the 
glutathione conjugate S-( 1,1,2,2-tetrafluoroethyl)glutathione (TFEG)
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Lash and Anders (1986) have also shown that DCVG toxicity to isolated rat renal proximal 
tubular cells is protected by AT-125, thereby concluding that further metabolism of DCVG 
is necessary for its cytotoxic effect. However, AT-125 does not protect against HCBD- 
induced nephrotoxicity (Davis, 1988), suggesting that some glutathione conjugates may 
undergo non-enzymic hydrolysis. Lash and Anders (1986) have shown that the addition of 
glycylglycine, ay-glutamyl acceptor to DCVG treated isolated rat renal proximal tubular 
cells, potentiates its toxicity. Furthermore, Nash et al., 1984, demonstrated that HCBD- 
treated rats fitted with a biliary cannula were completely protected from nephrotoxicity 
whereas naive rats administered with lyophilised bile collected from HCBD treated rats, 
produced renal necrosis analogous to that seen on administration of the parent compound.
The LLC-PKi cell line, derived from pig kidney, is sensitive to DCVG, and this toxicity is 
prevented by y -gt inhibitors (Stevens et al., 1986a). These cells have been characterised as 
a model for the investigation of proximal tubular function in vitro. Phenylalanyl glycine, an 
inhibitor of cysteinylglycine dipeptidase, also decreases the nephrotoxicity of halogenated 
alkenes (Lash and Anders, 1986). Thus the above evidence strongly suggests the 
requirement of glutathione conjugate metabolism to the corresponding cysteine conjugates, 
in order to express renal toxicity.
Experiments with isolated kidney cells have demonstrated that DCVG transport into 
isolated kidney cells occurs via a Na+-coupled transport system located on the basolateral 
membrane (Lash and Jones, 1985). This transport system may therefore be very important 
in determining the selective nephrotoxicity of haloalkene glutathione conjugates.
1.6.3. Nephrotoxicity of haloalkene cysteine conjugates
In vitro and in vivo studies have been undertaken to investigate the toxicity to rats of a 
numberof haloalkene cysteine conjugates; DC VC (Hassall et al., 1984), CTFEC, (Hassall 
et al., 1984, Dohn et al., 1985), PCBDC, (Jaffe et al., 1983; Schnellmann et al., 1987), 
and TFEC (Odum and Green, 1984). These compounds show pathological lesions identical
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to those seen with the parent compounds. Nash et al., (1984), proposed that the production 
of a toxic thiol by renal cytosolic p-lyase cleavage of the cysteine S-conjugate of HCBD is 
responsible for localised kidney damage. This was found to be consistent with the presence 
of a urinary sulphenic acid metabolite of HCBD. DC VC toxicity to isolated rabbit renal 
tubule cells results in decreased active transport of PAH and TEA, which may result from 
covalent binding of an active intermediate to membrane associated nucleophilic groups 
(Hassall et al., 1983). Lash and Anders (1989), demonstrated that aminooxyacetic add 
(AO A A), a selective inhibitor of pyridoxal phosphate dependent enzymes and thus cysteine 
conjugate j^-lyase, also reduces the renal cell toxicity induced by the homocysteine analogue 
of DC VC, S-(l,2-dichlorovinyl)-L-homocysteine (DCVHC) (figure 1.7). DCVHC proved 
to be a potent nephrotoxin in rats, where it was demonstrated to have far greater toxicity 
than DCVC (Elfarra et al., 1986). The greater potency of DCVHC is also observed in 
isolated renal proximal tubular cells, and therefore demonstrates that the large difference in 
the in vivo nephrotoxicity is not due to extrarenal factors but to differences in the intrarenal 
metabolism of the two compounds (Elfarra et al., 1986).
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dichlorovinyl)-L-homocysteine (DCVHC), S-( 1,2-dichlorovinyl)-DL-a-methylcysteine 
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Experiments by Elfarra et al., (1986) and Lash et al., (1986a), implicate cysteine conjugate 
(3-lyase in cysteine S-conjugate induced nephrotoxicity, using a-methyl analogues of 
DCVC, DCVHC (figure 1.7) and CTFC in their studies. The use of a-methyl analogues of 
nephrotoxic cysteine S-conjugates is a powerful approach to test the requirement of 
metabolism by (3-lyase in the expression of nephrotoxicity. In contrast to the effect of 13- 
lyase on cysteine S-conjugates, where the abstraction of the a-proton occurs readily after 
the formation of the Schiffs base and thus results in the cleavage of the carbon-sulphur 
bond, substitution of the a-proton with a methyl group, makes the molecule non- 
metabolisable by (3-lyase. Thus these analogues are not cytotoxic to isolated renal cells. The 
observation that AOAA blocks the toxicity of DCVHC and that the a-methyl analogue 
DCVMeHC is not toxic are consistent with a role for a PLP dependent bioactivation 
reaction. Furthermore, treatment of rats with DL-propargylglycine, an inhibitor of several 
PLP-dependent enzymes, also blocked the toxicity of DCVHC (Elfarra et al., 1986).
The use of a-ketoacids, such as a-keto-y-methiol butyrate and a-ketobutyrate, enhanced 
both renal cytosolic and mitochondrial p-lyase activities (Elfarra et al., 1987). These 
experiments also support the hypothesis for the role of^PLP-dependent enzymes in 
nephrotoxicity, as a-keto acids re-convert the pyridoxamine phosphate form of the enzyme 
back to the active PLP form, a requirement for (3-lyase catalysed (3-elimination reactions (see 
section 1.12).
The effects of DCVC and DCVHC on the maintenance of cellular glutathione and ATP 
concentrations and on cellular calcium homeostasis were examined by Anders et al., (1987) 
and revealed that, although both DCVC and DCVHC inhibited several mitochondrial 
processes in the intact cell, DCVHC also inhibited processes not linked to mitochondrial 
function, indicating that DCVHC also has extramitochondrial targets. This difference may 
also account for the greater toxicity of DCVHC. Furthermore, N-acetylation of DCVC was 
approximately four fold faster than with DCVHC as substrate (Elfarra et al., 1986), which 
also may attribute to the greater nephrotoxicity of DCVHC.
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1.6.3.1. Cellular transport of cysteine conjugates
Studies indicate that cellular transport is an important determinant of cysteine S-conjugate 
induced nephrotoxicity. The in vivo nephrotoxicity of DCVC was blocked by probenecid, 
which is an inhibitor of the basolateral membrane anion transport system. Probenecid 
inhibits glutathione S-conjugate transport in rat renal basolateral membrane vesicles (Lash 
and Jones, 1985), prevents HCBD induced toxicity to rat renal proximal tubule cells (Lock 
and Ishmael, 1985) and inhibits the nephrotoxicity of the direct acting nephrotoxin S-2- 
chloroethyl-DL-cysteine (Elfarra et al., 1985). The sodium-dependent, probenecid-sensitive 
organic anion transport system and the sodium independent L-amino acid transport system, 
have been shown to participate in the renal tubular uptake of DCVC and DCVHC 
conjugates (Lash and Anders, 1989). The L-amino acid transport system is responsible for 
the uptake of DCVC into a porcine kidney cell line (LLC-PKi cells) (Schaeffer and 
Stevens, 1987), and saturable uptake of DCVC in these cells did not require sodium. 
Mercapturates may also be transported via the probenecid sensitive transport system (Lock 
et al., 1986) and undergo further metabolism to cysteine S-conjugates in the tubule cell. 
Inhibitors of the renal organic anion transporter are effective blockers of cysteine conjugate 
toxicity, therefore it can be concluded that the transport of cysteine conjugates into the renal 
tubular cells for subsequent cysteine conjugate (3-lyase activity is essential for cysteine 
conjugate-induced nephrotoxicity.
24
1.7 THE ROLE OF S-OXIDASE IN NEPHROTOXICITY
Both DCVC and its putative metabolite DCVC sulphoxide (DCVCO) are potent 
nephrotoxicants in rats in vivo, however, at equimolar doses DCVCO produces greater 
renal injury (Lash et al., 1994). Although renal microsomes possess the flavin containing 
monooxygenases required for the sulphoxidation of cysteine S-conjugates (Sausen et al., 
1993), DCVCO has not been detected from microsomal incubations (Sausen and Elfarra, 
1990).
Lash et al., (1994) have proposed a scheme for the metabolism of DCVC to DCVCO by the 
S-oxidase pathway. DCVCO can react directly as a Michael acceptor with cellular 
nucleophiles (Sausen and Elfarra, 1991) to form covalent adducts, or it can be further 
metabolised by (3-lyase to form pyruvate ammonia and 1,2-dichlorovinyl sulphenic acid 
(Bhattacharya and Shultze 1967). AOAA provides significant but incomplete protection 
from DCVC toxicity (Lash and Anders 1986; Lash et al., 1994), supporting the role of 
additional bioactivation mechanisms. AOAA does not effect S-oxidase activity and does not 
protect rats from DCVCO-induced nephrotoxicity (Lash et al., 1994).
The following evidence supports S-oxidase metabolism in the toxicity of DCVC: Although 
DCVCO is the more potent nephrotoxic agent in vivo, DCVC is more cytotoxic than 
DCVCO in proximal tubular cells, whereas, DCVCO is much more cytotoxic than DCVC 
in distal tubule cells. (3-lyase activity is much higher in proximal tubule cells than distal 
tubule cells (Jones et al., 1988; MacFarlane et al., 1989; Lash et al., 1994), and agrees 
with the moderately greater susceptibility of proximal tubule cells than distal tubule cells to 
DCVC induced toxicity and the ability of AOAA to protect proximal but not distal tubule 
cells. The inability of AOAA to protect distal tubule cells from DCVC suggests that 
cytotoxicity in these cells is not dependent on bioactivation by (3-lyase. The finding that 13- 
lyase activity in the distal tubule is inhibited by AOAA supports this hypothesis and 
supports the role of S-oxidase in the bioactivation and nephrotoxicity of DCVC (Lash et 
al., 1994). The findings above and those of Sausen and Elfarra (1991), which demonstrate
the reaction of DCVCO with glutathione, and the significant reduction of hepatic and renal 
non-protein thiol concentrations subsequent to in vivo treatment of DCVCO to rats, suggest 
that DCVCO may play a role in DC VC-induced toxicity.
Recently Werner et al., (1995), have demonstrated (E)-N-acetyl-S-(l,2,3,4,4-penta- 
chlorobuta-l,3-dienyl)-L-cysteine sulphoxide in the urine of male rats after administration 
of 1 4 C-HCBD, whereas no sulphoxide was detected in the urine of female rats. This group 
have also investigated the formation of (E)-N-acetyl-S-(l,2,3,4,4-pentachlorobuta-l,3- 
dienyl)-L-cysteine sulphoxide in 13 individual human liver microsomes of both sexes, and 
have demonstrated that the mercapturate of HCBD (N-Ac-PCBC) is the substrate of this 
monooxygenase activity in both sexes. PCBG and PCBC, the glutathione and cysteine 
conjugates are not substrates. Using selective inhibitors of cytochrome P450 and the flavin- 
containing-monooxygenases (FMO), they identified that only the cytochrome P450 family 
could participate in the oxidation of the mercapturate, and of these, only the CYP3A family 
was involved. Since the CYP3A family constitute a major proportion of the cytochrome 
P450s in human liver, exposure of humans to HCBD is very likely to give rise to 
chlorovinyl sulphoxides which are Michael acceptors and may bind to macromolecules, 
exerting toxic effects (Werner et al., 1995), although it must be emphasised that no 
experimental evidence is currently available on the toxicity of the sulphoxide.
1.7.1 The formation of thiol metabolites is a possible pathway for the 
detoxication of sulphenic acids
Tomisawa et.al. (1993), have proposed a pathway for the formation of thiol metabolites 
and cysteine conjugates from cysteine conjugate sulphoxides and propose that it may be an 
alternative pathway for the detoxification of sulphenic acids, which have relatively higher 
chemical reactivity compared to the thiols. The results of their study indicate initial C-S 
bond cleavage of the sulphoxide to give a putative sulphenic acid, followed by non- 
enzymatic conversion to the thiol and subsequent transformation of the thiol to the cysteine 
conjugate by the reverse reaction of cysteine conjugate (3-lyase (fig 1 .8 ).
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1.7.2 Cis  -Platin nephrotoxicity
Ban et al., (1994) have demonstrated that after subcutaneous administration of ds-platin to 
mice, renal proximal tubule damage is observed. In this latter study, pre-treatment with 13- 
lyase and S-oxidase inhibitors reduced the percentage of injured tubules by approximately 
40 and 75% respectively. It is proposed that (3-lyase causes the gradual and continuous 
release of platinum which is able to attack a subcellular organelle and produce a toxic event. 
The findings of Ban et al., (1994), suggest that the nephrotoxicity of c/s-platin is dependent 
on a probenecid-sensitive transport mechanism, and on intracellular bioactivation by renal 
(3-lyase and S-oxidase.
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Figure 1.8: Putative pathway for the formation of a cysteine S-conjugate from a cysteine 
conjugate sulphoxide, adapted from Tomisawa et al., (1993)
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1.8. MECHANISMS OF TOXICITY
The toxicity of halogenated alkenes involves initial hepatic glutathione S-conjugate 
formation, translocation to the kidney, formation of cysteine S-conjugates and metabolism 
by kidney cysteine conjugate (3-lyase. As discussed cysteine S-conjugates are potent and 
selective nephrotoxicants which exert their effects either by enzyme dependent activation to 
yield unstable thiols, or by spontaneous non-enzymatic formation of electrophilic 
episulphonium ions from sulphur mustards (Schasteen and Reed, 1983). The latter are 
known as direct acting nephrotoxins.
1.8.1. Formation of reactive thiols
The precise chemical nature of the toxic metabolite produced by (3-lyase cleavage of cysteine 
S-conjugates is not known in all cases. Unstable thiols formed subsequent to (3-lyase 
metabolism of S-halo alkyl conjugates, eg., CTFC (S-(2-chloro-1,1,2-trifluoroethyl)-L- 
cysteine and S-haloalkenyl conjugates eg., DCVC, are responsible for the observed 
nephrotoxicity as they further rearrange to chemically reactive intermediates which can bind 
to macromolecules.
The bioactivation of CTFEC has been studied in an in vitro model system (Dekant et al., 
1987). These studies demonstrate the initial formation of an unstable nucleophilic thiol, 2- 
ch loro-l,l,2 -trifluoroethane thiol (thiolate) which loses hydrogen fluoride with the 
formation of the acylating intermediate chlorofluorothionoacetyl fluoride. Subsequent 
hydrolysis of this latter compound gives the terminal metabolites chlorofluoroacetic acid, 
inorganic fluoride and hydrogen sulphide (figure 1.9). Both inorganic fluoride and 
chlorofluoroacetic acid are cytotoxic to rat renal proximal tubular cells (Dekant et al., 
1987), suggesting that these metabolites as well as the reactive intermediate 
chlorofluorothionoacetyl fluoride may be responsible for the cytotoxicity of CTFEC. The 
(3-lyase dependent bioactivation of the cysteine conjugate of TFEC was studied in rat renal 
cytosol (Commandeur et al., 1989). These studies indicate difluorothionoacyl fluoride, a 
potent acylating agent as the main reactive intermediate (figure 1 . 1 0 ).
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adapted from Dekant et al., (1987).
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The bioactivation mechanisms above, demonstrate that fluoroalkyl cysteine S-conjugates 
are transformed to reactive thionoacyl fluorides. Thioketenes (haloalkenyl S-conjugates) are 
formed from the enethiols produced by p-lyase-mediated cleavage of halovinyl cysteine S- 
conjugates (Dekant al., 1991). The bioactivation of the halovinyl cysteine S-conjugate 
DCVC to chlorothioketene is illustrated in figure 1.11. Both thionoacyl fluorides and 
thioketenes are potent acylating agents which most likely cause cytotoxicity by non- 
selectiveacylationof cellular macromolecules such as proteins, lipids, and as a result may 
cause functional inactivation of these macromolecules. Thioketenes interact with DNA, 
which may explain the potent, (3-lyase dependent mutagenicity of halovinyl cysteine S- 
conjugates in Salmonella typhimurium (Dekant, 1994).
1.8.2 Reactive intermediates of bromine containing cysteine S-conjugates
Bromine-lacking, fluoroalkene-derived cysteine S-conjugates are toxic in vivo and in vitro, 
however, they are not mutagenic in the Ames test, whereas bromine-containing, fluoro­
alkene-derived cysteine S-conjugates are both toxic and mutagenic (Finkelstein et al. , 
1994a). Experiments using rat kidney homogenate, demonstrated that the metabolism of 
bromine-containing, fluoroalkene derived cysteine S-conjugates, produced inorganic 
fluoride but no organofluorine compounds in the reaction mixture (Dekant et al., 1987), 
and HPLC analysis demonstrated glyoxylate (Stijntjes etal., 1992), which is not observed 
with bromine-lacking cysteine S-conjugates. Bromofluoroacetic acid was not detected.
Finkelstein et al., (1994b) predict that the formation of glyoxylate in bromine-containing 
fluoroalkene derived cysteine S-conjugate metabolism, is via the bioactivation pathway in 
figure 1.12. Evidence to support this is the formation of inorganic fluoride and 
mercaptoacetate from S-(2-bromo-l,l-difluoroethyl)cysteine metabolism, and the 
formation of mercaptoacetate upon incubation of bromothioacetic acid in phosphate buffer 
(pH 7.4). The 1,2 migration required for the formation of a mercaptoacetate from thiolate, 
and the formation of glyoxylate as a terminal metabolite of bromine-containing cysteine S- 
conjugates, via an a-thiolactone intermediate (figure 1 . 1 2 ) provides strong evidence for this 
pathway.
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Figure 1.11: (3-lyase mediated cleavage of the halovinyl cysteine conjugates S-(l,2- 
dichlorovinyl)cysteine (DCVC), S-(l,2-dichlorovinyl)homocysteine (DCVHC) and the 
formation of the reactive chlorothioketene metabolite, a potent acylating agent.
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1.8.2.1 a-thiolactones: a possible role in mutagenicity
Although the properties of a-thiolactones have not been investigated, the analogue p- 
propiolactone is mutagenic and carcinogenic (Fukuda et al., 1970), and suggests a possible 
role for a-thiolactones in the observed mutagenicity of bromine containing cysteine S- 
conjugates (Finkelstein et al., 1994b).
1.8.3. Formation of direct acting nephrotoxins
The vicinal dihaloalkanes 1,2-dibromoethane, 1,2-dichloroethane and l-bromo-2- 
chloroethane are toxic and carcinogenic (Spencer et al., 1951, Weisburger, 1977). These 
compounds are transformed by glutathione S-transferase catalysed reactions to mutagenic 
and nephrotoxic S-(2-haloethyl)glutathione S-conjugates which form electrophilic 
episulphonium ions (figure 1.13)
i
The glutathione-dependent formation of these sulphur half-mustards is responsible for the 
binding of 1,2-dibromoethane-metabolites to DNA and for 1 ,2 -dibromoethane-induced 
mutagenicity (van Bladeren et al., 1980). S-[2-(N7 -guanyl)ethyl]-L-glutathione is a major 
DNA-adduct formed in vivo (Ozawa and Guengerich, 1983) subsequent to glutathione 
conjugation of 1,2-dibromoethane, and is a mutagenic DNA-adduct inducing base 
substitutions (Dekant and Vamvakas, 1993). The formation of direct acting nephrotoxins 
plays an important role in S-2-chloroethyl-DL-cysteine (CEC) induced nephrotoxicity. CEC 
is the cysteine conjugate of 1 ,2 -dichloroethane formed by further metabolism of the 
glutathione conjugate. Treatment of rats with CEC at doses greater than 50mg/kg results in 
marked renal dysfunction, accompanied by histopathological changes in the kidney (Elfarra 
et al., 1985). CEC is not a substrate for cysteine conjugate p-lyase and analogues of CEC 
in which the chlorine atom is replaced by a hydrogen atom or hydroxyl group are not toxic 
(Elfarra et al., 1985, Webb et al., 1987). These results show that with CEC, internal 
displacement of the chlorine atom by the S-atom to form an electrophilic episulphonium ion 
may be responsible for the toxicity.
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Agents that inhibit the organic anion transport system, such as probenecid, protect against 
both the nephro- and cytotoxicity of CEC, indicating the importance of transport 
mechanisms in determining the target organ selectivity (Elfarra et al., 1985). The addition 
of CEC to rat hepatocytes results in rapid depletion of intracellular glutathione 
concentrations, which is partially due to the intracellular reaction of the episulphonium ion 
and glutathione to form S-[(2-DL-cysteinyl)ethyl]glutathione (Webb et al., 1987).
In vitro, CEC is a direct acting mutagen (Rannug et al., 1978). This toxicity is associated 
with a rapid depletion of GSH, inhibition of Ca2+ ATPase, and initiation of lipid 
peroxidation. The nephrotoxicity of CEC is probably a result of alkylation of essential renal 
macromolecules by episulphonium ions. Target organ selectivity of CEC suggests that 
active transport by renal tubular cells may result in the accumulation of CEC in renal tissue 
in toxic concentrations (Elfarra et al., 1985).
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1.9. MUTAGENICITY AND CYTOTOXICITY OF HALOALKENE-S- 
CONJUGATES
Glutathione and cysteine S-conjugates of haloalkenes are cytotoxic to renal proximal 
tubular cells, as discussed above. However, the cysteine S-conjugates derived from 
chloroalkenes also demonstrate mutagenicity whilst the fluorinated alkenes do not (Green 
and Odum, 1985). DCVC, TCVC and PCBC demonstrate a genotoxic effect in mammalian 
cells, whereas CTFEC does not, despite (3-lyase dependent cytotoxicity (Vamvakas et al., 
1989). This lack of genotoxicity is in agreement with results obtained in bacteria, where 
CTFEC is also not mutagenic (Vamvakas et ah, 1988a).
As (3-lyase metabolism of both chloroalkenyl and fluoroalkenyl S-conjugates yields 
reactive, acylating intermediates as the ultimate electrophiles, differences in the stability of 
these reactive intermediates must account for their differences in genotoxicity (Vamvakas et 
al., 1989). (3-lyase-dependent activation of fluoroalkyl cysteine S-conjugates (eg., CTFEC) 
yield thionoacyl fluorides as the putative ultimate electrophile, whereas halovinyl cysteine 
conjugates (eg., DCVC, TCVC and PCBC) yield thioketenes (Dekant et al., 1991). Due to 
the low binding energy of the carbon-fluoride bond in thionoacetyl fluorides they are 
expected to have a short half life and therefore may be unable to react with DNA 
(Vamvakas et al., 1989).
1.9.1 Mutagenicity
The glutathione and cysteine conjugates of HCBD are potent mutagens, as demonstrated by 
the Ames test (Green and Odum, 1985). HCBD caused an increased incidence of renal 
tumours, adenomas and adenocarcinomas in rats (Kociba et al., 1977). DCVC is also 
mutagenic in the Ames test. The pioneering work of Bhattacharya and Shultze (1972;1973) 
demonstrated that on (3-lyase cleavage of DCVC a reactive metabolite is formed, which 
binds to DNA resulting in structural modifications which might influence gene expression. 
More recently Vamvakas et al., (1988b) have demonstrated that the mutagenicity of 
chloroalkenes is dependent upon y -glutamyl transpeptidase and (3-lyase. Chloroalkene
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glutathione S-conjugates induce unscheduled DNA synthesis in LLC-PKi cells at 
concentrations which do not give rise to cytotoxicity (Vamvakas et al., 1989). Mercapturic 
acids have been found to be mutagenic only after metabolism by deacetylase followed by 13- 
lyase (Vamvakas et al., 1987). PCBDC demonstrates chloroalkene mediated genotoxicity, 
with the formation of DNA-DNA cross links (Jaffe et al., 1983). Other studies with HCBD 
have confirmed that after in vivo metabolism, the binding of metabolites to DNA was much 
higher in the kidney than the liver and was almost exclusive to the mitochondrial DNA. 
Indirect evidence using PCBDC suggests that the DNA adducts are formed subsequent to 
(3-lyase metabolism (Schrenk and Dekant, 1989), however, the structure formed between 
the DNA and HCBD metabolites is not known.
Halovinyl S-conjugates induce a (3-lyase-dependent DNA repair in LLC-PKi cells, a 
porcine kidney cell line (Vamvakas et al., 1989). The extent of genotoxicity observed is 
very low and the concentration range over which DNA repair occurs in the absence of 
cytotoxicity and cell death is very small. The results of Vamvakas et al., (1989) clearly 
demonstrated that in contrast to DCVC, TCVC, and PCBC, the cysteine conjugate CTFEC 
failed to induce unscheduled DNA synthesis in LLC-PKi cells, despite (3-lyase dependent 
cytotoxicity. This lack of genotoxicity of CTFEC is in agreement with the results obtained 
in bacteria, where CTFEC is also not mutagenic (Vamvakas et al., 1988a).
The reactive intermediates produced by p-lyase cleavage of DCVC have been shown to 
react directly with DNA: DCVC is a potent mutagen in Salmonella typhimurium (Dekant et 
al., 1986). DCVC induces DNA repair in kidney cells in culture (LLC-PKi), and DNA 
single strand breaks in the rat kidney in vivo (Vamvakas et al., 1989; Jaffe et al., 1985). 
More recent studies indicate that DCVC forms adducts with adenine, guanine and cytosine 
(Vamvakas et al., 1993).
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1.9.2 Cytotoxicity
Cellular respiration and ATP levels of freshly isolated renal proximal tubular cells are 
markedly reduced by PCBDC, and DCVC. DCVC and DCVHC are equally potent 
inhibitors of oxygen consumption in isolated kidney cells (Anders et al., 1987). As most 
proximal tubular cellular O2  consumption is due to mitochondrial respiration, this result 
indicates that mitochondria are cellular targets for both compounds. AOAA substantially 
protects against the inhibition of respiration produced by DCVC, and propargylglycine 
protects against the inhibition of respiration by DCVHC. The a-methyl analogue of 
DCVMeHC had no effect on cellular O2  consumption. DCVHC as well as inhibiting 
mitochondrial processes in the intact cell, also inhibits processes not linked to 
mitochondrial function, indicating that DCVHC also has extra mitochondrial targets. As 
discussed previously this difference may partially explain the greater nephrotoxic potency 
of DCVHC compared to DCVC. The difference in toxicity may also be attributed to 
competing detoxication reactions, eg., N-acetylation is approximately 4 fold more rapid 
with DCVC as substrate than with DCVHC (Elfarra et al., 1986).
Mitochondria and mitoplasts were treated with DCVC, DCVMeC, and CEC [S-(2- 
chloroethyl)DL-cysteine], a direct acting nephrotoxic and hepatotoxic conjugate (Elfarra et 
al., 1984; Elfarra et al., 1985). DCVC was a potent inhibitor of state 3 respiration in intact 
mitochondria and AOAA provided protection. DCVMeC was not toxic. CEC inhibited 
respiration in intact mitochondria indicating that direct-acting cysteine conjugates also 
inhibit mitochondrial function. Studies by Lash and Anders (1987), have shown that 
DCVC inhibits the generation of the mitochondrial membrane potential. They have also 
shown that DCVC inhibits succinate-linked state 3 respiration (ie., ADP-dependent) and 
alters the concentration of several citric acid cycle intermediates. Later experiments (Hayden 
and Stevens, 1990; Schnellmann, et al., 1989), showed that oxidative phosphorylation was 
uncoupled by treatment with PCBDC. These studies suggest that the primary subcellular 
target for cysteine S-conjugate induced cytotoxicity is the mitochondria, resulting in 
disruption of the processes requiring energy in the form of ATP.
39
Binding of S-conjugates to mitochondrial macromolecules was demonstrated in studies 
using 35S labelled DCVC, CTFEC, TFEC, PCBC and HFPC (Hayden and Stevens 1990). 
However, mitochondrial toxicity did not correlate with the relative extent of metabolism and 
binding of 3 5 S-containing metabolites. The correlation between covalent binding to 
mitochondria, mitochondrial toxicity and S-conjugate induced cell death, is not fully 
understood, and the contribution of mitochondrial dysfunction to cysteine conjugate 
toxicity has been questioned. It is doubtful that the mitochondrial dysfunction above 
contributes to cell death, and another mechanism that leads to cell death via p-lyase activity 
on cysteine S-conjugates has been suggested, in which an alteration in intracellular Ca2+ 
homeostasis appears to be responsible (see 1.9.2.1).
1.9.2.1 Intracellular Ca2+ homeostasis
PCBDG and DCVC selectively deplete renal mitochondrial calcium, with a concomitant 
increase in cytosolic calcium (Jones et al., 1986), thereby suggesting a central role for 
alterations in the compartmentalisation of intracellular calcium in S-conjugate induced cell 
death. Earlier studies demonstrated the rapid appearance of plasma membrane blebs after 
treatment with PCBDG (Jones et al., 1986), and was associated with disturbances of 
intracellular calcium homeostasis and subsequent cytoskeletal alterations. Using 
fluorescence microscopy, isolated porcine renal cells (LLC-PKi) show rapid changes in 
Ca2+ compartmentalisation after treatment with DCVC (Vamvakas et al., 1990). Freshly 
isolated rat kidney cells following treatment with normally toxic concentrations of DCVC, 
are protected against these Ca2+ alterations using Ca2+ chelators (such as quin-2- 
ethoxyethyl- ester, which prevents Ca2+ movement in the cell) (Koob et al., 1990).
The intracellular Ca2+ homeostasis is controlled by transport systems on the plasma 
membrane, the mitochondria and the endoplasmic reticulum, which control transient 
increases in intracellular Ca2+ concentrations for processes such as transduction of 
extracellular signals, secretion of neurotransmitters and muscle contraction. Uncontrolled 
or sustained increases of intracellular Ca2+ levels can occur via enhanced influx of
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extracellular Ca2+ or by impairment of the intracellular buffering systems, or both, and may 
result in disruption of the integrity of cell membranes and of the cytoskeleton resulting in 
cell death. This toxicity may occur via activation of calcium-dependent phospholipases and 
proteases.
Studies by van der Water et al., (1994) have demonstrated that exposure of proximal 
tubular cells to DCVC results in increased flux of Ca2+ into the mitochondrial matrix, 
which induces the formation of hydroperoxides which strongly potentiate the dissipation of 
the mitochondrial membrane potential, resulting in cell death. The decrease in membrane 
potential was completely prevented by the inhibition of the (3-lyase mediated metabolism of 
DCVC with AOAA. Increased intracellular Ca2+ concentrations may also disturb DNA 
structure and function by the activation of endonucleases that catalyse the formation of 
DNA strand breaks followed by the induction of poly(ADP-ribosyl)ation of nuclear 
proteins (see section 1 .9.2.2).
1.9.2.2 PoIy(ADP-ribosyl)ation
Chromatin structure plays an important role in the initiation of DNA repair, DNA 
replication and in the modulation of gene expression. The access and binding of enzymes 
and proteins to DNA is regulated by changes in chromatin structure, which are brought 
about by poly(ADP-ribosyl)ation of the histone proteins. Poly(ADP-ribose) conjugates 
may act by opening up the higher order chromatin structure or in removing core histone 
octamers from DNA, thus increasing the accessibility of enzymes to the DNA (Boulikas, 
1992). Double-strand DNA breaks are the most potent inducers of poly(ADP-ribosyl)ation.
DCVC induces DNA repair in the cultured kidney cell line LLC-PKX (Vamvakas et al.,
1989), and induces impairment of the ability of the mitochondria to sequester Ca2+ with a 
resultant increase in intracellular Ca2+concentration in these cells. Studies by Vamvakas et 
al., (1992) suggest that S-(l,2-dichlorovinyl)-L-cysteine may cause a selective depletion of 
mitochondrial Ca2+ by modification of mitochondrial membrane proteins by the ADP-
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ribose moieties formed subsequent to the hydrolysis of the oxidised pyridine nucleotides. 
The subsequent activation of Ca2+ dependent endonucleases gives rise to an increased 
formation of DNA double-strand breaks followed by increased poly(ADP-ribosyl)ation of 
nuclear proteins (Vamvakas and Anders, 1990; Vamvakas et al., 1992). Recent studies by 
McLaren et a l, (1993), have demonstrated that in vivo administration of DCVC to male 
Wistar rats induces DNA double strand breaks and poly(ADP-ribosyl)ation in the renal 
cortex, and suggest a possible role of this post-translational modification of nuclear 
proteins in the formation of renal cell tumours by DCVC. This mechanism is supported by 
reduction of PCBG mediated renal toxicity after treatment with 3-aminobenzamide, an 
inhibitor of poly(ADP-ribosyl) polymerase (Brown et al., 1990).
Extensive increase in the formation of nuclear poly(ADP-ribosyl)conjugates may deplete 
the cellular NAD+ concentration. Since NAD+ is the substrate for poly(ADP- 
ribosyl)transferase, this in turn will deplete the ATP pool resulting in cell death. 
Alternatively the degree of nuclear protein poly(ADP-ribosyl)ation may be non lethal, 
however, it may change the structure and function of proteins involved in regulation of 
gene expression. Interference with the expression of genes required for the physiological 
integrity of cell proliferation and differentiation may contribute to malignant transformation 
and tumour formation.
1.9.2.3 Expression of c-myc  and c - fo s  in normal and malignant renal 
growth
c-myc and c-fos are protooncogenes involved in the transduction of extracellular growth 
signals to the genetic level, thus playing an important role in the regulation of cell 
proliferation. These short lived phosphoproteins bind to DNA and alter the expression of 
several inducible genes. In non-transformed cells the expression of c-myc is strictly 
regulated, however in transformed cells these regulatory mechanisms are often impaired 
resulting in a permanent increased expression (Campisi et al., 1984).
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Vamvakas et al., (1993) demonstrated that DCVC (500jxM) induced a time dependent 
increase in c-fos and c-myc gene expression in LLC-PKi cells incubated for 0.5 to 5 
hours and that the induction of c-myc and c-fos gene expression did not persist after 
removal of DCVC. However, if the induction of gene expression results from the 
formation of DNA-adducts that are converted into heritable mutations, the effects would 
persist after removal of DCVC (Vamvakas and Koster, 1993). The study provides indirect 
evidence that the DCVC induced expression of c-myc and c-fos, the increased formation of 
DNA double strand breaks and the temporarily increased poly(ADP-ribosyl)ation of nuclear 
proteins, by perturbation of the intracellular Ca2+ homeostasis, may therefore be more 
important than persistent DNA mutations.
Both direct interactions of DCVC derived electrophiles with the DNA and the Ca2+ induced 
DNA double strand breaks may modulate gene expression, however greater understanding 
of both cytotoxicity and genotoxic interaction is required in order to elucidate the 
mechanism of S-conjugate induced cell death and carcinogenicity.
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1.10 CYSTEINE CONJUGATE p-LYASE
Cysteine conjugate (3-lyase activity, or C-S lyase (EC 4.4.1.13), has been demonstrated in 
several mammalian tissues. The greatest specific activity is seen in the kidney, followed by 
the liver. However, (3-lyase activity has also been demonstrated in heart, muscle, brain, 
testes, pancreas and lung (Tateishi et al., 1978; Stevens et al., 1986b; Cooper et al., 1993; 
Jones et al., 1988) as well as intestinal microflora (Larsen et al., 1983). Cysteine conjugate 
(3-lyase is a general term for a group of enzymes which have been shown to metabolise 
several cysteine S-conjugates by a (3-elimination reaction (Figure 1.14a), and is a subsidiary 
activity of some of the transaminase group of enzymes. The products of the C-S cleavage 
are thiol compounds and the acrylic compound, dihydroalanine, which rapidly hydrolyses 
to ammonia and pyruvic acid. The thiols may be methylated by S-methyl-transferases to 
yield stable and non toxic methylthioderivatives (Jakoby et al., 1984). In contrast, when 
DCVC is metabolised by (3-lyase, a very reactive intermediate containing the sulphur and 
vinyl carbon atoms of DCVC is formed, which reacts with proteins, including the (3-lyases 
as well as to nucleic acids (Stevens and Jakoby, 1983).
Selective and potent toxic affects on the kidney are observed on administration of DCVC to 
rats. This toxicity is not seen in the liver and therefore indicates that renal (3-lyase, rather 
than the enzymes present in the liver or the gut microflora is responsible for the 
bioactivation of DCVC to nephrotoxic metabolites.
1.10.1. Bacterial p-Iyase
Bacterial (3-lyases have been identified in three species of gastrointestinal bacteria; the 13- 
lyase of Fusobacteriumnecrophorum (Larsen et al., 1983), has a molecular weight of 
approximately 228kDa, with a pyridoxal phosphate (PLP) requirement. This enzyme 
catalyses the cleavage of propachlor (2-S-cysteinyl)-N-isopropylanilide, 1 ,2-dihydro-1- 
hydroxy-2-cysteinylnapthalene, and S-(2-benzothiazolyl)cysteine. It is not known if this 
enzyme is active as a monomer or polymer. Fusobacterium varium (Tomisawa et al., 
1984), has a (3-lyase of approximately 70kDa, which was shown to be most active with
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aromatic cysteine S-conjugates (eg., phenyl-, benzyl-, p-bromophenyl-), however, some 
activity was demonstrated with alkyl cysteine S-conjugates. Larsen and Stevens (1986), 
purified a (3-lyase from Eubacterium limosum, with a molecular weight of 75kDa, which is 
active as a dimer. The cofactor is possibly PLP, however, the activity does not require 
added PLP. The enzyme has a broad specificity and is active with the cysteine conjugate of 
propachlor, and is moderately active with the S-alkyl conjugate S-ethyl-L-cysteine. In 
contrast to F. necropkorum and F. varium (3-lyases, the E. limosum enzyme also exhibits 
(3-cystathionase activity.
1.10.2. Hepatic p-lyase
Hepatic p-lyase was partially purified from rat by Tateishi et al., (1978) and later purified to 
homogeneity (Stevens, 1985). This PLP containing enzyme, active as a lOOkDa dimer is 
identical to kynureninase. Kynurenine a degradation product of tryptophan metabolism, is 
metabolised by kynureninase (Figure 1.14b) producing the metabolites anthranilic acid and 
alanine (Soda and Tanizawa ,1979).
Human liver p-lyase has been characterised by Tomisawa et al., 1986. This enzyme was 
shown to have a molecular weight of 8 8 kDa by gel filtration, and a pH optimum of 8.5. In 
contrast to the rat liver p-lyase, the human enzyme did not possess kynureninase activity. 
Human liver cysteine conjugate p-lyase has however, been demonstrated to co-purify with 
kynurenine aminotransferase activity in the liver by Blagbrough et al., (1992) and 
Buckberry et al., (1992), who propose that the physiological role of human hepatic p-lyase 
is that of kynurenine aminotransferase (figure 1.14c). Two isoenzymes of kynurenine 
aminotransferase have been reported to be present in human liver (Kido, 1984), with pis of 
8.0 and 5.0, each enzyme consisting of two identical subunits of dimeric molecular weight 
90kDa. The liver and kidney cytosolic enzymes are distinct proteins in that the antibody to 
the liver cytosolic enzyme does not cross-react with the kidney cytosolic enzyme and only 
10-15% of the renal cytosolic p-lyase can be accounted for as kynureninase (Stevens and 
Jakoby 1983; Stevens 1985).
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1.10.3. Renal p-lyase
Rat kidney p-lyase is an intracellular enzyme, present mainly in the cytosol and to a lesser 
extent in the mitochondria (approximately 90% and 10% respectively). It has been isolated, 
purified and characterised from cytosol (Stevens et al., 1986b; MacFarlane et al., 1989; 
Yamauchi et al., 1993), and reported to be of molecular weight of approximately 50kDa, 
active as a dimer. This cytosolic p-lyase is a thermostable, PLP dependent enzyme 
(Stevens et al., 1986b), with a pH optimum of 8 . 8  (50mM Tris-HCl). A mitochondrial 
form has also been isolated (Stevens et al., 1988. Lash et al., 1986a). Both the cytosolic 
and mitochondrial proteins have glutamine transaminase K (GTK) activity (EC 2.6.1.64) 
(figure 1.14d), p-lyase being a subsidiary activity of this transaminase.
Stevens et al., (1988), reported that S-(2-benzothiazoyl)-L-cysteine (BTC) is a poor 
substrate for the purified enzyme, however, BTC is as active as DCVC in crude 
mitochondrial matrix suggesting that p-lyases other than GTK may be present. The results 
of Stevens et al., (1988) differ from those of Lash et.al, (1986a), who report that most of 
the mitochondrial p-lyase activity is present in the outer mitochondrial membrane. The 
reason for this discrepancy, may be due to a number of differences in experimental 
procedures. Lash et al., (1986a) support their localisation of p-lyase to the outer membrane 
by the demonstration that neither DCVC nor CTFC were toxic to mitoplasts. In contrast, 
the direct acting nephrotoxin S-(2-chloroethyl)-DL-cysteine was toxic to both mitochondria 
and mitoplasts. Antibodies raised against the kidney cytosolic enzyme cross-reacted with 
the mitochondrial form, and demonstrated a similar molecular weight of approximately 
50kDa by Western blot analysis. (MacFarlane et al., 1989). Recently the rat kidney 
cytosolic p-lyase cDNA has been isolated (Perry et al., 1993, work reported in this thesis). 
From this the predicted molecular weight of the monomer is 47.8 kDa, which is consistent 
with the literature value of 47.4 kDa for the purified protein (Yamauchi et al., 1993; 
MacFarlane et al., 1989). The cDNA for rat kidney p-lyase has recently been reported to be 
identical to that for rat kidney, kynurenine aminotransferase (Mosca et al., 1994).
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Cytosolic, mitochondrial, and microsomal p-lyase activity has been demonstrated in human 
kidney (Lash et al., 1990), with the greatest activity in the cytosol. The human kidney 
cytosolic p-lyase isolated by Lash et al., (1990) has a molecular weight of approximately 
45kDa and also uses PLP as cofactor, it copurifies with glutamine transaminase K and is 
strongly inhibited by aminooxyacetic acid. A human kidney p-lyase cDNA has been 
isolated (Perry et al., FEBS Lets., in press, work reported in this thesis), and the predicted 
molecular weight of the protein (47.9 kDa) is consistent with the value of the purified 
protein (Lash et al., 1990). The total enzyme activity of human kidney per gram of tissue 
was only 10% of that in rat kidney (Lash et al., 1990). However, recent studies by 
Buckberry et al., (1994), have reported that the specific activity of human kidney cytosolic 
preparations may be as much as 28% of the rat cytosolic specific activity. It is interesting to 
note that the male subject in these experiments had 14% cytosolic specific activity, whereas 
the females had 26 and 28% cytosolic specific activity when compared to rat kidney 
cytosol. Additionally, the ratio of cytosolic to mitochondrial specific activity is less than 
that observed in rat kidney, therefore, as the mitochondria are the target site for DCVC- 
induced nephrotoxicity, humans could be at greater risk than previously thought. The 
addition of exogenous a-keto acids has a potentiating effect (approximately 30 fold) on rat 
kidney p-lyase activity (Stevens et al., 1986b) which can be explained by the conversion of 
pyridoxamine phosphate (PMP), which results from the intrinsic transaminase activity of p- 
lyase, to PLP, the active form (Stevens et al., 1986a). Consistent with this, the addition of 
a-keto acid stimulates p-lyase activity, presumably by being transaminated into the amino 
acid (Stevens et al., 1986a), and potentiates cysteine S-conjugate toxicity (Lash et al., 
1986b; Elfarra et al., 1987). In contrast to the rat cytosolic kidney enzyme, the human 
enzyme was only stimulated 1.3 fold by the a-keto acid, a-KMB (Lash et al., 1990). 
Buckberry et al., (1990), reported the isolation and purification of two human cytosolic 
renal isoenzymes of p-lyase, with identical isoelectric points but different molecular 
weights. These enzymes display physico-chemical and biochemical properties consistent 
with glutamine transaminase K.
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Abraham and Cooper, (1991), demonstrated the presence of a 330kDa protein in rat kidney 
homogenate, which possesses weak transaminase activity, but higher p-lyase activity with 
DCVC as substrate. The enzyme is immunologically distinct from kidney cytosolic GTK, 
and is not detected in the brain (Cooper et al., 1993). The 330kDa species can convert 
leukotriene E4  (a cysteine conjugate) to pyruvate, ammonia and a reactive sulphydryl- 
containing compound (Cooper, 1994).
1.10.4 Neural fMyase
Abraham and Cooper (1991) demonstrated that rat brain contains cysteine conjugate p-lyase 
which has an apparent molecular weight on non-denaturing-PAGE comparable with the 
liver and kidney enzymes and comigrates with the purified glutamine transaminase K. 
Cooper etal., (1993) have demonstrated the presence of both cytosolic and mitochondrial 
GTK activity in brain tissue, and using DCVC as substrate, have demonstrated that the 
only detectable cysteine conjugate p-lyase in rat brain homogenate is identical to rat 
glutamine transaminase K. Approximately 80-85% of the GTK activity in the rat brain is in 
the mitochondrial fraction (Cooper, 1988), and there is only 10% cross reactivity of the 
mitochondrial form with the cytosolic p-lyase antibody, suggesting two distinct enzymes 
(Cooper et al., 1993). The mitochondrially associated and cytosolic enzymes have been 
purified from rat brain tissue (van Leuven, 1975; Cooper and Gross, 1977). As with the 
cytosolic enzyme, rat mitochondrial p-lyase/GTK is composed of two identical subunits, 
with a molecular weight of approximately 90kDa, and contains tightly bound PLP. The 
substrate specificity is very similar to that of the cytosolic enzyme, however, there are 
subtle differences in substrate affinities between the two enzymes (Cooper and Gross, 
1977).
Recently the cDNA for kynurenine aminotransferase (KAT) has been isolated from rat 
brain (Alberati-Giani et al., J. Neurochem., in press) and its sequence shown to be 
identical to rat kidney p-lyase/GTK (Perry et al., 1993), and to rat kidney KAT (except for 
two amino acid differences, probably due to strain difference) (Mosca et al., 1994).
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1.11. TARGET ORGAN SPECIFICITY
Despite the widespread localisation of p-lyase in rat tissues and gut microflora, the 
halogenated alkene bioactivation by p-lyase results in nephrotoxicity specific to the pars 
recta (S3 ) region of the kidney proximal tubule of rats (Lock and Ishmael, 1979; Ishmael et 
al., 1882), and has more recently been implicated in subtle kidney changes in humans 
exposed to perchloroethylene (Mutti et al., 1992), and neurotoxicity in humans exposed to 
trichloroethylene (Schaumburg, 1992).
Target organ specificity of xenobiotic metabolites may be due to a number of factors. The 
tissue distribution of the toxic agent is important, as accumulation of a xenobiotic in a 
specific organ may lead to toxic concentrations. The tissue distribution of the bioactivating 
enzymes is also a major factor in determining the organ specific toxicity of xenobiotics. To 
protect against harmful interactions between reactive intermediates and critical cellular 
macromolecules, tissues possess defence systems. These include, repair of the initially 
affected cellular elements and deactivation of the toxicant. The activity of deactivating 
enzymes plays an important role in determining target organ toxicity.
1.11.1 Kidney
The kidney has several physiologically important functions for the maintenance of stable 
ionic conditions in the extracellular fluid. Electrolyte concentrations (sodium, potassium, 
calcium and hydrogen ion) and water volume are controlled by a combination of active and 
passive transport processes and hormonal regulation. Many substances in the glomerular 
filtrate are reabsorbed by active transport and include glucose, amino acids and water 
soluble vitamins. The kidney is also responsible for the elimination of waste products (eg., 
urea, uric acid, creatinine and urobilinogen) in the urine, and the elimination from the body 
of foreign chemicals (drugs, pesticides, food additives). In addition to their excretory 
functions, the kidneys act as endocrine glands, secreting erythropoietin, renin and the 
active form of vitamin D. It is therefore apparent that toxicity to the kidney may have severe 
or even fatal consequences to organisms.
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The kidney is exposed to high concentrations of chemicals due to several factors. The 
kidney is the major organ for elimination of chemicals and their metabolites, receiving 
approximately 25% of the cardiac output. The mechanisms by which chemicals produce 
their toxic effects on the kidney are generally poorly understood. Concentration of 
potentially toxic chemicals in the kidney occurs by both passive and active mechanisms. 
Furthermore, in-situ bioactivation of foreign chemicals may occur as the kidney contains 
most of the drug metabolising enzymes also found in the liver. Thus the high blood flow 
and ability to concentrate xenobiotics increases the susceptibility of the kidney to toxic 
agents compared with other tissues.
The kidney is the primary organ for handling plasma glutathione and cysteine S-conjugates. 
After glomerular filtration and processing of the glutathione S-conjugates by y -gt and 
dipeptidases, the cysteine S-conjugates are taken up by a sodium dependent organic anion 
transport mechanism at the luminal (brush border) membrane that is inhibited by 
probenecid but not by cysteine conjugates (Lash and Jones 1984;1985). The anionic 
transporter also facilitates the entry of N-acetylcysteine conjugates, after which they are 
deacylated to the cysteine S-conjugate. Influx of glutathione and cysteine-S-conjugates also 
occurs across the basolateral membrane. In the renal proximal tubule the cysteine S- 
conjugates may form mercapturic acids by microsomal cysteine S-conjugate N-acetyl 
transferase. These may be excreted in the urine or can be enzymatically deacetylated to 
reform the cysteine conjugate.
1.11.1.1 Selective nephrotoxicity in rodents
A number of studies support the role of p-lyase in site specific nephrotoxicity produced by 
certain halogenated alkenes. Renal necrosis produced in rats subsequent to HCBD 
exposure, corresponds to specific localisation of cytosolic p-lyase in rat kidney 
(MacFarlane et al., 1989). Localisation was carried out using immunohistochemistry 
techniques, with an antibody raised against purified rat kidney cytosolic p-lyase protein. 
Cytosolic p-lyase was found to be located primarily in the pars recta (S3 ) of the proximal
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tubule, supporting the findings of Jones et. al., (1988). This confinement is thought to be 
due to accumulation of N-acetylated cysteine S-conjugates in this region which are 
subsequently processed via the cysteine conjugate p-lyase enzyme. However, the studies 
by MacFarlane et al., (1989) show that cytosolic cysteine conjugate p-lyase is also present 
in minor quantities in the pars convoluta (Si and S2  segments), suggesting that additional 
factors may be involved in HCBD elicited site specific nephrotoxicity. Such factors include 
the distribution and specificity of the enzymes glutathione S-transferases, y -glutamyl 
transpeptidase, dipeptidases, acylases, deacylases and other cysteine conjugate p-lyases, 
the transporters for the glutathione conjugate, cysteinylglycine conjugate, cysteine 
conjugate and mercapturate, as well as sulphoxidation reactions and the availability of a- 
keto acid.
Further studies by MacFarlane et al., (1993) show that p-lyase and the associated glutamine 
transaminase K activity, is induced by treatment of female rats with the N-acetyl conjugate 
of HCBD (NAc-PCBD). After a single dose of 3mg/kg, significant increases in enzyme 
activity, protein levels and corresponding mRNA synthesis were demonstrated. It is not 
known however, whether NAc-PCBD or one of its metabolites is the proximate inducer of 
cysteine conjugate p-lyase. These effects appeared to be specific to the cytosolic form of the 
enzyme as no changes in mitochondrial p-lyase enzyme activity or protein levels were 
observed.
1.11.1.2 Selective nephrotoxicity in humans
The total activity of microsomal glutathione S-transferases in the lung is about 3% relative 
to that in the liver (de Pierre and Morgenstern 1983). However, it is conceivable that 
inhalation of highly reactive xenobiotics, such as dichloroacetylene, may lead to substantial 
glutathione S-conjugate formation in the lung (Patel et al., 1993). Experimental evidence 
for the metabolism of trichloroethene by the mercapturic acid pathway, and thus via 
glutathione S-conjugate formation, in human subjects is given below.
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Urine samples of workers exposed to trichloroethene were analysed for N-acetyl-S-(l,2- 
dichlorovinyl)-L-cysteine and N-acetyl-S-(2,2-dichlorovinyl)-L-cysteine conjugates (Bimer 
et al., 1993) and were shown to contain appreciable amounts of the two mercapturate 
isomers. These experiments demonstrated relatively higher mercapturate levels excreted in 
human urine than in rats and mice. As the concentration of the mercapturates in urine may 
be dependent on the balance between deacetylation of the mercapturic acid and acetylation 
of the cysteine S-conjugates, the levels of deacetylase in rat and human kidney cytosol were 
measured and were found to be comparable. This suggests that the high excretion rates of 
N-acetyl-S-(l,2-dichlorovinyl)-L-cysteine in humans may be due to greater metabolism of 
trichloroethene by glutathione conjugation, and thus increased mercapturate synthesis in 
humans than in Wistar rats.
Studies using isolated human proximal tubular cells, have demonstrated cysteine conjugate 
p-lyase mediated toxicity (Chen et al, 1990). More recently a study based on a large battery 
of markers of renal damage and/or dysfunction, demonstrates early renal changes among 
workers occupationally exposed to the dry cleaning solvent perchloroethylene (Mutti et al.,
1992). Diffuse abnormalities occurred at the glomerular and proximal and distal tubule 
level. Although these changes are subtle, and do not compare with the acute damage 
observed in rats exposed to halogenated alkene compounds, they may represent an early 
stage of clinically silent but potentially progressive renal disease (Mutti et al., 1992).
In humans, renal carcinomas appear to arise from the proximal nephron (Cordon-Cardo et 
al., 1989, and references therein) and as noted in section 1.6, this region of the kidney is 
most susceptible to damage from cysteine S-conjugates in experimental animals. Also as 
discussed previously chloroalkene derived cysteine S-conjugates are mutagenic, probably 
due to the actions of cysteine conjugate p-lyase (Vamvakas et al., 1988b). This evidence 
has led to the speculation that low-level exposure to chloroalkenes may give rise to kidney 
cancer (Cooper et al., 1989).
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1.11.2 Brain
The adult human brain contains more than a thousand million neurons, which relay signals 
of afferent input and efferent output between the spinal cord and the higher brain centres. 
Although the adult brain is only 2 percent of the body weight, it receives 15% of the total 
blood supply to support the high oxygen and glucose requirement of the neural tissues. The 
exchange of substances between the blood and neurons in the central nervous system is 
different from the more or less unrestricted diffusion of nonprotein substances from 
capillaries in other organs. A complex group of blood-brain barrier mechanisms closely 
controls both the kinds of substances that enter the extracellular fluid of the brain and the 
rate at which they enter. This capillary barrier comprises both anatomical structures and 
physiological transport systems that handle different classes of substances, precisely 
regulating the chemical composition of the extracellular fluid of the brain and minimising 
the ability of many harmful substances to reach neural tissue. In addition to its blood 
supply, the central nervous system is perfused by a second fluid, the cerebrospinal fluid 
(CSF). This clear fluid fills the ventricles within the brain and surrounds its outer surfaces. 
Most of the CSF is secreted into the ventricles by the highly vascular choroid plexus 
tissues. Xenobiotic metabolites which are able to bypass the blood brain barrier by 
exploiting active transport mechanisms, may be substrates for neural enzymes, producing 
toxic metabolites, which may lead to neuromodulatory effects.
1.11.2.1 Neurotoxicity and neuromodulation by cysteine conjugate p-lyase
For many years the haloalkenes dichloroacetylene and trichloroethylene have been 
implicated in neurotoxic effects observed in experimental animals and humans (Reichert et 
al., 1976; Buxton and Hayward, 1967). Reichert et al., (1976), demonstrated that 
inhalation of dichloroacetylene is directly neurotoxic to rabbits. The sensory trigeminal 
nucleus was involved most severely, followed in decreasing intensity by the facial and 
oculomotor nerves and the motor trigeminal nucleus. Dichloroacetylene may occur as a 
decomposition product of trichloroethylene and tetrachloroethane, and is also found as a 
contaminant in some chlorinated plastic monomers. In humans, exposure to
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trichloroethylene (or more likely the contaminating dichloroacetylene) causes facial cold 
sores and trigeminal analgesia, sometimes accompanied by facial paresis, ptosis, 
dysarthria, vocal cord paralysis, visual loss, and dysphagia. Most patients recover within 2 
years, but severely affected individuals do not (Schaumburg, 1992). A post mortem study 
of a severely affected individual revealed neuronal degeneration within the brainstem 
sensory nucleus of the trigeminal nerve and degeneration of axons within its tract (Buxton 
and Hayward 1967; Schaumburg, 1992).
Recently it has been proposed that as in rodent and possibly human nephrotoxicity by 
halogenated alkenes, cysteine conjugate activation to a reactive species in the brain also 
occurs via cysteine conjugate p-lyase (Patel et a l, 1994). Exposure to dichloroacetylene 
may lead to the formation of high concentrations of DCVG and DCVC in the pulmonary 
circulation. Research by Patel et al., (1993) indicated that DCVC, but not DCVG may be 
taken up into rat brain tissue by the sodium-independent system L-transporter for neutral 
amino acids, and that DCVG can be hydrolysed to DCVC by rat brain cells and bioactivated 
by p-lyase in the brain, with the subsequent formation of toxic intermediates.
Evidence to support the presence of p-lyase activity in brain tissue comes from a number of 
sources. Pyruvate formation from DCVC has been detected in the cerebellum region of rat 
brain tissue (Patel et al., 1994). Glutamine transaminase K activity was shown to be 
widespread throughout the rat brain, however, the choroid plexus demonstrated 
approximately 6  fold increase over the brain as a whole (Cooper et al., 1993). Activity 
staining using DCVC as substrate shows that the cysteine conjugate p-lyase reaction in the 
rat brain appears to be catalysed exclusively by glutamine transaminase K, and 
immunohistochemistry demonstrates the presence of GTK in the choroid plexus of rat brain 
using a polyclonal rabbit antibody to cytosolic rat kidney GTK. Further evidence for the 
presence of p-lyase in rat brain comes from the isolation of a cDNA from rat brain 
(Alberati-Giani et al., in press) which is identical to rat kidney p-lyase/GTK (Perry et al.,
1993) and from reverse transcriptase-PCR studies described in this thesis.
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Makar et al., (1994) have demonstrated GTK/p-lyase activity in the chick brain. This group 
report marked changes in GTK/(3-lyase activity during embryogenesis and in the early 
neonatal period. Also an approximate 15 fold increase in the cerebral GTK level is 
observed in the chick embryo on the day of hatching. The authors suggest that this increase 
correlates with the maturation of astrocytes, and that GTK may be involved in glutamine 
cycling in astrocytes. As GTK appears to be the major cysteine conjugate (3-lyase of the 
brain it may, as discussed above, be involved in neurotoxicity associated with exposure to 
halogenated alkene compounds. As yet it is not known if the neural GTK levels of other 
species demonstrate similar patterns of elevation to those seen in the chick embryo, and 
whether this may result in an elevated antenatal risk in man remains to be determined.
Lesions due to dichloroacetylene are localised mainly in the sensory trigeminal nucleus and 
to a lesser extent in the oculomotor nerves, facial nerves and motor trigeminal nucleus 
(Buxton and Hayward, 1967; Schaumburg, 1992), which suggests that the mechanism of 
the neurotoxicity must involve factors besides the predominant location of GTK/(3-lyase in 
astrocytes and choroid plexus. The exact mechanism by which DC VC exerts its toxicity 
remains to be determined.
The recent discovery that the rat kidney cysteine conjugate (3-lyase enzyme is identical in 
both rat brain (Alberati-Giani et al., J. Neurochem. in press), and kidney (Mosca et al.,
1994) to kynurenine amino-transferase (KAT), has implicated this enzyme in 
neuromodulation and neurotoxicity. The tryptophan metabolites kynurenic acid and 
quinolinic acid (figure 1.16), interfere with glutamate excitatory receptors. These 
compounds influence ionotropic N-methyl-D-aspartate (NMDA) receptors in opposite 
ways, with kynurenic acid acting as an antagonist and quinolinic acid as an agonist at the 
glycine co-agonist site of NMDA receptors. The enzyme KAT/GTK/(3-lyase directs the 
tryptophan metabolites away from quinolinic acid metabolism, with the formation of 
kynurenic acid from L-kynurenine. The kynureninase enzyme (which also has (3-lyase 
activity), directs kynurenine metabolism towards quinolinic acid synthesis (figure 1.16).
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Figure 1.16: Kynurenine pathway from tryptophan (adapted from Stone, 1993)
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In the nervous system quinolinic acid is a powerful excitatory agonist and convulsant that 
activates the NMDA receptors (Stone and Burton, 1988). Direct infusion of quinolinic acid 
into brain causes a lesion that resembles that found in Huntington's disease and temporal 
lobe epilepsy (Schwarcz et al., 1988). It has been postulated that alteration of the balance 
between kynurenic acid and quinolinic acid may exert a neuromodulatory function and may 
lead to several neurological disorders such as Alzheimer's disease and Parkinsonism (for 
review see Stone, 1993).
An alteration in KAT activity would alter the balance of kynurenic and quinolinic acid, for 
example, inactivation of KAT would result in greater excitation of NMDA receptors due to 
a fall in the levels of the antagonist kynurenic acid, and would increase the levels of 
quinolinic acid as more kynurenine is available for metabolism by kynureninase. The 
overall imbalance may lead to neurodegenerative and psychiatric diseases (Stone and 
Burton, 1988; Holzman, 1993). Inactivation of KAT activity in the liver and brain, 
possibly by the alkylating products of (3-lyase metabolism, could profoundly affect the 
cerebral levels of kynurenine and its metabolites. Similarly inactivation of kynureninase 
would increase the cerebral levels of kynurenic acid, the consequences of which are not 
known.
In the cytosol fraction of rat brain, KAT, a single protein dimer, with a subunit mass of 
approximately 47kDa, appears to be responsible for kynurenic acid synthesis (Okuno et ah,
1990). As mentioned above this enzyme is identical to rat GTK/(3-lyase. Human brain 
contains two distinct aminotransferases, KAT I and KAT II, able to produce kynurenic add 
(Okuno et al., 1991; Schmidt et al., 1993). KAT I has been purified and characterised 
(Baran et al., 1994). The pure enzyme was found to be a dimer consisting of two identical 
subunits of approximately 60kDa. KAT I activity was substantially inhibited by L- 
glutamine, L-phenylalanine and L-tryptophan, using pyruvate as co-substrate. Polyclonal 
anti KAT I antibodies demonstrated that KAT I is distinct from KAT II. Additionally,
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immunological analysis using an antibody to rat brain KAT demonstrates that the rat and 
human KAT enzymes are distinct.
Although preferentially located in astroglial cells (Du et al., 1992), immunological studies 
have indicated that KAT is widely distributed in neurons of the rat CNS, (Schwarcz et al., 
1992; Roberts et al., 1992). The immunostaining in astroglial cells was diffuse and 
abundant, while in neurons the reaction product was punctate and confined to restricted 
intracellular compartments and the subtypes of neurons exhibited a striking difference in the 
number of immunoreactive regions present (Roberts et al., 1992). These studies have 
shown that KAT-containing astroglial cells frequently surround glutamatergic synapses, 
suggesting that kynurenic acid appears to be in an excellent position to modulate excitatory 
amino acid receptor function in the rat striatum. Additionally, the fact that kynurenic acid 
can freely enter the extracellular compartment after its production in glial cells (Turski et al., 
1989) gives rise to the possibility that local synaptic concentrations of kynurenic acid, may 
be sufficient to inhibit glutamatergic activity (Roberts et al., 1992).
As enzymes with (3-lyase activity are present in human kidney (Lash et al., 1990), brain 
(Cooper and Gross, 1977) and liver (Buckberry et al., 1994), the production of mutagenic, 
nephrotoxic, neurotoxic and hepatotoxic metabolites may occur in the kidney, brain and 
liver during trichloroethene metabolism, and therefore a risk of nephrotoxicity, 
neurotoxicity and hepatotoxicity may be associated with human exposure to trichloroethene 
exposure.
1.11.2.2 The role of GTK in the CNS
GTK has a broad substrate specificity (Cooper and Anders 1990), however, because of (a) 
the much higher glutamine concentration in tissues than that of other amino acid substrates 
(such as cysteine, cystathionine, methionine, homocysteine and phenylalanine), and (b) 
rapid removal of product a-ketoglutaramate by cyclisation or by co-amidase catalysed 
conversion to a-ketoglutarate, it is likely that the physiological substrate is predominantly
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glutamine. Cooper et al., (1993), suggest that the natural substrate of GTK in rat brain is 
glutamine and that the metabolism of glutamine through the glutaminase II pathway (ie., L- 
glutamine and a-keto acid, gives a-ketoglutarate, L-amino acid and ammonia) is an 
important function of the choroid plexus.
Makar et al., (1994) propose that a combination of the enzymes glutamine transaminase K, 
co-amidase, glutamate dehydrogenase and glutamine synthetase result in a cycling of 
glutamine and glutamate, with the net removal of ammonia (figure 1.17). Glutamine 
transaminases may have a salvage function for phenyl pyruvate, a-keto-y-methiolbutyrate 
and other a-keto acids which are formed in the cell. This salvage function thereby 
preventing a drain on essential amino acid carbon chains and sulphur, and/or removing 
some a-keto acids (eg., phenyl pyruvate, a-keto-y-methiolbutyrate), which may be toxic to 
the cell at elevated levels (Cooper, 1994). These enzymes therefore appear to play a role in 
the homeostatic metabolic mechanism for the preservation of amino acid balance in which 
glutamine, a dietary non-essential amino acid, functions to maintain the tissue levels of 
amino acids and to prevent loss of essential amino acid carbon chains.
A role for glutamine transaminase in the transport of amino acids across the inner 
mitochondrial membrane has also been postulated by Cooper, (1994), who suggests that a- 
keto acids formed on one side of the membrane by an a-ketoglutarate- or pyruvate-linked 
transaminase may be taken up by a carrier and reaminated on the other side by a glutamine- 
linked transaminase. This proposal remains to be investigated.
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L-glutamine + a-keto acid ^  w  a-ketoglutaramate + L-amino acid
co-amidase
a-ketoglutaramate + H20  ^  w  a-ketoglutarate + NH3
glutamate DH
a-ketoglutarate + NH4+ + NADH   L-glutamate + NAD+
glutamine synthetase
L-glutamate +NH3 + ATP % * L-glutamine + ADP + Pj
Figure 1.17: Proposed cycling of glutamine and glutamate, adapted from Makar et al., 
1994. GTK; glutamine transaminase K, DH; dehydrogenase.
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1.12 THE MECHANISM OF THE p-LYASE REACTION
Kynureninase and cysteine conjugate (3-lyase activities are both pyridoxal phosphate 
dependent. However, their reaction mechanisms are very different (Soda and Tanizawa, 
1979). Kynureninase results in a hydrolysis reaction (Figure 1.14b), whereas the 13- 
elimination reaction produces pyruvate, ammonia and thiol of the original compound 
(Figure 1.14a). Both reactions proceed through an eneamino acid intermediate, however, 
they differ in that the eneamino acid of the kynurenine cleavage has carbanion character at 
the (3-carbon, whereas, the eneamino acid from the (3-lyase reaction has carbonium ion 
character at the (3-carbon (Stevens et al., 1986c; Walsh, 1979).
(3-lyase is inactivated by its substrates, this apparent ‘suicide’ inactivation is accounted for 
by the electrophilic nature of the eneamine product of the (3-lyase reaction, which has 
carbonium ion character. Two mechanisms of enzyme inactivation, dependent on the 
unique nature of the eneamino intermediate of the (3-elimination reaction have been 
proposed: (a) Nucleophilic attack of an enzyme bound nucleophile on the (3-carbon of the 
eneamino acid intermediate (ReyleaeJ al., 1974; Wang and Walsh, 1978). (b) an aldol-type 
condensation reaction between an imino acid released following (3-elimination and the 
internal Schiff’s base formed by the S-amino group of an enzyme bound lysine and 
pyridoxal phosphate (Ueno et al., 1982; Likos et al., 1982).
Stevens et al., (1986a) carried out studies using LLC-PKi cells with DCVC as substrate, 
from which they proposed a reaction scheme for (3-lyase (Figure 1.18). They propose that 
when the free amino group of DCVC enters into a Schiffs base with PLP, two reactions are 
possible:
(1) (3-elimination with thiol formation
(2) Half transamination resulting in a pyridoxamine form of the enzyme.
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Figure 1.18: Reaction scheme for (3-lyase (adapted from Stevens et al., 1986a)
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(3-lyase activity is therefore regulated by concurrent transamination and is markedly 
increased by the addition of hydrophobic a-keto acids, eg., a-keto-y-methiolbutyrate. 
These pathways interact through a complex regulatory scheme; when an inadequate supply 
of a-keto acid (eg., pyruvate) is present, the transamination reaction regulates the rate of 13- 
elimination. This is due to the accumulation of the enzyme in the pyridoxamine phosphate 
form after the half transamination. Subsequent (3-elimination is inhibited as substrates eg., 
DCVC cannot form a Schiffs base with the pyridoxamine enzyme, a-keto acids stimulate 
the (5-elimination reaction by converting the pyridoxamine phosphate form of the enzyme to 
the pyridoxal phosphate form (by acting as amino group acceptors), which is then 
competent to catalyse (5-elimination reactions.
Stevens et al., (1986a), have proposed that the regulation of (3-elimination by the competing 
transamination pathway is different for each substrate and that multiple (3-lyases may exist 
in rat kidney. Work by Stevens et al., (1989), has demonstrated that 65% of the DCVC 
administered to rats, is metabolised to its corresponding a-keto acid (S-(l,2-dichlorovinyl)- 
2-oxo-3-mercaptopropionate), 35% of the a-keto acid is produced by the transaminase 
activity of (5-lyase and the remaining 30% by the enzyme L-a-hydroxy acid oxidase.
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1.13 THE MECHANISM OF THE TRANSAMINASE ENZYMES
The prosthetic group of all transaminases is pyridoxal phosphate (PLP), which is derived 
from pyridoxine (vitamin B6). During transamination (figure 1.19), pyridoxal phosphate is 
transiently converted to pyridoxamine phosphate (PMP) (Walsh, 1979);
(1) In the absence of substrate, the aldehyde group of PLP is in Schiff-base linkage with 
the s-amino group of a specific lysine residue at the active site.
(2) The a-amino group of the amino acid substrate displaces the E-NH2  group of the active 
site. The amino acid Schiff base that is formed remains tightly bound to the enzyme by 
non-covalent forces.
(3) During catalysis, the double bond in the amino acid-PLP Schiff-base linkage shifts 
position to form a ketimine which is then hydrolysed to (4) PMP and an a-keto acid.
The second half of the reaction occurs by a reversal of steps 1 to 4, a second a-keto acid 
reacts with the enzyme-PMP complex to yield a second amino acid and regenerate the 
enzyme-PLP complex.
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1.14. AIMS OF THIS RESEARCH
The role of rat kidney cysteine conjugate (3-lyase in the bioactivation of certain halogenated 
alkene cysteine conjugates and the production of nephrotoxic thiols has been well 
established (Commandeur and Vermeulen 1990). An understanding of the structure and 
function of (3-lyase enzymes and their selectivity towards xenobiotic cysteine conjugates 
will assist in the prediction of chemical toxicity of compounds metabolised by this 
pathway. The potential for human exposure to these compounds has focused interest on 
human kidney and brain (3-lyase activities, particularly in terms of structure-activity 
relationships. However, attempts to compare activities between rat and human have not 
been performed with purified enzyme. In order to fully understand the mechanisms of 13- 
lyase in halogenated alkene induced toxicity, and to determine the structure-activity 
relationships for the rat and human enzymes, it was decided that rat kidney (3-lyase should 
be studied at a molecular level.
A truncated rat kidney (3-lyase cDNA of 746bp had previously been isolated by Dr. Miles 
Schofield (PhD thesis, 1993, University of Surrey), from a Wistar rat kidney cDNA library 
in the expression vector kgt 11, by screening with a desorbed monospecific sheep 
polyclonal antibody (MacFarlane et al., 1989) against purified rat kidney cytosolic cysteine- 
conjugate (3-lyase. The aim of the work in this thesis was to isolate a full-length rat kidney 
(3-lyase cDNA as a first step in the isolation of the corresponding human kidney cDNA. 
Subsequent expression of the rat and human kidney cDNAs in COS-1 tissue culture cells 
would enable a comparison of their corresponding enzyme activities to be made. 
Additionally, reverse transcriptase PCR analysis of (3-lyase mRNA expression in rat brain 
could be performed, using oligonucleotide primers to the 5' and 3' non-coding regions of 
the rat cDNA.
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 INTRODUCTION
The experimental procedures used throughout this investigation are described within this 
chapter in detail. Where a procedure is common to more than one of the protocols it is 
described in section 2.3. Recipes for the buffers, media and solutions used, appear in 
alphabetical order in appendix I. Where procedures used are modifications of previously 
reported methods, the original references are given. A brief discussion of the major 
principles of each method is given, followed by details of the procedure.
2.2 MATERIALS
Where enzymes and kits are used, the suppliers are given in the appropriate methods 
sections, as are the suppliers of commercially available reagents and equipment.
2.2.1 Chemicals
All chemicals purchased were of the highest purity available and unless otherwise stated 
were supplied by BDH Chemicals Ltd.
Agarose: Boehringer Mannheim GmbH.
5, Bromo-4 chloro-3-indoyl-p-D galactosidase (X-Gal), IPTG: Cal biochem.
Decon 90: Fisons.
NuSieve® GTG® Agarose FMC BioProducts; Flowgen Instruments Ltd.
Phenol (Tris-HCl buffer saturated, pH 7.4) trypsin (0.125% (w/v))/EDTA (ImM): Gibco 
BRL.
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30% (w/v) acrylamide solution, 2% (w/v) N',N' methylene bis acrylamide solution: 
National Diagnostics.
Agar N° 1, Bacto tryptone, PBS (Dulbecco 'A'), yeast extract: Oxoid Ltd. 
DEAE-dextran(Mr 500,000), Ficol 400: Pharmacia.
Easigel (6% (w/v) acrylamide, 0.3% (w/v) bis acrylamide, 7M urea, lx  TBE): Scotlab.
a-keto-y-methiol-butyric acid (a-KMB), ampicillin, bovine serum albumin (BSA) protein 
standard, bromophenol blue, citric acid (trisodium salt), 4-chloronapthol, chloroquine, 
DMSO (ACS) reagent, ethylenediaminetetraacetic acid (EDTA), ethidium bromide, Folin- 
Ciocalteu reagent, formaldehyde, formamide, glutathione, lauryl sulphate (sodium dodecyl 
sulphate), 3[N-morpholino] propane sulphonic acid (MOPS, free acid), p-nicotinamide 
adenine dinucleotide (p-NADH), L-phenylalanine, polyvinylpyrollidone, SDS-7B pre­
stained protein markers, sodium chloride, spermidine trihydrochloride, N,N,N',N'- 
tetramethylethylenediamine (TEMED), Trizma™ base (Tris[hydroxymethyl] amino- 
methane), xylene cyanol: Sigma Chemical Company.
2.2.2 Radiochemicals
All procedures involving the use of radiochemicals were carried out in accordance with the 
guidelines set out in the 'Local Rules for Protection against Ionising Radiation', published 
by the University of Surrey Safety Office.
Deoxycytidine 5'-[32P] triphosphate, tri ethyl ammonium salt. Specific activity 
approximately 3000 Ci/mmol., ICN Flow.
Deoxyadenosine 5'-[35S] thiotriphosphate, triethylammonium salt. Specific activity 
approximately 1000 Ci/mmol., ICN Flow.
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2.2.3 Antibodies
(I) The antibody to rat kidney cytosolic (3-lyase was kindly supplied by Dr. Marion 
MacFarlane, University of Surrey (MacFarlane et al., 1989). The p-lyase antibody was 
raised in a female Soay Tan sheep subsequent to an intradermal injection of the 
electrophoretically homogeneous antigen prepared from rat kidney cytosol. The antigen 
was administered in an emulsion of Freund's complete adjuvant containing heat killed BCG 
mycobacteria. A booster containing 125/*g of antigen was carried out after 12 months, and 
the antisera was purified as detailed in MacFarlane et ah, (1989).
(II) Biotinylated anti-sheep IgG (H and L), raised in rabbit and affinity purified (1.5mg/ml 
in PBS/glycerol), was obtained from Sera Lab .
(III) Streptavidin-biotinylated-horseradish peroxidase (HRP) complex (55 peroxidase 
units/ml). An affinity isolated antigen specific antibody solution in 0.01M PBS, pH 7.4, 
containing 1% (w/v) BSA and 0.01% (w/v) thimerosal) was obtained from Sigma.
2.2.4 Cloning vectors 
Bacteriophage:
XgtlO and A,gtll are two bacteriophage strains commonly used for library screening. 
XgtlO is used where some information about the DNA sequence is known enabling 
hybridisation probing. Xgtll is able to express the cDNA insert as polypeptide and is used 
when there is no knowledge of the DNA sequence and library screening is performed using 
a purified antibody to the protein encoded by the cDNA of interest. Restriction maps of 
bacteriophage XgtlO and Xgtll are shown in figures 2.1 and 2.2 respectively.
Plasmids
The plasmids pGEM®-7Zf(+), pUSlOOO and pCR™II were used in several of the cloning 
techniques described in this chapter. Maps of these plasmids are shown in figures 2.3, 2.4 
and 2.5 respectively.
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S ea l 1872
pGEM®-7Zf(+)
p lasm id
nnnnhn'i
lacZ
T7 i
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Apa I 14
Aafll 20
Sph I 26
Xba I 31
Xho I 37
EcoR I 43
Kpn I 53
Sma I 56
Csp 45 I 61
Cla I 67
Hind III 72
BamH I 78
Sac I 91
SsrXI 100
Nsi I 109
t  SP6 123
pGEM-7Zf(+) v ecto r c ircle  m ap .
T7 Transcription Start
I-------—^
5 ' .  . . TGTAA TACGA CTCAC TATAG GGCGA ATTGG GCCCG ACGTC GCATG CTCCT CTAGA
T7 Prom oter ! I I________ ! I________ I I________I
Apa I Aar II Sph I Xba\I
CTCGA GGAAT TCGGT ACCCC GGGTT CGAAA TCGAT AAGCT TGGAT CCGGA
Xho I EcoR I Kpn I Sma I C sp 4 5 1 Cla I Hind III 6am H I
SP6 Transcription Start 
^  1
GAGCT CCCAA CGCGT TGGAT GCATA GCTTG AGTAT TCTAT AGTGT CACCT AAAT . . .  3 '
I------------ 1 I 1 I_______ I SP6 Prom oter
Sac I B stx  I Nsi I
Figure 2.3: Plasmid vector pGEM®-7Zf(+), promoter and multiple cloning site 
sequences are indicated.
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EH
AMP
B
Figure 2.4: Expression vector pUSlOOO (Jackson et.al., 1992), HCMV.P-E = human 
cytomegalovirus promoter-enhancer element, AMP= ampicillin resistance, MCS = multiple 
cloning site, B = BamHl, E = EcoRl, H = Hindlll, arrow indicates the direction of 
transcription.
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M l3 Reverse Primer  Sp6 Promoter
CAG GAA ACA GCT ATG A c jc  ATG ATT ACG CCA AGC T| AT TTA GGT GAC ACT ATa] GAA 
GTC CTT TGT CGA TAC TG|G TAC TAA TGC GGT TCG A TA AAT CCA CTG TGA TATI CTT
Nsil Hindlll Kpnl Sacl BamHI Spel
TAC TGA AGC TAT GCA TCA AGC TTG GTA CCG AGC TCG GAT CCA CTA GTA ACG GCC 
ATG AGT TCG ATA CGT AGT TCG AAC CAT GGC TCG AGC CTA GGT GAT CAT TGC CGG
BstXI EcoRI
GCC AGT GTG CTG GAA TTC GGC TT  
CGG TCA CAC GAC CTT AAG CCG
EcoRI
[A GCC GAA TTC TGC AGA TAT 
____________________ IT T  CGG CTT AAG ACG TCT ATA
Aval 
PaeR7l
BstXI Notl Xhol Nsil Xbal Apal
CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG 
GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC
CCC TAT 
GGG ATA
T7 Promoter
AGT GAG TCG TAT TA 
TCA CTC AGC ATA AT
CAAT TCA 
GTTA AGT
M13 (-201 Forward Primer
CTG GCC GTC GTT TTA C 
GAC CGG CAG CAA AAT G
AA CG 
TT GC
M13(-401 Forward Primer
T CGT GAC TGG GAA AAC
A GCA CTG ACC CTT TTG
pCR
3.9 kb
Figure 2 .5 : Plasmid vector pCR™II; restriction sites, promoter sequences and primer 
sequences of the multiple cloning site are indicated.
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2.2.5 Bacterial strains
The E.coli bacterial strains used for propagation of bacteriophage and plasmid vectors are 
shown in table 2.1.
2.2.6. cDNA libraries and hybridisation probes
2.6.6.1 cDNA libraries
Rat kidney cDNA library in Xgt 10 (RL103la):
Cloning vector: XgtlO (figure 2.1)
Cloning site: EcoRI 
Priming method: Oligo(dT)
Host Strain C600 Hfl
mRNA Source: Adult male Sprague-Dawley kidney
Human kidney cDNA library in Xgt 10 (HL1123a):
Cloning vector: A,gtlO (figure 2.1)
Cloning site: EcoRI
Priming method: Oligo(dT) and random primed 
Host Strain C600 Hfl
mRNA Source: 20 year old Caucasian female, cause of death: trauma
Human kidney cDNA library in Xgt 11 (HL3001b):
Cloning vector: 7-gtll (figure 2.2)
Cloning site: EcoRI
Priming method: Oligo(dT) and random primed 
Host Strain Y 1090
mRNA Source: 55 year old black female, cause of death: trauma
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Strains Use of strain Genotype
C600 HF1 Host for XgtlO supEM hsdR thi-1 thr-1 
leuB6 lacY 1 ton A l l
Y1090 Host for Xgt 11 Mac U169 pro A+ Alonara 
D139 str A sup FtrpC22: 
TnlO(tetr) pMC9
JM109 Supports the replication of 
pUSlOOO and 
pGEM®-7Zf(+)
recAl supEAA end A l  
hsdRllgyrA96 relAl 
thi A(lac-proAB)
F’ [traD3 6proAB+lacIQ 
lacZMAl5\
INVaF' Supports the replication of 
pCR™II
endA l, rec A l ,  
hsdRl7(r-k, m+k), supEAA, 
X-, thi-1, gyr A, relA l, 080 
fecZa AM 15A( lacZY A- argF), 
deoR=F'
Table 2.1: E.coli strains and their genotypes
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2.2.6.2 cDNA hybridisation probes
Rat kidney cytosolic cysteine conjugate (3-lyase cDNA probe (i): A 0.75kb cDNA (ppl-1.0), 
isolated from a rat (Wistar) kidney cDNA library in Xgt 11, was kindly supplied by Dr. 
Miles Schofield (Perry et al., 1993).
Rat kidney cytosolic cysteine conjugate (3-lyase cDNA probe (ii): A 1.8kb cDNA (p(3l-2.0) 
was isolated from a rat (Sprague Dawley) kidney cDNA library in XgtlO (RL1031a) using 
rat probe (i) above (Perry et al., 1993, work reported in this thesis).
Human kidney cytosolic cysteine conjugate (3-lyase cDNA probe (i): A 1.2kb cDNA (ph(3l-
1.0) was isolated from a human kidney cDNA library in XgtlO (HL1123a) using rat probe 
(ii) above (work reported in this thesis).
Human kidney cytosolic cysteine conjugate (3-lyase cDNA probe (ii): A 1.5kb cDNA (ph(3l-
2.0) was isolated from a human kidney cDNA library in XgtlO (HL1123a) using rat probe 
(ii) above (work reported in this thesis).
2.2.7 Tissue culture cells
COS-1 monkey kidney cells were used to support the expression of rat and human (3-lyase 
cDNAs cloned into the expression vector pUSlOOO (Jackson et ah, 1992). COS-1 cells 
originate from African green monkey kidney CV-1 cells (Gluzman, 1981). The CV-1 cells 
were transformed by an origin defective mutant of SV-40 which codes for wildtype T 
antigen, to produce the stable COS-1 cell line which expresses SV-40 T antigen and will 
replicate SV-40 ori containing plasmids.
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2.3 GENERAL PROCEDURES
Those methods routinely used in a number of procedures are described below and will be 
referred to when necessary.
2.3.1 Sterilisation by autoclaving
Glassware, plasticware and all solutions prepared for use in nucleic acid procedures, were 
sterilised using an RSI series 32 automatic autoclave. Sterilisation was for 20 min at 121°C 
at a pressure of 15 lb/in2. Water was treated with DEPC (final concentration of 0.1% 
(v/v)), stirred for lhr and autoclaved to destroy any nucleases present.
2.3.2 Quantitation of nucleic acids in solution
A number of procedures require very pure nucleic acid samples as well as accurate nucleic 
acid concentration measurements. The purity and concentration of nucleic acids in aqueous 
solutions was determined by measuring the UV absorbance of the solutions over the 
wavelength range of 200-300nm. The samples were blanked against water and calculated 
using the following equations (Sambrook et al., 1989):
Nucleic acid cone11 = A2 6 O x dilution x 33000 / number of nucleotides x 330 
(pmol//d)
where the average molecular weight of a nucleotide = 330
Nucleic acid cone11 = A2 6 O x dilution x 1 absorbance unit (/<g/ml) /1000 
Q*g//d)
where 1 absorbance unit (A2 6 0 ) = 50/^g/ml dsDNA
40/<g/ml RNA 
20/<g/ml oligonucleotides
Nucleic acid Purity (A26O/A28O) = 1.8 for pure DNA
2.0 for pure RNA
Impurities such as protein, salt and phenol will decrease the ratios
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2.3.3 Restriction enzyme digests
A large number of type II restriction enzymes have been isolated from bacteria. These 
endonucleases recognise specific palindromic DNA sequences of, in general, four to six 
nucleotides, and cut the DNA between two specific bases within the target sequence. These 
enzymes have been crucial to the development of recombinant DNA procedures. Different 
enzymes have optimal activity in specific salt concentrations, therefore, restriction enzymes 
are provided with specific buffers. Spermidine is used (final concentration of 4mM) in 
restriction enzyme digests as it prevents non-specific digestion (star activity) and stabilises 
the net negative charge of the DNA. Unless otherwise specified restriction enzyme digests 
were carried out as follows:
1 pig of DNA was digested in a microcentrifuge tube, using 1/d of enzyme, in a total 
volume of not less than 10X the volume of enzyme used (enzymes are stored in glycerol 
which will interfere with enzyme activity if not sufficiently diluted). Appropriate volumes 
of 10X enzyme reaction buffer and 10X spermidine were included in the mixture. After 
incubation at 37°C for a minimum of 90 min, preferably overnight, the sample was 
analysed by 1% (w/v) agarose gel electrophoresis (see section 2.3.4).
A typical reaction mixture: H2 O 18/d
Buffer (10X) 
Spermidine (40mM)
2.5/d
2.5/d
1/d
1/d
25/d
DNA(l//g//d)
Enzyme
Total volume
Enzymes used in this study are listed in table 2.2.
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Enzyme Recognition Sequence *Buffer Supplier
EcoR! GAAATTC R3 Gibco BRL
Avail GAG(A/T)CC R2 Gibco BRL
Sma I CCCAGGG R4 Gibco BRL
Xba I TACTAGA R2 Gibco BRL
S s tl GAGCTAC R2 Gibco BRL
Apa I GGGACCC R4 Gibco BRL
Ban I GAG(T/C)(A/G)CC G Promega
Table 2.2: A table of the restriction enzymes used in this study, the recognition sequences 
and the reaction buffers for optimum digestion. Arrows indicate cutting site. * see appendix 
for buffer concentrations.
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2.3.4 Agarose gel electrophoresis
Agarose gel electrophoresis is a procedure used for the analysis of DNA and RNA 
samples. With the use of standard markers it provides an indication of the nucleic acid 
concentration and enables a fairly accurate estimate of nucleotide length. The negatively 
charged nucleic acid samples are loaded into sample wells, an electric current is passed 
across the length of the gel resulting in movement of the molecules toward the positive 
electrode (anode). The smaller molecules travel more easily through the gel matrix, whilst 
the larger molecules are retarded, thus they separate according to size.
2.3.4.1 Agarose gel electrophoresis of DNA
Agarose gel electrophoresis of DNA was carried out using the standard method described 
by Sambrook et al., (1989). The percentage of agarose used was dependent on the sizes of 
the DNA to be separated. Agarose gels of 0.7-4% (w/v) were prepared in TAE buffer. For 
most purposes 1% (w/v) agarose was used, however, for DNA greater than 9kb, 0.7% 
(w/v) agarose gels were used. PCR products are generally 0.1-1.0kb and require a higher 
percentage gel to clearly resolve the DNA bands. Generally, 4% (w/v) agarose gels (1% 
(w/v) agarose, 3% (w/v) NuSieve® GTG® Agarose) were used for PCR products. DNA 
markers of appropriate size were run along side the samples in order to estimate the size of 
the DNA molecules. 0X174 phage DNA Hae III fragments (Promega Corporation) were 
used to size molecules between 0.2 and 1.3 kb in length, and KHind III phage DNA 
fragments (Promega Corporation) were used for sizing DNA molecules between 0.6 and 9 
kb in length. 3/d (greater than 0.1X the sample volume) of DNA dye (10% (w/v) 
bromophenol blue, 40% (w/v) sucrose) was added to the samples (25/d), and heated to 
65°C (to denature tertiary structure or aggregations) for 4 min prior to loading of the gel. 
The gel was run at 150mA at room temperature until the bromophenol blue dye was 
approximately three quarters along the gel. The DNA was visualised as in section 2.3.5.
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2.3.4.2 Agarose gel electrophoresis of RNA
RNA was electrophoresed in formaldehyde denaturing gels as described by Sambrook et 
al., (1989). 10ml of 10X RNA electrophoresis buffer and 75ml DEPC-treated water were 
added to lg  agarose and the mixture was boiled until the agarose dissolved. After cooling 
to 50°C, 15ml of formaldehyde was added, the solution was mixed and the gel was poured 
(final concentration 1% (w/v) agarose). The RNA sample was denatured by heating to 65 
°C for 5 min in the following mixture: 6/d of RNA sample (20/<g), 12.5/d deionised 
formamide, 4/d formaldehyde and 2.5/d RNA electrophoresis buffer (10X). 3/d of RNA 
dye (4% (w/v) bromophenol blue, 4% (w/v) xylene cyanol and lOmM EDTA, pH 8.0 in 
50% (v/v) glycerol) was added after heating. The gel was run at room temperature at 
100mA until the bromophenol blue marker reached approximately three quarters along the 
gel. The RNA was visualised as in section 2.3.5.
2.3.5 Visualisation of nucleic acids in agarose gels
Ethidium bromide is a dye routinely used to visualise nucleic acids in agarose gels. The 
ethidium bromide intercalates into the nucleic acid molecules, and upon exposure to UV 
light the UV radiation is absorbed by the ethidium bromide at 300nm and is re-emitted at 
590nm in the red/orange region of the visible spectrum. The nucleic acids can be seen as 
brightly staining orange bands on the gel. The gels were immersed in 3/<g/ml ethidium 
bromide solution in TAE buffer for 10 min with shaking and excess stain removed by 
washing in TAE for a further 10 min, or longer if necessary. The nucleic acids were 
visualised on a transilluminator (model TM20, Genetic Research Instrumentation Ltd).
2.3.6 Photography
Ethidium bromide stained agarose gels were photographed through an orange filter using a 
Polaroid Land Speed MP-4 camera and Polaroid type 665 (positive/negative film) or type 
667 (positive only film). The film was exposed for 13 sec with an aperture or f4.5 (type 
665 film) or f32 (type 667 film). Negatives were soaked in water for 30 min and air dried.
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2.3.7 Recovery of DNA from Agarose gels
After electrophoresis of DNA samples on an agarose gel (section 2.3.4.1), and ethidium 
bromide staining (section 2.3.5), the bands of interest were excised from the gel using a 
sterile scalpel and then purified using the Geneclean II® kit (Stratech Scientific) based on 
the iodide/glass bead method of Vogelstein and Gillespie (1979). This procedure is 
effective for the purification of small samples of DNA from agarose gels. The range of 
DNA fragments for which this method may be used is lOObp to lOkb.
The excised band was placed into a 14ml Greiner tube (polycarbonate) and 3 volumes of 
Nal solution was added. The agarose was melted by placing the tube in a 45-55°C 
waterbath with occasional mixing. 1/d of glass milk® (silica matrix) was added for each pig 
of DNA in the gel (with a minimum of 5/d) and the mixture was incubated on ice for 15 
min, mixing every 1-2 min. The mixture was transferred to 1.5ml microcentrifuge tubes 
and centrifuged for 10 sec at 13000 x g. The supernatant was removed and the pellet 
washed with 700/d of ice cold NEWwash solution, re-centrifuged for 10 sec and the 
supernatant removed. This was repeated twice. After the final wash, 10/d of sterile Milli Q 
water was added to the pellet and heated to 55° C for 3 min to elute the DNA from the 
matrix. The tube was centrifuged for 10 sec at 13,000 x g and the supernatant transferred to 
a new tube. A further 10/d of sterile Milli Q water was used to elute the remaining DNA 
from the silica matrix. 2/d of the eluant was run on a 1% (w/v) agarose gel (section 
2.3.4.1) to determine the purity and to estimate the concentration of the fragment.
2.3.8 DNA purification by phenol extraction
Phenol extraction was used in order to purify DNA from proteins, SDS and agarose. An 
equal volume of cold (4°C) TE-saturated phenol (pH 8.0) was added to the aqueous 
solution and vortexed for 1 min to form an emulsion. This was centrifuged at 10,000 rpm 
(12,900 x g), 4°C for 5 min in a Beckman J2-21 centrifuge. Alternatively, small volumes 
(up to 1.5ml) were centrifuged in a microfuge at 14,000 x g for 5 min. After centrifugation 
the lower, organic phase contained agarose, SDS and proteins (where large quantities of
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protein were present a white band of protein precipitate was observed at the interface), 
whereas the DNA remained in the aqueous supernatant. The supernatant was removed and 
extracted with TE-saturated phenol a further two times or until the protein interface 
disappeared. The resulting supernatant was further extracted once with phenol/chloroform 
(1:1 (v/v)), followed by chloroform/isoamyl alcohol (24:1 (v:v)) to remove the residual 
phenol.
2.3.9 Ethanol precipitation of nucleic acids
Precipitation of DNA from an aqueous solution was used in order to concentrate the DNA 
or to purify it subsequent to alkaline denaturation or enzyme modification procedures. 0.5 
volumes of 7.5M, ammonium acetate was added to the aqueous DNA solution which was 
vortexed briefly to mix the solutions, 2 volumes of ice cold (-20°C) absolute ethanol 
(96.8% (v/v)) was added, mixed and incubated at -70°C for 30 min to precipitate the DNA. 
The precipitated nucleic acids were pelleted by centrifugation at 12900 x g (10,000 rpm, 
J2-21 Beckman centrifuge or 14,000 rpm microcentrifuge) for 20 min. The supernatant 
was removed immediately and the pellet washed with 70% (v/v) ethanol to dissolve any 
remaining salt and centrifuged as above for 5 min. The pellet was either air dried or more 
rapidly dried by heat under vacuum in a Univap apparatus (section 2.3.10).
2.3.10 Drying DNA samples by heat under vacuum
The Univap centrifugal evaporator (Uniscience Ltd) is a low speed centrifuge which dries 
samples by heating them under a vacuum. Two rotors are available to take either 1.5ml 
microcentrifuge tubes, or 14ml polycarbonate tubes (Greiner). The rotor was pre-warmed 
to 45°C, the tubes were added, and the vacuum applied (Aquavac vacuum pump, 
Uniscience Ltd) once the centrifuge reached 1000 rpm (500 x g). The maximum speed of 
the rotor is approximately 2000 rpm (1100 x g) and samples of 25/d are dry after 10-15 
min.
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2.3.11 Autoradiography
For all procedures, Kodak X-Omat AR high speed X-ray film was used. For 
autoradiography of 35S sequencing gels, the film was placed over the dried gel in a film 
cassette (X-ray accessories Ltd) and exposed for 1-2 days at room temperature. For 
autoradiography using 32P, the moist filters/membranes were enclosed between two pieces 
of thin plastic, and placed in a film cassette with an intensifying screen (Croner Lightening 
Plus intensifying screen). The film was exposed for an appropriate amount of time 
(depending upon the maximum CPS, measured by a Geiger Counter) at -70°C. After 
exposure the films were returned to room temperature and developed, fixed, washed and 
dried in an automatic film processor (Fuji medical film processor RGII). The chemicals 
used were RG developer and RG fixer supplied by Wardray Products Ltd.
2.4 cDNA LIBRARY SCREENING
2.4.1 Library titration
The appropriate strain of E. coli (section 2.2.5) was streaked from a glycerol stock onto an 
LB agar plate and incubated overnight at 37°C. A single colony was picked and used to 
inoculate 10ml of LB broth containing 0.2% (w/v) maltose (maltose addition is required for 
proper receptivity of cells to phage) and lOmM MgSC>4 , which was incubated overnight (or 
until stationary phase was reached) in a shaking incubator.
The library was diluted in duplicate from 1 X106 to 1 XIO10 plaque forming units (PFUs) 
in SM buffer (X diluent), and 100/d of each dilution was added to 100/d of the E.coli 
culture above. After mixing they were incubated for 20 min in a 37°C waterbath during 
which time the bacteriophage adsorb to bacterial cells. The addition of MgSC>4 (final 
concentration of lOmM) greatly enhances the adsorption process. For each dilution, 3ml of 
molten (48°C) top agarose was added to the adsorption mixture, mixed by inversion and 
poured onto a pre-warmed LB plate (9 cm diameter). After the agarose had set the plates 
were inverted and incubated at 37°C overnight or for a minimum of 8 hr. The plaques were 
counted and the titre (PFU/ml) was determined.
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2.4.2 Library plating and filter replicas
In order to screen 1X105 bacteriophage, 100/d of a 1X106 dilution of bacteriophage 
(2.4.1) was added to 1.5ml of E.coli, and incubated at 37°C for 20 min. 30ml of top 
agarose was added to the mixture and poured onto a 22cm x 22cm LB-agar plate 
(containing 150 ml of LB-agar). After the agarose had set the plate was inverted and 
incubated overnight at 37°C. The plates were chilled at 4°C for 1-2 hr to harden the top 
agarose. A Hybond N™ nylon membrane (Amersham) was carefully positioned on the 
plate (ensuring no air bubbles) and left for 1 min for the transfer of bacteriophage to the 
filter. The position of the filter on the plate was marked using a syringe needle, and the 
filter carefully removed and floated DNA side up, on top of a DNA denaturing solution 
(1.5 M NaCl, 0.5 M NaOH) for 30 seconds and then immersed for 60 sec. The filter was 
removed and placed DNA side up in a neutralising solution (1.5 M NaCl, 0.5 M Tris-HCl, 
pH 8.0) for 5 min. The filter was briefly rinsed in 3X SSC, and placed on Whatman 3MM 
paper to air dry. A duplicate filter was prepared by the same procedure, however, this filter 
was left on the plate for 3 min. The second filter was marked in the same positions as the 
first. The air dried filters were baked at 80°C for 10 min, and the DNA was fixed to the 
nylon membrane filter by UV crosslinking, which required exposure to UV irradiation for 
3 min on a UV transilluminator (model TM20, Genetic Research Instrumentation Ltd).
2.4.3 Preparation of 32P labelled cDNA probes
cDNA probes were labelled with 32P using the Amersham Megaprime™ DNA labelling 
system. This procedure, based on the method of Feinberg and Vogelstein (1983 & 1984) 
randomly primes DNA synthesis from the cDNA template using random nonomers. 32P 
labelled dCTP is incorporated along with cold dNTPs using the Klenow fragment 
(exonuclease free) of DNA polymerase.
25-50ng (5/d) of the cDNA template was boiled for 5 min with 5/d of primer mixture, the 
tube centrifuged to collect the contents and 10/d of labelling buffer (containing unlabelled 
dNTPs) was added. 23/d of sterile Milli Q water, 2/d of enzyme (Klenow) and 5/d of 32P
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dCTP (1.85 Mbq, specific activity 3000 Ci/mmol) were added. The mixture was incubated 
at 37°C for exactly 10 min and the reaction stopped with 5/d of 0.2M EDTA. 
Unincorporated nucleotides were removed using Pharmacia NICK™ columns (Pharmacia 
LKB). The column (Sephadex G-50) was equilibrated using 3.33ml of NICK column 
buffer, and the reaction mixture was applied directly to the top. 400/d of NICK buffer was 
added to the column and the eluate discarded. 600/d of NICK buffer was added and the 
eluate, containing the labelled probe was retained in a screw cap microcentrifuge tube, the 
unincorporated nucleotides remaining on the column. The probe was boiled for 5 min and 
added to the hybridisation buffer (section 2.4.4).
2.4.4 DNA hybridisation Screening
2.4.4.1 DNA hybridisation with homologous-species probes
The Hybond N™ membranes were placed between two layers of bolting cloth in a 
Hybaid™ hybridisation bottle. The membranes were pre-wetted with 5X SSC and 
prehybridised in hybridisation solution (approximately 1ml of hybridisation buffer per 
square cm of filter), in a Hybaid incubator and rotisserie, for a minimum of 6 hr at 65°C. 
This ensured that all non specific binding sites were blocked. The hybridisation buffer was 
transferred into a 50ml Falcon tube, the boiled 32P labelled cDNA probe (section 2.4.3) 
was added to the buffer, and the buffer returned to the hybridisation bottle. The filters were 
hybridised at 65°C in the rotisserie oven overnight.
2.4.4.2 DNA hybridisation with cross-species probes
Where hybridisation was across species, deionised formamide was present in the 
hybridisation buffer. Deionised formamide reduces the melting temperature (Tm) of nucleic 
acid hybrids and enables hybridisation to be performed at lower temperatures. Lower 
hybridisation temperatures are less stringent and therefore allow for some nucleotide 
mismatching, and is important when probing with cDNAs of different species as their 
similarity will be less than 100%. The hybridisation method used was the same as in
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section 2.4.4.1, except that 50% (v/v) deionised formamide was included in the 
hybridisation buffer and the hybridisation temperature was lowered to 42°C.
2.4.5 Washing of hybridised filters
Moderate stringency washing conditions were used for the majority of hybridisation 
experiments, and are described below. However, where this was not appropriate, 
alternative conditions are given in the relevant sections.
1. 2 x 15 min washes at room temperature in 2 X SSC/0.5% (w/v) SDS.
2. 2 x 30 min washes at 42°C in 1 X SSC/0.1% (w/v) SDS.
3. 2 x 30 min washes at 65°C in 1 X SSC/0.1% (w/v) SDS.
If the background radioactivity remained high, the stringency was raised by lowering the 
salt concentration to 0.1 X SSC and washing for a further 30 min at 65°C. The filters were 
rinsed in 5 X SSC at room temperature and autoradiographed (section 2.3.11).
2.4.6 Purification of positive plaques
After autoradiography the positions of the filters were marked on the autoradiograph. The 
library plate was aligned with the autoradiograph and positive plaques picked using the tip 
of a glass Pasteur pipette. The plug of agar removed from the plate was placed in 1ml of 
SM buffer with one drop of chloroform and left at room temperature for 2 hr for the phage 
to diffuse into the buffer. The phage were diluted so that they formed a semi-confluent 
lawn on 90mm diameter agar plates, using the plating procedure above (section 2.4.2). 
Filter replicas (section 2.4.2) were prepared and processed as above (sections 2.4.3, 2.4.4, 
2.4.5). Plaque purification by hybridisation screening was performed at least a further two 
times until all the plaques on the plate were positive.
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2.4.7 Preparation of recombinant bacteriophage DNA
Two confluent lawns of bacteriophage were prepared (section 2.4.2) for each plaque 
purified positive clone using 150mm diameter plates. The plates were placed on a rotatory 
shaker, 25ml of SM buffer was added and incubated for 6 hr at room temperature to elute 
the phage. The buffer from duplicate plates was pooled in 50ml Falcon tubes. 50/d of 
chloroform was added to each tube and incubated at 37°C for 30 min to kill the bacteria, 
which were subsequently removed by centrifugation at 1,600 x g for 10 min. The 
supernatant was decanted into a polycarbonate centrifuge tube, DNase I was added to a 
final concentration of lpg/ml and incubated at 37°C for 30 min to destroy the bacterial 
DNA. The bacteriophage were lysed in 15ml of X bacteriophage lysis buffer at 70°C for 15 
min and cooled on ice. 11ml of 8M potassium acetate was added, and incubated on ice for 
15min to precipitate the proteins. The precipitate was removed by centrifugation in a 
Beckman J2.21 centrifuge at 13000 x g for 30 min. The supernatant was added to 35ml of 
isopropanol and after incubation at room temperature for 1 hr, was centrifuged again at 
13000 x g for 30 min. The pellet was resuspended in 2.5ml of water and incubated with 
RNase A (DNase free) at a final concentration of lpg/ml for 15min at 37°C, and for a 
further 15 min with proteinase K at a final concentration of 50pg/ml. The samples were 
phenol extracted, ethanol precipitated and dried as in sections 2.3.8, 2.3.9 and 2.3.10 
respectively. The DNA was resuspended in 100/d of sterile Milli Q water and a 5/d sample 
was analysed on a 1% (w/v) agarose gel (section 2.3.4.1).
2.4.8 Analysis of the bacteriophage cDNA inserts
lOpig of DNA sample (section 2.4.7) was digested at 37°C overnight with the restriction 
enzyme EcoRl:
REact 3 buffer 6 /d
Spermidine 40mM 6 /d
DNA
EcoRl (lOU/pl) 
Milli Q water
1 0 ] A g  
1 //I
to a final volume of 60 /d
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The digested sample was run on a 1% (w/v) agarose gel (section 2.3.4.1) alongside 
kHind III, DNA markers, in order to calculate the cDNA fragment size.
2.4.9 Preparation of cDNA inserts for subcloning.
A total of 50/^g of bacteriophage DNA from section 2.4.7 was digested with EcoRl in 5 
separate reactions (section 2.4.8), subsequently pooled and run on a 1% (w/v) agarose gel 
(section 2.3.4.1). The cDNA insert band was removed from the gel using a sterile scalpel 
and was purified using the Geneclean™ method (section 2.3.7).
2.5 SUBCLONING OF cDNA FRAGMENTS INTO PLASMID VECTORS
Plasmid cloning vectors have advantages over bacteriophage vectors. For example, for a 
2kb insert in a 40kb bacteriophage the phage:insert ratio is approximately 20:1, whereas for 
a3kb plasmid, the plasmid:insert ratio is approximately 1.5:1. The latter provides a greater 
proportion of insert DNA and therefore has greater potential for amplification of the cDNA 
insert. Plasmid vectors are also better for DNA sequencing procedures as there is less 
chance of non-specific priming, and a lower concentration of DNA is required in the 
reaction mixture. For these reasons the cDNA was removed from the bacteriophage by 
restriction enzyme digestion, and religated into the plasmid DNA previously linearised by 
digestion using the same enzyme.
Subcloning into pGEM®-7Zf(+)
The plasmid cloning vector pGEM®-7Zf(+) (figure 2.3), was chosen because it contains a 
large number of restriction sites in the multiple cloning site, which enables greater 
versatility for further subcloning. DNA sequencing can be performed directly using T7 and 
SP6 primers (Gibco BRL). The cloning site is situated within the plasmid p-galactosidase 
(p-gal) gene which codes for the a-peptide of p-gal. Non recombinant plasmids produce a 
functional a-peptide which complements the defective product of the host cell lacZAM15 
gene and gives rise to functional p-gal activity. Bacterial colonies which carry the 
lacZAM15 gene on an F  episome and also contain the plasmid pGEM®-7Zf(+) produce a
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blue colour (p-gal+) when plated on X-Gal /IPTG media. In the presence of insert the p-gal 
gene is not transcribed and E coli produce p-gal- (white) colonies. This enables rapid 
identification of recombinants. Small, in-frame inserts, however, may give rise to the 
transcription of p-gal, which may translate to give active enzyme, ie., blue colonies and 
thus false negatives.
Subcloning into pUSlOOO
The expression plasmid pUSlOOO (figure 2.4) contains a small multiple cloning site, which 
makes it less useful for routine subcloning. Transcription of the inserted cDNA is placed 
under the control of the strong immediate early promoter of human Cytomegalovirus. 
Amplification of the recombinant DNA in COS-1 cells is controlled by an SV40 virus 
origin of replication in the vector. This vector does not have a selectable marker for 
recombinants and religated plasmid clones cannot be distinguished from recombinants. 
Therefore, the cut plasmid DNA has to be pre-treated to prevent self-ligation. Treatment of 
the plasmid with calf intestinal alkaline phosphatase (CIAP) removes 5' phosphate groups 
and thus prevents recircularisation of the plasmid during ligation (section 2.5.1). The insert 
cDNA is not dephosphorylated and thus provides 5' phosphate groups to enable ligation to 
the dephosphorylated plasmid. Thus if 100% dephosphorylation is achieved only those 
molecules which contain DNA inserts should recircularise and all subsequent transformant 
colonies should contain recombinants.
2.5.1 Dephosphorylation of linearised vectors
Where the vector was digested with a single restriction enzyme and had no selectable 
marker for recombinants, the DNA was treated with CIAP (Pharmacia) as follows:
The mixture was incubated for 1 hr at 37°C, after which the CIAP was heat inactivated at 
85°C for 15 min. The plasmid was diluted to lOOngl]A for ligation (section 2.5.2).
CIAP 10X buffer 
CIAP
10 ]A
O.OlU/pmol ends (2 jAg of 5kb plasmid =1.4 pmol ends)
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2.5.2 Ligation of cDNA into plasmid
The ligation reactions were set up as 1:1 and 1:3 molar ratios of vector to cDNA fragment. 
A typical reaction mixture is shown below for a 3kb vector and a 2kb cDNA fragment, 
where both vector and cDNA are at concentrations of lOOngIjA.
Li eation Reaction 111 13
Sterile Milli Q water 5.3 ]A 4 pi\
5x ligation buffer 2 ja\ 2 pil
EcoRl cut vector (100 ng//d) 1 pil 1 jA
EcoRl cut cDNA fragment (100 ng//d) 0.7 ]A 2 ]A
T4 DNA ligase (1U/j<1) 1 y, 1 1 ]A\
Total volume 10 /d 10 jA
Control ligations
For blue/white screening the following controls were carried out, and the volume adjusted 
to 10jA with sterile water:
(1) No vector, no cDNA and no DNA ligase: Checks that the ampicillin is working; E.coli 
cells should not grow on ampicillin plates as they are ampicillin sensitive.
(2) Uncut vector DNA, no cDNA and no DNA ligase: Checks for p-galactosidase activity in 
transformants; all colonies should be blue.
(3) EcoRl digested vector, no cDNA, no DNA ligase: Checks for spontaneous ligation; a 
few blue colonies may be present.
(4) EcoRl digested vector and DNA ligase: Checks the ligase enzyme is working; all 
colonies should be blue.
and where appropriate:
(5) EcoRl digested, dephosphorylated vector and DNA ligase; Checks that 
dephosphorylation has worked, no colonies should appear.
The ligation reactions were incubated overnight at 14°C.
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2.5.3 Transformation of competent E .coli cells
The preparation of competent E. coli cells for transformation with plasmid DNA, was 
performed using the method of Cohen et al., (1972). In this procedure, the bacteria are 
treated with ice cold solutions of CaCl2  which induces a state of 'competence', during 
which they are able to take up plasmid DNA.
2.5.3.1 Preparation of competent cells
JM109 glycerol stocks were plated on M-9 plates containing ImM thiamine-HCl (this 
selects for the presence of the f' episome which carries the defective lacZAM15 gene which 
is necessary for colour selection) and incubated overnight at 37°C. A single colony was 
used to inoculate 10ml of LB medium which was incubated overnight at 37°C in a shaking 
incubator (225 rpm). 5ml of the overnight culture was added to 500ml of LB medium and 
the culture was shaken at 200 rpm at 37°C until the A600 reached 0.55. The cells were 
chilled on ice for 2 hr and collected by centrifugation at 2,500 x g for 15 min at 4°C. The 
cells were resuspended in 20ml of ice cold trituration buffer and then diluted to 500ml with 
trituration buffer. The cells were incubated on ice for a further 45 min and centrifuged at 
1,800 x g for 10 min, after which they were gently resuspended in 50ml of trituration 
buffer. 80% (v/v) glycerol was added with gentle swirling to a final concentration of 15% 
(v/v). The cells were aliquoted in 1ml quantities, frozen on dry ice and stored at -70°C
2.5.3.2 Transformation of competent cells using DMSO and heat shock
For each ligation reaction, 200/d of competent cells (E coli strain JM109) was thawed on 
ice. 3/d of DMSO was added to each tube of cells and mixed by gentle tapping. 2/d of 
ligation mixture (~20ng) was added to the competent cells, and after gentle tapping the 
mixture was incubated on ice for 30 min (The remaining ligation mixture was stored at 
-20°C). The tubes were incubated for 60 sec without mixing in a 42°C water bath, and 
chilled for a further 2 min on ice (heat shock encourages the bacteria to take up the 
plasmid). 2ml of LB medium was added to the tubes which were subsequently shaken at 
37°C for exactly 1 hr at 225 rpm in a gyratory shaker incubator. The cells were centrifuged
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at 2,500 x g for 10 min, the supernatant was removed and the cells were gently 
resuspended in 500/d of LB medium. 200/d and 100/d of each transformation were spread 
on separate LB agar plates using a glass spreader. For the vector pUSlOOO, the LB agar 
plates contained ampicillin at a concentration of 50 /<g/ml. For the vector pGEM®7Zf(+), 
the plates contained ampicillin (50 /<g/ml), X-Gal (40 /<g/ml) and IPTG (0.5 mM). The 
plates were incubated overnight and positive colonies were recultured on fresh agar plates 
to provide sufficient material for the cracking procedure, a method which demonstrates the 
presence of insert DNA (section 2.5.4).
2.5.4 Cracking procedure
The cracking procedure is a rapid and inexpensive method to determine if transformed 
bacteria possess plasmid containing a cDNA insert. Although the vectors have selection 
markers, there are usually approximately 10% false positives, and the cracking procedure 
identifies these before expensive plasmid isolation procedures are performed.
Individual positive colonies were picked from the agar plates and smeared at the bottom of 
a microcentrifuge tube containing 50/d of lOmM EDTA, pH 8.0. 50/d of freshly prepared 
2X cracking buffer was added to the tubes and the cells were resuspended by vortexing. 
The samples were incubated at 70°C for 15 min to lyse the cells and release the plasmids. 
The tubes were cooled to room temperature and 1.5/d of 4M KC1 was added to precipitate 
the proteins, 1/d of DNA dye was added and the tubes were vortexed and incubated on ice 
for 5 min. The samples were centrifuged at 14,000 x g in a microcentrifuge at 4°C and 50/d 
was run on a 1% (w/v) agarose gel (section 2.3.4) alongside a control lane containing 
plasmid with no insert DNA. Those plasmids which contain insert DNA will be retarded on 
the agarose gel in comparison to the control plasmid.
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2.5.5 Plasmid preparation
A number of procedures using plasmid DNA require that the samples are very pure, 
without protein or genomic DNA contamination. Two commercial kit procedures have been 
used as they provide large quantities (20-1000 pig) of very clean DNA (A26O/28O 
approximately 1.8).
2.5.5.1 Qiagen™ midi and maxi plasmid preparation
(Maxi prep volumes are given in brackets)
5ml (150ml) of overnight culture was centrifuged for 10 min at 2,500 x g and the pellet 
resuspended in 0.3ml (4ml) of PI which contains RNase. The cells were lysed with 0.3ml 
(4ml) of P2, mixed gently and incubated for 5 min at room temperature. To the lysed cells 
0.3ml (4ml) of P3 solution was added on ice, mixed gently by inversion and centrifuged at
14,000 x g for 30 min at 4°C. The supernatant (containing the plasmid DNA) was removed 
promptly and applied to a pre-equilibrated (equilibrated with 1ml (10ml) QBT buffer) 
column. The sample flowed through the column under gravity and was washed with 2 X 
lml (4ml) wash buffer (QC). The plasmid DNA was eluted with 0.8ml (5ml) of elution 
buffer (QF). The DNA was precipitated with 0.7 volumes of isopropanol (room 
temperature for 30 min), and the precipitate collected by centrifugation at 14,000 x g for 30 
min at4°C. After centrifugation the pellet was washed with ice cold 70% (v/v) ethanol and 
dried in the Univap (section 2.3.10). The DNA was resuspended in an appropriate amount 
of water and stored at -20°C.
2.5.5.2 Promega Wizard™ mini and maxi preparation 
Mini preparation
3ml of bacterial cells (overnight culture), were pelleted by centrifugation at 14000 x g for 2 
min in a microcentrifuge and resuspended in 0.2ml of cell resuspension solution. 0.2ml of 
cell lysis solution was added to the resuspended cells which were mixed by inversion until 
the solution became clear. 0.2ml of neutralising solution was added, the contents of the 
tube were mixed by inversion and centrifuged at 14000 x g in a microcentrifuge. The
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cleared supernatant was decanted to a new microcentrifuge tube, 1ml of DNA binding resin 
was added and the solution mixed by inversion. The plunger was removed from a 3ml 
disposable syringe and the barrel was attached to the luer-lock extension of a minicolumn. 
The resin/DNA mix was pipetted into the syringe and was gently pushed onto the 
minicolumn with the plunger. The minicolumn was washed with 2ml column wash 
solution and transferred to a 1.5ml microcentrifuge tube. The minicolumn was centrifuged 
at 14000 x g for 20 sec to dry the resin and transferred to a clean microcentrifuge tube. 
50/d of sterile Milli Q water (preheated to 65°C) was added to the column and after 1 min 
the DNA was eluted by centrifugation at 14000 x g for 20 sec. The DNA was stored at 
-20°C.
Maxi preparation
500ml of bacterial cells (overnight culture), were pelleted by centrifugation at 2,500 x g for 
10 min and resuspended in 15ml of resuspension solution. 15ml of cell lysis solution was 
added and incubated at room temperature until the solution became clear (up to 20 min). 
15ml of neutralisation solution was added and the mixture was centrifuged at 14,000 x g 
for 30 min. The supernatant containing the plasmid DNA was removed and added to 0.6 
volumes of isopropanol. The precipitated DNA was pelleted by centrifugation at 14,000 x g 
for 30 min at 4°C. The pellet was resuspended in 2ml of TE buffer and added to 10ml of 
DNA binding resin. The resin was added to a maxi column and drawn through by a 
vacuum. 13ml of wash buffer was added to the tube in which the DNA and binding resin 
were mixed, added to the column and drawn through by vacuum. A further 12ml of wash 
buffer was added to the column followed by 5ml of 80% (v/v) ethanol. The column was 
dried by centrifugation (2,500 rpm for 5 min in a bench centrifuge) in the tube provided 
and the eluant discarded. The DNA was eluted from the column by the addition of 1.5 ml 
of sterile Milli Q water pre-incubated at 65°C. After 1 minute the column was centrifuged at 
2,500 rpm for 5 min. The eluant containing the DNA was stored at -20° C.
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2.5.6 Preparation of glycerol stocks
Bacterial cultures containing plasmids with cDNA inserts of interest can be stored in 
glycerol at -70°C for many years. A 10ml overnight culture in LB medium containing 
50/<g/ml ampicillin was prepared. 850/d of bacteria was added to 150/d of sterile glycerol 
in a sterile 1.5 ml microcentrifuge tube. The tube was mixed by brief vortexing and stored 
at -70°C. To grow cells from glycerol stocks either (i) 10/ri was added to 10ml of LB 
medium containing 50//g/ml ampicillin and incubated overnight at 37°C with shaking, or 
(ii) 10/d was plated on an ampicillin (50//g/ml) LB plate and incubated overnight at 37°C.
2.6 DNA SEQUENCING IN PLASMID VECTORS
cDNA inserts were sequenced in plasmid vectors using the Sequenase® version 2.0 DNA 
sequencing kit (United States Biochemicals) which is based on a modification of the 
dideoxy sequencing strategy of Sanger et aL, (1977).
2.6.1 Sequencing gel electrophoresis apparatus
The sequencing gel electrophoresis apparatus was manufactured in the School of Biological 
Sciences workshop at the University of Surrey. The apparatus comprised of two glass 
plates held vertically between upper and lower buffer reserviors, which housed the negative 
and positive electrodes respectively. The glass plate dimensions were 58x20x0.5 cm. The 
top of the back plate had a trough cut out to allow loading of samples into the comb wells. 
Before use, the plates were scrubbed with Decon 90 (Fisons), to remove any residues. The 
plates were then washed with distilled water, and wiped with acetone followed by absolute 
ethanol. To ensure easy removal of the gel from the plates, the inside face of each plate was 
siliconised with dimethyl-dichlorosilane, prior to cleaning with water, acetone and ethanol. 
The plates were re-siliconised every six gel runs. The gel spacers and combs (0.4 mm 
thick) were cleaned with water and absolute ethanol. The spacers were put in place and the 
plates were taped together, along the sides and across the bottom using electrical tape 
(Genetic Research Instrumentation Ltd.). Bulldog clips were used to hold the plates tightly 
together whilst the gel was poured.
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2.6.2 Preparation of sequencing gels
For the majority of this work, 6% (w/v) polyacrylamide gels (7M urea, IX TBE) were 
prepared according to the method of Sanger and Coulson (1978). Towards the end of this 
work, 6% (w/v) polyacrylamide solution containing 7M urea and lxTBE was purchased 
from Scotlab. This resolved the safety problems associated with handling high 
concentrations of acrylamide.
Polymerisation of 75ml of either gel solution above was initiated by the addition of 75/d of 
TEMED and 420/d of 10% (w/v) ammonium persulphate (freshly prepared). The solution 
was swirled to mix, drawn up into a pre chilled syringe, and released gently between the 
two plates, held at an angle of 45°. The flat end of a sharks tooth comb was inserted at the 
top of the gel, 5mm from the top of the back plate, and was held in place with a bulldog 
clip. The gel was left at room temperature to polymerise, (approximately 20 min) after 
which the top of the gel was wrapped in damp tissue and Saran Wrap™ film to prevent the 
gel drying out, and stored at4°C for a minimum of 2 hr. and maximum of 3 days prior to 
use.
2.6.3 Preparation of single stranded template DNA
Double stranded plasmid was denatured to provide a single stranded template for the T7 
DNA polymerase to copy. 3-5/<g of plasmid DNA was diluted to a final volume of 16 /d 
with sterile milli Q water. 2/d of 2M NaOH and 2/d of 2mM EDTA were added and 
incubated for 5 min at room temperature to denature the DNA. The sample was neutralised 
by the addition of 2/d of 2M ammonium acetate (pH 4.6). The denatured DNA was 
precipitated with 60/d of ice cold (-20°C) 100% (v/v) ethanol and left at -70°C for 20 min. 
The precipitate was collected by centrifugation in a microcentrifuge, at 14,000 x g, 4°C for 
30 min, the supernatant was removed and the DNA pellet washed with 50/d of 70% (v/v) 
ethanol to remove salt residues. The resulting DNA pellet was dried in a Univap (2.3.10) to 
remove all traces of ethanol (The denatured DNA may be stored at -20°C for up to 1 week 
prior to use).
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2.6.4 Sequencing reaction
All reagents and buffers were provided in the Sequenase® version 2.0 DNA sequencing kit 
(United States Biochemicals). M13 single stranded DNA was provided as a control for the 
enzyme reaction.
2.6.4.1 Annealing of primers
The denatured DNA was reconstituted in 7/d of sterile Milli Q water and 2/d of sequencing 
buffer was added. 1/d (10 //g/ml) of the appropriate oligonucleotide primer was added and 
the mixture was heated to 65°C for 4 min in a beaker in a 65°C water bath. The beaker was 
removed and allowed to cool to below 37°C (slow cooling ensures specific annealing of 
oligonucleotide primers), and placed on ice.
2.6.4.2 Labelling reaction (primer extension)
In this reaction the primer was extended in the presence of limiting concentrations of 
deoxyribonucleotide triphosphates (dNTPs) and 35S dATP. To the chilled annealing 
reaction, 1/d of DTT (0.1M), 2/d of diluted labelling mix (7.5/<M dTTP, dCTP and dGTP) 
and 0.5/d of 35S dATP (0.185 Mbq) were added. The reaction was initiated by the 
addition of 2/d (3.25 U) of diluted Sequenase™ enzyme to the DNA/primer mixture which 
was incubated at room temperature for 5 min.
2.6.4.3 Termination reaction
After the above 5 min incubation, 3.5/d of the labelling reaction mixture was removed and 
placed into each of 4 pre-prepared termination tubes, containing 2.5/d of dideoxynucleotide 
triphosphates, ddATP, ddCTP, ddGTP, or ddGTP (pre-incubated at 37°C). Elongation is 
terminated when one of the ddNTPs is incorporated into the sequence, since the ddNTP 
has no free 3' OH group for the next nucleotide to bind. It is a statistical probability that 
there will be a polymer terminated at each of the nucleotide positions in the template, thus 
the termination mixtures will contain a whole set of DNA fragments each one base longer 
than the next. By running the contents of the four termination mixes alongside each other
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on the gel, which separates according to size, it is possible to determine the nucleotide 
sequence of the DNA. Any remaining elongation, not terminated by ddNTPs is terminated 
by the addition of 4/d of stop solution, which contains a running dye (a mixture of two 
dyes; xylene-cyanol and bromophenol blue). These dyes travel at different speeds through 
the sequencing gel and are used as a guide for the running times of long and short gel runs. 
The reactions can be stored at -20°C for 1 week prior to running on a gel.
This protocol enabled the sequencing of approximately 250-300 nucleotides from a single 
primer. It was possible however, to increase the number of nucleotides sequenced, by 
adding an extension mix to the termination mixture. This contains a lower proportion of 
ddNTPs relative to dNTPs resulting in a lower termination rate, and thus relatively longer 
DNA fragments enabling the sequence to be read for a greater distance from the primer.
2.6.5 Running a sequencing gel
The tape at the bottom of the plates was removed and the gel was positioned vertically in 
the electrophoresis apparatus. The top and bottom reservoirs were filled with IX TBE 
buffer and the comb removed from the gel. The resulting well was washed out with IX 
TBE and the comb re-inserted so that the teeth just entered the gel. The gel was pre-run at 
50W in order to heat the gel to the optimum temperature of 45-55°C (a metal back plate was 
clipped to the back of the two glass plates in order to evenly distribute the heat through the 
gel and prevent band distortion or 'smiling'). The samples in loading buffer were heated to 
75°C for 4 min, and 3/d of each sample was loaded into the wells. Electrophoresis was 
performed at 50W constant power until either the bromophenol blue ('short' gel, 
approximately 3hr) or the slower migrating xylene-cyanol ('long' gel, approximately 7hr) 
had travelled the length of the plates. Extended samples were run for 9-12hr.
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2.6.6 Fixing and processing of sequencing gels
The tape, comb and spacers were removed from the gel and the plates gently prised apart so 
that the gel remained attached to one plate. The plate with the gel attached was carefully 
placed into a 10% (v/v) acetic acid 10% (v/v) methanol solution for 20 min to fix the gel. 
The plate was subsequently placed in water for 20 min to rinse off the fixing solution and 
to leach out the urea which may interfere with autoradiography. The gel was removed from 
the water and a sheet of Whatman 3MM paper, previously soaked in water was placed over 
the gel. A further two sheets of dry 3MM paper were added on top of the wet sheet and 
light pressure was applied across the gel to absorb excess water. The gel sandwiched 
between the plate and paper was turned over, and the plate was gently lifted so that the gel 
remained attached to the paper. The gel was dried on a vacuum dryer at 80°C for 45 min 
and autoradiographed (section 2.3.11) overnight (or longer if necessary).
2.6.7 Analysis of DNA sequences
The sequence was read starting from the bottom of the gel (5'-3' direction), using the 
Sequence Boy base recorder (Integra Biosciences). The sequence was subsequently 
downloaded onto the Macintosh Gene Jockey DNA analysis program. Using this system it 
was possible to compare two sequences, join two sequences together, look at different 
reading frames, and translate reading frames into protein sequences.
Comparison of nucleic acid sequences with a data base containing over 70,000 verified 
sequences was made in order to ensure that they were unique and had not previously been 
reported. The sequences were sent via computer to the SEQNET database at the SERC 
Daresbury laboratory, Warrington and later to EMBL Heidelberg, using the E-mail BLITZ 
procedure.
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2.6.8 Synthesis of oligonucleotide primers
Oligonucleotides were synthesised on an Applied Biosystems Model 381A DNA 
Synthesiser in the School of Biological Sciences, University of Surrey, using the standard 
procedure. The oligonucleotide was synthesised on a column support from which it had to 
be removed prior to use. 1.5ml of neat 880 ammonia was drawn up into a syringe, which 
was attached to one end of the column. A second syringe with the plunger removed was 
attached to the other end of the column. 0.5ml of the ammonia solution was passed into the 
column and incubated at room temperature for 20 min. This was repeated twice, the 
plunger of the second syringe was replaced and the ammonia was gently passed through 
the column 5-6 times. This procedure liberates the oligonucleotides and removes the 
cyanoethyl groups which were protecting the phosphates. The solution was placed into a 
screw cap tube and heated to 55°C for a minimum of 8 hr (usually overnight). This 
removed the benzoyl and isobutyryl groups present on the exocyclic amines of A and C 
(benzoyl) and G (isobutyryl) during synthesis in order to prevent side reactions from taking 
place. The solution was cooled to room temperature, ethanol precipitated (section 2.3.9) 
dried (2.3.10) and reconstituted with an appropriate volume of sterile Milli Q water. The rat 
and human oligonucleotide primer sequences are given in table 2.2.
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RAT PRIMERS HUMAN PRIMERS
PI C C C T G T C T C C A C A T T C T T C A G Ph4 ACTGGCTGGAAGGTGG
P2 CTATTGGGTTGGGGGCCAGT Ph5 GCTCTTCCG CCAA CCC
P3 ACTACGTTTGGGGTCG Ph6 AAGGCTGTGAACAGGGCCCC
P4 TGTGTTGAGGACCAGG Ph7 GTCTCCTTCGTCC ACCAGG G
P5 GACAGGAGATGGACCC Ph8 T G A C C A C T A T A T C C G C
P6 TGAG CAT GAAGT T CCC Ph9 TCTAGGATGGAGCTGG
P7 AGTGCCATCCCTGTGC PhlO T CA CCT T T CA G ACA G G AG G C
P8 AAACGTA GTCCCAAGG P h il A C T C AA AG AG G AT C T C T G C G
P9 AGCTGGAGCTGGTGGC Phl2 T A G T G A A T G A C T TG G G
P10 G T C C A TC T C C TG TC C C Phl3 AG T G G AG ACT T CAT G C
P l l GAGGAAGTAGCTCCCC Phl4 CC A T G AC A AT G AT G G C
HUMAN PRIMERS Phl5 GC AC AT C A G C AT T G C C
Phi CATTCTGGATGGGACC Phl6 AAG C G T CT G T CAT AG G
Ph2 CT GCTAAATCCCCGCC Phl7 GAAG GT T CCAGAA TCG
Ph3 CCATAGCCACCAACAG Phl8 AT GG CCAAACAGCTGC
Table 2.2: Rat and human oligonucleotide primer sequences in 5 -3 ' orientation.
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2.7 EXPRESSION OF p-LYASE cDNAs IN COS-1 CELLS
In order to demonstrate that the cloned rat and human cDNAs coded for p-lyase enzymes 
and to compare their activities, their full length cDNAs were subcloned into the expression 
vector pUSlOOO (section 2.5). Transcription of the cDNA was under the control of the 
strong immediate early promoter of human cytomegalovirus. Amplification of the DNA in 
monkey kidney COS-1 cells was ensured by the presence of an SV-40 virus origin of 
replication in the vector. Rat and human cDNAs were inserted into the vector EcoRl site in 
both the sense and antisense orientations to produce recombinant plasmids.
2.7.1 COS-1 cell culture
COS-1 cells were cultured as monolayers in 75cm2 tissue culture flasks in growth medium 
(Dulbecco’s Modified Eagles Medium (DMEM) supplemented with 10% (v/v) foetal calf 
serum (FCS), 200mM glutamine, gentamicin (0.5mg/ml)) and 5% CO2  in air at 37°C. Cells 
were subcultured just prior to confluency (approximately 95% confluence) to prevent the 
formation of sincitia.
2.7.2 COS-1 cell subculture
Growth media was removed from the flask and 5ml of PBS was added to wash the cells. 
The PBS was aspirated and replaced with 5ml trypsin/EDTA (0.125% trypsin in ImM 
EDTA). The flask was tilted to ensure coverage of all the cells and the trypsin/EDTA 
solution was removed. The flask was incubated at37°C for 1 to 2 min after which the cells 
had lifted from the flask and become detached from each other. 10ml of fresh tissue culture 
media was immediately added to the cells to neutralise the trypsin/EDTA and the cells 
resuspended by pipetting gently up and down a 10ml pipette. New flasks were seeded at a 
1 in 3 dilution in fresh growth media to a final volume of 25ml.
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2.7.3 Cell counting and viability
The number of cells/ml were counted using a Hawksley cristalite Neubauer 
haemocytometer. After trypsinisation and resuspension in 10ml of growth medium (2.7.1, 
2.7.1) an aliquot of the cell suspension was diluted in trypan blue (0.4% (w/v) in saline), 
and the number of viable cells counted. Those cells which take up the dye have damaged 
cell membranes and were considered non-viable. Exclusion of the dye indicated viability.
2.7.4 Freezing cells in liquid nitrogen for long term storage
Cells were trypsinised (2.7.2) and resuspended in 10ml of growth media. The cells were 
centrifuged at 80 x g for 5 min and resuspended in DMEM containing 20% (v/v) FCS and 
10% (v/v) DMSO to a final concentration of 1 x 107 cells/ml. The cells were dispensed into 
lml aliquots and frozen overnight at -70°C before storing in liquid nitrogen. To recover 
cells from liquid nitrogen storage, an aliquot was thawed at 37°C and the cells diluted with 
10ml of growth media. The cells were sedimented by centrifugation (80 x g, 5 min), gently 
resuspended in a further 10ml of growth media, transferred to a 75cm2 tissue culture flask 
and incubated at 37°C with 5% CO2  in a final volume of 25ml.
2.7.5 DNA transfection of COS-1 cells (DEAE dextran method)
DNA transfection was performed on 80-90% confluent cells using a modified method of 
Cullen (1987). This method utilises DEAE-dextran which sticks to the cell membranes, 
promoting pinocytosis during which DNA in the surrounding medium is taken up into the 
cell.
75cm2 tissue culture flasks (Greigner Labortechnik Ltd. UK.) were seeded with 9 xlO5 
cells the day before transfection in order to give a semiconfluent monolayer. A transfection 
cocktail containing lOpig of recombinant plasmid DNA, and 30/d of DEAE-dextran (Mw 
500,000, lOmg/ml in PBS) was prepared in a total volume of 600/d of PBS (Dulbecco A ' 
(Ca2+/Mg2+ free), Oxoid Ltd). All PBS solutions for this procedure were Ca2+/Mg2+ free. 
The tissue culture media was aspirated from the flasks and the cells were washed with 6ml
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of PBS. The PBS was aspirated and the transfection cocktail vortexed and applied to the 
monolayer with even distribution. The cells were incubated at37°C, 5% CO2  for 30 min, 
with occasional gentle tilting to prevent drying of the monolayer. 6ml of tissue culture 
media supplemented with SOpiM chloroquine was applied to the cells/cocktail and incubated 
for a further 2.5 hours. The cocktail media was aspirated and 3ml of media containing 10% 
(v/v) DMSO was added for 2.5 min (It is important not to leave DMSO on the cells longer 
than this as their membranes become damaged), after which it was removed and 
immediately replaced with 10ml of fresh tissue culture media. The cells were incubated for 
48-72 hours at 37°C with 5% CO2  for the cDNA to be transcribed and translated by the 
COS-1 cell “machinery”. The above procedure was performed using the recombinant 
expression vector containing the rat and human cDNAs in the sense direction. The control 
cells were transfected with (i) the vector containing the cDNA in the antisense orientation 
and (ii) no DNA.
2.7.6 Preparation of cytosol from transfected COS-1 cells
The cells were harvested using trypsin (2.7.2) and centrifuged at 2,500 rpm (1,300 x g) in 
a bench centrifuge, washed twice with ice cold PBS, followed by resuspension in 
homogenisation buffer (lml/flask of cells). The cells were freeze thawed three times in 
liquid nitrogen and sonicated twice in a sonicating bath for 10 secs with a 30 sec cooling 
interval on ice. Following centrifugation at 3,000 x g for 5 min the crude cytosol was 
removed and stored at -70°C prior to further analysis.
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2.8 ASSAYS FOR PROTEIN CONCENTRATION AND ENZYME 
ACTIVITY
2.8.1 Protein determination
The concentration of protein in cytosolic extracts prepared from transfected cells was 
determined using modified methods based on Lowry et.al. (1951). Method 2 was found to 
be more reproducible.
Method 1
A standard curve was generated using duplicate dilutions of bovine serum albumin (BSA) 
(0.05, 0.1, 0.2, 0.4, 0.6 and 0.8 //g/ml). 1.0ml of the protein standards, samples and a 
water blank were added to 3ml of freshly prepared Lowry reagent-1, mixed by vortexing 
and incubated at room temperature for 15 min. Folin-Ciocalteu reagent was diluted 1:1 with 
distilled water and 0.3ml was added to the samples, standards and blank, which were 
vortexed and incubated for a further 30 min at room temperature. The blue colour was 
stable for 1 hr and the absorbance was determined at 750nm on a Uvikon 860 
spectrophotometer (Kontron Instruments). The sample and standard absorbance values 
were corrected by subtraction of the water blank.
Method 2
A standard curve was generated using duplicate dilutions of bovine serum albumin (BSA) 
(0.05, 0.1, 0.2, 0.4, 0.6 and 0.8 /<g/ml). 1.0ml of the protein standards, samples and a 
water blank were added to 1ml of freshly prepared Lowry reagent-2, mixed by vortexing 
and incubated at room temperature for 10 min. Folin-Ciocalteu reagent was diluted 1:10 
with distilled water and 3ml was added to the samples, standards and blank, which were 
vortexed and incubated for a further 10 min at 50°C. The samples were cooled and the 
absorbance determined at 650nm on a Uvikon 860 spectrophotometer (Kontron 
Instruments). The sample and standard absorbance values were corrected by subtraction of 
the water blank.
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2.8.2 Glutamine transaminase K (GTK) assay
GTK activity was determined using the method of Cooper and Meister (1985). This assay 
is based on the transamination reaction between L-phenyl alanine and a-keto-y -methiol- 
butyric acid (a-KMB) with the formation of phenylpyruvate and L-methionine.
GTKL-phenyl alanine + a-KMB --------  — >- phenyl pyruvate + L-methionine
35 /d of pre-warmed (37°C) GTK reagent (0.2M ammediol buffer, pH 9.0, lOmM L- 
phenylalanine and 5mM a-KMB) was added to 65/d samples (15, 25, 35, 45 and 65 ]A 
of cytosol diluted to 65/d in sterile Milli Q water) in a water bath at 37°C. The reaction was 
stopped after 10 min with the addition of 0.9ml of 3.33M NaOH. This procedure was 
carried out in duplicate along with duplicate blanks which were carried through the same 
procedure except that the cytosol was added after the reaction was terminated with NaOH. 
The reaction was carried out at pH 9.0 ensuring that the transaminase activity was only due 
to GTK. The product of the reaction, phenylpyruvate, absorbs strongly at 322nm (in 
3.33M NaOH, E=24,100 M-1cm_1), whereas the absorbance due to a-KMB is negligible. 
The samples were measured against 3.33M NaOH in quartz cuvettes at 322nm (absorbance 
is stable for only 15 min) and the control blanks were subtracted from the readings. A unit 
of enzyme activity was defined as the amount of enzyme catalysing the formation of lnmol 
of product per min under standard assay conditions. The specific activity was defined as 
units of activity per mg of protein.
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2.8.3 Cysteine conjugate p-Iyase assay
(3-lyase activity was based on the method of Stevens and Jakoby (1983). This method 
measured continuous spectrophotometric estimation of activity with time using the 
substrates TFEC and DC VC.
DCVC/TFEC ----------p-lyase------ — ► R-SH + pyruvate + NH3 (i)
pyruvate + NADH/H+   ► lactate + NAD+ (ii)
where R = halogenated alkene moiety
The pyruvate formed in reaction (i), is measured using a coupled reaction (ii) in which 
pyruvate undergoes reduction by lactate dehydrogenase (LDH) with the formation of 
lactate. The concurrent oxidation of NADH/H+, which absorbs at 340nm, to NAD+ is 
measured by the decrease in absorbance at 340nm and is proportional to (3-lyase activity 
(E=6.2 M’W 1).
The reaction mixture (800/d) containing 0.1M sodium phosphate buffer, pH 7.4, 5mM 
glutathione (GSH), 140/<M NADH/H+, 4 units of lactate dehydrogenase (LDH), 0. ImM - 
KMB and 5 mM of substrate (TFEC of DCVC) was pre incubated at 37°C. A baseline was 
obtained by measuring the absorbance of the mixture against a water blank for 2 min at 
340nm and a constant temperature of 37°C. 200/d of cytosol was added to the cuvette, 
mixed thoroughly with a pipette and the absorbance measured for a further 8 min. The 
difference between the reaction rate in the presence and absence of substrate was taken as a 
measure of p-lyase activity. A second control was carried out in which O.lmM 
aminooxyacetic acid (AOAA) was added to the reaction mixture, prior to the addition of 
cytosol. AOAA is an inhibitor of pyridoxal phosphate (PLP) dependent enzymes and was 
used to determine if the activity was PLP dependent.
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2.8.4 Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS- 
PAGE)
SDS-PAGE analysis of proteins was carried out according to the method of Laemmli 
(1970). The cellular extracts were treated with SDS in the presence of 2-mercaptoethanol to 
denature protein structure and give the resultant monomers a relative negative charge. The 
monomeric proteins were then separated on a polyacrylamide gel according to molecular 
weight.
Electrophoresis was performed at room temperature using a vertical slab gel assembly 
(Hoefer Scientific Instruments). The glass plates were washed in detergent, distilled water, 
acetone and ethanol prior to use. The plates were clamped together with the spacers in place 
and assembled vertically in the electrophoresis apparatus. The lower separating gel (20ml) 
was prepared to give a final acrylamide concentration of 10% (w/v). Polymerisation was 
initiated by the addition of 20/d of TEMED and 120/d of freshly prepared 10% (w/v) 
ammonium persulphate. This solution was poured between the two glass plates to a height 
of 80mm. A layer of distilled water was poured on top of the gel mixture to ensure a flat 
interface between the stacking and separating gels. When polymerisation was complete (20- 
30 min) the water layer was removed, and an upper stacking gel (10ml) with a final 
concentration of 3% (w/v) acrylamide was poured on top of the separating gel. 10/d of 
TEMED and 60/d of 10% (w/v) ammonium persulphate were used to initiate 
polymerisation. The sample wells were formed by the introduction of a perspex comb prior 
to polymerisation. After polymerisation the comb was removed and the upper and lower 
buffer reservoirs were filled with electrophoresis buffer. Any air bubbles trapped in the 
wells or at the bottom of the gel were removed using a syringe.
The protein samples to be analysed were diluted to a concentration of l//g//d and a 20/d 
aliquot was further diluted 1:1 with 2X sample buffer (containing bromophenol blue dye) 
and placed in a boiling waterbath for 3 min. The samples were cooled and loaded into the 
sample wells using a Hamilton syringe. Protein molecular weight markers (SDS-7B
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prestained markers, Sigma), 32-198 kDa were run in adjacent wells to enable estimation of 
sample protein sizes. The samples were run through the stacking gel under a 20mA 
constant current until the bromophenol blue indicator dye entered the separating gel, after 
which it was increased to 40mA. Electrophoresis was complete when the dye front reached 
5mm from the bottom of the gel. The plates were separated and the lower gel carefully 
removed for transfer on to a nitrocellulose membrane for Western blot analysis (section 
2.8.5).
2.8.5 Western blot analysis
2.8.5.1 Electrophoretic transfer
The method used was a modification of the procedures of Towbin et.ai. (1979) and Burnett 
(1981). After electrophoresis the gels were immersed in transfer buffer for 45 min to allow 
for any swelling or shrinkage to occur. A sheet of nitrocellulose membrane cut to the 
appropriate size was laid on top of two sheets of Whatman 3MM blotting paper immersed 
in transfer buffer. The gel to be transferred was placed on top of the nitrocellulose 
membrane with a further two sheets of 3MM paper placed on top. The assembly was 
placed between two Scotch Brite scouring pads (larger than the gel/membrane sandwich) 
which in turn was placed between a rigid plastic grid. The whole immobilised assembly 
was then inserted into the electrophoresis transfer tank with the nitrocellulose paper facing 
the anode. The tank was filled with transfer buffer and electrophoretic transfer was 
achieved overnight at a constant 20 volts.
2.8.5.2 Detection of p-lyase apoprotein using an anti-p-lyase antibody
Following electrophoretic transfer the nitrocellulose filter was washed in PBS-BT for 2 hr, 
to block any non-specific binding sites. This and all subsequent incubations were carried 
out at room temperature with gentle agitation on a rotary shaker (Luckham). The filter was 
incubated with 40ml of the primary antibody solution (anti-sheep p-lyase, 0.6ml/40ml 
PBS) for 1 hr. Excess antibody was removed by 3 x 15 min washing in PBS-BT and 
incubated with the secondary antibody (biotinylated rabbit anti-sheep IgG), at a dilution of
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50/d/50ml PBS, for 1 hr. The filter was again washed 3 times with PBS-BT and incubated 
with the tertiary antibody, streptavidin HRP complex, at a dilution of 100/d in 50ml PBS 
for 1 hr. A further 3 x 15 min washes with PBS-BT were carried out, followed by a final 
wash for 15 min with PBS alone to remove the detergent Triton.
The colour reaction was developed by incubation of the filter with the substrate for HRP, 
4-chloronapthol. The substrate was prepared by dissolving 30mg of 4-chloronapthol in 8ml 
of methanol and diluting to 50ml with PBS. 20/d of hydrogen peroxide (20% (v/v)) was 
added immediately before use. The antibody solutions were retained and stored at 4°C for 
up to two weeks for use in later experiments.
2.9 ISOLATION AND HYBRIDISATION ANALYSIS OF NUCLEIC  
ACIDS
2.9.1 Isolation of total RNA
RNA extraction was performed using the commercially prepared reagent RNAzol™ B 
(Biogenesis Ltd), based on the protocol of Chomczynski and Sacchi (1987). RNAzol™ 
promotes the formation of complexes of RNA with guanidium and water molecules and 
abolishes hydrophilic interactions of DNA and proteins. This results in the efficient 
removal of DNA and proteins from the aqueous phase, without removal of the RNA .
Kidney tissue was frozen in liquid nitrogen immediately after removal from the body, and 
stored at -70°C until required. It was essential that the tissue was collected and stored in this 
way so that RNases present in the tissue were rendered inactive. For extraction of RNA the 
tissue was ground into a fine powder in liquid nitrogen using a pestle and mortar. lOOmg 
of the powder was weighed into 2ml of RNAzol™B solution, which contains RNase 
inhibitors. The mixture was vortexed briefly to ensure that all tissue fragments were coated 
in solution. The tissue was homogenised using a Polytron (Kinemtica GmbH, Switzerland) 
for 20 sec, starting slowly and gradually building up to maximum speed. The samples were 
transferred to sterile microcentrifuge tubes and 100/d of chloroform added, the tubes were
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shaken for 15 sec and incubated on ice for 5 min. The samples were centrifuged at 14,000 
x g in a microcentrifuge at 4°C for 30 min, and the supernatant carefully removed into a 
sterile microcentrifuge tube. An equal volume of isopropanol was added, mixed and 
incubated on ice for 45 min. The RNA was pelleted by centrifugation in a microcentrifuge 
at 14,000 x g for 15 min at 4°C. The supernatant was removed and the RNA pellet washed 
with 1ml of 75% (v/v) ethanol, vortexed briefly and centrifuged at 14,000 x g for 10 min at 
4°C. The supernatant was removed and the pellet air dried and resuspended in 50/d of 
DEPC treated water. The RNA was incubated at 65°C for 5 min to fully dissolve it and the 
concentration and purity were determined spectrophotometrically (section 2.3.2).
2.9.2 Isolation of mRNA
mRNA was isolated from total RNA using the PolyATract® mRNA isolation system 
(Promega Corporation). This system uses a biotinylated oligo(dT) primer to hybridise to 
the 3' poly(A) region present in most mature eukaryotic mRNA species. The hybrids are 
captured by paramagnetic particles coated with streptavidin and washed at high stringency. 
The mRNA is eluted from the solid phase by the addition of ribonuclease free water.
Total RNA (0.1-1 mg) was added to a sterile, microcentrifuge tube and made up to a final 
volume of 500/d in DEPC treated water. The RNA was heated to 65°C in a heating block 
for 10 min. 3/d of the biotinylated-oligo(dT) probe and 13/d of 20X SSC were added to 
the RNA. The solution was mixed gently until it reached room temperature (approximately 
10 min). Streptavidin-paramagnetic particles (SA-PMPs), supplied in a kit, were washed 
three times with 0.3ml 0.5X SSC, each time capturing them using the magnetic stand. The 
washed SA-PMPs were resuspended with 0.1ml of 0.5X SSC.
The annealing reaction was added to the washed SA-PMPs and incubated for 10 min at 
room temperature. The SA-PMPs were captured using the magnetic stand and the 
supernatant carefully removed without disturbing the SA-PMP pellet. The pellet was 
washed four times with 0.3ml 0.1X SSC, each time capturing the SA-PMPs with the
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magnetic stand. The mRNA was eluted by resuspension of the SA-PMPs in 0.1ml of 
DEPC treated water and capture of the magnetic particles and the supernatant removed to a 
sterile tube. The elution was repeated using 0.15ml of DEPC treated water and the 
supernatants containing the mRNA were pooled. The concentration of the mRNA was 
calculated using the protocol in section 2.3.2.
2.9.3 Isolation of genomic DNA
Genomic DNA for use in Southern blot and PCR protocols was prepared from frozen rat 
and human tissue. The sample (up to 2g) was ground in liquid nitrogen with a pestle and 
mortar and the powdered tissue was added to 20ml of DNA isolation buffer in a 50ml 
Falcon tube. The mixture was incubated at 37°C for 24 hours with 2mg of proteinase K 
(final concentration of 100 /<g/ml). 20ml of TE-saturated phenol was added to the sample 
and mixed on a rotary mixer for 30 min to 1 hr. The mixture was centrifuged for 5 min at
10,000 x g and the aqueous phase removed to a clean tube. Phenol extraction was repeated 
until the interface was clear. The resulting supernatant was further extracted once with 
phenol/chloroform (1:1 (v/v)), followed by chloroform/ isoamyl alcohol (24:1 (v/v)) to 
remove the residual phenol. The DNA was precipitated from the aqueous phase by the 
addition of 1/10 volume of 3M sodium acetate, pH 5.4 and 2.5 volumes of absolute 
ethanol. Precipitation took place at -70°C for 30 min and the DNA recovered by 
centrifugation at 13000 x g for 20 min. The pellet was washed with 2ml of 70% (v/v) 
ethanol, re-centrifuged at 13000 x g for 5 min, air dried and re-dissolved in sterile Milli Q 
water. The purity and concentration were determined spectrophotometrically (2.3.2).
2.9.4 Southern blot analysis
The method was adapted from that reported by Sambrook et.al. (1989), after the original 
technique described by Southern, (1975), and was used for recombinant plasmid DNA, 
PCR products and genomic DNA analysis.
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2.9.4.1 Sample preparation and electrophoresis 
Plasm id DNA
0.5ptg of recombinant plasmid DNA digested with EcoRl (the site of insert ligation) to give 
linearised plasmid and insert DNA bands, was electrophoresed on a 1% (w/v) agarose gel, 
stained, and photographed as in sections 2.3.3, 2.3.4, 2.3.4.1, 2.3.5 and 2.3.6.
Genomic DNA
20pig of DNA was digested with EcoRl, Xbal or Sstl. DNA digestion (section 2.3.3) was 
performed in a total volume of 200/d with 10/d of enzyme, after which the DNA was 
concentrated by ethanol precipitation (section 2.3.9), resuspended in 20/d of TAE buffer 
and electrophoresed on a 0.7% (w/v) agarose gel at 50 mA, stained and photographed as 
above.
PCR DNA samples
15/d of the PCR reaction was electrophoresed on a 4% (w/v) agarose gel (section 2.3.4.1) 
and stained and photographed as above.
2.9.4.2 Depurination and denaturation of DNA fragments
DNA fragments require denaturing prior to transfer and probing in order to produce single 
strands for the hybridisation. The transfer of large DNA molecules (>14kb) is not very 
efficient, and can be improved by depurination using 0.25M HC1.
After electrophoresis the gels were incubated with gentle mixing on a rotary mixer in 
0.25M HC1 for 10 min (or until the running dye changed from blue to yellow). The gel was 
briefly washed in distilled water and transferred to a denaturing buffer for 2 X 20 min, and 
finally in a neutralising buffer for 2 X 20 min. The DNA was transferred to nylon 
membrane using the procedure in section 2.9.4.3
115
2.9.4.3 Transfer of DNA to nylon membrane
After depurination, the single stranded DNA was transferred to nylon membrane (Hybond 
N™, Amersham) by capillary action, essentially by the method of Sambrook et al., (1989) 
using 20X SSC. Transfer was usually complete after 16 hr, after which the membrane was 
removed and baked at 80°C for 10 min. Finally the nucleic acid was fixed to the nylon 
membrane by UV crosslinking, which required exposure to UV irradiation for 3 min on a 
UV transilluminator (model TM20, Genetic Research Instrumentation Ltd).
2.10 RAPID AMPLIFICATION OF cDNA ENDS (S' RACE)
2.10.1 5' RACE (homopolymeric tail procedure)
5' RACE is a procedure for amplification of nucleic acid sequences from an mRNA 
template between a defined internal site and the unknown sequences at the 5' end of the 
mRNA (Frohman, et al., 1988) (see figure 2.6). This procedure, otherwise known as 
‘anchored’ PCR, provides a solution for the isolation and amplification of cDNAs which 
may escape or prove challenging for conventional cDNA cloning. First strand cDNA 
synthesis is primed using a gene specific antisense oligonucleotide (GSP1). The first strand 
cDNA product is purified and a homopolymeric tail (eg., poly dC) is added to the 3' end. 
The tailed cDNA is amplified by PCR using a second gene specific nested primer GSP2 
which anneals 3' to GSP1 and an anchor primer (eg., poly dG), which anneals to the 
homopolymeric tail. 5' RACE was performed using a 5' RACE kit (Gibco BRL).
Anchor Primer
The anchor primer (figure 2.7) has been designed by Gibco BRL to contain cloning sites 
and to maximise specific priming. Deoxyinosine has the capacity to base-pair with all four 
bases. Their stability's from greatest to least stable are as follows: I:C, I:A, I:T and I:G. 
The selective placement of deoxyinosine residues in the 3' region of the Anchor primer 
creates a melting temperature (Tm) for the anchor region, which is comparable to that of a 
typical 20-mer primer with a 50% GC rich content. This maximises specific priming from 
the oligo-dC tail and minimises priming at internal GC rich regions of the cDNA.
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2.10.1.1 First strand synthesis of cDNA from RNA
In this procedure a specific RNA sequence (from a background of up to l/*g of total RNA) 
is converted to first strand cDNA.
The following components were added to a 0.5ml microcentrifuge tube:
GSP1 
total RNA 
DEPC-treated water
2 pmols 
s  i/<g
to a final volume of 14 jA
This mixture was incubated for 10 min at 70°C to denature the RNA, chilled on ice for 1 
min, and the following components added:
Final composition of the reaction:
20 mM Tris-HCl (pH 8.4)
50 mM KC1
2.5 mM MgCl2
100 /<g/ml bovine serum albumin 
lOmMDTT
100 nM cDNA primer (GSP1)
500 j a M  each dATP, dCTP, dGTP, dTTP 
<1 /<g (<50 ng//d) RNA
The reaction was mixed gently and collected by brief centrifugation. The mixture was 
incubated for 2 min at 42°C, 1/d of Superscript™ reverse transcriptase (RT) (Gibco BRL, 
200 U//d) was added and the reaction was incubated for a further 30 min at 42°C. After 
incubation for 5 min at 55°C, 1/d of E. coli RNase H (Gibco BRL, 2 U//d) was added for a 
further 10 min at55°C in order to destroy the mRNA template. The reaction was collected 
by brief centrifugation and placed on ice (At this stage the reaction may be stored at -20°C).
10X synthesis buffer 
10 mM dNTP mix 
0.1MDTT
2/d
1/d
2/d
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2.10.1.2 GlassMAX spin cartridge purification of cDNA
95/d of binding solution (equilibrated to room temperature) was added to the first strand 
reaction and transferred to a GlassMAX spin cartridge (Gibco BRL). The mixture was 
centrifuged at 13,000 x g for 20 sec, the flow-through was discarded and the cDNA was 
washed by adding 400/d of cold (4°C) IX wash buffer to the cartridge and centrifuging 
again at 13,000 x g for 20 sec. The wash step was repeated a further 2 times, followed by a 
cold (4°C) 70% (v/v) ethanol wash. After removing the 70% (v/v) ethanol by centrifuging 
as above, the cartridge was centrifuged for a further 1 min at 13,000 x g to remove any 
remaining ethanol. The spin cartridge was transferred to a new microcentrifuge tube, 50/d 
of water (preheated to 65°C) was added and the cDNA eluted by centrifugation at 13,000 x 
g for 20 sec.
2.10.1.3 Terminal deoxynucleotidyl transferase (TdT) tailing of cDNA
16/d of the cDNA eluate (above) was transferred to a 0.5ml microcentrifuge tube and 
heated for 10 min at 70°C, followed by 1 min on ice and brief centrifugation to collect the 
contents of the tube. The following components were added:
10X synthesis buffer 1/d
2 M dCTP 2/d
TdT 1/d
Final composition of the reaction:
10 mM Tris-HCl (pH 8.4)
25 mM KC1
1.25 mM MgCl2
50 //g/ml Bovine serum albumin
0.5 Units //d TdT
The mixture was incubated for 10 min at 37°C, followed by 10 min at 70°C to inactivate the 
TdT. The contents were collected by brief centrifugation and placed on ice.
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2.10.1.4 PCR amplification of dC-tailed cDNA
Optimal conditions for amplification are dependent on the nature of each particular primer 
and target sequence used. Alteration of primer, dNTP or magnesium concentration, as well 
as thermocycling protocol, may be required. For a discussion of parameters affecting PCR 
see Innis and Gelfand et al., (1990).
The following reagents were added to a 0.5ml microcentrifuge tube on ice:
Reagents Volume
sterilised distilled water 35/d
10X synthesis buffer 4.5/d
10 mM dNTP mix 1 /d
nested GSP2 (10 piM) 2/d
anchor primer (10 j a M )  2/d
dC-tailedcDNA 5/d
final volume 49.5/d
Final composition
20 mM Tris-HCl (pH 8.4)
50 mM KC1
2.5 mM MgCl2
100 /<g/ml Bovine serum albumin 
200 nM each dATP, dCTP, dGTP, dTTP 
400 nM GSP2 
400 nM Anchor Primer
The contents of the tube were mixed and overlaid with 50/d of mineral oil, and centrifuged 
briefly to collect the contents. The tube was incubated at 95°C for 5 min, and maintained at 
80°C prior to the next step. 0.5/d of Taq DNA polymerase (Promega Corporation, 5 U//d) 
was added beneath the layer of the mineral oil.
After an initial denaturing step of 94°C for 1 min, 35 cycles of PCR were performed
(HYBAID™ Thermal cycler, model HBTR1) using the following parameters:
annealing 55°C for 30 sec 
primer extension 1.5 min 
denaturing 94°Cfor30sec
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The reaction was incubated at 72° C for 10 min after the last cycle of PCR and stored at 4°C. 
15/d of the amplified sample was analysed on a 4% (w/v) agarose gel (1% (w/v) agarose, 
3% (w/v) NuSieve® GTG® Agarose) and after staining with ethidium bromide was sized 
against 0X174 Hae III DNA markers (Promega Corporation).
2.10.2 5' RACE-Ready cDNA with anchor oligonucleotide
5' RACE ready cDNA is a product manufactured by Cion tech laboratories, Inc USA, 
which overcomes the drawbacks imposed by the homopolymeric tailing required in the 
method above (2.10.1). The modified RACE method described by Edwards et al., (1991) 
is termed SLIC (single strand ligation to single-stranded cDNA), and involves the ligation 
of a single stranded oligonucleotide anchor directly to 31 end of the first strand cDNA by 
T4RNA ligase.
The RACE-ready cDNA provided in the kit was prepared from highly purified poly A+ 
RNA, primed with random hexamers. The RNA template was hydrolysed with NaOH, the 
cDNA purified and the anchor nucleotide (figure 2.8) ligated to the 3' end of the cDNA. 
This cDNA was provided with an oligonucleotide anchor primer complementary to the 
anchor nucleotide ligated to the cDNA.
The 5! end of the cDNA of interest is amplified using two antisense gene specific primers, 
one to perform a primary amplification and a second nested primer to obtain the highest 
possible specificity.
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Figure 2.6: Schematic diagram of the 5' RACE procedure
5'-CUA CUA CUA CUA GGC CAC GCG TCG ACT AGT ACG GGI IGG GI I GGG I I G -3 ’ 
cloning site Sal I anchor region
Figure 2.7: The nucleotide sequence of the 5' RACE anchor primer (homopolymeric tail 
method); the cloning site, Sal I restriction site and anchor region are indicated.
Anchor nucleotide: B ' - G G A G A C T T C C A A G G T C T T A G C T A T C A C T T A A G CAC-S*
Anchor primer: 5 !- C C T C T G A A G G T T C C A G A A T C G A T A G - 3 '
Figure 2.8: RACE-Ready anchor nucleotide and anchor primer, the EcoRI restriction 
site is underlined
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2.10.2.1 PCR of RACE-ready cDNA using gene specific primers 
Prim ary PCR reaction
A primary PCR amplification was carried out on lng of RACE-Ready cDNA using GSP1 
and the anchor primer in the following reaction mixture:
Reagents Volume
Sterile Milli Q water 35.5 /d
10X PCR reaction buffer 5/d
Tris-HCl 
KC1 
Gelatin
MgCl2 5/d
dNTP Mix (lOmM each) 1 ]A
5’ RACE-Ready cDNA 2.0/d
Anchor primer 1 /d
GSP1 1/d
The contents of the tube were mixed and overlaid with 50/d of mineral oil, and centrifuged 
briefly to collect the contents. The tube was incubated at 95°C for 5 min, and maintained at 
80°C prior to the next step. 0.5/d of Taq DNA polymerase (Promega Corporation, 5 U//d) 
was added beneath the layer of the mineral oil.
35 cycles of PCR were performed (HYBAID™ Thermal cycler, model HBTR1) using the 
following parameters:
annealing 57° C for 30sec 
primer extension 2 min 
denaturing 94°Cfor30sec
The reaction was incubated at 72°C for 10 min following the last cycle of PCR and 
maintained at 4° C.
Final composition
lOmM
5QmM
0.001 % (w/v) 
2.5mM 
0.2mM (each)
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2.10.2.2 PCR amplification using a nested primer
A secondary PCR reaction was performed using the above protocol, substituting GSP2 for 
GSP1 and using 2/d of a 1 in 20 dilution of the primary reaction in place of the RACE- 
ready cDNA. 15/d of the amplified sample was analysed on a 4% (w/v) agarose gel 
(2.3.4.1) and after staining with ethidium bromide, PCR products were sized against 
0X174 Hae III DNA markers (2.3.5, 2.3.6).
2.11 REVERSE TRANSCRIPTASE PCR
This procedure was used to obtain a full-length human p-lyase cDNA from a human kidney 
mRNA template. Three gene specific oligonucleotides were used in this procedure (figure 
2.9).
2.11.1 First strand synthesis of cDNA from mRNA
First strand synthesis was performed as in section 2.10.1.1 using oligonucleotide GSP1 as 
the primer
2.11.2 PCR amplification of the first strand product
The first strand product was amplified using a sense primer GSP2 and a second antisense 
primer GSP3 nested approximately 100 bases inside GSP1. The second antisense primer 
(GSP3) ensures greater specificity of the amplification.
The following reagents were added to a fresh 0.5ml microcentrifuge tube on ice:
Reagent Volume Final concentration
sterilised distilled water 31.5/d
10X reaction buffer 5/d 20 mM Tris-HCl (pH 8.4), 50 mM KC1
MgCh (25mM) 3/d 1.5 mM MgCl2
10 mM dNTP mix 1/d 200 nM each dATP, dCTP, dGTP, dTTP
GSP2 (10 //M ) 2/d 400 nM GSP2
Nested GSP3 (10 piM) 2/d 400 nM GSP3
First strand product 2/d
final volume 49.5/d
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The contents of the tube were mixed and overlaid with 50/d of mineral oil, and centrifuged 
briefly to collect the contents. The tube was incubated at 95°C for 5 min, and maintained at 
80°C prior to the next step. 0.5/d of Taq DNA polymerase (Promega Corporation, 5 U//d) 
was added beneath the layer of the mineral oil.
After an initial denaturing step of 94°C for 1 min, 35 cycles of PCR were performed 
(HYBAID™ Thermal cycler, model HBTR1) using the following parameters:
annealing 57°C for 30sec 
primer extension 2.0 min 
denaturing 94°Cfor30sec
The reaction was incubated at 72°C for 10 min following the last cycle of PCR and 
maintained 4°C. 15/d of the amplified sample was analysed on a 1% (w/v) agarose gel and 
after staining with ethidium bromide was sized against 0X174 HaeIII DNA markers 
(Promega Corporation).
2.12 SUBCLONING OF PCR PRODUCTS USING THE TA CLONING™ 
SYSTEM
This cloning system produced by Invitrogen corporation (California, US), provides a quick 
one-step cloning system for the direct insertion of a PCR product into a plasmid vector. 
This system takes advantage of the non-template dependent activity of the thermostable 
polymerase used in PCR. This polymerase adds a single deoxyadenosine to the 3' end of 
all duplex molecules. The vector supplied in the kit is a linear molecule with single 3' T 
overhangs at the insertion site. This allows simple cloning without the need for enzyme 
modification of the PCR product.
125
2.12.1 Ligation of PCR products into the TA Cloning™ vector
The ligations were set up as 1:1 and 1:3 molar ratio of vector to PCR product, where the 
vector size was taken as 3.9kb and the insert 0.7kb. The molar ratios were calculated using 
the following equation:
Xng of cDNA insert = N° of bp of cDNA (700) x 50 (ng of vector)
N° of bp of vector (3900)
For a 1:1 molar ratio, 50ng of vector was used with 9ng of PCR product.
Li eation Reaction 111 L3
Sterile water 6 /d 4 //I
lOx ligation buffer 1/d 1 /d
pCRTMji vector (25ng//d) 2 /d 2 /d
diluted PCR product (9ng//d) 1 /d 3 /d
T4DNALigase 1 /d 1 /d
The ligation reaction was incubated at 12°C overnight.
2.12.2 Transformation of competent INVaF' cells
INVaF' is an E.coli strain which provides stable replication of high copy number 
plasmids. INVaF' enables blue/white screening of recombinant plasmids by a- 
complementation of (Tgalactosidase with the lacZ/SM15 genotype (see section 2.5).
For each ligation reaction, a 50/d vial of competent cells was thawed on ice. 2/d of 0.5M p- 
mercaptoethanol was added to each vial of competent cells and was mixed by gentle 
tapping. 1/d of ligation mixture was added to the competent cells, and after gentle tapping 
the mixture was incubated on ice for 30 min (The remaining ligation mixture was stored at 
-20°C). The vials were incubated for 60 sec, without mixing, in a 42°C water bath, and 
chilled for a further 2 min on ice (this heat shock encourages the bacteria to take up the
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plasmid). 450/d of SOC (a rich growth medium) media was added to the vials which were 
subsequently shaken at 37°C for exactly 1 hr at 225 rpm in a gyratory shaker incubator. 
25/d and 100/d of each transformation were spread on separate LB agar plates (containing 
ampicillin, 50 /<g/ml and X-Gal, 40 /<g/ml), using a glass spreader. The plates were 
incubated for up to 40 hours at 37 °C to allow the blue colour of background colonies to 
develop. White colonies were picked for plasmid isolation (See section 2.5.4).
2.13. CHROMOSOME ASSIGNMENT OF THE HUMAN p-LYASE GENE 
BY PCR
Reverse and forward p-lyase gene specific primers, Phi and Ph2 respectively, were used to 
determine the chromosomal location of the human p-lyase gene by PCR analysis. The first 
step was to optimise the PCR reaction using human genomic DNA, followed by PCR 
analysis of DNA samples prepared from a panel of human-rodent somatic cell hybrid cells.
Volume 
34.5 /d 
5/d
2.13.1 PCR of human genomic DNA
PCR was carried out as follows:
Reagents 
Sterile H2 O
10X PCR reaction buffer 
Tris-HCl 
KC1 
Gelatin 
MgCl2
dNTP Mix (lOmM each)
Genomic DNA (0.05//g//d)
Phi (10/iM)
Ph2 (10/dVl)
Total volume
4/d
1/d
1/d
2/d
2/d
49.5
Final concentration
lOmM
5QmM
0.001% (w/v) 
2.0mM 
0.2mM (each)
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The contents of the tube were mixed and overlaid with 50/d of mineral oil, and centrifuged 
briefly to collect the contents. The tube was incubated at 95°C for 5 min, and maintained at 
80°C prior to the next step. 0.5/d of Taq DNA polymerase (Promega Corporation, 5 U//d) 
was added beneath the layer of the mineral oil.
35 cycles of PCR were performed (HYBAID™ Thermal cycler, model HBTR1) using the 
following parameters:
annealing 57° C for 30sec 
primer extension 72° C for 2.0 min 
denaturing 94°Cfor30sec
The reaction was incubated at 72°C for 10 min following the last cycle of PCR and 
maintained at 4°C.
15/d of the amplified sample was analysed on a 4% (w/v) agarose gel (2.3.4.1) and after 
staining with ethidium bromide was sized against 0X174 Hae III DNA markers (2.3.5, 
2.3.6).
2.13.2 PCR analysis of DNA from human-rodent somatic cell hybrids
A panel of human/rodent somatic cell hybridomas (table 2.4, a gift from Dr. Lesley Rooke, 
Imperial Cancer Research Fund, London), encompassing the entire human genome was 
screened using the PCR procedure in section 2.13.1. 0.05pg of genomic DNA sample 
was used in the PCR amplification.
2.13.3 PCR analysis of DNA from human-rodent somatic cell hybrids 
containing chromosome 9 subfragments
In order to further localise the p-lyase gene to a specific region of chromosome 9, two DNA 
hybrid samples, CJ9q and SV340/BW, containing fragments of chromosome 9 (a gift of 
Dr. Sue Povey, MRC) were analysed using the PCR procedure in section 2.13.1. 0.05ug 
of genomic DNA sample was used in the PCR amplification. CJ9q is reported to contain 
the whole q arm of chromosome 9 and SV340/BW, the region 9Pter to 9q223.
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HYBRID DNA reported chromosomal content
GM07299 1 + X
GM10826B 2
GM10253 3
HHW416 4
GM10114 5
MCP6BRA 6p21-qter +Xq
CLONE21E 7
C4a 8
GM10611 9
7628a 10+Y
JIcI4 11
laA9602+VE 12 + X + 21
289 13 + bits of 8,11,12
GM10479 14 + part of 16 (PCR=pl3.1-q22.1)
HORLI 15,1 lq,part of Xp and prox long arm
2860H7 16
PCTBA1.8 17
DL18TS 18
GM10612 19
GM10478 Heterogeneous 4,20,x
THYB1.33 21q + X
PGME25nu 22 + part of Xp
HORL9X X
853 Y
Table 2.4: Human-rodent somatic cell hybrid genomic DNA samples
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CHAPTER 3
ISOLATION, CHARACTERISATION AND EXPRESSION OF THE cDNA 
CODING FOR RAT KIDNEY CYTOSOLIC CYSTEINE CONJUGATE
P-LYASE
3.1 INTRODUCTION
The role of rat kidney cysteine conjugate p-lyase in the bioactivation of certain halogenated 
alkene cysteine conjugates and the production of nephrotoxic thiols has been well 
established (Commandeur and Vermeulen, 1990). An understanding of the structure and 
function of p-lyase enzymes and their selectivity towards xenobiotic cysteine conjugates 
will assist in the prediction of chemical toxicity of compounds metabolised by this 
pathway.
The potential for human exposure to these compounds has recently focused interest on 
human kidney p-lyase, particularly in terms of structure activity relationships. The aim of 
this research was to isolate the rat kidney p-lyase cDNA as a first step in the isolation of the 
corresponding human cDNA (chapter 4), and to compare the relative kinetic properties of 
kidney p-lyase from these two species.
The results presented in this chapter describe the isolation, of a full-length rat kidney 
cytosolic cysteine-conjugate p-lyase cDNA from a rat kidney cDNA library in XgtlO. The 
cDNA was sequenced and expressed in COS-1 cells in order to demonstrate that it did in 
fact code for rat kidney p-lyase.
All the experiments presented in this chapter were carried out by the author, with the 
exception of some DNA sequencing reactions which were performed by Michelle Pitt (an 
undergraduate project student) and Dr. Madlyn Denyer (a visitor to the laboratory).
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3.2 ISOLATION OF RECOMBINANT 0-LYASE cDNA CLONES FROM A 
SPRAGUE-DAWLEY RAT KIDNEY 5’ STRETCH cDNA LIBRARY.
A rat kidney 5' stretch cDNA library (Cion tech) was screened using a 648bp (3-lyase 
cDNA probe, kindly provided by Dr. Miles Schofield. The (3-lyase probe had been isolated 
from a Wistar rat kidney cDNA library (Cion tech) in the expression vector X gtll, using a 
desorbed monospecific sheep polyclonal antibody, to purified rat kidney cytosolic cysteine 
conjugate (3-lyase (MacFarlane et al., 1989).
The commercially prepared 51 Stretch rat kidney cDNA library, RL1031a (2.2.6.1) was 
chosen because it was reported to contain a high proportion of cDNAs with complete 5' 
sequences, and would therefore increase the chance of isolating a full-length (3-lyase cDNA. 
The library cDNA (average size of 1.6kb) was prepared from the mRNA of an adult male 
Sprague-Dawley rat.
3.2.1 Preparation of the Wistar rat p-lyase cDNA probe.
The 746bp Wistar rat kidney putative (3-lyase cDNA (figure 3.1) isolated by Miles 
Schofield (PhD thesis, University of Surrey, 1993) was provided in the plasmid vector 
pGEM®7Zf(+), inserted into the EcoRL restriction site of the plasmid (figure 3.2a). The 
cDNA of this recombinant clone (p(3l-1.0) contained 268 nucleotides of open reading 
frame, 380 nucleotides of non-coding region and a 98 nucleotide poly A tail. The probe 
cDNA was excised from ppl-1.0 by double digestion with EcoKL and Avail (section 2.3.3) 
to produce a 0.641kb cDNA fragment lacking poly-adenosine sequences. The presence of 
poly adenosine sequences would give rise to false positive signals as the probe would 
hybridise to any recombinant bacteriophage cDNA containing a poly A tail. The digested 
DNA was purified by 1% (w/v) agarose gel electrophoresis (figure 3.2b), (2.3.4) and the 
cDNA fragment extracted using Geneclean™ (2.3.7).
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(a) £coRI* Sstl Apal Kpnl Avail £coRI*
p ( 3 1 - 1 . 0 p A
o
J_______ L
746 b
_ l
G in G ly S e r T y r Phe Leu I le A la Asp l i e S e r Asp 12
1 CAG GGG AGC TAC TTC CTC ATT GCA GAC ATC TCA GAC
Phe L ys S e r Lys M et P ro Asp Leu P ro G ly A la G lu 2 4
37 TTC AAG AGC AAG ATG CCT GAC CTG CCT GGA GCT GAG
Asp G lu P ro T y r Asp A rg A rg Phe A la L ys T rp M et 3 6
73 GAT GAG CCT TAT GAC AGA CGC TTT GCC AAG TGG ATG
I le L ys Asn M et G ly Leu V a l G ly l i e P ro V a l S e r 48
109 ATC AAA AAC ATG GGC TTG GTG GGC ATC CCT GTC TCC
T h r Phe Phe S e r A rg P ro H i s G 1 n Lys Asp P he Asp 6 0
145 ACA TTC TTC AGT CGG CCC CAT CAG AAG GAC TTT GAC
H 1 s T y r I  le A rg Phe Cys Phe V a l Lys Asp Lys A la 72
181 CAC TAC ATC CGA TTC TGT TTT GTC AAG GAC AAG GCC
T h r Leu G in A la M et Asp G lu A rg Leu A rg Lys T rp 8 4
2 1 7 ACA CTC CAG GCC ATG GAT GAG AGA CTG CGC AAG TGG
Lys G lu Leu G 1 n P ro S to p 8 9
2 5 3 AAA GAG CTC CAA CCC TGA GGAGGCTGCCCTCAGCCCCACCT
2 9 4  CGAACACAGGCCTCAGCTATGCCTTAGCACAGGGATGGCACTGGAGG 
341 GCCCAGCTGTGTGACTGCGCATGTTTCCAGAAAAGAGGCCATGTCTT 
3 8 8  GGGGGTTGAAGCCATCCTTTCCCAGTGTCCATCTGGACTATTGGGTT 
4 3 5  GGGGGCCAGTTCTGGGTCTCAGCCTACTCCTCTGTAGGTTGCCTGTA 
482  GGGTTTTGATTGTTTCTGGCCTCTCTGCCTGGGGCAGGAAAGGGTGG 
5 2 9  AATATCAGGCCCGGTACCACCTTAGCCCTGCCGAGGCTCTGTGGCTT 
5 7 6  CTCTACATCTTCTCCTGTGACCTCAGGATGTTGCTACTGTTCCTAAT 
6 2 3  AAAGTTTTAAGTTATTAGGACCCTCA n=98
Figure 3.1: (a) Restriction enzyme map of the cDNA insert from p (31-1.0, isolated by 
Miles Schofield, from a Wistar rat kidney cDNA library using the purified antibody to rat 
kidney (3-lyase. EcoKl linkers are indicated by *, gene-specific sequencing primers are 
indicated by solid boxes and the direction and extent of sequencing is indicated by arrows, 
(b) Nucleotide and deduced amino acid sequence of ppl-1.0.
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(a) ppl-1.0
EcoRI Avail ZscoRI Avail Avail EcoRl
641bp 105 1530bp 222 1248bp
cDNA (746bp) pGEM7Zf(+) (3000bp)
(b) Kb 1 2
23.14
9.42 
6.52
4.42
2.32
2.03
0.6
1.530
1.248
0.641
(0.222)
(0.105)
Figure 3.2: (a) Restriction enzyme map of ppl-1.0 indicating the positions of Avail and 
EcoRl cutting sites, (b) 1% (w/v) agarose gel electrophoresis of ppl-1.0 digested with 
Avail and EcoRl (lane 2). Lane 1 contains XHindlll molecular weight markers. Figures in 
brackets indicate DNA fragments which are too faint to observe on the gel.
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3.2.2 Hybridisation screening of a cDNA library
The library was titrated using the method detailed in section 2.4.1. The titre was calculated 
to be 4x l010 PFU/ml, and was used to determine the dilution required to achieve lxlO5 
PFU/22cm2 agar plate. Two plates were prepared and filter replicas were made in duplicate 
according to the method in section 2.4.2. Screening was performed using the 641 bp cDNA 
fragment (3.2.1) radiolabelled (2.4.3) with [a32P]-dCTP (3000 Ci/mmol, ICN How), and 
gave rise to 17 positive clones. Following 3 rounds of plaque purification at a lower plaque 
density (section 2.4.6), all 17 of the clones remained positive. Figure 3.3 shows the 
autoradiograph of a 3rd round purification filter. Small scale recombinant DNA 
preparations were made for each of the 17 clones (as in 2.4.7).
3.2.3 Determination of the size of the bacteriophage cDNA insert
The cDNA inserts were sized by 1% (w/v) agarose gel electrophoresis (2.3.4) following 
digestion of the bacteriophage DNA (lOpg) with EcoRl (2.4.8). The approximate sizes of 
the 17 clones are given in table 3.1. It can be seen from the table that clones A 1, A6 and B 1 
do not demonstrate bands on EcoRl restriction analysis. Southern blot analysis (data not 
shown) demonstrated that the cDNA remained attached to one of the bacteriophage arms 
indicating that one of the EcoRl restriction sites had been damaged or altered.
Two clones (B2 and B8) contained the longest cDNAs of approximately 2kb in length. 
Their cDNAs contained an EcoRl restriction site which is illustrated by the presence of two 
fragments on complete EcoRl digestion. Clone B2 was chosen for further analysis.
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Figure 3.3: Autoradiograph of a filter from the 3rd round plaque purification using p(3l- 
1.0 as a hybridisation probe
No. Insert size (kb) No. Insert size (kb)
A1 0.65 B1 No bands*
A2 No bands* B2 1.15 kb +0.85
A3 0.65 B3 0.6
A4 1.0 kb +0.45 B4 0.6
A5 0.65 B5 0.9 + 0.65
A6 No bands* B6 0.6
A7 0.65 B7 1.15 + 0.4
A8 L. 1 1 5 B8 1.15 + 0.85
A9 0.6
Table 3.1: Sizes of cDNA inserts, from EcoRl digests of the recombinant bacteriophage 
clones, isolated from the rat kidney cDNA library using the 0.641 kb cDNA as a probe. 
* indicates that one of the EcoRl restriction sites was damaged.
3.3 SUBCLONING OF THE cDNA INTO pGEM®7Zf(+)
The plasmid vector pGEM®7Zf(+) (figure 2.3) provides a greater ratio of insert to vector 
compared with X bacteriophage, thus enabling recovery of substantial insert DNA from a 
single plasmid preparation. Additionally pGEM®7Zf(+) contains the promoter sequences 
SP6 and T7 which are used as vector priming sites in DNA sequencing.
As can be seen from section 3.2.3, digestion of B2 with EcoRl gives rise to two bands, 
demonstrating the presence of an internal EcoRl restriction site. This was to my advantage 
for DNA sequencing, as the two fragments could be subcloned separately into the EcoRl 
site of pGEM®7Zf(+). Therefore, more sequencing data could be achieved using the 
vector-specific primers, thus reducing the requirement for expensive gene-specific primers. 
However, it was also necessary to subclone the whole cDNA as a single fragment in order 
to establish the orientation of the two fragments relative to one another. A partial digest of 
the bacteriophage DNA was required in order to achieve the digestion of the 2kb cDNA 
from the bacteriophage as an intact fragment (section 3.3.1).
3.3.1 Preparation of bacteriophage cDNA inserts and plasmid DNA for 
subcloning
A partial digest of the bacteriophage cDNA was achieved by the addition of a small quantity 
of enzyme to a relatively large amount of DNA. lOpg of B2 was digested overnight with 
lpl (lOU/pl) of EcoRl (section 2.4.8) and electrophoresed on a 1% (w/v) agarose gel 
(section 2.3.4) producing two bacteriophage vector DNA bands of 34.5kb and llk b  and 3 
cDNA insert bands of approximately 2kb, 1.15kb and 0.85kb (see figure 3.4). In order to 
produce sufficient cDNA for subcloning, 5 separate digestion reactions were carried out 
each with lOpg of B2 DNA and lp l of enzyme. After digestion, the samples were pooled 
and run in a large well of a 1% (w/v) agarose gel (figure 3.5) and visualised by ethidium 
bromide staining (2.3.4, 2.3.5). The three (3-lyase cDNAs were separately excised from 
the gel and purified by Geneclean™ (2.3.7). The concentrations of the purified cDNA 
inserts were estimated by visualising a small sample on an ethidium bromide stained
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agarose gel. Dilutions of the insert DNAs were prepared to give an estimated concentration 
of lOOng/pl. pGEM®7Zf(+) plasmid DNA was digested with EcoRl as described in 
section 2.3.3, and diluted to a concentration of lOOng/pl.
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Kb
23.14
9.42 
6.52
4.42
2.32
2.03
0.6
35
11
2.0
1.15
0.85
Figure 3.4: Partial digestion of recombinant bacteriophage DNA with EcoRl, the sizes of 
cDNA insert fragments of B2 are indicated:
Lane 1: XHindWl molecular weight markers 
Lane 2: recombinant bacteriophage A4 
Lane 3 recombinant bacteriophage B2 
Lane 4 recombinant bacteriophage B5 
Lane 5 recombinant bacteriophage B7 
Lane 6 recombinant bacteriophage B8
1 2 kb
R N A /degraded D N A
Figure 3.5: Preparative 1% (w/v) agarose gel electrophoresis of bacteriophage clone B2 
after digestion with £h?RI (lane 1), lane 2 contains DNA molecular weight markers a Hind 
III.
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3.3.2 Ligation and transformation reactions
The three cDNA fragments were ligated into the EcoRl linearised vector pGEM®7Zf(+) as 
detailed in section 2.5.2. using 1:3 and 1:1 molar ratios of vector to insert, and transformed 
into E.coli JM109 bacterial cells (as in 2.5.3). The transformed bacteria were cultured on 
agar plates containing ampicillin (50pg/ml), X-Gal (40pg/ml) and IPTG (0.5mM) and 
incubated overnight at 37°C. The results of the ligation/transformation experiments for each 
of the 3 cDNAs are shown in table 3.2. Each white colony was streaked onto a 1 cm 
square of an agar plate containing ampicillin, X-Gal and IPTG and incubated overnight at 
37°C. Colonies remaining white were examined for inserts using the cracking procedure 
(3.3.3).
3.3.3 Cracking Procedure
In order to determine the presence of insert DNA, a selection of white colonies were 
analysed by the cracking procedure using a crude preparation of plasmid DNA (see 2.5.4). 
The samples were run (figure 3.6) on a 1% (w/v) agarose gel (as in 2.3.4) along side a 
sample of pGEM®7Zf(+). The plasmid DNA from clones 51, 66 and 132, was retarded, 
compared with the control pGEM®7Zf(+). Small scale plasmid preparations of clones 51, 
66 and 132 were made using the Qiagen™ method, (section 2.5.5.1).
3.3.4 Analysis of insert size
Restriction digest analysis of the plasmid DNA with EcoRl, followed by agarose gel 
electrophoresis and ethidium bromide staining (figure 3.7) demonstrated that clone 132 
contained the 2kb fragment (0.85kb + 1.15kb) and clones 51 and 66 contained the 0.85kb 
and 1.15kb cDNAs respectively. The recombinant clones 132, 66 and 51 were renamed 
ppl-2.0, ppl-2.1 and ppl-2.2 respectively.
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Plate Plasmid 
(EcoRl cut)
cDNA insert Molar
ratio
White
colonies
Blue
colonies
1. — * — — — —
2. pGEM7Zf(+)*u — — 2 510
3. pGEM7Zf(+)* — — 0 50
4. pGEM7Zf(+)* — — 5 480
5a. pGEM7Zf(+) 0.85kb 1:1(V:I) 8 265
5b. pGEM7Zf(+) 0.85kb 1:1(V:I) 17 570
6a. pGEM7Zf(+) 0.85kb 1:3(V:I) 12 302
6b. pGEM7Zf(+) 0.85kb 1:3(V:I) 23 593
7a. pGEM7Zf(+) 1.15.kb 1:1(V:I) 10 250
7b. pGEM7Zf(+) 1.15kb 1:1(Y:I) 19 511
8a. pGEM7Zf(+) 1.15kb 1:3(V:I) 11 294
8b. pGEM7Zf(+) 1.15kb 1:3(V:I) 26 547
9a. pGEM7Zf(+) 2kb 1:1(V:I) 8 304
9b. pGEM7Zf(+) 2kb 1:1(V:I) 12 563
10a. pGEM7Zf(+) 2kb 1:3(V:I) 7 275
10b. pGEM7Zf(+) 2kb 1:3(V:I) 18 462
Table 3.2: Cloning strategy and results for subcloning of the cDNA fragments (0.85kb, 
1.15kb and 2kb) from the EcoRl digested recombinant bacteriophage clone B2 into the 
plasmid vector pGEM7Zf(+). Plates l-A  were plated at one dilution (lOOpl). plates 5-10 
were plated at two dilutions (a=100pl, b=200pl), *= no ligase added, u= not digested with 
EcoRl.
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1 2  3 4
Lane 1: Pgem®7Zf(+) 
Lane 2: clone 132 
Lane 3: clone 66. 
Lane 4: clone 51
Figure 3.6: Electrophoretic analysis of plasmid DNA prepared from putative (3-lyase 
recombinant clones 132, 66 and 51, using the cracking procedure.
kb 1 2 3 4 5
3 .0
1 .1 5
0 .8 5
Lane 1: AHincHII 
Lane 2: <(>X174 
Lane 3: clone 132 
Lane 4: clone 66 
Lane 5: clone 51
Figure 3.7: EcoRl restriction digest analysis of purified plasmid DNA from clones 132, 
66 and 51.
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3.4 SEQUENCING OF THE RECOMBINANT cDNAs ppl-2.0, ppl-2.1 AND 
ppl-2.2.
3.4.1 Sequencing with SP6 and T7 primers
Plasmid DNA sequencing was performed using Sequenase™ version 2.0 as described in 
section 2.6. Both primers gave clear, readable sequence, however, the T7 primer only gave 
261 bases of clone ppl-2.0, after which the sequence came to an abrupt stop. This was 
mirrored by the SP6 sequence of ppl-2.1. The abrupt nature of the termination of the 
sequencing reactions above, compared with the normal gradual tailing off, suggested that 
the cDNA contained a region of strongly self-hybridising secondary structure. In order to 
try to eliminate this and achieve further sequencing, the DNA was heated to 80°C and 90°C 
during the annealing step of the sequencing reaction, however, neither temperature was 
successful in extending the sequence. To overcome this problem, a nucleotide analogue of 
dGTP (dITP) was used in the sequencing reaction. dITP forms a weaker secondary 
structure within the DNA allowing full denaturation of GC rich regions during 
electrophoresis, therefore eliminating compressions. An example of a sequencing gel 
autoradiograph is shown in figure 3.8.
Figure 3.9 illustrates the extent of sequencing of ppl-2.0, ppl-2.1 and ppl-2.2 using SP6 
and T7 primers. The SP6 DNA sequence of the Sprague-Dawley clone ppl-2.0 is identical 
to the antisense strand of the Wistar clone ppl-1.0 (figure 3.10), with the exception of 2 
single base changes in the non-coding region. The poly A tail and the last 25 nucleotides of 
non-coding region are also absent in ppl-2.0. This information shows that the T7 primer 
sequenced the sense DNA strand of ppl-2.0.
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SP6 T7
G C  A T  G C  A T
Figure 3.8: Autoradiograph from a sequencing gel of ppl-2.0, using SP6 and T7 
primers.
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T7: 261 bases
llll ppl-2 .0 llll
SP6: 261 bases
ppl-2.1
T7: 364 bases
SP6: 346 bases
SP6: 316 bases 
 ►
ppl-2 .2
T7: 346 bases
Figure 3.9: Map of rat cDNA clones ppl-2.0, p(4-2.1 and ppl-2.2. Arrows indicate the 
extent and the direction of the initial sequencing using SP6 and T7 primers.
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CTGCCCTCAG CCCCACCTCG AACACAGGCC TCAGCTATGC 40
CTGCCCTCAG CCCCACCTCG AACACAGGCC TCAGCTATGC
CTTAGCACAG GGATGGCACT GGAGGGCCCA GCTGTGTGAC 80
CTTAGCACAG GGATGGCACT GGAGGGCCCA GCTGTGTGAC
TGCGCATGTT TCCAGAAAAG AGGCCATGTC TTGGGGGTTG 120
TGCGCATGTT TCCAGAAAAG AGGCCATGTC TTGGGGGTTG
AAGCCATCCT TTCCCAGTGT CCATCTGGAC TATTGGGTTG 160
AAGCCATCCT TTCCCAGTGT CCATCTGGAC TATTGGGTTG
GGGGCCAGTT CTGGGTCTCA GCCTACTCCT CTGTAGGTTG 200
GGGGCCAGTT CTGGGTCTCA GCCTACTCCT CTGTAGGTTG
CCTGTAGGGT TTTGATTGTT TCTGGCCTCT CTGCCTGGGG 240
CCTGTAGGGT TTTGATTGTT TCTGGCCTCT CTGCCTGGGG
CAGGAAAGGG TGGAATATCA GGCCCGGTAC CACCTTAACC 280
CAGGAAAGGG TGGAATATCA GGCCCGGTAC CACCTTAGCC
CTGCCAAGGC TCTGTGGCTT CTCTACATCT TCTCCTGTGA 320
CTGCCGAGGC
*
TCTGTGGCTT CTCTACATCT TCTCCTGTGA
CCTCAGGATG TTGCTACTGT TCCTAATAAA GTTTTAAGTT 360
CCTCAGGATG TTGCTACTGT TCCTAAT 346
ATTAGGACCC TCAn=98
Figure 3.10: Comparison of the DNA sequence from the antisense strand of the Wistar 
cDNA, ppl-1.0 (top) with the SP6 DNA sequence of the Sprague-Dawley cDNA ppl-2.0 
(bottom). Base changes are indicated by *, polyadenylation sequence is underlined.
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3.4.2 Sequencing with gene-specific oligonucleotide primers
As is shown in section 3.4.1, the SP6 and T7 vector specific primers will only sequence a 
finite number of nucleotides, which for DNA sequences of approximately 300 bases or 
longer necessitates the requirement for gene-specific oligonucleotide primers (see 2.6.8). 
These are primers generally of 16-24 nucleotides, designed to bind specifically to a unique 
sequence of the DNA approximately 50 bases upstream of the region to be sequenced. The 
primers should be designed so that they do not snap back on themselves or form dimers, 
and require an approximate GC content of 50%. In order to fully sequence clone ppl-2.0, in 
both sense and antisense directions, 11 primers of 16 nucleotides were designed (section 
2.6.8). The oligonucleotide primers were checked against the rest of the sequenced plasmid 
insert as well as the plasmid DNA to ensure that the primer would bind specifically to the 
desired sequence and to no other DNA sequence in the sequencing mixture. The 
approximate melting temperature of the oligonucleotides was calculated using the equation;
Tm (°C) = 2(A+T) + 4(G+C)
The primers were used at a concentration calculated to give a 1:1 ratio of primer to template 
(2.6.8) and the annealing temperature used in the sequencing reaction (2.6.4.1) was Tm- 
5°C. Sequencing was confirmed by a minimum of three reactions, in both directions.
A restriction enzyme map of ppl-2.0 is shown in figure 3.11, the direction and extent of 
sequencing is indicated by arrows. The sequences of ppl-2.0, derived from both the vector 
and gene-specific primers were assembled, translated and analysed using the GeneJockey
1.1 software package (Biosoft Ltd, UK). The complete nucleotide and deduced amino acid 
sequences are shown in figure 3.12. Comparison with the EMBL DNA sequence database 
was performed using the Wisconsin GCG DNA analysis software. No significant matches 
were found, strongly suggesting that ppl-2.0 was a novel cDNA.
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1 AAACTGACCAAGGAGTATGATCAATCCCGTCCAGCCTCCGAG
4 3  CCTGCAGCCGTTTGGTCATGGTGAGCTGCTTCAGCTAACAATTG CACTG AChGTGCTCTTGAGCCAA 
1 10 GTTGCTTCTGGGCGGAAGTAGTCCATCTAGGGCTCGGCCTCTTT/!A4£r/fy4rf016ACTTCTGCAACCT  
17 7  TGGGACTACGTTTGGGGTCGCCGGCTATTGGACGGAGCAGCGCAATTGTTAGCTGAAGCAGCTCACC
M et T h r L y s A rg L e u G in A 1 a A r g A r g L eu A sp G l y I l e A s p G i n A sn L e u 17
2 4 4 ATG ACC AAA CGG CTG CAG GCT CGG AGG CTG GAC GGG ATT GAT CAA AAC CTC
T r p Val G lu P h e G l y L ys L e u T h r L y s G lu T y r A sp Val V al A sn L e u G l y 3 4
2 9 5 TGG GTG GAG TTT GGC AAA CTG ACC AAG GAG TAT GAC GTC GTG AAC TTG GGT
G i n G l y P h e P r o A sp P h e S e r P r o P r o A sp P h e A l a T h r G in A l a P h e G 1 n 51
3 4 6 CAG GGC TTC CCT GAC TTC TCG CCT CCG GAC TTT GCA ACG CAA GCT TTT CAG
G i n A l a T h r S e r G l y Asn P h e Met L e u Asn G in T y r T h r A r g A l a P h e G l y 6 8
3 9 7 CAG GCT ACC AGT GGG AAC TTC ATG CTC AAC CAG TAC ACC AGG GCA TTT GGT
T y r P r o P r o Leu T h r Asn V al L eu A l a S e r P h e P h e G l y L y s L e u L eu G l y 8 5
4 4 8 TAC CCA CCA CTG ACA AAC GTC CTG GCA AGT TTC TTT GGC AAG CTG CTG GGA
G i n G lu M et Asp P r o Leu T h r Asn Val L eu V al T h r V al G l y A l a T y r G l y 102
4 9 9 CAG GAG ATG GAC CCA CTC ACG AAT GTG CTG GTG ACA GTG GGT GCC TAT GGG
A l a L eu P h e T h r A 1 a P h e G in A l a L e u V al A sp G 1 u G ly A s p G lu V al I l e 11 9
5 5 0 GCC TTG TTC ACA GCC TTT CAG GCC CTG GTG GAT GAA GGA GAT GAG GTC ATC
l i e Met G l u P r o A 1 a P h e A sp Cys T y r G lu P r o Met T h r Met Met A l a G l y 136
601 ATC ATG GAA CCT GCT TTT GAC TGT TAT GAA CCC ATG ACA ATG ATG GCT GGA
G l y Cys P r o Val P h e Val T h r Leu L y s P r o S e r P r o A l a P r o L y s G l y L y s 15 3
6 52 GGT TGC CCT GTG TTC GTG ACT CTG AAG CCG AGC CCT GCT CCT AAG GGG AAA
L e u G ly A l a S e r A sn Asp T r p G in L e u A sp P r o A l a G lu L e u A l a S e r L y s 17 0
7 0 3 CTG GGA GCC AGC AAT GAT TGG CAA CTG GAT CCT GCA GAA CTG GCC AGC AAG
P h e T h r P r o A rg T h r L y s H e Leu Val L eu Asn T h r P r o A sn A sn P r o L eu 18 7
7 5 4 TTC ACA CCT CGC ACC AAG ATC CTG GTC CTC AAC ACA CCC AAC AAC CCT TTA
G l y L y s V al P h e S e r A rg Met G lu L e u G 1 u L e u V al A l a Asn L e u C y s G in 2 0 4
8 0 5 GGA AAG GTA TTC TCT AGG ATG GAG CTG GAG CTG GTG GCT AAT CTG TGC CAG
G in H i s A sp Val Val Cys H e S e r A sp G 1 u Val T y r G in T r p L e u V al T y r 221
8 5 6 CAG CAC GAT GTC GTG TGC ATC TCT GAT GAG GTC TAC CAG TGG CTG GTC TAT
A sp G l y H i s G in H i s Val S e r I l e A 1 a S e r L e u P r o G ly Met T r p A s p A r g 2 3 8
9 0 7 GAC GGG CAC CAG CAC GTC AGC ATC GCC AGC CTC CCT GGC ATG TGG GAT CGG
T h r Leu T h r l i e G l y S e r A 1 a G ly L y s S e r P h e S e r A l a T h r G l y T r p L y s 2 5 5
9 5 8 ACC CTG ACC ATC GGC AGT GCA GGC AAA AGC TTC AGT GCC ACT GGC TGG AAG
Val G ly T r p Val Met G ly P r o Asp Asn H e Met L y s H i s L e u A r g T h r V al 2 7 2
1 0 0 9 GTG GGC TGG GTC ATG GGT CCA GAT AAC ATC ATG AAG CAC CTG AGG ACA GTG
H i s GI n A sn S e r I l e P h e H i s C ys P r o T h r G 1 n A 1 a G 1 n A 1 a A l a V al A 1 a 2 8 9
1 0 6 0 CAC CAG AAT TCT ATC TTC CAC TGC CCC ACC CAG GCC CAG GCT GCA GTA GCC
G in C ys P h e G lu A r g G lu G in G in H j s P h e G ly G 1 n P r o S e r S e r T y r P h e 3 0 6
1111 CAG TGC TTT GAG CGG GAG CAG CAA CAC TTT GGA CAA CCC AGC AGC TAC TTT
L eu G in L e u P r o G in A l a Met G lu L e u Asn A r g A sp H i s Met I l e A r g S e r 3 2 3
1162 TTG CAG CTG CCA CAG GCC ATG GAG CTG AAC CGA GAC CAC ATG ATC CGT AGC
L eu G in S e r Val G l y Leu L y s L eu T r p H e S e r G in G l y S e r T y r P h e L e u 3 4 0
1 2 1 3 CTG CAG TCA GTG GGC CTC AAG CTC TGG ATC TCC CAG GGG AGC TAC TTC CTC
l i e A l a A sp H e S e r Asp P h e L y s S e r L y s Met P r o A sp L e u P r o G l y A l a 3 5 7
1 2 6 4 ATT GCA GAC ATC TCA GAC TTC AAG AGC AAG ATG CCT GAC CTG CCC GGA GCT
G lu A sp G I u P r o T y r Asp A rg A rg P h e A 1 a L y s T r p Met H e L y s A sn Met 3 7 4
1 3 1 5 GAG GAT GAG CCT TAT GAC AGA CGC TTT GCC AAG TGG ATG ATC AAA AAC ATG
G l y Leu Val G ly I l e P r o Val S e r T h r P h e P h e S e r A rg P r o H i s G i n L y s 391
1 3 6 6 GGC TTG GTG GGC ATC CCT GTC TCC ACA TTC TTC AGT CGG CCC CAT CAG AAG
A sp P h e A sp H i s T y r l i e A r g P h e C y s P h e Val L y s A sp L y s A 1 a T h r L e u 4 0 8
1 4 1 7 GAC TTT GAC CAC TAC ATC CGA TTC TGT TTT GTC AAG GAC AAG GCC ACA CTC
G i n A l a Met Asp G l u A rg L eu A r g L y s T r p L y s G lu L eu G 1 n P r o S t o p 4 2 3
1 4 6 8 CAG GCC ATG GAT GAG AGA CTG CGC AAG TGG AAA GAG CTC CAA CCC TGA GGA
1 5 1 9  GGCTGCCCTCAGCCCCACCTCGAACACAGGCCTCAGCTATGCCTTAGCACAGGGATGGCACTGGAGG 
1 5 8 6  GCCCAGCTGTGTGACTGCGCATGTTTCCAGAAAAGAGGCCATGTCTTGGGGGTTGAAGCCATCCTTT 
1 6 5 3  CCCAGTGTCCATCTGGACTATTGGGTTGGGGGCCAGTTCTGGGTCTCAGCCTACTCCTCTGTAGGTT 
1 7 2 0  GCCTGTAGGGTTTTGATTGTTTCTGGCCTCTCTGCCTGGGGCAGGAAAGGGTGGAATATCAGGCCCG 
1 7 8 7  GTACCACCTTAGCCCTGCCGAGGCTCTGTGGCTTCTCTACATCTTCTCCTGTGACCTCAGGATGTTG 
1 8 5 4  CTACTGTTCCTAAT 1 8 6 7
Figure 3.12: Nucleotide and deduced amino acid sequence of the rat kidney cytosolic 
cysteine conjugate p-lyase cDNA (ppl-2.0). The underlined nucleotide sequences indicate 
two 70 nucleotide inverted repeats. Cryptic branch site and splice acceptor nucleotide 
sequences are shown in italic. The PLP binding site Ser Ala Gly Lys Ser Phe, is indicated 
by the box.
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3.5 CHARACTERISATION OF ppl-2.0
DNA sequence analysis of the cDNA insert in ppl-2.0 demonstrated an overlap with the 
DNA sequence of ppl-1.0 (figure 3.10) As shown in figure 3.12 the cDNA of ppl-2.0 is 
1867 nucleotides in length. A single 1269 nucleotide open reading frame initiated by an 
ATG codon embedded in a translation start consensus sequence is present. This open 
reading frame is preceded by a 243 nucleotide 5' non-coding region containing in-frame 
stop codons, and is followed by a 355 nucleotide 3' non-coding region. In the region of 
overlap between ppl-1.0 and ppl-2.0 only 3 nucleotide differences due to animal strain 
variation are observed, of these only one (nucleotide 1308 of ppl-2.0 and nucleotide 64 of 
ppl-1.0) is found in the coding region and does not alter the amino acid sequence. The 
nucleotide changes in the non-coding region are shown in figure 3.10.
A molecular weight of 47.8kDa for p-lyase, deduced from the amino acid sequence (table 
3.3) is in good agreement with the value obtained from polyacrylamide electrophoresis of 
the purified protein (data not shown, Dr. Miles Schofield, personal communication). 
Examination of the deduced amino acid sequence for the presence of a consensus PLP 
binding site demonstrates a putative site at residues 244-249 when compared to the PLP 
binding sites in other PLP-dependent enzymes (figure 3.13).
The deduced amino acid % composition of the cDNA is in agreement with that derived 
from complete acid hydrolysis of the purified p-lyase enzyme (J. Commandeur and N. 
Vermeulen, personal communication). A plot of amino acid composition (HPLC analysis) 
versus deduced amino acid composition gives a correlation coefficient of 0.98 (figure 
3.14), strongly indicating that the cDNA codes for p-lyase.
As shown in figure 3.12, a 70bp inverted nucleotide repeat is found in the 5' end of the 
cDNA, the two elements of which are separated by 130 nucleotides of 5' non-coding 
region. A cryptic branch site and splice acceptor site can also be identified in this region, 
suggesting that residual intronic material may be present. Comparison of the 3' non-coding
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region of ppl-2.0 with ppl-1.0, demonstrates that the former is truncated at the poly 
adenylation site (AATAAA). The 3' end of ppl-2.0 terminates after the third nucleotide of 
the poly adenylation site. The poly adenylation sequence is seen in ppl-1.0, followed by a 
further 25 nucleotides prior to the poly A tail (figure 3.10).
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Amino acid Quantity Amino acid Quantity
Alanine 30 Leucine 40
Arginine 17 Lysine 23
Aspartate 26 Methionine 17
Asparagine 15 Phenylalanine 28
Cysteine 7 Proline 27
Glutamate 18 Serine 24
Glutamine 28 Threonine 21
Glycine 29 Tryptophan 9
Histidine 10 Tyrosine 11
Isoleucine 16 Valine 27
Total Molecular Weight = 47793.28 Da
Table 3.3: The number of each type of amino acid, predicted from the cDNA sequence of 
p(31-2.0, and the predicted total molecular weight of the rat kidney p-lyase protein.
P-lyase rat
SDH rat
AT pig
AspT pig
AspT human
AspT pig mitochondria
AspT human mitochondria
TAT rat
Mil
Mil
HI
M l
11!
Ill
Mi
Ala Gly
Val
Val
Alia:
Phe
tee:
ISer
§ef
Ser
Tyr
Tyr
Ala
iii
Pte: Gly
| | ! | |Ser |
H i Ala
l l l l Gly
i i ; Ash
I I I Asii
l l l l Asii
l l l l Ash
M i! Ser
m
W :
Met; 
I V l c i t :
F igu re  3.13: Relationship between the putative p-lyase PLP binding site and the 
corresponding sites in other PLP-dependent enzymes. The degree of the amino acid 
conservation is indicated by the intensity of the box fill. SDH, serine dehydratase; AT, 
alanine aminotransferase; AspT, aspartate aminotransferase; TAT, tyrosine amino­
transferase.
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Figure 3.14: The predicted amino acid composition of rat kidney p-lyase, determined by 
HPLC analysis of the purified protein (data from N. Vermeulen and J. Commandeur) vs. 
the predicted amino acid composition from the cDNA ppl-2.0.
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3.6 SOUTHERN BLOT ANALYSIS OF RAT GENOMIC DNA
Cysteine conjugate p-lyase activity has been located to both cytosolic and mitochondrial 
fractions of rat kidney cells (Buckbeny et al., 1990, 1994; Stevens et al., 1988; Lash et al., 
1990). Due to differences in the enzyme kinetics of the p-lyase enzymes in these fractions 
(Stevens et al., 1988), it has been suggested that the kidney mitochondrial enzyme is 
different from the cytosolic form and may be coded by a separate gene.
In order to determine whether the kidney mitochondrial and cytosolic cysteine conjugate p- 
lyase enzymes were coded for by separate members of a gene family, Southern blot 
analysis of rat genomic DNA was performed.
20 pg of rat genomic DNA was digested overnight at 37°C in separate reactions with the 
restriction enzymes £coRI, Xbal and Sstl (section 2.9.4.1). The digested DNA was 
concentrated by ethanol precipitation (section 2.3.9), and run on a 0.7% (w/v) agarose gel 
alongside XHindlll DNA markers (2.3.4). The DNA was depurinated/denatured (2.9.4.2), 
blotted to nylon membrane (2.9.4.3) and Southern blot analysis was performed using the 
deionised formamide hybridisation procedure (2.4.4.2), and the full-length rat p-lyase 
cDNA from ppl-2.0 (labelled with 32P, as in 2.4.3), as the probe. Washing conditions 
were of low-moderate stringency (2X SSC/0.5% (w/v) SDS at 21°C for 30 min, followed 
by IX SSC/0.1% (w/v) SDS at 42°C for 30 min and IX SSC/0.1% (w/v) SDS at 50°C for 
30 min). The blot was exposed to X-ray film for 72 hrs.
The restriction enzyme pattern of the Southern blot (figure 3.15) is consistent with that of a 
single gene for p-lyase, with a maximum size of approximately 9kb. The importance of this 
finding for the concept that the cytosolic and mitochondrially located enzymes are different 
is discussed later.
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SstI Xba I EcoR I Kb
>23.13
9.42
■6.56
>4.36
,2.32
2.03
Figure 3.15: Southern blot analysis of rat genomic DNA digested with the restriction 
enzymes Sstl, Xbal and EcoRl, probed with ppl-2.0 labelled with 32P.
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3.7 HETEROLOGOUS EXPRESSION OF THE RAT KIDNEY 0-LYASE
cDNA IN COS-1 CELLS.
3.7.1 Introduction
In order to confirm that the clone ppl-2.0 was indeed a cDNA for p-lyase, the cDNA was 
expressed in tissue culture cells. The aim was to demonstrate by Western blot analysis and 
enzyme assay that an increase in p-lyase protein levels and enzyme activity followed 
transfection of COS-1 monkey kidney cells with the cDNA. As kidney p-lyase activity is a 
subsidiary activity of the enzyme GTK, the cytosolic extracts of transfected cells were 
assayed for both p-lyase and GTK activity.
COS-1 cells are a cell line derivative of the CV-1 monkey cell line, transformed by a 
segment of SV40 early region DNA (cloned in an E.coli Plasmid) in which the SV40 origin 
of replication had been inactivated (Gluzman, 1981). The resulting COS-1 cell line (CV-1, 
origin of SV40) expresses T protein from the integrated SV40 sequences and does so in a 
cellular background which is permissive for SV40 DNA replication. In COS-1 cells any 
circular DNA, containing a functional SV40 origin of replication should be replicated 
independently of the cellular DNA as a plasmid-like episome. However, permanent cell 
lines are not established on transfection by these vectors because the massive vector 
replication makes the cells unviable (after about 72 hours). Even when only a small 
proportion of the cells are transfected, the high copy number of the plasmid enables 
sufficient DNA synthesis for subsequent high level transcription, translation and 
expression.
The full-length cDNA insert from ppl-2.0 was recloned into the expression vector 
pUS 1000 (see 3.7.2), placing transcription of the cDNA under control of the strong 
immediate-early promoter of human cytomegalovirus. Amplification in COS-1 cells was 
ensured by the presence of an SV40 origin of replication in the vector.
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3.7.2 Subcloning of the cDNA insert from ppl-2.0 into the expression  
vector pUSlOOO
The full-length cDNA fragment obtained by partial EcoRl digestion (3.3.1) was ligated into 
the EcoRl linearised vector pUSlOOO as detailed in section 2.5 using 3:1 and 1:1 molar 
ratios of vector to insert. The recombinant plasmids were transformed into E.coli JM109 
bacterial cells (see 2.5.3), and cultured on ampicillin (50pg/ml) plates overnight at37°C.
As pUS 1000 does not have a selection marker for blue/white screening, it was not possible 
to distinguish recombinants from recircularised plasmid. Therefore, the linearised plasmid 
was treated with calf intestinal alkaline phosphatase prior to ligation (2.5.1) in order to 
dephosphorylate the 5' ends, thus preventing recircularisation of the plasmid. The 
dephosphorylated ends can ligate to DNA which has not been dephosphorylated, therefore, 
if dephosphorylation of the linearised plasmid is 100%, only recombinant plasmids will 
produce transformants on ampicillin (50pg/ml) plates. False positives do occur as it is 
difficult to achieve complete dephosphorylation.
The results of the ligation/transformation experiments are shown in table 3.4. A selection of 
colonies were streaked onto a 1 cm square of an ampicillin (50pg/ml) agar plate and 
incubated overnight at 37°C. These colonies were examined for inserts using the cracking 
procedure (3.7.2.1).
3.7.2.1 Analysis of plasmids from transformed bacteria
Preparations of plasmid DNA were made using the cracking procedure (2.5.4) and the 
samples were analysed on a 1% (w/v) agarose gel (2.3.4), alongside a sample of 
pUS 1000. The plasmid migration of clones 50,75,100 and 169 showed retarded mobility, 
compared with the control pUSlOOO (data not shown). Small scale plasmid preparations, 
made using the Qiagen™ method (section 2.5.5.1), were digested with EcoRl, followed 
by 1% (w/v) agarose gel electrophoresis (2.3.4). Inserts of approximately 2kb were 
present in all four clones (data not shown).
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Plate Plasmid 
(EcoKl cut)
cDNA
insert
Molar ratio N°. of 
Colonies
1 pUSlOOO
(phosphorylated)
— — 378
2 pUSlOOO(de-phosphorylated)
— — 200
3a pUSlOOO
(de-phosphorylated)
2kb 1:1(V:I) 221
3b pUSlOOO
(de-phosphorylated)
2kb 1:1(V:I) 441
4a
pUSlOOO
(de-phosphorylated)
2kb 1:3(V:I) 210
4b pUSlOOO
(de-phosphorylated)
2kb 1:3(V:I) 436
Table 3 .4: Cloning strategy and results for subcloning of the 2kb cDNA fragment from 
the EcoRl digested recombinant bacteriophage clone B2 into the plasmid vector pUSlOOO. 
Plates 1-2 were plated at one dilution (lOOpl), plates 3-4  were plated at two dilutions (a= 
lOOpl, b=200pl)
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3.7.2.2 Orientation of the recombinant cDNA clones
In order to perform expression experiments it was necessary to determine which clones 
contained plasmid vector orientated in the sense direction so that the promoter was 
upstream of the cDNA consensus start site. An antisense orientation recombinant was also 
required as a negative control. Restriction enzyme mapping with Apal was used to 
determine the orientation of each of the four recombinants (figure 3.16). The orientations of 
clones 100 and 169 were sense and antisense respectively and were re-named pUSpl- 
2.0(+) and pUSpl-2.0 (-).
3.7.3 Transfection of COS-1 cells using DEAE-dextran
COS-1 cells were cultured in Dulbecco’s Modified Eagles Medium, 10% (v/v) foetal calf 
serum, 5% CO2  in air at 37°C. DNA transfection of subconfluent cells was performed 
using DEAE-dextran as detailed in section 2.7.5. In order to provide sufficient cytosol for 
enzyme assays and Western blot analysis, three 75cm2 flasks were used for each of the 
sense DNA, antisense DNA control and no DNA control transfections. The cells were 
incubated at 37°C with 5% CO2  for 48 hours, prior to harvesting and cytosol preparation 
(see 3.7.3.1).
3.7.3.1 Preparation of COS-1 cell cytosol
COS-1 cell cytosol was prepared as detailed in section 2.7.6. The samples were kept on ice 
throughout the procedure in order to prevent inactivation by proteases, and were stored at 
-70°C until required.
3.7.4 Enzyme analysis of COS-1 cell cytosol
The crude cytosol prepared from the COS-1 cells transfected with the sense DNA, 
antisense DNA and no DNA, was assayed for (3-lyase and glutamine transaminase K 
activity. The specific activities of the samples were calculated using protein concentration 
values determined by the method of Lowry (method 1 in section 2.8.1).
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23.14
Figure 3.16: Strategy to determine the orientation of the 1.9kb cDNA fragment (shaded) 
in the expression vector pUSlOOO, for both sense and antisense orientations, indicating the 
sizes of DNA fragments on Apal digestion, (b) 1% (w/v) agarose gel electrophoresis of 
recombinant clones 50 (lane 1), 75 (lane 2), 100 (lane 3) and 169 (lane 4) after digestion 
with Apal. 'KHindlll DNA markers (lane 5). DNA bands not indicated by arrows are 
undigested plasmid.
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3.7.4.1 Western blot analysis of COS-1 cell cytosol
Western blot analysis of the (3-lyase apoprotein in the cytosol samples was performed by 
electrophoresis of samples in a 10% (w/v) SDS-polyacrylamide gel (2.8.4) and 
electrophoretic transfer of the proteins to a nitrocellulose membrane (2.8.5.1). (3-lyase was 
detected using the desorbed monospecific polyclonal anti-(3-lyase antibody (2.8.5.2). The 
results (figure 3.17) demonstrate the presence of a protein of 48kDa reacting with the 
monospecific (3-lyase antibody in the cytosol of cells transfected with the vector with the 
cDNA in the sense direction. The control cells containing antisense cDNA and no DNA do 
not demonstrate this protein band on Western blot analysis.
3.7.4.2 Glutamine transaminase K activity
Glutamine transaminase K (GTK) activity was determined using the method of Cooper and 
Meister (1985), as detailed in section 2.8.2. Analysis of GTK activity in the cytosolic 
extracts of control and transfected cells, demonstrated that while a low level of activity 
could be detected in the antisense (pUS(3l-2.0(-)), and no DNA controls, significant GTK 
activity was observed in the cytosol of cells transfected with the sense cDNA (pUS(3l- 
2 .0(+)).
The GTK results of three transfection experiments are presented as a bar chart in figure 
3.18, demonstrating a significant 8 fold increase in GTK activity in the cytosol of cells 
transfected with the sense cDNA compared to control cytosol. Although slight variation in 
levels of activity was seen between separate transfection experiments, activity was 
reproducible within single transfections and on storage.
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kDa M 1 2 3 4
p-lyase
Figure 1.17: Western blot analysis of cytosolic proteins from COS-1 cells transfected 
with the ratcDNAs. Lane 1, rat kidney cytosol; lane 2, transfection with pUS(3l-2.0(+) 
(sense orientation); lane 3, pUS(3l-2.0(-) (antisense orientation); lane 4, no DNA control 
transfection. The position and size of the protein standards (Lane M; SDS-7B prestained 
markers, Sigma chemical company UK) are indicated.
100
GTK activity80
60
40
20
0
ANTISENSESENSE CONTROL
cDNA construct
Figure 3 .18 : Glutamine transaminase K activity in the cytosolic extracts from COS-1 
cells transfected with the rat kidney (3-lyase cDNA. Results are expressed as the mean (+/- 
SEM) of 8 determinations.
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3.7.4.3 p-lyase activity
Cysteine conjugate p-lyase activity was determined using a modified method of Stevens and 
Jakoby (1983) as detailed in section 2.8.3. Two substrates used to assay the samples for 15- 
lyase activity were the cysteine conjugates TFEC and DC VC. The activities were also 
measured in the presence of 0. ImM AOAA, an inhibitor of pyridoxal phosphate dependent 
enzymes. As with the GTK results, the enzyme activity was variable between transfection 
experiments, however, reproducible for assays using cytosolic extracts from a single 
transfection.
Analysis of the cytosolic extracts for p-lyase activity using TFEC as substrate mirrored the 
results of the GTK assay. A significant increase in p-lyase activity was seen in cells 
transfected with the sense cDNA compared to the antisense and no DNA transfected cells. 
This activity was inhibited by AOAA. The results for three transfection experiments using 
TFEC as substrate (figure 3.19a), demonstrate a significant 6.5 fold increase in the cells 
transfected with the sense cDNA compared to the controls.
When DC VC was used as substrate, the enzyme activity was only just above the level of 
detection. The results of a single DCVC experiment are shown in figure 3.19b and 
demonstrate p-lyase activity in the cytosol of cells transfected with the sense cDNA (pUSpl- 
2.0(+)). This activity is inhibited by AOAA.
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Figure 3.19: Cysteine conjugate p-lyase specific activity (+/- SEM) in the cytosolic 
extracts from COS-1 cells transfected with the rat kidney p-lyase cDNA. The p-lyase 
substrates; (a) tetrafluoroethyl cysteine (n=3) and (b) dichlorovinyl cysteine (n=l) were 
used in the presence and absence of the pyridoxal phosphate dependent enzyme inhibitor 
aminooxyacetic acid (AOAA).
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3.8 ISOLATION OF p-LYASE cDNAs FROM RAT BRAIN BY REVERSE 
TRANSCRIPTASE PCR
The observation of neurotoxicity and neurodegeneration in humans exposed to 
trichloroethylene (Buxton and Hayward, 1967), has led to an interest in the localisation and 
characterisation of p-lyase enzymes in the brain. Immunohistochemical analysis of rat 
brain, using an antibody raised to the rat kidney GTK/p-lyase protein, demonstrated, the 
widespread presence of GTK in rat brain tissue (Cooper et aL, 1993), and suggested that 
the mitochondrial enzyme is similar, but different from the cytosolic form. In this 
investigation, reverse transcriptase PCR analysis of rat brain RNA, using rat kidney 
cytosolic p-lyase gene-specific oligonucleotides, was performed in order to amplify neural 
p-lyase cDNA species, for subsequent characterisation.
Reverse transcriptase PCR was performed on total rat brain mRNA using the protocol in 
section 2.11. Oligonucleotide P7, which anneals to the 3' non-coding region of the RNA 
message, was used for the first strand cDNA synthesis (as in 2.11.1). As a suitable nested 
primer was not available for the amplification reaction, P7 was used with oligonucleotide 
P3, for amplification of the rat brain p-lyase cDNA by PCR (2.11.2). A negative control 
containing all reagents except the mRNA was performed alongside the test reaction. The 
amplified products were purified by 1% (w/v) agarose gel electrophoresis (as in 2.3.4) and 
visualised by ethidium bromide staining (2.3.5). The expected size for a cDNA, identical to 
the kidney form was 1380nucleotides.
Four cDNA bands of approximately 1.4, 1.0, 0.8 and 0.6kb were observed on the agarose 
gel (lane 2 of figure 3.20a). The negative control (lane 1 of figure 3.20a), demonstrates no 
contaminating DNA products. The DNA on the gel was depurinated, denatured and 
transferred to nylon membrane, as in 2.9.4.2 and 2.9.4.3. The rat cDNA from ppl-2.0 was 
labelled with 32P (2.4.3) and DNA hybridisation was performed using the protocol in 
section 2.4.4.2. The blot was washed with moderate stringency (2.4.5), and exposed to X- 
ray film for 24 hours. Two hybridising bands were present in lane 2 of the autoradiograph,
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the most intense band corresponded to the 1.4kb cDNA fragment. A faint band very close 
to the 1.4kb fragment, was also present and measured approximately 1.7kb. This product 
was was not visible on the agarose gel. No hybridising contaminants were observed in the 
control lane.
As Southern blot analysis of rat genomic DNA (see section 3.6) indicated the presence of a 
single gene for p-lyase, the presence of two brain cDNAs which hybridise with the kidney 
enzyme, suggested the possibility of alternate mRNA splicing and is discussed in section 
3.9.
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(a) 1 2 3 4 kb
Figure 3.20: (a) 1% (w/v) agarose gel electrophoresis of DNA products from reverse 
transcriptase PCR amplification of RAT brain RNA, using the gene-specific 
oligonucleotide primers P3 and P7, Lane 2; negative control, lane 1; 0X174 Hae III, lane 
3 and XHind III, lane 4. (b) Southern blot analysis of the agarose gel in (a), using the rat 
cDNA ppl-2.0 as a hybridisation probe.
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3.9 DISCUSSION
Kidney cysteine conjugate p-lyase metabolises cysteine adducts of halogenated alkene 
compounds, yielding metabolites which are nephrotoxic in rodents and possibly neurotoxic 
in man. In order to further understand the toxicity of cysteine conjugates and to determine 
whether exposure to these compounds is a potential hazard for man, isolation and 
characterisation of partially purified kidney p-lyase enzymes has previously been pursued 
(Stevens et al., 1988; Buckberry et al., 1990,1994; Lash et al., 1990).
However, since kidney cysteine conjugate p-lyase enzymes are difficult to purify and can 
only be obtained in low yields from rat kidney tissue, a molecular biology approach was 
chosen to isolate the cDNA for rat kidney cytosolic cysteine conjugate p-lyase. The ultimate 
aim was to isolate the human cDNA for expression of the human protein, in order to 
determine whether humans have the same potential as rats for the production of nephrotoxic 
thiols. As no DNA sequence data was available, hybridisation probing was not a possibility 
for human cDNA library screening, therefore, a purified antibody to rat kidney cytosolic 
cysteine conjugate p-lyase was raised in order to screen a rat kidney cDNA expression 
library. The aim was to use the rat cDNA as a hybridisation probe for the isolation of the 
corresponding human cDNA and to express the rat and human cDNAs in vitro in order to 
compare their kinetic properties.
Work prior to this thesis led to the isolation of a 746bp cDNA from a Wistar rat kidney 
expression library (Miles Schofield, PhD thesis, 1993), using a purified antibody to rat 
kidney cytosolic cysteine conjugate p-lyase. The literature value for the molecular weight of 
the p-lyase protein ranged from 43-50kDa, and therefore required a cDNA with a minimum 
of 1200 bp, indicating that the 746bp cDNA was incomplete. The truncated 746bp cDNA 
clone was therefore used in my studies as a hybridisation probe in order to isolate the full- 
length p-lyase cDNA.
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The work presented in this chapter demonstrates the successful isolation of a full-length 
cDNA for rat kidney cytosolic cysteine conjugate p-lyase. The 1867 nucleotide cDNA 
contains a 1269 nucleotide open reading frame encoding a protein of 423 amino acids. The 
molecular weight of the protein, determined from the predicted amino acid sequence is 
47.8kDa, and is in good agreement with the literature value of 47.4kDa for the purified 
enzyme (Yamauchi et.al., 1993).
Analysis of the 5' non-coding region indicates the presence of a 70bp inverted repeat, 
separated by 130 nucleotides, which is able to form a secondary stem-loop structure. The 
methionine start codon is situated within the stem of this secondary structure and it is 
therefore postulated that the 5' non-coding region of the mRNA may be involved in the 
regulation of p-lyase expression via the formation of a secondary loop structure which may 
effect ribosome progression. Additionally, a cryptic branch site and splice acceptor have 
also been identified within this stem-loop region and suggests the potential for alternate 
splicing of the pre-mRNA.
A putative PLP-binding site, identified in the rat cDNA sequence, compares well with the 
conserved PLP-binding sites of other transaminases. Also on comparison to the amino acid 
sequence of aspartate aminotransferase, other conserved amino acids such as lysine 
(residue 267), tyrosine (residue 216) and arginine (residue 387) which are postulated to 
play a role in the mechanism of action of PLP-dependent enzymes, have been identified 
(Dr. David Lewis, personal communication). Additionally the comparison of the amino 
acid composition, deduced from HPLC analysis of the purified p-lyase protein (J. 
Commandeur and N. Vermeulen, personal communication), with the predicted amino acid 
composition from the cDNA, gave a correlation coefficient of 0.98. The results above 
strongly indicated that the cDNA of ppl-2.0 codes for p-lyase.
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Final confirmation that the cDNA for rat kidney p-lyase had been isolated, came from 
transfection studies in COS-1 monkey kidney cells. Western blot analysis of transfected 
COS-1 cell cytosol, using the purified antibody to rat kidney cytosolic p-lyase has 
demonstrated the presence of a 48kDa protein band identical in its position to that of 
authentic p-lyase.
Significant GTK and p-lyase activities (using TFEC and DC VC as substrates) were 
measured in cytosolic extracts from cells transfected with the cDNA in the sense direction. 
This activity was inhibited by AOAA, an inhibitor of pyridoxal phosphate dependent 
enzymes. The enzyme activity of transfected cells varied slightly from one experiment to 
another. This may be due to factors which effect the efficiency of the transfection, such as, 
the condition of the tissue culture cells, their confluency and the phase of cell growth at the 
time of transfection. A crucial stage in the transfection procedure was the addition of 
DMSO, to boost the uptake of plasmid DNA. DMSO permeablises the cell membrane and 
may cause cell damage and death upon prolonged exposure, thus effecting the levels of 
enzyme activity.
The question of whether rat kidney mitochondrial p-lyase is a modified version of the 
cytoplasmic form has yet to be resolved. The genomic Southern blot analysis, indicates the 
presence of a single gene for rat kidney p-lyase with a maximum size of approximately 9kb. 
However, the presence of a cryptic branch site and splice acceptor indicate a potential for 
alternate splicing which could produce both mitochondrial targeting and the observed 
differences in substrate specificity.
Further work (Helen Harries, this laboratory) has demonstrated that on transfection of 
COS-1 cells with the rat p-lyase cDNA, approximately 1-2% of the expressed p-lyase 
activity becomes associated with the mitochondrial fraction, even when the mitochondria 
are washed 3 times prior to sonication and enzyme assay. It is not clear yet whether the rat 
enzyme gains entry into the mitochondria or whether it becomes attached to the outer
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membrane. If this is the case, further investigation is required to determine whether it 
occurs in vivo or whether it is an artefact of the mitochondrial preparation.
Further evidence to support the suggestion that the mitochondrial and cytosolic forms are 
one and the same comes from work by Stevens et al., (1988), which demonstrates that on 
purification of the mitochondrial form, its properties become more similar to that of the 
cytoplasmic form. Other evidence for this comes from MacFarlane et al., (1989) who 
showed that the antibody raised against cytosolic p-lyase did react with mitochondrially 
associated enzyme.
Reverse transcriptase PCR of rat brain using oligonucleotide primers to the 5' and 3' non­
coding regions of the rat kidney cDNA gave rise to four PCR products, one of which 
hybridised to the rat kidney cDNA probe on Southern blot analysis. A second but less 
intense hybridisation band, slightly larger in size, was observed on the autoradiograph. The 
smaller and most intense hybridising band corresponds to the expected size (1380 
nucleotides) for the oligonucleotide primers used in the PCR amplification reaction. The 
larger and less intense band is approximately 1700 nucleotides in length. As genomic 
Southern blot analysis indicates that the rat kidney GTK/p-lyase cDNA is coded for by a 
unique gene, these results suggest that the 1380bp cDNA isolated from rat brain, is 
identical to the kidney form (see chapter 5 for further discussion). Whether the larger 
product is an alternate spliced cDNA, or a cDNA from an incompletely spliced message 
remains to be determined.
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CHAPTER 4
ISOLATION, CHARACTERISATION AND EXPRESSION OF A cDNA 
CODING FOR HUMAN KIDNEY CYSTEINE CONJUGATE
p-LYASE
4.1 INTRODUCTION
The central role of cysteine conjugate p-lyase in the bioactivation of halogenated 
hydrocarbons to nephrotoxic metabolites and the potential for human exposure to these 
compounds, has recently focused interest on human kidney p-lyase. The successful 
isolation of a full-length rat kidney p-lyase cDNA (chapter 3), has now provided a tool for 
the subsequent isolation of the corresponding human kidney cDNA.
The results presented in this chapter describe the isolation of a full-length human kidney 
cysteine conjugate p-lyase cDNA. The cDNA was isolated (as summarised in figure 4.1) by 
a combination of hybridisation screening of a human kidney cDNA library using the full- 
length rat cDNA (Perry et ah, 1993) as a probe, 5' rapid amplification of cDNA ends (5' 
RACE) using gene-specific oligonucleotide primers and reverse transcriptase-PCR from 
human kidney RNA. The human cDNA was sequenced and subcloned into the vector 
pUSlOOO for expression in COS-1 cells, to demonstrate p-lyase/GTK activity. Expression 
of the rat and human cDNAs was performed in parallel in order for comparative kinetic 
studies of the rat and human enzymes, which may enable an assessment of their relative 
potential for nephrotoxic thiol production.
All the experiments presented in this chapter were carried out by the author, with the 
exception of some transfection experiments and GTK assays which were performed by a 
postgraduate colleague in the laboratory, Helen Harries, under my supervision.
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(a) Human cDNA library screening
1 ATG 1867
5?NCR‘ ppl-2.0 ::3'3STC£:;:
4- — — ►i------- ---------- ►4— ™ -------- ►
1st human library screen
.Intron
i7 Phi
537647 2nd human library screen
463240 738
Phil PhlO
Rat cDNA probe
Hioo)
(b) 5' RACE
[Anchor |-
AP
I Ph7
AP I
Phl8 ▼
phpi-3.1
-A(n) Race-Ready cDNA
30 rounds of PCR with oligonucleotides Ph i and Anchor primer (AP)
30 rounds of PCR with oligonucleotides Ph7 and Anchor primer (AP)
Amplified region of the 5'sequence of human kidney p-lyase
377
(c) Reverse transcriptase PCR
g i____________human kidney B-lvase mRNA
Phl8
Reverse transcriptase PhlO
I
Phil
1266 1328
phpl-5.0
A (n) 3 '
cDNA synthesis, primed with 
oligonucleotide PhlO
30 rounds of PCR with 
oligonucleotides P h il  and Phl8
Full-length human p-lyase cDNA
Figure 4.1 : The isolation of a full-length cDNA for human kidney p-lyase: (a) Truncated 
cDNA clones, isolated from human cDNA library screening, with the rat kidney p-lyase 
cDNA as a probe, (b) 5' RACE-ready cDNA amplification of the 5' p-lyase sequence, (c) 
Amplification of a full-length human kidney cDNA from total kidney RNA using reverse 
transcriptase-PCR with gene-specific oligonucleotide primers. Non-coding areas are 
shaded, coding are unshaded. Oligonucleotide primers are indicated by solid boxes.
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4.2 ISOLATION OF RECOMBINANT HUMAN p-LYASE cDNA CLONES 
FROM A HUMAN KIDNEY cDNA LIBRARY
A human kidney 5' stretch cDNA library (Cion tech) was screened using a full-length 
(1867bp) rat cDNA probe, previously isolated from a rat kidney cDNA library (Cion tech), 
in the vector kgtlO, as described in chapter 3. The reasons for choosing the commercially 
prepared 5' stretch human kidney cDNA library, HL1123a (2.2.6.1) were two fold; (i) this 
library was reported to contain a high proportion of cDNAs with complete 5' sequences, 
and therefore was likely to contain a full-length p-lyase cDNA, (ii) the full-length rat kidney 
cDNA was successfully isolated as a complete fragment from a cDNA library prepared by 
the same manufacturer. The human library cDNA (average size of 1.6kb) was prepared 
from the mRNA of a 20 year old Caucasian female, using both poly T and random priming, 
and ligated into the bacteriophage vector XgtlO.
4.2.1 Preparation of the Sprague-Dawley rat kidney p-lyase cDNA probe
In order to maximise the hybridisation signal, the full-length (1867bp) Sprague-Dawley rat 
cDNA from ppl-2.0 (figure 3.12) was used to screen the human library. The rat cDNA 
insert from ppl-2.0 was excised from the plasmid by double digestion with the restriction 
enzymes Xbal and Smal (2.3.3). The digested DNA was purified by 1% (w/v) agarose gel 
electrophoresis (2.3.4) and the p-lyase cDNA extracted using Geneclean™ (2.3.7).
4.2.2 Hybridisation screening of a human cDNA library
The library was titrated using the method detailed in section 2.4.1, and the titre was 
calculated as 1.5xl08 PFU/ml. 2xl05 PFUs were plated as detailed in section 2.4.2, and 
were probed using the rat p-lyase cDNA (4.2.1), radiolabelled (2.4.3) with [a32P]-dCTP 
(3000 Ci/mmol, ICN Flow). Two positive clones (HI & H2) were isolated and remained 
positive after three rounds of plaque purification at a lower plaque density (2.4.6). 
Recombinant DNA was prepared from HI and H2 as detailed in section 2.4.7.
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4.2.3 Determination of the size of the bacteriophage cDNA inserts
DNA (lOjxg) from clones HI and H2 was digested overnight at 37°C with lgl (lOU/pl) of 
EcoRl (section 2.4.8) and electrophoresed on a 1% (w/v) agarose gel (section 2.3.4), 
producing two bacteriophage DNA bands of 34.5kb and 1 lkb and a cDNA insert band of 
approximately 1.2kb (figure 4.2). Although 1.2kb was not sufficient to code for the full- 
length human p-lyase cDNA, it was thought possible that the combined sequences of the 
two clones, might represent the complete coding region. It was therefore decided, to 
subclone and characterise HI and H2 before rescreening the library.
4.3 SUBCLONING OF THE cDNAs INTO pGEM®7Zf(+)
As plasmid vectors provide a greater ratio of insert to vector compared with X 
bacteriophage, the cDNAs were subcloned into pGEM®7Zf(+). pGEM®7Zf(+) also 
enables DNA sequencing using the promoter sequences SP6 and T7 as vector priming 
sites.
4.3.1 Preparation of bacteriophage cDNA inserts and plasmid DNA for 
subcloning
In order to produce sufficient cDNA for subcloning, 5 separate digestion reactions for HI 
and H2, were performed as in 4.2.3 above, each with 10gg of DNA and lgl (lOU/pl) of 
EcoRl. After digestion the samples were pooled and run in a large well of a 1% (w/v) 
agarose gel and visualised by ethidium bromide staining (2.3.4, 2.3.5). The p-lyase 
cDNAs were excised from the gel and extracted by Geneclean™ (section 2.3.7). The 
concentration of the purified cDNA inserts were estimated by visualising a small sample on 
an ethidium bromide stained agarose gel. The insert cDNAs were diluted to give an 
estimated concentration of lOOng/pl. pGEM®7Zf(+) plasmid DNA was digested with 
EcoRl as described in section 2.3.3, and diluted to a concentration of lOOng/pl.
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Figure 4.2: 1% (w/v) agarose gel electrophoresis of the bacteriophage clones HI (lane 1) 
and H2 (lane 2) following digestion of the bacteriophage DNA with EcoRl. Lane 3 
contains the molecular weight markers 'kHindlll and 0X174 Hoe III.
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4.3.2 Ligation and transformation reactions
The cDNA fragments from HI and H2 were ligated into the EcoRl linearised vector 
pGEM®7Zf(+) as detailed in section 2.5.2., using 1:3 and 1:1 molar ratios of vector to 
insert, and transformed into E.coli, JM109 bacterial cells as in 2.5.3. The transformed 
bacteria were cultured on agar plates containing ampicillin (50pg/ml), X-Gal (40jig/ml) and 
IPTG (0.5mM) and incubated overnight at37°C. White colonies were streaked onto a 1 cm 
square of an agar plate containing ampicillin, X-Gal and IPTG as above and incubated 
overnight at 37°C. Colonies remaining white, were examined for inserts using the cracking 
procedure (4.3.3).
4.3.3 Cracking procedure
White colonies were analysed by the cracking procedure, using a crude preparation of 
plasmid DNA (see 2.5.4). The samples were run on a 1% (w/v) agarose gel as in 2.3.4 
along side the control pGEM®7Zf(+), which contained no insert DNA and the control ppl- 
2.1, with a cDNA insert of 1066bp (figure 4.3). Clones containing inserts of 
approximately 1.2kb were expected to be significantly retarded compared with the control 
pGEM®7Zf(+), and slightly retarded compared to ppl-2.1. Subclones 2 and 26, from HI 
and H2 respectively were chosen for a small scale plasmid preparation using the Qiagen™ 
method (section 2.5.5.1).
4.3.4 Restriction digest analysis of subclones 2 and 26
Restriction digest analysis with EcoRl and Avail in separate reactions and in a double 
digest, followed by 1% (w/v) agarose gel electrophoresis and ethidium bromide staining 
was performed on subclones 2 and 26 (figure 4.4). Both clones demonstrated the presence 
of 1.2kb cDNA inserts on EcoRl digestion, and demonstrated identical restriction fragment 
patterns on double digestion with EcoRl and Avail. However, digestion with Avail alone 
demonstrated different restriction fragments. The restriction analysis above indicated that 
the two cDNAs were identical, however, they were inserted into the vector in opposite 
directions.
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1 2 3 4 5 6 7 8 9 10 11 12 1314 Key:
1. ppl-2.1
2. subclone 1
3. subclone 2 
4.. subclone 3
5. subclone 4
6. subclone 5
7. subclone 6
8. subclone 22
9. subclone 26
10. subclone 27
11. subclone 30
12. subclone 31
13. subclone 32
14. pGEM7Zf(+)
Figure 4.3: A cracking gel to demonstrate recombinant clones by retardation on 1% 
(w/v) agarose gel electrophoresis
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Key
1. MindlIl/<kX174
2. 2 (EcoRl)
3. 2 (EcoRUAvail)
4. 2 (Avail)
5. 26 (EcoRl)
6. 26 (EcoRl/Avail)
7. 26 (Avail)
8. ;tf///aflII/(t>X174
Figure 4.4: 1% (w/v) agarose gel electrophoresis of the bacteriophage clones 2 and 26 
following digestion of the recombinant plasmid DNA with the restriction enzymes indicated 
in the key above. Lanes 1 & 8 contain the molecular weight markers 'kHindlll and 0X174 
Hoe III.
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4.3.5 Southern blot analysis of plasmid subclones 2 and 26
Southern blot analysis of the EcoRIIAvail double restriction digest (figure 4.5a) of clones 2 
and 26, was performed as detailed in section 2.9.4 and is illustrated in figure 4.5b. The 
restriction digest demonstrates six fragments on a 1% (w/v) agarose gel. Three of the 
fragments were vector DNA and the remaining three were insert (see figure 4.5c). There 
were however, only two hybridising bands on the Southern blot which suggested that the 
non-hybridising cDNA band might be; (i) an intron or a non-coding region which has little 
or no sequence similarity to the rat cDNA, or (ii) a coding region with little or no sequence 
similarity to the rat cDNA. In order to determine which of the possibilities was correct, the 
cDNA inserts of subclones 2 and 26 were sequenced as detailed in section 4.4.
4.4 SEQUENCING OF THE RECOMBINANT SUBCLONES 2 AND 26
4.4.1 Sequencing with SP6 and T7 primers
DNA sequencing of plasmid clones 2 and 26 was performed using Sequenase™ version
2.0 as described in section 2.6. Sequence data obtained using the vector primers SP6 and 
T7, provided sufficient information to confirm that the sequences were identical, however, 
orientated in opposite directions (data not shown). Subclone 2 was renamed phpl-1.0.
4.4.2 Sequencing with gene-specific oligonucleotide primers
DNA sequencing was completed using two gene-specific primers (Phi and Ph2) 16 
nucleotides in length, which were designed to bind specifically to a unique sequence of the 
DNA approximately 50 bases upstream of the region to be sequenced (see section 3.4.2 for 
primer requirements). Most sequencing reactions gave clear, readable sequence, however, 
in order to overcome compression artefacts, a nucleotide analogue of dGTP (dITP) was 
used in the sequencing reaction. dITP forms a weaker secondary structure with the DNA 
allowing full denaturation of GC rich regions during electrophoresis, therefore eliminating 
compressions. All sequences were confirmed by a minimum of three experiments.
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“5
1487 22 1291 m: : 1:340::
Figure 4.5: (a) 1% (w/v) agarose gel electrophoresis of subclones 2 (lane 1) and 26 (lane 
2) after double digestion with Avail and EcoRl, lane 3 contains the molecular weight 
markers XHindlll and 0X174 Hae III. (b) Southern blot analysis of (a) using the rat cDNA 
ppl-2.0 as the hybridisation probe, and (c) A restriction map to show the known positions 
of Avail and EcoRl sites in the vector (unshaded area) and the putative positions of the 
Avail sites in the cDNA insert, HI (shaded region). Fragments positive for Southern blot 
analysis are indicated by an asterisk.
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A restriction enzyme map of phpl-1.0 is shown in figure 4.6, the direction and extent of 
sequencing is indicated by arrows. The sequences of phpl-1.0, derived from both the 
vector and gene-specific primers were assembled, translated and analysed using the 
GeneJockey 1.1 software package (Biosoft Ltd, UK).
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Figure 4.6: Restriction enzyme map of phpl-1.0, isolated from a human kidney cDNA 
library (HL1123a), using ppl-2.0 as a probe. The direction and extent of the DNA 
sequencing reactions are shown as arrows. Internal oligonucleotides are shown as solid 
boxes.
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4.5 CHARACTERISATION OF Phpl-1.0
The cDNA insert from phpl-1.0 was 1184 nucleotides in length. Comparison of the cDNA 
sequence of phpl-1.0 with the rat p-lyase cDNA ppl-2.0 (figure 4.7) shows that nucleotides 
1-647 of phpl-1.0 are not homologous to the rat cDNA. Nucleotides 648-1133 from phpl-
1.0 demonstrate approximately 80% sequence similarity to nucleotides 445-930 of the rat 
ppl-2.0 and 1166-1184 are identical to 931-949 of ppl-2.0. Nucleotides 1134—1165 of 
phpl-1.0 are not homologous to the rat sequence, they interrupt the human coding region, 
resulting in a frame shift. The two non-coding regions (1-647 and 1134-1165) of phpl-1.0 
were thought to be introns, incompletely spliced from the mRNA.
The nucleotide and deduced amino acid sequence of phpl-1.0 is shown in figure 4.8. 
Nucleotides 1-647 which do not contain an open reading frame are followed by 486 
nucleotides (648-1133) which code for 162 amino acids. A second open reading frame of 
18 nucleotides (coding for 6 amino acids) is present between nucleotides 1166-1184, and 
is separated from the first open reading frame by 32 bases of non-coding sequence.
The location of a splice site is dictated by short sequences at the intron/exon boundaries in 
the gene. A GT sequence found at the 5' end of each intron and an AG sequence at the 3' 
end of each intron are normally essential, but not sufficient for correct splicing. It can be 
seen in figure 4.8 that the two nucleotides preceding nucleotide 648 are A and G and the 
two following nucleotide 1133 are G and T, therefore suggesting incomplete splicing. The 
absence of a splice donor consensus sequence at nucleotides 1165 and 1166, indicates 
aberrant splicing.
As phpl-1.0 contained only 504 nucleotides of p-lyase coding region compared with the 
1269 nucleotide open reading frame of the rat cDNA, the human kidney library was re­
examined for the presence of a full-length human p-lyase cDNA. The library was re­
screened using both the rat and human cDNAs of ppl-2.0 and phpl-1.0 respectively.
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1 I I  I I  1 1 I I  I I  I I  1 1 I t I I
R a t
1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 I I  1
------------------------------------------------------------ 9 31 GCCAGCCTCCCTGGCATGT 94 9
Figure 4.7: Alignment of human phpl-1.0 (top) with rat ppl-2.0 (bottom). Homologous 
bases are indicated by vertical lines.
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1 TGGGCAATATAACAAGACCCTGTCTCTACCAAAATAAATGAATA
45  AATAAATAAATAAATAAATAAATAAATAAATAAAAGCCTCTCCCGCAAAGCTGCTGGGAGGATCAAG 
112 TGGGCACAAACATGCTTCTTAAACTTACAGATGTGGAAAGTGGGGAGTTTCTACTGCCTTGTGGGCT 
179 CTTGGACTGAGGTTCATGGAGGCAAGCACTTCCTCTGGTTCT CTGCTAAATCCCCGCdTGGGCTTC 
2 4 6  GGGCCTGGCACAGAACAGGCCTGTGGCAAATGCTGGTGGAGGAGATGGAAGAGCTTAGCACTGGATA 
3 1 3  TCTGAGTCAGTGCAGGCCTGGTGGTTGGCACCCTGGAGTCTGGGACCATATAGATTGTGTGACCTTT 
3 8 0  ACCTCCCAGAGTACACAGGGATCACAATAGCACCTGCCTCTGGGTTGTTGAGAGGATGAGATCAAAG 
44 7  AAATCCCACAAATAGCTTGGTGTGTAGAGGAATCCAGAGTGTTGAAAGCTGATCTATCCCACGTCCC 
5 1 4  CTGGGGCCCAGGCTACCAGTACCTGACTTTGCCCCCAGGCCTGCTGCTGGAAGGTGCTAGAATTGCC
581 tg g a ta c a g c tg g g c c g g a g g a t g g g c c c a g g c tg a g c tg g a c a g tt a a c c c c tg c tg tc c t g g c Iag I
G ly T y r P ro P ro Leu T h r Lys H e Leu AI a S e r Phe Phe G ly G lu Leu Leu 17
6 4 8 GGT TAC CCA CCA CTG ACG AAG ATC CTG GCA AGT TTC TTT GGG GAG CTG CTG
G ly G in G I u I le Asp P ro Leu A rg Asn V al Leu V a l T h r V al G ly G ly T y r 34
6 9 9 GGT CAG GAG ATA GAC CCG CTC AGG AAT GTG CTG GTG ACT GTT GGT GGC TAT
G ly A la Leu Phe T h r AI a Phe G in A la Leu Val Asp G lu G ly Asp G lu V a l 51
7 5 0 GGG GCC CTG TTC ACA GCC TTC CAG GCC CTG GTG GAC GAA GGA GAC GAG GTC
I le I le l i e G I u P ro Phe Phe Asp Cys T y r G lu P ro M et T h r M et Met A la 68
801 ATC ATC ATC GAA CCC TTT TTT GAC TGC TAC GAG CCC ATG ACA ATG ATG GCA
G ly G ly A rg P ro Va I Phe V a l S e r Leu Lys P ro G ly P ro I le G in Asn G ly 85
852 GGG GGT CGT CCT GTG TTT GTG TCC CTG AAG CCG GGT CCC ATC CAG AAT GGA
G I u Leu G ly S e r S e r S e r Asn T rp G in Leu Asp P ro Met G lu Leu A 1 a G 1 y 102
9 0 3 GAA CTG GGT TCC AGC AGC AAC TGG CAG CTG GAC CCC ATG GAG CTG GCC GGC
Lys Phe T h r S e r Arg T h r Lys A la Leu V al Leu Asn T h r P ro Asn Asn P ro 119
9 5 4 AAA TTC ACA TCA CGC ACC AAA GCC CTG GTC CTC AAC ACC CCC AAC AAC CCC
Leu G ly Lys Va I Phe S e r A rg G I u G I u Leu G lu Leu V al A 1 a S e r Leu Cys 136
1005 CTG GGC AAG GTG TTC TCC AGG GAA GAG CTG GAG CTG GTG GCC AGC CTT TGC
G in G in H i s Asp Va I Val Cys H e T h r Asp G lu V a l T y r G in T rp Met V a l 153
1056 CAG CAG CAT GAC GTG GTG TGT ATC ACT GAT GAA GTC TAC CAG TGG ATG GTC
T y r Asp G ly H i s G in H i s l i e S er I  le 162
1107 TAC GAC GGG CAC CAG CAC ATC AGC ATT WL|  CTC AGG AGG TGT TGT GTT GGG
AI a S e r Leu P ro G ly Met 168
1157 CCT TGG GCA GCC AGC CTC CCT GGC ATG T 11 84
Figure 4 .8: Nucleotide and deduced amino acid sequence of phpl-1.0. A 32bp intron 
within the coding region is indicated by italics; splice acceptor (GT) and donor (AG) sites 
are boxed; oligonucleotide, Phi used in subsequent 5'RACE studies (see section 4.10) is 
underlined. Oligonucleotide Ph2, used in the chromosome mapping studies (section 4.17) 
is both underlined and italic. Aberrant splicing is illustrated by the absence of a splice donor 
consensus sequence at nucleotides 1165 and 1166.
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4.6  R E -S C R E E N IN G  T H E  H U M A N  K ID N E Y  L IB R A R Y  U S IN G  B O T H  
R A T  AND H U M A N  cDNAs AS A P R O B E S
The cDNA library HL1123a, was re-screened as in 4.2.2 using both the full-length rat and 
truncated human cDNAs together. The homologous human cDNA probe was used in order 
to increase the sensitivity of the hybridisation, and the rat cDNA was used in conjunction 
with the human so that clones containing the regions either side of the human probe, would 
not be missed. Screening with both probes thereby increasing the probability of isolating 
the missing region of the cDNA.
8xl05 PFUs were screened giving rise to 7 positive clones, six of which were identical (by 
restriction enzyme mapping, data not shown) to the 1184bp human cDNA of phpl-1.0, 
previously isolated. The remaining clone J2, approximately 1.5kb (figure 4.9), was 
sufficiently large to encode the full-length human cDNA. This cDNA was purified and 
subcloned into pGEM®7Zf(+) as in section 4.3 above. The recombinant clone was named 
phpl-2.0, and sequenced as in section 4.7.
4.7 S E Q U E N C IN G  O F  T H E  R E C O M B IN A N T  C L O N E  P h p l-2 .0
DNA sequencing was performed using both vector primers SP6 and T7, and gene specific 
primers using Sequenase™ version 2.0 as in section 4.4. A restriction enzyme map of 
phpl-2.0 is shown in figure 4.10, the direction and extent of sequencing is indicated by 
arrows. The sequences of phpl-2.0, derived from both the vector and gene-specific primers 
were assembled, and analysed using the GeneJockey 1.1 software package (Biosoft Ltd, 
UK). The nucleotide and deduced amino acid sequences are shown in figure 4.11.
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1 2 kb
23.14 35
9.42 11 
6.52
4.42
Figure 4.9: 1% (w/v) agarose gel electrophoresis of the bacteriophage clone J2 (lane 2) 
following digestion of the bacteriophage DNA with EcoRI. Lane 1 contains the molecular 
weight markers XHindlll and 0X174 Hae III.
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Figure 4.10: Restriction enzyme map of ph(3l-2.0 isolated from a human kidney cDNA 
library (HL1123a), using ppl-2.0 and phpl-1.0 as hybridisation probes. The direction and 
extent of the DNA sequencing reactions are shown as arrows. Internal oligonucleotides are 
shown as solid boxes. EcoRl sites of the cloning linkers are indicated by *
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1 CGGTGCCGGCCAGCTCCATGGGGTCCAGCTGCCAGTTGCTGCTGGAACCCA
52 GTTCTCCATTCTGGATGGGACCCGGCTTCAGGGACACAAACACAGGACGACCCCCTGCCATCA 
115 TTGTCATGGGCTCGTAGCAGTCAAAAAAGGGTTCGATGATGATGACCTCGTCTCCTTCGTCCA 
178 CCAGGGCCTGGAAGGCTGTGAACAGGGCCCCATAGCCACCAACAGTCACCAGCACATTCCTGA
A la Leu V a l Leu Asn T h r P ro Asn Asn P ro Leu G ly L y s V a l Phe S e r 16
241 GCC CTG GTC CTC AAC ACC CCC AAC AAC CCC CTG GGC AAG GTG TTC TCC
A rg G lu G lu Leu G lu Leu V a l A la S e r Leu Cys G in G I n H i s Asp V a l 32
2 8 9 AGG GAA GAG CTG GAG CTG GTG GCC AGC CTT TGC CAG CAG CAT GAC GTG
V a l Cys I  le T h r Asp G lu V a l T y r G I n T rp M et V a l T y r Asp G ly H i s 48
3 3 7 GTG TGT ATC ACT GAT GAA GTC TAC CAG TGG ATG GTC TAC GAC GGG CAC
G in H i s I  le S e r l i e A la S e r Leu P ro G ly M et T rp G lu A rg T h r Leu 64
3 8 5 CAG CAC ATC AGC ATT GCC AGC CTC CCT GGC ATG TGG GAA CGG ACC CTG
T h r l i e G ly S e r TTa G ly Lys Thr Phe S e r A la T h r G 1 y Trp Lys V a l
4 3 3 ACC ATC GGC AGC GGC AAG ACC TTC AGC GCC ACT GGC TGG AAG GTG
G ly T rp V a l Leu G ly Pro Asp H i s H e M et Lys H i s Leu A rg T h r V a l
481 GGC TGG GTC CTG GGT CCA GAT CAC ATC ATG AAG CAC CTG CGG ACC GTG
H i s G I n Asn S e r V a l Phe H i s Cys P ro T h r G 1 n S e r G in A la A la V a l
5 2 9 CAC CAG AAC TCC GTC TTC CAC TGC CCC ACG CAG AGC CAG GCT GCA GTA
A la G lu S e r Phe G lu A rg G 1 u G in Leu Leu Phe A rg G in P ro S e r S e r
5 7 7 GCC GAG AGC TTT GAA CGG GAG CAG CTG CTC TTC CGC CAA CCC AGC AGC
T y r Phe V a l G I n Phe P ro G 1 n A la M et G 1 n A rg Cys A rg Asp H i s M et
6 2 5 TAC TTT GTG CAG TTC CCG CAG GCC ATG CAG CGC TGC CGT GAC CAC ATG
I le A rg S e r Leu G 1 n S e r V a l G ly Leu L ys P ro H e H e P ro G 1 n G 1 y
6 7 3 ATA CGT AGC CTA CAG TCA GTG GGC CTG AAG CCC ATC ATC CCT CAG GGC
S e r T y r Phe Leu H e T h r Asp I le S e r Asp Phe Lys A rg Lys M et P ro
721 AGC TAC TTC CTC ATC ACA GAC ATC TCA GAC TTC AAG AGG AAG ATG CCT
Asp Leu P ro G ly A la V a l Asp G lu P ro T y r Asp A rg A rg Phe V a l L ys
7 6 9 GAC TTG CCT GGA GCT GTG GAT GAG CCC TAT GAC AGA CGC TTC GTC AAG
T rp M et I le L ys Asn L ys G ly Leu V a l A la H e P ro V a l S e r I  le Phe
8 1 7 TGG ATG ATC AAG AAC AAG GGC TTG GTG GCC ATC CCT GTC TCC ATC TTC
T y r S e r V a l P ro H i s G in Lys H i s Phe Asp H i s T y r H e A rg Phe Cys
8 6 5 TAT AGT GTG CCA CAT CAG AAG CAC TTT GAC CAC TAT ATC CGC TTC TGT
Phe V a l L ys Asp G 1 u A la T h r Leu G in A la M et Asp G lu Lys Leu A rg
9 1 3 TTT GTG AAG GAT GAA GCC ACG CTC CAG GCC ATG GAC GAG AAG CTG CGG
L ys T rp L ys V a l G lu Leu S to p
961 AAG TGG AAG GTG GAA CTC TAG CCCTGAAGTCACGCCTTGGCCCTGACATCCCCACA
1017  TGCCCGCAGAGATCCTCTTTGAGTGTCTGTCTTTGTCCAGGTTTCAGACATTTCTAGGTTGGG 
1080  GAAGATGCTATTGGGAAACCTCTTCTCCGTGACACAGAATGTTCTGGGTGGGAGCCGCCCTTC 
1143  TTCATCTTAGAGAACCAAGTGCCTCCTGTCTGAAAGGTGAGGGTGGCCTGACCTGGGCCTCTC 
1206  CCTGCCCCTCCATAGGTGGGTTTGTAGGGTCTTGTGTTGCTTCTGGTCTCTCCAGGCTTGGCT 
1269  GAGACGGACGGTAGACTTCCACCATGTACCGATCACATCCCAGCTCTGCATGGCCCCTGCTAA 
1332 GGCTCAGGTATAACCTCACCTTCCCTGGCTCATCTTGGCCTTGGGGAGTTGCCTTTAGGTTGA
1395  g t c c t c a a g c c t c t c c t t n n n n n c c a t a a t a a a a t g t t t a a g t t a t t 1441a (100)
Figure 4.11: Nucleotide and deduced amino acid sequence of phpl-2.0. The PLP site is 
indicated by a box. The polyadenylation sequence is underlined.
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4.8 CHARACTERISATION OF THE RECOMBINANT CLONE Phpl-2.0
As shown in figure 4.11 the clone phpl-2.0 contains a cDNA of 1441 nucleotides, plus a 
poly A tail of approximately 100 nucleotides. A single 738 nucleotide open reading frame is 
present, preceded by a 240 nucleotides of non-coding sequence, and followed by a 463 
nucleotide 3 ’ non-coding region plus approximately 100 bases of poly A tail. A poly 
adenylation signal sequence is present 20 nucleotides upstream of the poly A tail.
Alignment of the cDNA sequences of ppl-2.0 and phpl-2.0 (figure 4.12a), shows that 
nucleotides 1-240 of phpl-2.0 have no homology with ppl-2.0. Nucleotides 241-978 of 
phpl-2.0 demonstrate approximately 80% sequence homology with nucleotides 774-1509 
of ppl-2.0. Nucleotides 979-1441 of phpl-2.0 show no sequence homology with ppl-2.0 
(data not shown). Initially it was thought that the first 240 bases were part of an intron, 
however, a splice acceptor sequence was not present at the 'intron'/exon boundary. It was 
later determined using alignment analysis, that this region was coding sequence, which had 
somehow broken away and religated 3' to 5' ('flip-flopped'). This 'flip-flop' is illustrated 
in figure 4.12b, in which the nucleotide sequence (1-316) of phpl-2.0 is inverted and 
complemented to give the opposite strand. Alignment of this sequence with rat ppl-2.0 
shows homology with nucleotides 439-751 of the cDNA, therefore demonstrating the 
apparent breaking and religating of the cDNA . At the position of the break, 19 nucleotides 
corresponding to 755-773 of the rat sequence ppl-2.0 are missing in the corresponding 
region of human phpl-2.0, and are indicated in figure 4.12 by an underlined region.
The coding regions of phpl-1.0 and phpl-2.0 overlapped, giving a combined sequence of 
355 amino acids (figure 4.13). On comparison of the human amino acid sequence with that 
of the rat, (figure 4.14) it can be seen that the human protein has one amino acid less than 
the rat at the 3' end, and the pyridoxal phosphate binding site has a single conserved amino 
acid substitution of a serine to threonine. Taking into account that the human sequence is 
one amino acid shorter than the rat sequence, the combined human cDNAs code for 
approximately 84% of the expected size of the protein.
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(a)
R a t  ( 1 - 5 1 4 )  CTCACGAATGTGCTGGTGACAGTGGGTGCCTATGGGGCCTTGTTCACAGCCTTTCAGGCCCTGGTGGAT
I I I  I I I I I I
Human (1)  CGGTGCCGGCCAGCTCCATGGGGTCCAGCTGCCAGTTGCTGCTGGAACCCA
R a t  ( 5 8 3 )  GAAGGAGATGAGGTCATCATCATGGAACCTGCTTTTGACTGTTATGAACCCATGACAATGATGGCTGGA 
I II I I I I I I I I I I I
Human (52 )  GTTCTCCATTCTGGATGGGACCCGGCTTCAGGGACACAAACACAGGACGACCCCCTGCCATCATTGTCA
R a t
R a t
(6 5 2 )  GGTTGCCCTGTGTTCGTGACTCTGAAGCCGAGCCCTGCTCCTAAGGGGAAACTGGGAGCCAGCAATGAT
(7 2 1 )
I I I
I I I I I I I
Human ( 1 2 1 )  TGGGCTCGTAGCAGTCAAAAAAGGGTTCGATGATGATGACCTCGTCTCCTTCGTCCACCAGGGCCTGGA
TGGCAACTGGATCCTGCAGAACTGGCCAGCAAGTTCACACCTCGCACCAAGAT CCTGGTCCTCAACACA
I I I I I I I I I I I I I I II I I I I I I I I
Human ( 1 9 0 )  AGGCTGTGAACAGGGCCCCATAGCCACCAACAGTCACCAGCACATTCCTGAGCCCTGGTCCTCAACACC
R a t  ( 7 9 0 )  CCCAACAACCCTTTAGGAAAGGTAATCTCTAGGATGGAGCTGGAGCTGGTGGCTAATC 8 4 7 . . . 1 5 0 9
I I I I I I I I I I I I I I  I I I I I I I I I I I I  I I I I I I I I I I I I I I I I I I I 
Human ( 2 5 9 )  CCCAACAACCCCCTGGGCAAGGTGTTCTCCAGGGAAGAGCTGGAGCTGGTGGCCAGCC 3 1 6 _____9 7 8
(b)
R a t
Human
( 1 . . .
[ 9 7 8 .
.4 3 9 )  GCATTTGGTTACCCACCACTGACAAACGTCCTGGCAAGTTTCTTTGGCAA 
I I  I I I I I I I I I I I
. 3 1 6 ]  GGCTGGCCACCAGCTCCAGCTCTTCCCTGGAGAACACCTTGCCCAGGGGG
R a t  (4 8 9 )  GCTGCTGGGACAGGAGATGGACCCACTCACGAATGTGCTGGTGACAGTGGGTGCCTATGGGGCCTTGTTC 
I I I  I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I
Human [2 6 6 ]  TTGTTGGGGGTGTTGAGGACCAGGGCTCAGGAATGTGCTGGTGACTGTTGGTGGCTATGGGGCCCTGTTC
R a t  (5 5 8 )  ACAGCCTTTCAGGCCCTGGTGGATGAAGGAGATGAGGTCATCATCATGGAACCTGCTTTTGACTGTTATG 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I  I 
Human [196]  ACAGCCTTCCAGGCCCTGGTGGACGAAGGAGACGAGGTCATCATCATCGAACCCTTTTTTGACTGCTACG
R a t  (6 2 7 )  AACCCATGACAATGATGGCTGGAGGTTGCCCTGTGTTCGTGACTCTGAAGCCGAGCCCTGCTCCTAAGGG 
I I I I I I I I I I I I I I I I I I II I I I  I I I I I I I I I I I I  I I I I I I I I I I I II I II II 
Human [126]  AGCCCATGACAATGATGGCAGGGGGTCGTCCTGTGTTTGTGTCCCTGAAGCCGGGTCCCATCCAGAATGG
R a t  (6 9 6 )  GAAACTGGGAGCCAGCAATGATTGGCAACTGGATCCTGCAGAACTGGCCAGCAAGTTCACACCTCGCACC 
I I I I I I I I I I I I I I I I I I I I I I I I II II I I I I I I III 
Human [56] AGAACTGGGTTCCAGCAGCAACTGGCAGCTGGACCCCATGGAGCTGGCCGGCACCG [1]
R a t  ( 7 6 5 )  AAGATCCTGGTCCTCAACACACA (7 8 7 )
Figure 4.12: (a) SP6 sequence of human clone phpl-2.0 (bottom) aligned with the rat 
ppl-2.0 sequence (top), (b) The reverse-complement of the human phpl-2.0, SP6 sequence 
(bottom), aligned with the rat ppl-2.0 sequence top. Vertical lines indicate homology. The 
number of the first nucleotide in each row is given in brackets. Numbers in square brackets 
indicate complementary nucleotides. The underlined region of ppl-2.0 (nucleotides 755- 
773) does not have homology with phpl-2.0 in either (a) or (b).
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G l y T y r P r o P r o L eu T h r L y s I l e L eu A l a S e r P h e P h e G l y G lu L e u Leu 17
1 GGT TAC CCA CCA CTG ACG AAG ATC CTG GCA AGT TTC TTT GGG GAG CTG CTG
G l y G I n G 1 u I l e A sp P r o L eu A rg Asn V al L eu V al T h r V al G l y G l y T y r 34
52 GGT CAG GAG ATA GAC CCG CTC AGG AAT GTG CTG GTG ACT GTT GGT GGC TAT
G l y A I a L e u P h e T h r A l a P h e G in A l a L eu Val A sp G lu G l y A sp G l u Val 51
103 GGG GCC CTG TTC ACA GCC TTC CAG G CC CTG GTG GAC GAA GGA GAC GAG GTC
l i e I l e H e G lu P r o P h e P h e A sp C ys T y r G lu P r o Met T h r Met M et A l a 68
154 ATC ATC ATC GAA CCC TTT TTT GAC TGC TAC GAG CCC ATG ACA ATG ATG GCA
G l y G l y A rg P r o Val P h e Val S e r L eu L y s P r o G l y P r o H e G in A sn G l y 85
205 GGG GGT CGT CCT GTG TTT GTG TCC CTG AAG CCG GGT CCC ATC CAG AAT GGA
G l u L e u G l y S e r S e r S e r Asn T r p G in L eu A sp P r o Met G lu L e u A l a G l y 102
256 GAA CTG GGT TCC AGC AGC AAC TGG CAG CTG GAC CCC ATG GAG CTG GCC GGC
L y s P h e T h r S e r A rg T h r L y s |A la L eu Val L eu A sn T h r P r o Asn A sn P r o 119
307 AAA TTC ACA TCA CGC ACC AAA k c c CTG GTC CTC AAC ACC CCC AAC AAC CCC
L e u G l y L y s V al P h e S e r A rg TTlu G lu L eu G lu L eu V al A l a S e r L e u C ys 136
358 CTG GGC AAG GTG TTC TCC AGG GAA GAG CTG GAG CTG GTG GCC AGC CTT TGC
GI n G in H i s A sp Val V al C y s I l e T h r A sp G lu Val T y r G i n T r p MeTl Val 153
409 CAG CAG CAT GAC GTG GTG TGT ATC ACT GAT GAA GTC TAC CAG TGG a t g | GTC
T y r A sp G l y H i s G 1 n H i s H e S e r l i e A l a S e r L eu P r o G l y Met T r p G lu 170
460 TAC GAC GGG CAC CAG CAC ATC AGC ATT GCC AGC CTC CCT GGC ATG TGG GAA
A r g T h r L e u T h r H e G l y S e r A l a G l y L y s T h r P h e S e r A 1 a T h r G ly T r p 187
511 CGG ACC CTG ACC ATC GGC AGC GCC GGC AAG ACC TTC AGC GCC ACT GGC TGG
204L y s Val G 1 y T r p Va 1 L e u b i y K ro A S p M  1 S 11 e n e t L y s H i s L eu A r g T h r
562 AAG GTG GGC TGG GTC CTG GGT CCA GAT CAC ATC ATG AAG CAC CTG CGG ACC
V al H i s G in Asn S e r V al P h e H i s C ys P r o T h r G in S e r G i n A 1 a A l a Val 221
613 GTG CAC CAG AAC TCC GTC TTC CAC TGC CCC ACG CAG AGC CAG GCT GCA GTA
A l a G lu S e r P h e G 1 u A r g G lu G in L eu L e u P h e A rg G i n P r o S e r S e r T y r 238
664 GCC GAG AGC TTT GAA CGG GAG CAG CTG CTC TTC CGC CAA CCC AGC AGC TAC
P h e V al G in P h e P r o G in A 1 a Met G 1 n A rg C y s A r g A sp H i s Met I l e A rg 255
715 TTT GTG CAG TTC CCG CAG GCC ATG CAG CGC TGC CGT GAC CAC ATG ATA CGT
S e r L eu G in S e r Val G l y L eu L y s P r o H e H e P r o G i n G 1 y S e r T y r P h e 272
766 AGC CTA CAG TCA GTC GGC CTG AAG CCC ATC ATC CCT CAG GGC AGC TAC TTC
L e u l i e T h r A sp H e S e r A sp P h e L y s A r g L y s Met P r o A sp L eu P r o G l y 289
817 CTC ATC ACA GAC ATC TCA GAC TTC AAG AGG AAG ATG CCT GAC TTG CCT GGA
A l a V al A sp G lu P r o T y r A sp A rg A r g P h e V al L y s T r p Met H e L y s Asn 306
868 GCT GTG GAT GAG CCC TAT GAC AGA CGC TTC GTC AAG TGG ATG ATC AAG AAC
L y s G l y L e u V al A 1 a H e P r o Val S e r H e P h e T y r S e r V al P r o H i s G 1 n 323
919 AAG GGC TTG GTG GCC ATC CCT GTC TCC ATC TTC TAT AGT GTG CCA CAT CAG
L y s H i s P h e A sp H i s T y r H e A rg P h e C y s P h e Val L y s A s p G 1 u A 1 a T h r 340
970 AAG CAC TTT GAC CAC TAT ATC CGC TTC TGT TTT GTG AAG GAT GAA GCC ACG
L e u G in A 1 a Met A sp G 1 u L y s L e u A rg L y s T r p L y s V al G l u L eu S t o p 355
1021 CTC CAG GCC ATG GAC GAG AAG CTG CGG AAG TGG AAG GTG GAA CTC TAG CCC
1072  TGAAGTCACGCCTTGGCCCTGACATCCCCACATGCCCGCAGAGATCCTCTTTGAGTGTCTGTCTTTG 
1 1 3 9  TCCAGGTTTCAGACATTTCTAGGTTGGGGAAGATGCTATTGGGAAACCTCTTCTCCGTGACACAGAA 
1 2 0 6  TGTTCTGGGTGGGAGCCGCCCTTCTTCATCTTAGAGAACCAAGTGCCTCCTGTCTGAAAGGTGAGGG 
1 2 7 3  TGGCCTGACCTGGGCCTCTCCCTGCCCCTCCATAGGTGGGTTTGTAGGGTCTTGTGTTGCTTCTGGT 
1 3 4 0  CTCTCCAGGCTTGGCTGAGACGGACGGTAGACTTCCACCATGTACCGATCACATCCCAGCTCTGCAT 
1 4 0 7  GGCCCCTGCTAAGGCTCAGGTATAACCTCACCTTCCCTGGCTCATCTTGGCCTTGGGGAGTTGCCTT 
1 4 7 4  TAGGTTGAGTCCTCAAGCCTCTCCTTNNNNNCCATAATAAAATGTTTAAGTTATT ( 1 5 2 8 )  A(t00)
(b) 454
1528329
(100)
phpl-1.0
phpl-2.0
Figure 4 .13: (a) combined coding regions of phpl-1.0 and phpl-2.0. The PLP site is 
boxed, ] indicates the end of phpl-1.0 and [ indicates the start of phpl-2.0, The 
oligonucleotide Phi is underlined, Ph6 is italic and Ph7 is both underlined and italic, (b) 
diagrammatic representation of the overlap between phpl-1.0 and phpl-2.0.
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Met T h r L y s A rg L e u G 1 n A l a A rg A r g Leu A sp G ly H e A sp G in A sn L e u T r p V al G l u RAT
P h e G l y L y s L eu T h r L y s G l u T y r A sp Val Val Asn L e u G l y G in G l y P h e P r o A s p P h e RAT
S e r P r o P r o A sp P h e A 1 a T h r G in Al a P h e G in G 1 n Al a T h r S e r G l y A sn P h e Met L eu RAT
A sn G 1 n T y r T h r A r g A l a P h e G ly T y r P r o P r o Leu T h r Asn Val L eu A 1 a S e r P h e P h e RAT
L y s I l e HUMAN
G 1 y L y s L e u L eu G l y G in G l u Met A sp P r o L e u T h r Asn Val L eu Val T h r Val G l y A l a RAT
— G l u — — — — H e — — — A rg — — — — — — — G l y HUMAN
T y r G 1 y A 1 a L eu P h e T h r A rg P h e G 1 n A 1 a L e u Val A sp G l u G l y A sp G 1 u Val H e I l e RAT
A l a HUMAN
Met G 1 u P r o Al a P h e Asp C y s T y r G 1 u P r o Met T h r Met Met Al a G ly G l y C y s P r o V al RAT
l i e — — P h e — — — •— — — — — — — — — A r g — — HUMAN
P h e V al T h r L eu L y s P r o S e r P no A l a P r o L y s G ly L y s L e u G 1 y A l a S e r A sn A s p T r p RAT
— — S e r — — — G l y — I l e G in Asn — G lu — — S e r — S e r Asn — HUMAN
G in L e u A sp P r o A l a G lu L e u A l a S e r L y s P h e T h r P r o A r g T h r L y s H e L eu V al L e u RAT
— — — — Met — — — G l y — — — S e r — — — A l a — — — HUMAN
Asn T h r P r o Asn A sn P r o L e u G ly L y s Val P h e S e r A rg Met G lu L e u G l u L e u V al A l a RAT
G 1 u HUMAN
Asn L e u C y s G 1 n G 1 n H i s A sp Val V al Cys l i e S e r A sp G lu V al T y r G i n T r p L e u V al RAT
S e r — — — — — — — — — — T h r — — — — — — Met — HUMAN
T y r A sp G l y H i s G in H i s Val S e r H e A 1 a S e r Leu P r o G l y Met T r p A s p A r g T h r L e u RAT
— — — — — — I l e — — — — — — — — — G lu — — — HUMAN
T h r H e G 1 y S e r A l a G ly L v s S e r P h e S e r A l a T h r G ly T r p L y s V al G l y T r p V al M et RAT
— — — — — — — T h r — — — — — — — — — — — V al HUMAN
G l y P r o A sp Asn I l e Met L y s H i s L e u A rg T h r Val H i s G in Asn S e r H e P h e H i s C y s RAT
— — — — L e u — — — H i s — — — — — — — — — — — HUMAN
P r o T h r G 1 n A l a G 1 n A l a A l a Val A l a G in C y s P h e G l u A rg G 1 u G 1 n G in H i s P h e G l y RAT
— — — S e r — — — — — G lu S e r — — — — — L e u L e u — A r g HUMAN
G in P r o S e r S e r T y r P h e L eu G in L e u P r o G i n A 1 a Met G 1 u L eu A sn A r g A sp H i s Met RAT
— — — — — — Val — P h e — — — — G 1 n A r g C y s — — — — HUMAN
l i e A rg S e r L eu G i n S e r V al G ly L e u L y s L eu T r p H e S e r G in G ly S e r T y r P h e L e u RAT
P r o H e — P r o HUMAN
I l e A l a A sp l i e S e r Asp P h e L y s S e r L y s Met P r o A sp L e u P r o G ly A 1 a P r o T y r A s p RAT
— T h r — — — — — — A r g — — — — — — — V al — — HUMAN
A rg A r g P h e Al a L y s T r p Met I l e L y s Asn Met G lu A sp G lu G l y L e u V al G l y H e P r o RAT
— — — — — — Val — — — — — — L y s — — — Al a — — HUMAN
Val S e r T h r P h e P h e S e r A rg P r o H i s G in L y s Asp P h e A sp H i s T y r H e A r g P h e C y s RAT
— — I l e — T y r — Val — — — — H i s — — — — — — — — HUMAN
P h e V al L y s A sp L y s A 1 a T h r Leu G 1 n A l a Met Asp G 1 u A r g L eu A r g L y s T r p L y s G 1 u RAT
— — — — G l u — — — — — — — — L y s — — — — — V al HUMAN
L eu G in P r o RAT
G 1 u L e u HUMAN
Figure 4.14: The deduced amino acid sequence from the rat and human p-lyase cDNAs. 
Unchanged amino acids are indicated with a dash (-), the PLP site is underlined.
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The presence of aberrantly or incompletely spliced introns in cDNA libraries is not unusual, 
however, the presence of cDNAs which appear to have broken and religated in a different 
orientation is not common. The fact that after screening 1X106 clones, only two different 
cDNAs had been isolated and both of them being of this nature, the library was regarded as 
unsatisfactory, and it was decided to screen a different human library in order to obtain a 
full-length clone without introns (section 4.9).
4.9 HYBRIDISATION SCREENING OF A SECOND HUMAN cDNA 
LIBRARY
A second 5' Stretch human kidney library in k g tll (HLSOOlb, Cion tech) (see 2.2.6.1) 
was screened as above. The library cDNA had been prepared from the kidney mRNA of a 
black female using both oligo(dT) and random priming. The library was titrated using the 
method detailed in section 2.4.1. lxlO6 PFUs were plated as in section 2.4.2, and were 
probed using a 600bp human p-lyase cDNA fragment. This 600bp probe was prepared by 
digestion of phpl-2.0 with EcoRl and Pst I (data not shown), to remove the 3' end and poly 
A tail (see figure 4.10). The cDNA fragment was purified on a 1% (w/v) agarose gel, and 
extracted using Geneclean (section 2.3.7). The cDNA was radiolabelled as in 2.4.3.
4.9.1 Results of the second human cDNA library screen
A total of lxlO6 PFUs were screened, yielding no positive plaques. It was therefore 
decided that further screening was unlikely to yield any further p-lyase cDNAs, thus work 
with this library was discontinued. No other human kidney cDNA libraries were available, 
therefore, 5' RACE procedures were chosen as an alternative means of isolating the 
missing 5' end and ultimately the complete human cDNA (section 4.10).
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4.10 5' RAPID AMPLIFICATION OF cDNA ENDS (5! RACE)
4.10.1 Homopolymeric tail procedure
5' RACE, alternatively known as anchored PCR, provides a solution for the isolation of 
cDNA ends which may escape, or prove challenging for conventional cDNA cloning (see 
section 2.10). First strand cDNA synthesis, from a messenger RNA template is primed 
using a gene- specific antisense, oligonucleotide primer (GSP1). The first strand product is 
purified and a homopolymeric dC-tail is added to the 3' end. The dC-tailed cDNA is 
amplified by PCR using a second, nested gene-specific primer GSP2 and an anchor 
primer, which anneals to the homopolymeric tail.
4.10.1.1 Preparation of total RNA
RNA was prepared from human kidney tissue, obtained from the nephrectomy of a 70 year 
old male. The kidney tissue was frozen in liquid nitrogen within minutes of removal from 
its blood supply, and stored at -70°C until ready for use. Total RNA was prepared using 
the commercial reagent, RNAzol™ B (Biogenesis Ltd) (section 2.9.1).
4.10.1.2 5'RACE procedure
First strand cDNA synthesis was performed (section 2.10.1.1) from Ipig of total RNA 
using oligonucleotide Phi (GSP1) to prime the reaction (see figure 4.13 for the position of 
Phi). The cDNA was purified (2.10.1.2), dC-tailed (2.10.1.3) and amplified using Ph6 
(GSP2) and the anchor primer provided in the kit (see section 2.10.1). Ph6 anneals to the 
cDNA approximately 100 nucleotides upstream of Phi (see figure 4.13).
4.10.1.3 Determination of the size of the 5' RACE product
A single band, approximately 0.7kb was observed (figure 4.15) after 4% (w/v) agarose gel 
electrophoresis (2.3.4) and ethidium bromide staining (2.3.5). The PCR product was 
within the size range expected (400 to 800 nucleotides), and was transferred to nylon 
membrane for Southern blot analysis as in section 2.9.4.
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Figure 4.15: 4% (w/v) agarose gel electrophoresis of the 5' RACE amplification 
products (lane 2). Lane 1 contains 0X174 Hae III molecular weight markers.
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4.10.1.4 Southern blot analysis of the 5' RACE product
Hybridisation was performed using the formamide method as in 2.4.4.2. The human 
cDNA from phpl-1.0 was used for the hybridisation probe together with the rat cDNA 
(ppl-2.0). This was to increase the hybridisation signal, as phpl-1.0 had only 100 
nucleotides of overlap with the putative human 5' RACE, p-lyase cDNA product. The 
probes were labelled with 32P, as in 2.4.3. After hybridisation at 42°C overnight, the blot 
was washed with moderate stringency (see section 2.4.5) and exposed to X-ray film 
(2.3.11) for 18 hours. The film was developed (2.3.11) and demonstrated no hybridising 
bands. Although 18 hours was considered to be more than sufficient exposure for the 
quantity of DNA on the membrane (0.5-1.0 pg), the blot was autoradiographed for up to a 
week, after which it remained negative.
Due to cross species probing it was possible that the washing stringency was too high, 
therefore, the procedure above was repeated, however, the nylon membrane was washed at 
a maximum of 50°C. Again, no hybridising bands were observed.
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4.10.1.5 Procedures to improve the specificity of the PCR amplification
Increasing the specificity o f  prim er binding
It was thought that the non-specific 0.7kb band may be amplified more readily than the 
band of interest, thereby preventing sufficient specific product to be detected on the 
Southern blot. The annealing temperature of the PCR reaction was raised to 60°C, in an 
attempt to prevent the synthesis of the non-specific product, however, this also was 
unsuccessful.
5 ' RACE fro m  mRNA
It was possible that the non-specific product came from a ribosomal or another RNA 
sequence in the total RNA, therefore the RACE procedure in 4.10.1.2 was repeated using 
mRNA prepared from total RNA (section 2.9.2) using a commercially prepared kit, 
PolyATract™ (Promega Corporation). First strand cDNA synthesis was performed from 
Ipg of mRNA using oligonucleotide Phi as GSP1. Upon amplification of the dC-tailed 
cDNA with Ph6 (GSP2) the non-specific band was still present, and was therefore 
concluded to be a member of the mRNA population.
Designing a second GSP2
A  second GSP2 (Ph7) was designed, in order to eliminate the false positive obtained with 
Ph6. Ph7 annealed 6 nucleotides downstream of Ph6 (see figure 4.13) The non-specific 
band was successfully prevented, however, no other bands were visible upon gel 
electrophoresis of the PCR reaction (figure 4.16a). Southern blot analysis (as above) 
demonstrated a single faint band of approximately 700bp (figure 4.16b), however, 
insufficient product was obtained for subcloning, and amplification by further PCR was 
unsuccessful. Failure to amplify the product was thought to be due to inadequate 5' d e ­
tailing, necessary for anchor primer binding in the PCR amplification. However, it 
indicated that 51 p-lyase sequences could be obtained by RACE procedures.
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Figure 4.16: (a) 1% (w/v) agarose gel electrophoresis of 5' RACE amplified products 
(lane 1), 0X174 Hae III molecular weight markers (lane 2). (b) Southern blot analysis of 
the 5’ RACE products in (a), using the rat (ppl-2.0) and human ( phpl-1.0) as hybridisation 
probes.
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4.10.2 Anchor primer procedure
Homopolymeric tailing in the procedure above is the critical step in the successful 
amplification of a 5' cDNA fragment. Efficient tailing is subject to precise buffer 
concentrations, which are very difficult to achieve due to the small pipette measurements 
necessary in the procedure. An alternative 5' RACE procedure, using a specific anchor 
sequence ligated to the cDNA, was used to overcome this problem. 5r RACE-Ready 
cDNA, a product manufactured by Cion tech Laboratories, Inc. (USA), was chosen. The 
cDNA provided in the kit was prepared from highly purified human kidney poly A+ RNA 
(see section 2.10.2). A specific anchor sequence had been ligated to the 5' ends of the 
cDNA, which was ready to use in PCR amplification procedures, using the anchor primer 
provided in the kit and specific-oligonucleotides designed for the gene of interest.
4.10.2.1 RACE-Ready amplification 
Prim ary am plification
Primary amplification of the p-lyase cDNA was performed on the RACE-Ready cDNA 
using the anchor primer and the gene-specific primer Phi, as in section 2.10.2.1. As the 
cDNA of interest would only contribute to a very small proportion of the total cDNA 
population, a second PCR amplification was performed. This was achieved using a primer 
which was nested upstream of the first primer, in order to eliminate amplification of any 
miss-primed products in the first amplification reaction (see figure 4.1).
Secondary am plification
Secondary amplification of the p-lyase cDNA was achieved using the nested gene specific 
primer, Ph7 and the anchor primer as in the method described in 2.10.2.2.
198
4.10.2.2 Sizing of amplified products.
A sample of 15pl from the secondary PCR amplification was electrophoresed on a 4% 
(w/v) agarose gel (2.3.4.1), and visualised by ethidium bromide staining (2.3.5). A 
number of bands were observed (figure 4 .17a), which was to be expected as the RACE- 
Ready cDNA population would contain cDNA copies of different lengths, due to the 
distance travelled by reverse transcriptase in the cDNA synthesis. 4 diffuse bands estimated 
from the gel to be approximately 450bp, 500bp, 610bp and 720bp, were of particular 
interest as they were within the required size range of 400-800bp. In order to determine 
which, if any of these cDNA products coded for human p-lyase, the DNA was transferred 
to nylon membrane for Southern blot analysis as in section 2.9.4
4.10.2.3 Southern blot analysis of the 5' RACE products
Hybridisation was performed as above (4.10.1.4) using human cDNA from phpl-1.0 
together with the rat cDNA (ppl-2.0) as hybridisation probes, labelled with 32P as in
2.4.3. After 18 hours exposure the autoradiograph (figure 4.17b) was developed and 
demonstrated hybridising bands corresponding to the positions of the 450, 500, 610, and 
720bp products (figure 4.17a). The PCR products were subcloned into the plasmid vector 
pCRTMji for sequencing as described in 4.11.
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Figure 4.17: 4% (w/v) agarose gel electrophoresis of 5' RACE-Ready amplification 
products (lanes 2 & 3), 0X174 Hae III molecular weight markers (lane 1). (b) Southern 
blot analysis of the 5' RACE-Ready products in (a), using the rat (ppl-2.0) and human 
(phpl-1.0) as hybridisation probes.
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4.11 SUBCLONING OF PCR PRODUCTS USING THE TA CLONING™ 
SYSTEM
The TA cloning system (Invitrogen corporation) takes advantage of the non-template 
dependent activity of the thermostable polymerase used in PCR, which adds a single 
deoxyadenosine to the 3! end of all duplex molecules. The vector, pCR™II, provided in 
the kit is supplied as a linear molecule with single 3' T overhangs at the insertion site. This 
allows one step cloning, without the need for modification of the PCR product. The E.coli 
strain INVaF' enables blue/white screening of recombinant plasmids by a- 
complementation of (Tgalactosidase with the ZaeZAM15 genotype (see section 2.5).
4.11.1 Preparation of the PCR products for subcloning.
The secondary PCR amplification in section 4.10.2.1 was repeated and the whole reaction 
mixture (50pl), was electrophoresed on a 4% (w/v) agarose gel (2.3.4). The DNA was 
visualised by ethidium bromide staining (2.3.5), and bands of 450bp, 500bp, 610bp and 
720bp, were excised from the gel using a sterile scalpel, and concentrated using the 
Geneclean method as in 2.3.7. The 500bp and 610bp fragments were present at a very low 
yield in the repeated PCR amplification, and could not be increased on subsequent 
amplifications.
4.11.2 Subcloning of the PCR products into the vector pCR™II
The PCR products were ligated into the vector pCR™II, using the protocol in section 
2.12.1. The yield of the 500bp and 610bp DNA products was so small they were not 
visible on agarose gel electrophoresis, therefore the maximum volume of sample (7pl) was 
used in the ligation reaction in the hope that it would be sufficient to generate positive 
subclones. Competent E. coli cells (INV'aF), were transformed with the ligation 
products, and cultured on LB agar plates (containing ampicillin, 50pg/ml and X-Gal, 
40pg/ml). The plates were incubated for up to 40 hours for the blue background colour to 
develop. White colonies were re-cultured on 1 cm square of an ampicillin/X-Gal plate, 
those colonies remaining white after 24 hours incubation at 37° C were examined for inserts
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using the cracking procedure (4.11.3). No white colonies were produced for the 500bp and 
610bp cDNAs, probably due to the low DNA concentration in the ligation mixture.
4.11.3 Cracking procedure
In order to determine the presence of insert DNA, white colonies were analysed by the 
cracking procedure (see 2.5.4). The samples were run on a 1% (w/v) agarose gel as in
2.3.4, alongside a sample of pCR™II (data not shown). Subclones 13 and 37, from the 
720bp and 450bp ligation/transformation reactions respectively, contained plasmid DNA 
which was retarded in comparison to the control pCR™II and were chosen for further 
analysis. Small scale plasmid preparations using the Promega Wizard mini preparation 
method (section 2.5.5.2) were performed, and the DNA was analysed by restriction 
digestion (2.3.3) to confirm the size of the insert DNA.
4.11.4 Analysis of insert size
Plasmid DNA from clones 13 and 37 was digested with EcoRL (as in 2.3.3), followed by 
4% (w/v) agarose gel electrophoresis (2.3.4) and ethidium bromide staining (2.3.5). EcoRl 
digestion of subclone 37 demonstrates a single insert band of approximately 450 bp and 
subclone 13 demonstrates two insert bands of approximately 450 and 250bp, indicating the 
presence of an internal £h?RI site in the cDNA (figure 4.18a). The DNA was denatured 
and blotted to nylon membrane (as in 2.9.4) for Southern blot analysis (see 4.11.5).
4.11.5 Southern blot analysis of subclones 13 and 37
Southern blot analysis (as in 4.10.2.3 above) was performed on the EcoRl digested DNA 
of subclones 13 and 37 (figure 4.18a), and demonstrated hybridising bands for the cDNA 
inserts of both subclones (see figure 4.18b). Both cDNAs were sufficiently large to code 
for the missing 5' coding sequence providing that they did not contain large unspliced 
intronic regions. Subclones 13 and 37 were re-named phpl-3.0 and phpl-3.1 respectively 
and DNA sequencing, as detailed in section 4.12 below, was performed in order to 
characterise these cDNAs.
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4.12 DNA SEQUENCING OF phpl-3.0 AND phpl-3.1
DNA sequencing was performed with both vector primers SP6 and T7, and gene specific 
primers using Sequenase™ version 2.0 as in section 4.4. The sequences of phpl-3.0 and 
phpl-3.1, derived from both the vector and gene-specific primers were assembled, and 
analysed using the GeneJockey 1.1 software package (Biosoft Ltd, UK). The nucleotide 
and deduced amino acid sequences of phpl-3.0 and phpl-3.1 are shown in figures 4.19a 
and 4.20a respectively. The anchor sequence and nucleotides from the multiple cloning site 
have been removed from the sequences.
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Figure 4.18: 4% (w/v) agarose gel electrophoresis of plasmid DNA from subclones 13 
(lane 2) and 37 (lane 3), following digestion with EcoRl. Lane 1 contains the molecular 
weight markers XHindlll and 0X174 Hae III.(b) Southern blot analysis of the EcoRI 
restriction fragments from (a), using the rat (ppl-2.0) and human (phpl-1.0) as 
hybridisation probes.
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(a)
1 GGAAAGTGGGGAGTTTCTACTGCCTTGTGGGTT
34  CTTGGACTGAGGTTCATGGAGGCAAGCACTTCCTCTGGTTCTCTGCTAAATCCCCGCCCCGGGCTTC 
101 GGGCCTGGCACAGAACAGGCCAGTGGCAAATGCTGGTGGAGGAGATGGAAGAGCTTAGCACTGGATA 
168 TCTGAGTCAGTGCAGGCCTGGTGGTTGGCACCCTGGAGTCTGGGACCATATAGATTGTGTGACCTTT 
2 3 5  ACCTCCCAGAGTACACAGGGATCACAATAGCACCTGCCTCTGGGTTGTTGAGAGGATGAGATCAAAG 
3 0 2  AAATCCCACAAATAGCTTGGTGTGTAGAGGAATCCAGAGTGTTGAAAGCTGATCTATCCCACGTCCC 
3 6 9  CTGGGGCCCAGGCTACCAGTACCTGACTTTGCCCCCAGGCCTGCTGCTGGAAGGTGCTAGAATTCCC 
436 TGGATACAGCTGGGCCGGAGGATGGGCCCAGGCTGAGCTGGACAGTTAACCCCTGCTGTCCTGGCAG
G ly  T y r  P ro  P ro  Leu T h r  Lys l i e  Leu A l a  S e r  Phe Phe G ly  G lu  Leu Leu 17
5 0 3  GGT TAC CCA CCA CTG ACG AAG ATC CTG GCA AGT TTC TTT GGG GAG CTG CTG
G ly  G in  G lu  l i e  Asp P ro  Leu Arg  Asn V a l  Leu V a l T h r  V a l G ly  G ly  T y r  34
5 5 4  GGT CAG GAG ATA GAC CCG CTC AGG AAT GTG CTG GTG ACT GTT GGT GGC TAT
G ly  A l a  Leu Phe T h r  A la  Phe G in  A l a  Leu Val Asp G lu  G ly  Asp 49
6 0 5  GGG GCC CTG TTC ACA GCC TTC CAG GCC CTG GTG GAC GAA GGA GAC 6 4 9
(b)
( 1 ) GGAAAGTGGGGAGTTTCTACTGCCTTGTGGGTTCTTGGACTGAGGTTCATGGAGGCAAGC 
( 1 4 6 ) GGAAAGTGGGGAGTTTCTACTGCCTTGTGGGCTCTTGGACTGAGGTTCATGGAGGCAAGC
ACTTCCTCTGGTTCTCTGCTAAATCCCCGCCCCGGGCTTCGGGCCTGGCACAGAACAGGC
ACTTCCTCTGGTTCTCTGCTAAATCCCCGCCCTGGGCTTCGGGCCTGGCACAGAACAGGC
K
CAGTGGCAAATGCTGGTGGAGGAGATGGAAGAGCTTAGCACTGGATATCTGAGTCAGTGC
CTGTGGCAAATGCTGGTGGAGGAGATGGAAGAGCTTAGCACTGGATATCTGAGTCAGTGC
AGGCCTGGTGGTTGGCACCCTGGAGTCTGGGACCATATAGATTGTGTGACCTTTACCTCC
AGGCCTGGTGGTTGGCACCCTGGAGTCTGGGACCATATAGATTGTGTGACCTTTACCTCC
CAGAGTACACAGGGATCACAATAGCACCTGCCTCTGGGTTGTTGAGAGGATGAGATCAAA
CAGAGTACACAGGGATCACAATAGCACCTGCCTCTGGGTTGTTGAGAGGATGAGATCAAA
GAAATCCCACAAATAGCTTGGTGTGTAGAGGAATCCAGAGTGTTGAAAGCTGATCTATCC
GAAATCCCACAAATAGCTTGGTGTGTAGAGGAATCCAGAGTGTTGAAAGCTGATCTATCC
CACGTCCCCTGGGGCCCAGGCTACCAGTACCTGACTTTGCCCCCAGGCCTGCTGCTGGAA
CACGTCCCCTGGGGCCCAGGCTACCAGTACCTGACTTTGCCCCCAGGCCTGCTGCTGGAA
GGTGCTAKAATTClCCTGGATACAGCTGGGCCGGAGGATGGGCCCAGGCTGAGCTGGACAG
GGTGCTAGAATTGCCTGGATACAGCTGGGCCGGAGGATGGGCCCAGGCTGAGCTGGACAG
TTAACCCCTGCTGTCCTGGCAGGGTTACCCACCACTGACGAAGATCCTGGCAAGTTTCTT
TTAACCCCTGCTGTCCTGGCAGGGTTACCCACCACTGACGAAGATCCTGGCAAGTTTCTT
TGGGGAGCTGCTGGGTCAGGAGATAGACCCGCTCAGGAATGTGCTGGTGACTGTTGGTGG
TGGGGAGCTGCTGGGTCAGGAGATAGACCCGCTCAGGAATGTGCTGGTGACTGTTGGTGG
6 0 )
2 0 5 )
120 )
2 6 5 )
1 80 )
3 2 5 )
2 4 0 )
3 8 5 )
3 0 0 )
4 4 5 )
3 6 0 )
5 0 5 )
4 2 0 )
5 6 5 )
4 8 0 )
6 2 5 )
5 4 0 )
6 8 5 )
6 0 0 )
7 4 5 )
CTATGGGGCCCTGTTCACAGCCTTCCAGGCCCTGGTGGACGAAGGAGAC (6 4 9 )  
CTATGGGGCCCTGTTCACAGCCTTCCAGGCCCTGGTGGACGAAGGAGAC ( 7 9 4 ) .................(1 1 8 4 )
Figure 4.19: (a) Nucleotide and deduced amino acid sequence of phpl-3.0. (b) 
Alignment of phpl-3.0 (top) with phpl-1.0 (bottom). * indicates nucleotide differences 
between the two sequences, and the £h?RI site in phpl-3.0 is indicated by a box.
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(a)
1 I A nchor regiQn~EGGGTGAAGCGGCCCAGGTG AGGCTCGCC
Met A l a Lys G in Leu G in A l a Arg Arg Leu Asp G 1 y I le Asp T y r Asn P ro 17
30 ATG GCC AAA CAG CTG CAG GCC CGA AGG CTA GAC GGG ATC GAC TAC AAC CCC
T rp Va I GI u Phe Va 1 Lys Leu A 1 a S e r G 1 u H i s Asp Val Val Asn Leu G ly 34
81 TGG GTG GAG TTT GTG AAA CTG GCC AGT GAG CAT GAC GTC GTG AAC TTG GGC
Gin G I y Phe P ro Asp Phe P ro Leu P ro Asp Phe A la Val G 1 u A l a Leu G in 51
132 CAG GGC TTC CCG GAT TTC CCA CTA CCA GAC TTT GCC GTG GAA GCC TTA CAG
H i s A l a Va I S e r G ly Asp Phe Met Leu Asn G in T y r T h r Lys T h r Phe [G ly 68
183 CAC GCT GTC AGT GGA GAC TTC ATG CTT AAC CAG TAC ACC AAG ACA TTT [gg t
T y r P ro P ro Leu T h r Lys l i e Leu A 1 a S e r Phe Phe G ly G lu Leu Leu G ly 85
2 3 4 TAC CCA CCA CTG ACG AAG ATC CTG GCA AGT TTC TTT GGG GAG CTG CTG GGT
Gin G I u I  le Asp P ro Leu Arg Asn Va 1 Leu Val T h r Val G ly G ly T y r G ly 102
28 5 CAG GAG ATA GAC CCG CTC AGG AAT GTG CTG GTG ACT GTT GGT GGC TAT GGG
A la Leu Phe T h r A la Phe Gin A la Leu Val Asp Glu G ly Asp 116
33 6 GCC CTG TTC ACA GCC TTC CAG GCC CTG GTG GAG GAA GGA GAG 3 7 7
(b)
Human
Rat
Human
Rat
Human
R a t
Human
Rat
Human
Rat
Human
Rat
Human
Rat
Human
R at
GGGGTGAAGC 
1 1 1
GGCCCAGGTG 
1 1 1
AGGCTCGCC|A TqGCCAAACA GCTGCAGGCC 
1 1 1 1 1 1 1 1 1
GCTGCAGGCT
(50)
1,1 1
AGCGCAATTG
1 1 1 
TTAGCTGAAG
1 1 1 1 I I I
CAGCTCACCJA
I I  1 1 1 1 1 1
1 GjACCAAACG (264)
CGAAGGCTAG ACGGGATCGA CTACAACCCC TGGGTGGAGT TTGTGAAACT (100)
I I  1 1 1 1 1 1 11 1 1 1 1 1 I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I I  1 1 1 1 1
CGGAGGCTGG ACGGGATTGA TCAAAACCTC TGGGTGGAGT TTGGCAAACT (314)
GGCCAGTGAG
1 I I I  I I I
CATGACGTCG 
1 1 1 1 1 1 1 1 1
TATGACGTCG
TGAACTTGGG 
1 1 1 1 1 1 1 1 1 1 
TGAACTTGGG
CCAGGGCTTC 
1 1 1 1 1 1 1 1 1
CCGGATTTCC
I I  I I  I I I
(150)
1 111 I I I  
GACCAAGGAG
1 1 1 1 1 1 1 1 1
TCAGGGCTTC
I I  I I  I I I  
CCTGACTTCT (364)
CACTACCAGA CTTTGCCGTG GAAGCCTTAC AGCACGCTGT CAGTGGAGAC (200)
I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 1 I I I 1 11 1 1 1 I I
CGCCTCCGGA CTTTGCAACG CAAGCTTTTC AGCAGGCTAC CAGTGGGAAC (414)
TTCATGCTTA 
1 1 1 1 1 1 1 1 1
ACCAGTACAC 
1 1 1 1 1 1 1 1 1 1
CAAGACATTT
I I  1 1 1 1 1 1
GGTTACCCAC 
1 1 1 1 1 1 1 1 1 1
CACTGACGAA 
1 1 1 1 1 1 1 I I  
CACTGACAAA
(250)
1 1 1 1 1 f I 1 1
TTCATGCTCA
1 I I  1 I I  1 1 1 1
ACCAGTACAC
I I  1 ( M i l  
CAGGGCATTT
1 1 1 1 1 1 1 1 1 1 
GGTTACCCAC (464)
GATCCTGGCA AGTTTCTTTG GGGAGCTGCT GGGTCAGGAG ATAGACCCGC (300)
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I I  1 1 1 1 1 1 I I  1 1 1 1 1 1
CGTCCTGGCA AGTTTCTTTG GCAAGCTGCT GGGACAGGAG ATGGACCCAC (514)
TCAGGAATGT GCTGGTGACT GTTGGTGGCT ATGGGGCCCT GTTCACAGCC (350)
I I I  1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I I  1 1 1 1 I I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
TCACGAATGT
TTCCAGGCCC 
I I  1 1 1 1 1 1 1 
TTTCAGGCCC
GCTGGTGACA
TGGTGGACGA 
1 1 1 1 1 1 1 I I  
TGGTGGATGA
GTGGGTGCCT ATGGGGCCTT
AGGAGAC (377)
1 1 1 1 1 1
GTTCACAGCC (564)
1 1 1 1 1 1
AGGAGAT ( 5 9 1 ) ................... (1 8 6 7 )
Figure 4.20: (a) Nucleotide and deduced amino acid sequence of phpl-3.1. 
Oligonucleotide Ph7 is underlined and the start of phpl-1.0 is indicated by [ and the anchor 
region is indicated, (b) Alignment analysis of human phpl-3.1 (top), with rat phpl-2.0 
(bottom). Homologous bases are indicated by vertical lines. ATG start codons are boxed.
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4.12.1 Characterisation of phpl-3 .0
As shown in figure 4 .19a the clone phpl-3.0 contains a cDNA of 649 nucleotides. A single 
147 nucleotide open reading frame, coding for 49 amino acids is present, preceded by 502 
nucleotides of non-coding sequence.
Alignment of phpl-3.0 with phpl-1.0 (figure 4.19b), shows that nucleotides 1-649 of phpl-
3.1 correspond to nucleotides 146-794 of phpl-1.0. Four base differences are present in 
the intronic region of these cDNAs, one of which produces an EcoRl restriction site at 
nucleotides 428^133 of the phpl-3.0 sequence. This EcoRl site is demonstrated by the 
presence of two insert fragments upon £a?RI digestion of phpl-3.0 (clone 13, lane 2, 
figure 4.18). The four differences in the intronic region of the human cDNAs phpl-3.0 and 
phpl-1.0, are probably due to inter-individual variation.
4.12.2 Characterisation of phpl-3.1
As shown in figure 4.20a the clone phpl-3.1 contains a cDNA of 377 nucleotides. 
Alignment of the cDNAs from rat ppl-2.0 and human phpl-3.1 (figure 4.20b), shows that 
nucleotides 23-377 of phpl-3.1 demonstrate approximately 80% sequence homology with 
nucleotides 237-591 of ppl-2.0. The 51 non-coding nucleotides 1-22 of phpl-3.1 show no 
sequence homology with ppl-2.0. The position of the anchor region used in the PCR 
reaction is illustrated by a box. DNA sequencing indicates that the EcoRl site within the 
anchor (see 2.10.2) is damaged, preventing its removal on EcoRl digestion (data not 
shown).
phpl-3.1 has a single 348 nucleotide open reading frame initiated by an ATG codon 
embedded in a consensus translation start sequence. This open reading frame is preceded 
by 29 nucleotides of 5' non-coding sequence. The presence of a start codon, the homology 
between phpl-3.1 and the rat ppl-2.0 and the 147 nucleotide overlap between phpl-3.1 and 
the coding region of phpl-1.0 (figure 4.21) indicated that the missing 5' end of the human 
p-lyase cDNA had finally been isolated.
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p h p l- 3 . 1  (1 ) GGGGTGAAGCGGCCCAGGTGAGGCTCGCCATGGCCAAACAGCTGCA (4 6 )
p h p i - 3 . 1 GGCCCGAAGGCTAGACGGGATCGACTACAACCCCTGGGTGGAGTTTGTGA (9 6 )
p h p i - 3 . 1 AACTGGCCAGTGAGCATGACGTCGTGAACTTGGGCCAGGGCTTCCCGGAT (1 4 6 )
p h p l- 3 . 1  TTCCCACTACCAGACTTTGCCGTGGAAGCCTTACAGCACGCTGTCAGTGG (1 9 6 )
p h p l- 3 . 1  AGACTTCATGCTTAACCAGTACACCAAGACATTTGGTTACCCACCACTGA (2 4 6 )  
p h p l- 1 . 0  (6 4 8 ) GGTTACCCACCACTGA (6 6 3 )
p h p i - 3 . 1 CGAAGATCCTGGCAAGTTTCTTTGGGGAGCTGCTGGGTCAGGAGATAGAC (2 9 6 )  
p h p i - 1 . 0  CGAAGATCCTGGCAAGTTTCTTTGGGGAGCTGCTGGGTCAGGAGATAGAC (7 1 3 )
p h p i - 3 . 1 CCGCTCAGGAATGTGCTGGTGACTGTTGGTGGCTATGGGGCCCTGTTCAC (3 4 6 )  
p h p I-  1 .0  CCGCTCAGGAATGTGCTGGTGACTGTTGGTGGCTATGGGGCCCTGTTCAC (7 6 3 )
p h p l - 3 .1  AGCCTTCCAGGCCCTGGTGGACGAAGGAGAC (3 7 7 )  
p h p i - 1 . 0  AGCCTTCCAGGCCCTGGTGGACGAAGGAGAC (7 9 4 )
Figure 4.21: Alignment of phpl-3.1 (top) and the coding region of phpl-1.0 (bottom).
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4.13 ISOLATION OF A FULL-LENGTH HUMAN p-LYASE cDNA
The complete human (3-lyase nucleotide and deduced amino acid sequence (figure 4.22) 
was compiled from the overlapping open reading frame sequences of phpl-1.0, phpl-2.0 
and phpl-3.1. However, in order to express the cDNA in COS-1 cells for structure-activity- 
relationship studies, the cDNA was required as a complete fragment. This was attempted 
by a three step procedure in which the overlapping fragments phpl-1.0, phpl-2.0 and phpl-
3.1 were digested with restriction enzymes which enabled them to be religated in a specific 
order. The religated cDNA was amplified by PCR using oligonucleotides either side of the 
coding region.
4.13 .1  D igestion of phpl-1.0, phpl-2.0 and phpl-3.1 with restriction  
enzymes
The cDNA inserts from phpl-1.0, phpl-2.0 and phpl-3.1 were removed from their plasmids 
by EcoRl digestion as in 2.3.3, purified by agarose gel electrophoresis (2.3.4) and 
extracted using Geneclean (2.3.7). The following digestion/ligation strategy is illustrated in 
figure 4.23a. The cDNA inserts of phpl-1.0, phpl-2.0 and phpl-3.1 were digested as 
detailed in table 4.1, and the fragments of interest as detailed in the same table were purified 
by agarose gel electrophoresis and concentrated by Geneclean as above (data not shown).
cDNA Insert Enzyme(s) Size of fragment recovered (bp)
phpl-1.0 ApallBanl 359
phpl-2.0 Banl 1160
phpl-3.1 Apal 381 (including anchor region)
Table 4.1: The human cDNA inserts used in the ligation of overlapping sequences to 
produce a full-length sequence, the restriction enzymes used to prepare fragments for 
religation and the size of the fragments to be ligated.
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1 GGGGTGAAGCGGCCCAGGTGAGGCTCGCC
Met A l a Lys Gin Leu G in A la Arg Arg Leu Asp G ly H e Asp T y r Asn P ro 17
3 0 ATG GCC AAA CAG CTG CAG GCC CGA AGG CTA GAC GGG ATC GAC TAC AAC CCC
T rp V al G lu Phe Val Lys Leu A 1 a S e r G lu H i s Asp V al Val Asn Leu G ly 34
81 TGG GTG GAG TTT GTG AAA CTG GCC AGT GAG CAT GAC GTC GTG AAC TTG GGC
G I n G ly Phe P ro Asp Phe Pro Leu P ro Asp Phe A 1 a Val Glu A 1 a Leu G in 51
132 CAG GGC TTC CCG GAT TTC CCA CTA CCA GAC TTT GCC GTG GAA GCC TTA CAG
H i s A la Val S e r G ly Asp Phe Met Leu Asn G in T y r T h r Lys T h r Phe G ly 68
183 CAC GCT GTC AGT GGA GAC TTC ATG CTT AAC CAG TAC ACC AAG ACA TTT GGT
T y r P ro P ro Leu T h r Lys I le Leu A 1 a S e r Phe Phe G ly Glu Leu Leu G ly 85
2 3 4 TAC CCA CCA CTG ACG AAG ATC CTG GCA AGT TTC TTT GGG GAG CTG CTG GGT
G in G lu I le Asp P ro Leu Arg Asn Val Leu Val T h r Val G ly G ly T y r G ly 102
2 8 5 CAG GAG ATA GAC CCG CTC AGG AAT GTG CTG GTG ACT GTT GGT GGC TAT GGG
A 1 a Leu Phe T h r A 1 a Phe Gin A 1 a Leu Val Asp G lu G ly Asp G lu Val I le 119
3 3 6 GCC CTG TTC ACA GCC TTC CAG GCC CTG GTG GAC GAA GGA GAC GAG GTC ATC
I le l i e G lu P ro Phe Phe Asp Cys T y r G lu P ro Met T h r Met Met A la G ly 136
3 8 7 ATC ATC GAA CCC TTT TTT GAC TGC TAC GAG CCC ATG ACA ATG ATG GCA GGG
G ly Arg P ro Val Phe V al S er Leu Lys P ro G ly P ro H e Gin Asn G ly G lu 153
438 GGT CGT CCT GTG TTT GTG TCC CTG AAG CCG GGT CCC ATC CAG AAT GGA GAA
Leu G ly S e r S e r S e r Asn Trp G in Leu Asp P ro Met G lu Leu A 1 a G ly Lys 170
489 CTG GGT TCC AGC AGC AAC TGG CAG CTG GAC CCC ATG GAG CTG GCC GGC AAA
Phe T h r S e r Arg T h r Lys A la Leu Val Leu Asn T h r P ro Asn Asn P ro Leu 187
5 4 0 TTC ACA TCA CGC ACC AAA GCC CTG GTC CTC AAC ACC CCC AAC AAC CCC CTG
G ly Lys Val Phe S e r Arg Glu Glu Leu Glu Leu V al A 1 a S e r Leu Cys G in 20 4
591 GGC AAG GTG TTC TCC AGG GAA GAG CTG GAG CTG GTG GCC AGC CTT TGC CAG
G in H i s Asp Val Val Cys H e T h r Asp Glu Val T y r G in T rp Met Val T y r 221
642 CAG CAT GAC GTG GTG TGT ATC ACT GAT GAA GTC TAC CAG TGG ATG GTC TAC
Asp G ly H i s G in H i s H e S er I le Al a S e r Leu P ro G ly Met T rp G lu Arg 23 8
6 9 3 GAC GGG CAC CAG CAC ATC AGC ATT GCC AGC CTC CCT GGC ATG TGG GAA CGG
T h r Leu T h r l i e G ly S e r A la G ly Lys T h r Phe S e r A 1 a T h r G ly T rp L ys 25 5
7 4 4 ACC CTG ACC ATC GGC AGC GCC GGC AAG ACC TTC AGC GCC ACT GGC TGG AAG
V al G ly T rp Val Leu G ly Pro Asp H i s I  le Met Lys H i s Leu A rg T h r V al 272
7 9 5 GTG GGC TGG GTC CTG GGT CCA GAT CAC ATC ATG AAG CAC CTG CGG ACC GTG
H i s G in Asn S e r Val Phe H i s Cys P ro T h r G in S e r G in A 1 a A 1 a Val A l a 2 8 9
8 4 6 CAC CAG AAC TCC GTC TTC CAC TGC CCC ACG CAG AGC CAG GCT GCA GTA GCC
G lu S e r Phe Glu Arg G lu Gin Leu Leu Phe Arg G in P ro S e r S e r T y r Phe 3 0 6
8 9 7 GAG AGC TTT GAA CGG GAG CAG CTG CTC TTC CGC CAA CCC AGC AGC TAC TTT
V al G in Phe P ro Gin A la Met G in Arg Cys Arg Asp H i s Met I  le Arg S e r 3 2 3
9 4 8 GTG CAG TTC CCG CAG GCC ATG CAG CGC TGC CGT GAC CAC ATG ATA CGT AGC
Leu G in S e r Val G ly Leu Lys P ro H e I le P ro G in G ly S e r T y r Phe Leu 3 4 0
9 9 9 CTA CAG TCA GTG GGC CTG AAG CCC ATC ATC CCT CAG GGC AGC TAC TTC CTC
I le T h r Asp H e S e r Asp Phe Lys Arg Lys Met P ro Asp Leu P ro G ly A l a 3 5 7
1050 ATC ACA GAC ATC TCA GAC TTC AAG AGG AAG ATG CCT GAC TTG CCT GGA GCT
V al Asp G lu P ro T y r Asp Arg Arg Phe Val Lys T rp Met H e Lys Asn Lys 3 7 4
1101 GTG GAT GAG CCC TAT GAC AG A CGC TTC GTC AAG TGG ATG ATC AAG AAC AAG
G ly Leu Val A 1 a I le P ro Val S e r H e Phe T y r S e r V al P ro H i s Gin L ys 391
1152 GGC TTG GTG GCC ATC CCT GTC TCC ATC TTC TAT AGT GTG CCA CAT CAG AAG
H i s Phe Asp H i s T y r H e Arg Phe Cys Phe Val Lys Asp Glu A 1 a T h r Leu 408
1203 CAC TTT GAC CAC TAT ATC CGC TTC TGT TTT GTG AAG GAT GAA GCC ACG CTC
G in A 1 a Met Asp Glu Lys Leu Arg Lys T rp Lys V a l G lu Leu S to p 422
1254 CAG GCC ATG GAC GAG AAG CTG CGG AAG TGG AAG GTG GAA CTC TAG CCCTGAA
1306 GTCACGCCTTGGCCCTGACATCCCCACATGCCCGCAGAGATCCTCTTTGAGTGTCTGTCTTTGTCCA 
1373 GGTTTCAGACATTTCTAGGTTGGGGAAGATGCTATTGGGAAACCTCTTCTCCGTGACACAGAATGTT 
1440 CTGGGTGGGAGCCGCCCTTCTTCATCTTAGAGAACCAAGTGCCTCCTGTCTGAAAGGTGAGGGTGGC 
1507 CTGACCTGGGCCTCTCCCTGCCCCTCCATAGGTGGGTTTGTAGGGTCTTGTGTTGCTTCTGGTCTCT 
1574 CCAGGCTTGGCTGAGACGGACGGTAGACTTCCACCATGTACCGATCACATCCCAGCTCTGCATGGCC 
1641 CCTGCTAAGGCTCAGGTATAACCTCACCTTCCCTGGCTCATCTTGGCCTTGGGGAGTTGCCTTTAGG 
1708 TTGAGTCCTCAAGCCTCTCCTTNNNNNCCATAATAAAATGTTTAAGTTATTA(10 0 )
Figure 4.22: The full-length nucleotide and deduced amino acid sequence compiled from 
the overlapping sequences of phpl-1.0, phpl-2.0 and phpl-3.1. PLP site is boxed.
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(a) E Apal E
AR phpl-3.1
^  381bp
E Apal
Intron
BanI E 
 I
phpl-1.0
359bp
E BanI _l___
'Flip-flop'
E
phpl-2.0
1160bp
(b) E
SFETT
1400bp
Figure 4.23: (a) Digestion strategy for religation of overlapping human p-lyase cDNAs 
(phpl-1.0, phpl-2.0 and phpl-3.1) to form a full-length cDNA. E, represents EcoRI 
restriction sites; AR, represents the anchor region of phpl-3.1; arrows illustrate the cDNA 
fragments to be religated, (b) Diagrammatic representation of the religated human fragments 
from (a) above, Phi 1 and the anchor primer (AP) are indicated by filled boxes.
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4.13.2 Ligation of phpl-1.0, phpl-2.0 and phpl-3.1 fragments
The fragments of 381bp, 359bp and 1160bp as in table 4.1 were joined together in a 
ligation reaction as in section 2.5.2, however, lOOng of each fragment was used. The 
choice of restriction enzymes ensured the correct orientation of the full-length sequence. 
The PCR amplification, used to amplify the full-length sequence from the ligation mixture, 
is described in section 4.13.3.
4.13.3. PCR amplification of a full-length human p-lyase cDNA
PCR amplification was performed as detailed in section 2.10.2.1, using 2pl of the ligation 
mixture from section 4.13.2. A 3' gene specific oligonucleotide primer (P h il) was used to 
prime the synthesis of the bottom strand, 60 nucleotides downstream of the stop codon, 
together with the 5' RACE-Ready anchor oligonucleotide to prime the synthesis of the top 
strand from the anchor region of the phpl-3.1 fragment (see figure 4.23b). The PCR 
amplification was electrophoresed on a 4% (w/v) agarose gel, demonstrating a PCR 
fragment of approximately 1400bp (figure 4.24).
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Figure 4.24: 4% (w/v) agarose gel electrophoresis of the PCR amplification of the full- 
length fragment from the ligated restriction fragments of phpl-1.0, phpl-2.0 and phpl-3.1 
(lane 2). Lane 1 contains 0X174 Hae III molecular weight markers.
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4.14 HETEROLOGOUS EXPRESSION OF THE HUMAN KIDNEY
P-LYASE cDNA IN COS-1 CELLS
4 .14 .1  In tro d u c t io n
Expression of the cDNA in tissue culture cells was performed to determine if the full-length 
cDNA had been correctly constructed and coded for an active p-lyase enzyme. The aim was 
to demonstrate an increase in cytosolic glutamine transaminase K and p-lyase activity, 
following transfection of COS-1 monkey kidney cells with the cDNA. A comparison of 
glutamine transaminase K and p-lyase activities for both the rat and human enzymes was 
made, with respect to making progress towards an initial assessment for the potential risk 
of human exposure to halogenated hydrocarbons.
The full-length human cDNA was cloned into the expression vector pUSlOOO, placing 
transcription of the cDNA under control of the strong immediate-early promoter of human 
cytomegalovirus. Amplification in COS-1 cells was ensured by the presence of an SV40 
origin of replication in the vector.
As the full-length PCR product did not have the necessary EcoRL sites required for ligation 
into pUSlOOO, it was first subcloned into the vector pCR™II (as described in 4.11). 
Subsequent digestion with EcoRL removed the cDNA insert from pCR™II, providing the 
EcoRL 'sticky ends' necessary for ligation into pUSlOOO.
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4.14.2 S u b c lo n in g  o f th e  fu ll- len g th  P C R  p ro d u c t in to  p C R ™ II
The 1400bp PCR fragment was purified by 1% (w/v) agarose gel electrophoresis (2.3.4) 
and extracted using Geneclean (2.3.7). The cDNA was ligated into the vector pCR™II 
using the protocol in section 2.12.1. Competent E. coli cells (INV'aF), were transformed 
with the ligation products, and cultured on LB agar plates containing 50pg/ml ampicillin, 
and 40pg/ml X-Gal (see 2.12.2). The plates were incubated for up to 40 hours for the blue 
background colour to develop. White colonies were re-cultured on 1 cm square of an 
ampicillin/X-Gal plate, those colonies remaining white after 24 hours incubation at 37°C 
were examined for inserts using the cracking procedure (4.14.3).
4.14.3  C ra c k in g  p ro c e d u re
In order to determine the presence of insert DNA, white colonies were analysed by the 
cracking procedure (as in 4.11.3). Clone 3 which was retarded relative to pCR™II on 1% 
(w/v) agarose gel electrophoresis (data not shown) was chosen for small scale plasmid 
preparation as in 2.5.5.2.
4.14 .4  A naly sis  o f  in s e r t  size
Plasmid DNA was digested with EcoRi (2.3.3), followed by 4% (w/v) agarose gel 
electrophoresis (2.3.4) and ethidium bromide staining (2.3.5). £coRI digestion 
demonstrates a plasmid band of 3.9kb and a single insert band of approximately 1.4kb 
(figure 4.25, lane 2). Clone 3 was re-named ph(3l-4.0.
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Figure 4.25: 1% (w/v) agarose gel electrophoresis of the plasmid clone 3 (phpl-4.0), 
following digestion with Apal (lane 1) and EcoRl (lane 2). Lanes 3 and 4 contain the 
molecular weight markers XHindlll and 0X174 Hoe III respectively.
4 .14.5  S eq u en c in g  o f  p h p l-4 .0
Sequencing was performed on phpl-4.0 to ensure that the restriction sites of the religated 
DNA were intact, and that errors had not occurred which might lead to a frame shift or 
nucleotide substitution. Gene specific oligonucleotide primers Phl3 and Phl4 were used to 
sequence across the Apal site and the BanI sites respectively. The restriction sites were 
shown to be intact (data not shown) and the cDNA was removed from the vector by EcoRl 
digestion (2.3.3) and purified by 1% (w/v) agarose gel electrophoresis. The cDNA was 
extracted from the agarose gel using Geneclean (2.3.7), and subcloned into the expression 
vector pUSlOOO (see 4.14.6).
4.14.6  S u b c lo n in g  o f th e  cDNA fro m  phpl-4 .0  in to  pUSlOOO
The full-length cDNA fragment obtained by EcoRl digestion in section 4.14.5 was ligated 
into the EcoRl linearised vector pUSlOOO as detailed in section 2.5 using 10:1 and 40:1 
molar ratios of vector to insert. As the linearised pUSlOOO was previously treated with calf 
intestinal alkaline phosphatase, only plasmids containing cDNA inserts should religate (see 
section 2.5.1). The recombinant plasmids were transformed into E.coli JM109 bacterial 
cells (section 2.5.3), and cultured on ampicillin (50pg/ml) plates overnight at 37°C. A 
selection of colonies were examined for inserts by the cracking procedure as in 4.14.6.1.
4.14.6 .1  A n aly sis  o f re c o m b in a n t p la sm id s
Crude preparations of plasmid DNA were made using the cracking procedure (2.5.4) and 
the samples were analysed on a 1% (w/v) agarose gel (2.3.4) alongside a sample of 
pUSlOOO (data not shown). Clones which were retarded relative to pUSlOOO were chosen 
for small scale plasmid preparations, using the Wizard mini preparation method (Promega 
Corporation, section 2.5.5.2). The DNA was digested with EcoRl, followed by 1% (w/v) 
agarose gel electrophoresis (2.3.4), demonstrating inserts of approximately 1.4kb (data not 
shown).
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4.14.7. Determination of the orientation of the recombinant cDNA clones.
In order to perform expression experiments it was necessary to determine which clones 
contained the cDNA orientated in the sense direction so that the promoter was upstream of 
the cDNA translation consensus start site. An antisense orientation recombinant was also 
required as a negative control. Restriction enzyme mapping with Apal was used to 
determine the orientation of six recombinants (figure 4.26). The orientations of clones 1 
and 18 were antisense and sense respectively and were re-named pUSpl-4.0 (-) and pUSpl- 
4.0 (+) respectively.
4.14.8 T ra n s fe c tio n  o f C O S-1 cells u s in g  D E A E -d ex tran
COS-1 cells were cultured in Dulbecco’s Modified Eagles Medium, 10% (v/v) foetal calf 
serum, 5% CO2  in air at 37°C. DNA transfection of subconfluent cells was performed 
using DEAE-dextran as detailed in section 2.7.5. In order to provide sufficient cytosol for 
enzyme assays three 75cm2 flasks were used for each of the sense DNA, antisense DNA 
control and no DNA control transfections. The cells were incubated at 37°C with 5% CO2  
for 48 hours prior to harvesting for cytosol preparation.
4.14.8.1 P re p a ra t io n  o f C O S-1 cell cy toso l
COS-1 cell cytosol was prepared as detailed in section 2.7.6. The samples were kept on ice 
throughout the procedure in order to prevent enzyme inactivation by protease activity, and 
were stored at -70°C until required.
4 .14 .8 .2  E n zym e an a ly s is  o f C O S-1 cell cy toso l
The crude cytosol prepared from the COS-1 cells transfected with the sense DNA, 
antisense DNA and no DNA was assayed for p-lyase and glutamine transaminase K 
activity. The specific activities of the samples were calculated using protein concentration 
values determined by the method of Lowry (method 2 in section 2.8.1).
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F igure 4.26: Strategy to determine the orientation of the 1.4kb cDNA fragment
(shaded), in the expression vector pUSlOOO (a) Restriction maps of the 1.4kb cDNA in 
pUS 1000 for both sense and antisense orientations, indicating the sizes of DNA fragments 
on Apal digestion, (b) 1% (w/v) agarose gel electrophoresis of recombinant subclones after 
digestion with Apal.
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Glutamine transaminase K activity
Glutamine transaminase K (GTK) activity was determined using the method of Cooper 
and Meister (1985) as detailed in section 2.8.2. Initial analysis of GTK activity in the 
cytosolic extracts of control and transfected cells, demonstrated no significant difference 
between pUSpl-4.0 (+), pUSpl-4.0 (-) and the no DNA control cells.
fi-lyase activity
Cysteine conjugate p-lyase activity was determined using a modified method of Stevens and 
Jakoby (1983) as detailed in section 2.8.3. Two substrates used to assay the samples for 13- 
lyase activity were the cysteine conjugates TFEC and DC VC.
No significant difference in p-lyase activity was seen between pUSpl-4.0 (+), pUSpl-4.0 
(-) and the no DNA control cells, using either TFEC or DC VC as substrates.
Initially it was thought that the lack of enzyme activity described above was due to 
unsuccessful transfection. Therefore, a second transfection was performed using the rat 
sense cDNA, pUSpl-2.0(+), as a control. This time, the cytosol from cells transfected with 
the rat cDNA, pUSpl-2.0(+), was positive for both GTK and p-lyase activity (data not 
shown), however, the cytosolic extracts from cells transfected with the human cDNAs 
pUSpl-4.0 (+), pUSpl-4.0 (-), were again all negative.
Due to the high sequence similarity between the rat and human cDNAs, and the fact that the 
purified human kidney enzyme does demonstrate easily measurable p-lyase activity (Lash et 
al., 1990), it was decided that the absence of human activity must be due to an error in the 
cDNA sequence. Although the fragments which were ligated together were previously fully 
sequenced individually, the PCR product was only sequenced across the ligation sites. 
Errors in PCR amplified fragments occur due to the inability of Taq DNA polymerase to 
proof read the newly synthesised cDNA sequence. In order to determine if the lack of
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expression was due to errors in the PCR amplification, the full coding region of phpl-4.0 
was sequenced (see 4.14.9).
4.14.9 Full-length sequencing of phpl-4.0
DNA sequencing of phpl-4.0 was performed using Sequenase™ version 2.0 as described 
in section 2.6. using the gene specific oligonucleotides Phl2, Phl3, Phl4, Phl5, P h il, 
PhlO, Phl6, Ph5, Ph8 and Ph7.
As shown in figure 4.27, six nucleotide changes are demonstrated in phpl-4.0 compared to 
the sequences determined from the overlapping cDNA coding regions of phpl-1.0, phpl-2.0 
and phpl-3.1 (figure 4.22). Four of these nucleotide changes produce amino acid 
substitutions, which may alter enzyme activity.
PCR errors occur on average once every 900 nucleotides, however, in this amplification 
the incidence of error was 6 out of 1400 nucleotides. The reason for this substantial 
increase was not known, however, two possibilities arose. It was thought that as the cDNA 
template for the PCR amplification was taken directly from the ligation mixture (4.13.3) for 
amplification, some of the reagents in the ligation buffer, may have interfered with the PCR 
amplification. An additional or alternative possibility is the magnesium chloride 
concentration (2.5mM) used in the PCR amplification (4.13.3). Magnesium concentrations 
between 0.5-2.5 mM are generally used in PCR amplifications. Different DNA samples 
and primers require different magnesium chloride concentrations for optimal product yield, 
however, the higher the concentration, the greater chance of nucleotide miss-incorporation 
by Taq DNA polymerase (Innis et. al., 1990).
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1 GGGGTGAAGCGGCCCAGGTGAGGCTCGCC
Met A la Lys Gin Leu G in Al a Arg Arg Leu Asp G ly I le Asp T y r Asn P ro 17
3 0 ATG GCC AAA CAG CTG CAG GCC CGA AGG CTA GAC GGG ATC GAC TAC AAC CCC
T rp Val G lu Phe V al Lys Leu A la iGlvl GI u H i s Asp V a l Val Asn Leu G ly 34
81 TGG GTG GAG TTT GTG AAA CTG GCC GGT GAG CAT GAC GTC GTG AAC TTG GGC
G in G ly Phe P ro Asp Phe P ro Leu P ro Asp Phe A la V al G lu A la Leu G in 51
132 CAG GGC TTC CCG GAT TTC CCA CTA CCA GAC TTT GCC GTG GAA GCC TTA CAG
H i s AI a Val S e r G ly Asp Phe Met Leu Asn G in T y r T h r Lys T h r Phe G ly 68
183 CAC GCT GTC AGT GGA GAC TTC ATG CTT AAC CAG TAC ACC AAG ACA TTT GGT
T y r P ro Pro Leu T h r Lys H e Leu A la S er Phe Phe G ly G lu Leu Leu G ly 85
2 3 4 TAC CCA CCA CTG ACG AAG ATC CTG GCA AGT TTC TTT GGG GAG CTG CTG GGT
G in G lu l i e Asp P ro Leu Arg Asn Val Leu Val T h r V a l G ly G ly T y r G ly 102
2 8 5 CAG GAG ATA GAC CCG CTC AGG AAT GTG CTG GTG ACT GTT GGT GGC TAT GGG
A l a Leu Phe T h r A l a Phe G in A la Leu Val Asp G lu G ly Asp Glu V al H e 119
3 3 6 GCC CTG TTC ACA GCC TTC CAG GCC CTG GTG GAC GAA GGA GAC GAG GTC ATC
I le l i e Glu P ro Phe Phe Asp Cys T y r Glu P ro Met T h r Met Met A l a G ly 136
3 8 7 ATC ATC GAA CCC TTT TTT GAC TGC TAC GAG CCC ATG ACA ATG ATG GCA GGG
G ly Arg Pro Val Phe Val S e r Leu Lys Pro G I y P ro I le G in Asn IsTTT] G lu 153
438 GGT CGT CCT GTG TTT GTG TCC CTG AAG CCG GGT CCC ATC CAG AAT GAA GAA
Leu G ly S er S e r S e r Asn T rp G in Leu Asp P ro Met G lu Leu A la G ly Lys 170
489 CTG GGT TCC AGC AGC AAC TGG CAG CTG GAC CCC ATG GAG CTG GCC GGC AAA
Phe T h r S e r Arg T h r Lys A la Leu Val Leu Asn T h r P ro Asn Asn P ro Leu 187
5 4 0 TTC ACA TCA CGC ACC AAA GCC CTG GTC CTC AAC ACC CCC AAC AAC CCC CTG
G ly Lys Val Phe S e r Arg G lu G lu Leu Glu Leu Val A la S e r Leu Cys G in 204
591 GGC AAG GTG TTC TCC AGG GAA GAG CTG GAG CTG GTG GCC AGC CTT TGC CAG
G in H i s Asp Val |Ala| Cys H e T h r Asp Glu Val T y r G in T rp Met V al T y r 221
642 CAG CAT GAC GTG GCG TGT ATC ACT GAT GAA GTC TAC CAG TGG ATG GTC TAC
Asp G ly H i s G in H i s I le S e r I le A la S er Leu P ro G ly Met T rp ( 0 1 m) Arg 238
6 9 3 GAC GGG CAC CAG CAC ATC AGC ATT GCC AGC CTC CCT GGC ATG TGG GAG. CGG
T h r Leu T h r I le G ly S e r AI a G ly Lys T h r Phe S e r A l a T h r G ly T rp Lys 255
7 4 4 ACC CTG ACC ATC GGC AGC GCC GGC AAG ACC TTC AGC GCC ACT GGC TGG AAG
Val G ly T rp Val Leu G ly P ro Asp H i s H e Met Lys H i s Leu Arg T h r V al 272
7 9 5 GTG GGC TGG GTC CTG GGT CCA GAT CAC ATC ATG AAG CAC CTG CGG ACC GTG
H i s G in Asn S e r V al Phe H i s Cys P ro T h r G in S e r G in A l a A la Va I AI a 289
8 4 6 CAC CAG AAC TCC GTC TTC CAC TGC CCC ACG CAG AGC CAG GCT GCA GTA GCC
Glu S e r Phe G lu Arg Glu G in Leu Leu Phe Arg G in P ro S e r S e r T y r Phe 306
8 9 7 GAG AGC TTT GAA CGG GAG CAG CTG CTC TTC CGC CAA CCC AGC AGC TAC TTT
Val G in Phe P ro G in A la Met G in Arg Cys Arg Asp H i s Met |Met| Arg S e r 323
9 4 8 GTG CAG TTC CCG CAG GCC ATG CAG CGC TGC CGT GAC CAC ATG ATG CGT AGC
Leu G in S er <SsDG ly Leu Lys P ro H e H e P ro G in G ly S e r T y r Phe Leu 340
999 CTA CAG TCA GTG GGC CTG AAG CCC ATC ATC CCT CAG GGC AGC TAC TTC CTC
I le T h r Asp I le S e r Asp Phe Lys Arg Lys Met P ro Asp Leu P ro G ly A l a 357
1050 ATC ACA GAC ATC TCA GAC TTC AAG AGG AAG ATG CCT GAC TTG CCT GGA GCT
Val Asp Glu P ro T y r Asp Arg Arg Phe Val Lys T rp Met H e Lys Asn Lys 374
1101 GTG GAT GAG CCC TAT GAC AG A CGC TTC GTC AAG TGG ATG ATC AAG AAC AAG
G ly Leu Val A la H e P ro Val S e r H e Phe T y r S e r V al P ro H i s G in Lys 391
1152 GGC TTG GTG GCC ATC CCT GTC TCC ATC TTC TAT AGT GTG CCA CAT CAG AAG
H i s Phe Asp H i s T y r I  le Arg Phe Cys Phe Val Lys Asp G lu AI a T h r Leu 408
1203 CAC TTT GAC CAC TAT ATC CGC TTC TGT TTT GTG AAG GAT GAA GCC ACG CTC
Gin AI a Met Asp G lu Lys Leu Arg Lys T rp Lys V al G lu Leu S to p 422
1254 CAG GCC ATG GAC GAG AAG CTG CGG AAG TGG AAG GTG GAA CTC TAG CCCTGAA
1306 GTCACGCCTTGGCCCTGACATCCCCACATGCCCGCAGAGATCCTCTTT
Figure 4.27: Nucleotide and deduced amino acid sequence of phpl-4.0. Nucleotide 
changes due to PCR error, are underlined, amino acid substitutions are illustrated with a 
box, and conserved amino acids are indicated with an ellipse.
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4.15 REVERSE TRANSCRIPTASE-PCR FROM TOTAL KIDNEY RNA
In view of the problems which had arisen, a different approach was taken for the isolation 
of a full-length p-lyase cDNA, in which reverse transcriptase PCR was used to amplify the 
p-lyase cDNA from a human kidney mRNA template (see section 2.11).
4.15.1 First strand synthesis of cDNA from mRNA
First strand synthesis was performed as in section 2.10.1.1, using the antisense gene 
specific oligonucleotide primer PhlO, which annealed 203 nucleotides downstream of the 
coding region. The first strand product was amplified by PCR as in section 4.15.2
4.15.2 PCR amplification of the first strand product.
The first strand product was amplified as in section 2.11.2, using the 3' gene specific 
oligonucleotide P h il, nested 123 nucleotides upstream of PhlO, together with a 5' 
oligonucleotide Phl8, which incorporated the methionine ATG start codon. In an attempt to 
eliminate the incorporation of PCR errors, the magnesium concentration used in the 
reaction was reduced to 1.5mM. The expected size of the PCR product, using 
oligonucleotides Phl8 and P h il was 1328bp. Two separate amplification reactions were 
performed so that the sequences of the PCR products could be compared in case of PCR 
errors, as it would be very unlikely for the same base substitution to occur in two separate 
reactions. 15pl of the PCR amplification from each reaction mixture was analysed by 1% 
(w/v) agarose gel electrophoresis, both demonstrating products of approximately 1.35kb 
(figure 4.28).
4.15.3 Subcloning of the 1.4kb PCR product into pCR™II
The 1328bp products from both PCR amplifications were purified by 1% (w/v) agarose gel 
electrophoresis (2.3.4), extracted by Geneclean (2.3.7) and subcloned into pCR™II as in
4.14.2, 4.14.3 and 4.14.4. The recombinant clones were named phpl-5.0 and phpl-5.1.
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1 2 3 kb
Figure 4.28: 1% (w/v) agarose gel electrophoresis of two separate RT-PCR amplified 
cDNA products from human kidney RNA (lanes 1 and 2). Lane 3 contains 0X174 Hae III 
molecular weight markers.
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4.15.4 Sequencing of phpl-5.0 and phpl-5.1
DNA sequencing of phpl-5.0 and phpl-5.1 was performed using Sequenase™ version 2.0 
as described in section 2.6, using the gene specific oligonucleotides Phl2, Phl3, Phl4, 
Phl5, P h il, PhlO, P h i6, Ph5, Ph8 and Ph7.
DNA sequencing demonstrated both sequences to be identical, therefore from this point 
onwards the sequence will be referred to as phpl-5.0. As shown in figure 4.29, two 
nucleotide differences (nucleotides 125 and 150) are seen between phpl-5.0 and the 
overlapping cDNA coding regions of phpl-1.0, phpl-2.0 and phpl-3.1 (figure 4.22). As 
both nucleotide changes are present in cDNAs from two separate PCR amplifications, they 
were very unlikely to be errors in phpl-5.0. The source of the error was thought to originate 
from the PCR amplification of phpl-3.1. This theory was re-enforced by the fact that the 
nucleotide changes in phpl-5.0 result in amino acid substitutions at positions 42 and 50, 
which are homologous to amino acids in the corresponding positions of the rat sequence 
(figure 4.30), thereby increasing the overall similarity between the rat and human enzymes.
As phpl-3.1 was amplified from the RACE-Ready cDNA and phpl-5.0 was amplified from 
kidney mRNA, it was just possible that the nucleotide differences were due to inter­
individual variation. PCR analysis of the RACE-Ready cDNA was performed using the 
protocols 4.15.1 & 4.15.2, and the 1328bp product was subcloned into pCR™II as in
4.15.3. DNA sequencing as in section 2.6 confirmed that the nucleotides 125 and 150 in 
phpl-5.0 were correct and that the previous problems had indeed arisen during the PCR 
amplification of phpl-3.1. The corrected nucleotide and deduced amino acid sequence of the 
human cDNA is shown in figure 4.30, and is compared with the rat cDNA sequence.
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M et A t o L y s G in L eu G\ n A la Arg Arg Leu Asp G ly I le Asp T y r Asn Pro 17
1 ATG GCC AAA CAG CTG CAG GCC CGA AGG CTA GAC GGG ATC GAC TAC AAC CCC
T rp Val Glu Phe V al Lys Leu A I a S e r Glu H i s Asp V al Val Asn Leu G ly 34
52 TGG GTG GAG TTT GTG AAA CTG GCC AGT GAG CAT GAC GTC GTG AAC TTG GGC
G in G ly Phe P ro Asp Phe P ro iProl P ro Asp Phe AI a V al G lu A la |Phe| G in 51
103 CAG GGC TTC CCG GAT TTC CCA CCA CCA GAC TTT GCC GTG GAA GCC TTT CAG
H i s AI a Val S e r G ly Asp Phe Met Leu Asn G in T y r T h r Lys T h r Phe G ly 68
154 CAC GCT GTC AGT GGA GAC TTC ATG CTT AAC CAG TAC ACC AAG ACA TTT GGT
T y r P ro P ro Leu T h r Lys H e Leu AI a S e r Phe Phe G ly G lu Leu Leu G ly 85
2 0 5 TAC CCA CCA CTG ACG AAG ATC CTG GCA AGT TTC TTT GGG GAG CTG CTG GGT
Gin G lu l i e Asp P ro Leu Arg Asn Val Leu Val T h r V al G ly G ly T y r G ly 102
2 5 6 CAG GAG ATA GAC CCG CTC AGG AAT GTG CTG GTG ACT GTT GGT GGC TAT GGG
A la Leu Phe T h r A l a Phe G in A la Leu Val Asp G lu G ly Asp G lu V al H e 119
3 0 7 GCC CTG TTC ACA GCC TTC CAG GCC CTG GTG GAC GAA GGA GAC GAG GTC ATC
I le l i e Glu P ro Phe Phe Asp Cys T y r Glu P ro Met T h r Met Met A la G ly 136
3 5 8 ATC ATC GAA CCC TTT TTT GAC TGC TAC GAG CCC ATG ACA ATG ATG GCA GGG
G ly Arg P ro Val Phe Val S e r Leu Lys P ro G ly P ro I le G in Asn G ly G lu 153
409 GGT CGT CCT GTG TTT GTG TCC CTG AAG CCG GGT CCC ATC CAG AAT GGA GAA
Leu G ly S er S e r S e r Asn T rp G in Leu Asp P ro Met G lu Leu A la G ly Lys 170
460 CTG GGT TCC AGC AGC AAC TGG CAG CTG GAC CCC ATG GAG CTG GCC GGC AAA
Phe T h r S e r Arg T h r Lys AI a Leu Val Leu Asn T h r P ro Asn Asn P ro Leu 187
511 TTC ACA TCA CGC ACC AAA GCC CTG GTC CTC AAC ACC CCC AAC AAC CCC CTG
G ly Lys Val Phe S e r Arg G lu G lu Leu Glu Leu V al A I a S e r Leu Cys G in 204
562 GGC AAG GTG TTC TCC AGG GAA GAG CTG GAG CTG GTG GCC AGC CTT TGC CAG
Gin H i s Asp Val V al Cys H e T h r Asp Glu Val T y r G in T rp Met Val T y r 221
6 1 3 CAG CAT GAC GTG GTG TGT ATC ACT GAT GAA GTC TAC CAG TGG ATG GTC TAC
Asp G ly H i s G I n H i s I le S e r I le A la S er Leu P ro G ly Met T rp G lu Arg 23 8
66 4 GAC GGG CAC CAG CAC ATC AGC ATT GCC AGC CTC CCT GGC ATG TGG GAA CGG
T h r Leu T h r I le G ly S e r AI a G ly Lys T h r Phe S e r A la T h r G ly T rp Lys 25 5
7 1 5 ACC CTG ACC ATC GGC AGC GCC GGC AAG ACC TTC AGC GCC ACT GGC TGG AAG
Val G ly Trp Val Leu G ly P ro Asp H i s H e Met Lys H i s Leu Arg T h r V al 272
7 6 6 GTG GGC TGG GTC CTG GGT CCA GAT CAC ATC ATG AAG CAC CTG CGG ACC GTG
H i s G in Asn S e r V al Phe H i s Cys P ro T hr G in S e r G in A la A la V al AI a 28 9
8 1 7 CAC CAG AAC TCC GTC TTC CAC TGC CCC ACG CAG AGC CAG GCT GCA GTA GCC
G lu S e r Phe Glu Arg Glu G in Leu Leu Phe Arg G in P ro S e r S e r T y r Phe 306
8 6 8 GAG AGC TTT GAA CGG GAG CAG CTG CTC TTC CGC CAA CCC AGC AGC TAC TTT
Val G in Phe P ro G in A la Met G in Arg Cys Arg Asp H i s Met H e Arg S e r 32 3
9 1 9 GTG CAG TTC CCG CAG GCC ATG CAG CGC TGC CGT GAC CAC ATG ATA CGT AGC
Leu G in S er Val G ly Leu Lys P ro H e H e P ro G in G ly S e r T y r Phe Leu 34 0
9 7 0 CTA CAG TCA GTG GGC CTG AAG CCC ATC ATC CCT CAG GGC AGC TAC TTC CTC
I le T h r Asp I le S e r Asp Phe Lys Arg Lys Met P ro Asp Leu P ro G ly A la 35 7
1021 ATC ACA GAC ATC TCA GAC TTC AAG AGG AAG ATG CCT GAC TTG CCT GGA GCT
Val Asp Glu P ro T y r Asp Arg Arg Phe Val Lys T rp Met H e Lys Asn Lys 37 4
1072 GTG GAT GAG CCC TAT GAC AG A CGC TTC GTC AAG TGG ATG ATC AAG AAC AAG
G ly Leu Val AI a H e P ro Val S e r H e Phe T y r S e r V al P ro H i s G in Lys 391
1123 GGC TTG GTG GCC ATC CCT GTC TCC ATC TTC TAT AGT GTG CCA CAT CAG AAG
H i s Phe Asp H i s T y r I  le Arg Phe Cys Phe Val Lys Asp G lu AI a T h r Leu 408
1174 CAC TTT GAC CAC TAT ATC CGC TTC TGT TTT GTG AAG GAT GAA GCC ACG CTC
G I n A la Met Asp G lu Lys Leu Arg Lys T rp Lys V al G lu Leu S to p 422
1225 CAG GCC ATG GAC GAG AAG CTG CGG AAG TGG AAG GTG GAA CTC TAG CCCTGAA
1277 GTCACGCCTTGGCCCTGACATCCCCACATGCCCGCA^^7rr7T77'7K4^7' 1328
Figure 4.29: Nucleotide and deduced amino acid sequence of phpl-5.0. Nucleotide 
differences from ppl-3.1 are underlined, amino acid substitutions are indicated by boxes. 
PCR primers are shown in italic.
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1 GGGGTGAAGCGGCCCAGGTGAGGCTCGCC H
30 ATG GCC AAA CAG CTG CAG GCC CGA AGG CTA GAC GGG ATC GAC TAC AAC CCC TGG GTG GAG TTT GTG AAA 23 H
Met Ala Lys Gin Leu Gin Ala Arg Arg Leu Asp Gly I le Asp Tyr Asn Pro T rp Val Glu Phe Val Lys
• Thr • Arg • • • • • • • • • • Gin • Leu • • • • Gly • R
99 CTG GCC AGT GAG CAT GAC GTC GTG AAC TTG GGC CAG GGC TTC CCG GAT TTC CCA CCA CCA GAC TTT GCC H
Leu Ala Ser Glu H i s Asp Val Val Asn Leu Gly Gin Gly Phe Pro Asp Phe Pro Pro Pro Asp Phe Ala 46
• Thr Lys R
168 GTG GAA GCC TTT CAG CAC GCT GTC AGT GGA GAC TTC ATG CTT AAC CAG TAC ACC AAG ACA TTT GGT TAC H
Val Glu A 1 a Phe Gin H i s Ala Val Ser Gly Asp Phe Met Leu Asn Gin Tyr Thr Lys Thr Phe Gly Tyr 69
Thr Gin • • • Gin • Thr • • Asn • • • • • • • Arg Ala • • • R
237 CCA CCA CTG ACG AAG ATC CTG GCA AGT TTC TTT GGG GAG CTG CTG GGT CAG GAG ATA GAC CCG CTC AGG H
Pro Pro Leu Thr Lys H e Leu Ala Ser Phe Phe Gly Glu Leu Leu Gly Gin Glu I le Asp Pro Leu Arg 92
• • • • Asn Val • • • • • • Lys • • • • • Met • • • Thr R
306 AAT GTG CTG GTG ACT GTT GGT GGC TAT GGG GCC CTG TTC ACA GCC TTC CAG GCC CTG GTG GAC GAA GGA H
Asn Val Leu Val Thr Val Gly Gly Tyr Gly A 1 a Leu Phe Thr Ala Phe Gin Ala Leu Val Asp Glu Gly 115
R
375 GAC GAG GTC ATC ATC ATC GAA CCC TTT TTT GAC TGC TAC GAG CCC ATG ACA ATG ATG GCA GGG GGT CGT H
Asp Glu Val I le lie I le Glu Pro Phe Phe Asp Cys Tyr Glu Pro Met Thr Met Met Ala Gly Gly Arg 138
• • • • • Met • • Ala • • • • • • • • • • • • • Cys R
444 CCT GTG TTT GTG TCC CTG AAG CCG GGT CCC ATC CAG AAT GGA GAA CTG GGT TCC AGC AGC AAC TGG CAG H
Pro Val Phe Val Ser Leu Lys Pro Gly Pro I le Gin Asn Gly Glu Leu Gly Ser Ser Ser Asn Trp Gin 161
• • • • Thr • • • Ser • Ala Pro Lys • Lys • • Ala • Asn Asp • • R
513 CTG GAC CCC ATG GAG CTG GCC GGC AAA TTC ACA TCA CGC ACC AAA GCC CTG GTC CTC AAC ACC CCC AAC H
Leu Asp Pro Met Glu Leu Ala Gly Lys Phe Thr Ser Arg Thr Lys A 1 a Leu Val Leu Asn Thr Pro Asn 184
• • • Ala • • • Ser • • • Pro • • • I le • • • • • • • R
582 AAC CCC CTG GGC AAG GTG TTC TCC AGG GAA GAG CTG GAG CTG GTG GCC AGC CTT TGC CAG CAG CAT GAC H
Asn Pro Leu Gly Lys Val Phe Ser Arg Glu Glu Leu Glu Leu Val Ala Ser Leu Cys Gin Gin H i s Asp 207
R
651 GTG GTG TGT ATC ACT GAT GAA GTC TAC CAG TGG ATG GTC TAC GAC GGG CAC CAG CAC ATC AGC ATT GCC H
Val Val Cys I le Thr Asp Glu Val Tyr Gin T rp Met Val Tyr Asp Gly H i s Gin H i s H e Ser H e Ala 230
• • • • Ser • • • • • • Leu • • • • • • • Val • • • R
720 AGC CTC CCT GGC ATG TGG GAA CGG ACC CTG ACC ATC GGC AGC GCC GGC AAG ACC TTC AGC GCC ACT GGC H
Ser Leu Pro Gly Met T rp Glu Arg Thr Leu Thr H e Gly Ser Ala Gly Lys Thr Phe Ser Ala Thr Gly 253
R
789 TGG AAG GTG GGC TGG GTC CTG GGT CCA GAT CAC ATC ATG AAG CAC CTG CGG ACC GTG CAC CAG AAC TCC H
T rp Lys Val Gly Trp Val Leu Gly Pro Asp H i s H e Met Lys H i s Leu Arg Thr Val H i s Gin Asn Ser 276
R
858 GTC TTC CAC TGC CCC ACG CAG AGC CAG GCT GCA GTA GCC GAG AGC TTT GAA CGG GAG CAG CTG CTC TTC H
Val Phe H i s Cys Pro Thr Gin Ser Gin Ala A 1 a Val Ala Glu Ser Phe Glu Arg Glu Gin Leu Leu Phe 299
I le • • • • • • A 1 a • • • • • Gin Cys • • • • • Gin Hi s • R
927 CGC CAA CCC AGC AGC TAC TTT GTG CAG TTC CCG CAG GCC ATG CAG CGC TGC CGT GAC CAC ATG ATA CGT H
Arg Gin Pro Ser Ser Tyr Phe Val Gin Phe Pro Gin Ala Met Gin Arg Cys Arg Asp H i s Met H e Arg 322
Gly • • • • • • Leu • Leu • • • • Glu Leu Asn • • • • • • R
996 AGC CTA CAG TCA GTG GGC CTG AAG CCC ATC ATC CCT CAG GGC AGC TAC TTC CTC ATC ACA GAC ATC TCA H
Ser Leu Gin Ser Val Gly Leu Lys Pro H e I le Pro Gin Gly Ser Tyr Phe Leu H e Thr Asp H e Ser 345
• • • • • • • • Leu Trp • Ser • • • • • • • A 1 a • • • R
1065 GAC TTC AAG AGG AAG ATG CCT GAC TTG CCT GGA GCT GTG GAT GAG CCC TAT GAC AGA CGC TTC GTC AAG H
Asp Phe Lys Arg Lys Met Pro Asp Leu Pro Gly Ala Val Asp Glu Pro Tyr Asp Arg Arg Phe Val Lys 368
• Ala • R
1134 TGG ATG ATC AAG AAC AAG GGC TTG GTG GCC ATC CCT GTC TCC ATC TTC TAT AGT GTG CCA CAT CAG AAG H
T rp Met lie Lys Asn Lys Gly Leu Val Ala 1 le Pro Val Ser I le Phe Tyr Ser Val Pro H i s Gin Lys 391
• • • • • Met ' • • • Gly • • • • Thr • Phe • Arg • • • • R
1203 CAC TTT GAC CAC TAT ATC CGC TTC TGT TTT GTG AAG GAT GAA GCC ACG CTC CAG GCC ATG GAC GAG AAG H
H i s Phe Asp H i s Tyr I le Arg Phe Cys Phe Val Lys Asp Glu Ala Thr Leu Gin Al a Met Asp Glu Lys 414
Asp R
1272 CTG CGG AAG TGG AAG GTG GAA CTC TAG CCCTGAAGTCACGCCTTGGCCCTGACATCCCCACATGCCCGCAGAGATCCTCTTT H
Leu Arg Lys T rp Lys Val Glu Leu Stop 422
• • • • • Glu Leu Gin Pro 423 R
Figure 4.30: Nucleotide and deduced amino acid sequence of the human kidney p-lyase 
(top and middle), rat deduced amino acid sequence (bottom). Unchanged amino acids are 
indicated by •, reverse transcriptase-PCR primers are underlined, PLP site is boxed. 
Human sequence is denoted by an H and rat by an R.
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4.15.5 Expression of the cDNA from phpl-5.0 in COS-1 cells
The full-length phpl-5.0 cDNA was subcloned into the expression vector as before (4.14.6) 
in both sense and antisense orientations (see 4.14.7), to give pUSpl-5.0(+) and pUSpl- 
5.0(-) respectively. Transfection in COS-1 cells was performed as in 4.14.8 with the sense 
DNA, antisense DNA negative control, no DNA negative control and the rat sense DNA 
(pUSpl-2.0(+) positive control.
4.15.6 Glutamine transaminase K activity
The GTK activity measured in the cytosolic extracts of transfected cells is presented as a 
bar chart in figure 4.31a. A significant 40 fold increase in GTK specific activity is seen in 
the cytosol of cells transfected with the human cDNA in the sense orientation compared to 
the cytosol of the antisense and no DNA controls. Expression with the human cDNA also 
produces a 1.7 fold greater specific enzyme activity than the rat cDNA, under the given 
experimental conditions. The level of specific activity varied slightly between transfections, 
however, the relative difference between the rat and human enzymes was reproducible both 
between transfections and on replicate assays within transfections. Km and Vmax values for 
the GTK activity of the rat and human enzymes were determined from 8 sets of duplicate 
reactions, using Hanes-Woolf analysis. Km values of 0.40 (+/- 0.05) mM and 0.85 (+/- 
0.05) mM were determined for the rat and human enzymes respectively. The Vmax values 
for the rat and human enzymes were 1247 (+/- 47) nmol/min/mg and 2115 (+/- 50) 
nmol/min/mg.
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4.15.7 p-lyase activity
Analysis of the cytosolic extracts for p-lyase activity using both TFEC and DC VC as 
substrate mirrored the results of the GTK assay (figure 4.31b). A significant increase in p- 
lyase activity, using both TFEC and DC VC as substrate, was seen in cells transfected with 
the sense cDNA compared to the antisense and no DNA transfected cells. Human p-lyase 
specific activity with TFEC was approximately 22 fold higher than the negative controls 
and a 5-6 fold greater activity than the rat enzyme. Using DC VC as substrate the negative 
controls demonstrated no background activity and the expressed human enzyme 
demonstrated a specific activity of 27.6 nmol/min/mg, which was 14 fold greater than the 
rat enzyme activity. TFEC is the better substrate for both the rat and human expressed p- 
lyase enzymes, under the given experimental conditions described. The rat and human 
specific enzyme activities are approximately 8 and 3 fold higher, respectively with TFEC 
thanDCVC.
Variability of p-lyase activity between separate transfection experiments was observed as 
with the GTK activity, however, due to low substrate availability, insufficient assays were 
performed to determine if p-lyase activity was reproducible within replicate assays from 
cytosolic extracts of a single transfection. As the specific activity obtained using DCVC 
was very close to the levels of detection using this procedure, the margin for error in these 
measurements is relatively high compared to TFEC. Thus, the ratios given above are only a 
rough estimate and require further analysis with a more sensitive assay.
Preliminary Km and Vmax values were calculated for the rat and human enzymes using 
TFEC as substrate, however, due to the shortage of substrate only one set of duplicate 
reactions could be performed. The rat and human Km values were 5.2 mM and 6.5 mM 
respectively, and the Vmax values were 90 nmol/min/mg and 354 nmol/min/mg.
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Figure 4.31: Enzyme activity in cytosolic extracts of COS-1 cells transfected with the 
human and rat p-lyase cDNAs. The human antisense cDNA and no DNA transfections were 
used as negative controls (a) Glutamine transaminase K activity, (b) Cysteine conjugate p- 
lyase activity using 5mM tetrafluoroethyl cysteine (TFEC) and 5mM dichlorovinyl cysteine 
(DCVC) as substrates.
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4.16 SOUTHERN BLOT ANALYSIS OF HUMAN GENOMIC DNA
Cysteine conjugate p-lyase enzyme activity has been located in both rat and human, 
cytosolic and mitochondrial fractions of kidney cells (Stevens et ah, 1988; Lash et al., 
1990). As with rat kidney (3-lyase, it is not known whether the cytosolic and mitochondrial 
forms are coded for by a single gene or by members of a gene family. Also some evidence 
has been presented to suggest the existence of more than one isozyme of human kidney 
cytosolic (3-lyase (Buckberry et al., 1990). Accordingly Southern blot analysis of human 
genomic DNA was performed to determine if human kidney (3-lyase is a member of a gene 
family.
20pg of human genomic DNA was digested overnight at 37°C in separate reactions with the 
restriction enzymes EcoRI, Xbal and Sstl (section 2.9.4.1). The digested DNA was 
concentrated by ethanol precipitation (section 2.3.9), and run on a 0.7% (w/v) agarose gel 
alongside XHindlll DNA markers. The DNA was depurinated, denatured (2.9.4.2) and 
blotted to nylon membrane (2.9.4.3). Southern blot analysis was performed using the 
deionised formamide hybridisation procedure (2.4.4.2), and the full-length human (5-lyase 
cDNA from p(3l-2.0 (labelled with 32P, see 2.4.3), as the probe. Washing conditions of 
moderate stringency (IX SSC/0.5% (w/v) SDS at 21°C for 30 min, IX SSC/0.1% (w/v) 
SDS at 42°C for 30 min and IX SSC/0.1% (w/v) SDS at 50°C for 30 min ) were used and 
the blot was exposed to X-ray film for 72 hrs.
The restriction enzyme pattern of the Southern blot (figure 4.32) is consistent with that of a 
single gene for human kidney p-lyase, with a maximum size of approximately 14kb. The 
importance of this finding with regard to the question of the human kidney, mitochondrial 
and cytosolic enzymes being identical to each other, and possibly to one of the brain KAT 
enzymes, is discussed in chapter 5.
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Figure 4.32: Southern blot analysis of human genomic DNA. XHindlll DNA markers 
are indicated.
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4.17 CHROMOSOMAL LOCALISATION OF THE HUMAN p-LYASE 
GENE
4.17.1 Introduction
Genes can be mapped to individual chromosomes or specific chromosomal loci using PCR 
analysis. Partial or total isolation of individual human chromosomes is necessary for this 
procedure, and can be essentially achieved using human-rodent somatic cell hybrids. 
Somatic cell hybrids derive from experimentally induced fusion of cultured cells from 
different species. Hybrids used in human genetic mapping are made by fusion of a human 
cell with a rodent cell (usually mouse or hamster). Cell fusion is achieved by treatment with 
polyethylene glycol or inactivated Sendai virus which allow intimate contact of adjacent cell 
membranes resulting in fusion.
Initial fusion products have a hybrid nucleus, a heterokaryon, which contains both human 
and rodent chromosomes. These cells are unstable and during subsequent rounds of cell 
division, there is a progressive loss of human chromosomes due to replication failure. 
Finally a stable fusion product is obtained, which contains only one or a few human 
chromosomes. These cells are grown in tissue culture providing sufficient DNA for 
analysis. Hybrid cells containing only fragments of human chromosomes can be produced 
using human fusion parents with chromosome translocations and deletions, or by radiation 
to induce chromosome fragmentation.
Enzyme markers are used to identify individual chromosomes or chromosomal fragments 
within cell hybrids, essentially providing a panel of human chromosomes on which PCR 
analysis of specific genes can be performed.
4.17.2 PCR analysis of human genomic DNA
Analysis of human genomic DNA using PCR was performed using the protocol in section 
2.13.1. Genomic DNA was analysed for the presence of p-lyase sequences using
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oligonucleotide Phi corresponding to nucleotides 886 to 901 in the phpl-1.0 sequence 
(figure 4.8), and oligonucleotide Ph2 corresponding to nucleotides 221 to 236 in the 
intronic region of this clone (figure 4.8). An intronic primer was chosen as it was thought 
that it would give rise to increased specificity when screening human/rodent hybrid DNA. 
A human intronic primer is less likely to be homologous to the intronic region of the 
corresponding rodent DNA, thereby preventing amplification of the corresponding rodent 
PCR products. The distance between the two primers is 680bp, however, as the cDNA 
from clone phpl-1.0 was part of an incompletely spliced sequence, the size of the PCR 
product was not necessarily expected to be the same.
PCR amplification of human genomic DNA using Phi and Ph2 gave rise to a lkb band 
(figure 4.33a), which was absent from the rat genomic DNA control (data not shown). The 
DNA was depurinated and denatured (2.9.4.2) prior to transfer to nylon membrane 
(2.9.4.3). Southern blot analysis performed using the deionised formamide hybridisation 
buffer (2.4.4.2), and the human cDNA labelled with 32P as the probe (see 2.4.3), 
demonstrated that the PCR product was indeed (3-lyase (figure 4.33b). However, a second 
hybridising band was observed approximately 700bp in size, corresponding to the distance 
between Phi and Ph2 in clone phpl-1.0. This 700bp band was difficult to see on the 
ethidium bromide stained gel (figure 4.33a). The PCR analysis was repeated in duplicate 
alongside a no DNA control. As can be seen in figure 4.34a one of the genomic DNA 
reactions (lane 3) demonstrates a significant quantity of the 0.7kb product, however, in the 
other reaction the band is absent. A very faint 0.7kb band is also present in the no-DNA 
control lane, suggesting that this product must arise from the presence of a contaminating 
template DNA in the PCR amplification on which the primers are separated by 0.7kb. This 
is confirmed by Southern blotting (figure 4.34b) which demonstrates the presence of a 
strongly hybridising band of 0.7kb in the no DNA control (lane 4, figure 4.34b) and in one 
of the genomic DNA reactions (lane 3, figure 4.34b).
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Figure 4.33: (a) 4% (w/v) agarose gel electrophoresis of human genomic PCR products 
(lane 2), and 0X174 Hae III molecular weight markers (lane 1), (b) Southern blot analysis 
of (a) using the human cDNA probe (ppl-1.0).
(a) 1 2 3 4 kb (b) 1 2  3 4
Figure 4.34: (a) 4% (w/v) agarose gel electrophoresis of human genomic PCR products 
(lanes 2 and 3), no DNA control (lane 4) and 0X174 Hae III molecular weight markers 
(lane 1), (b) Southern blot analysis of (a) using the human cDNA probe (ppl-1.0).
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The source of this contamination was thought to be from the cDNA insert of phpl-1.0. The 
primers used in this PCR amplification were originally used for the DNA sequencing of the 
insert fragment, and contamination of the primers with plasmid DNA could have occurred 
at this time. Despite the presence of the contaminating 0.7kb band, PCR analysis of 
genomic DNA from a panel of rodent-human chromosomal somatic cell hybrids (section 
4.17.3) could be performed in order to localise the (3-lyase gene to a specific chromosome, 
since the expected product size from the chromosomal DNA was lkb (as in the genomic 
DNA control). In fact the presence of the 0.7kb band in all the reactions acted as an internal 
control, indicating that amplification conditions were optimal in all tubes.
4.17.3 PCR analysis of genomic DNA from a series of rodent-human 
somatic cell hybrids
A panel of chromosomal DNA samples were kindly provided by Dr. Lesley Rooke from 
the ICRF, London. These samples, containing DNA from both mono and multi- 
chromosomal hybrid cells (table 4.2), were screened by PCR using the primers Phi and 
Ph2 as for the genomic DNA in section 4.17.2.
The results of the PCR amplification and Southern blot analysis are shown in figure 4.35. 
A PCR product of approximately lkb, as seen with the human genomic DNA in section
4.17.2 is amplified in only the hybrid DNA from sample GM10611 (lane 9 of figure 
4.35a), which is reported to contain the whole of chromosome 9. Although the 
contaminating 0.7kb band (see section 4.17.2) is not visible on the agarose gel, it is 
detected in all, except one lane, by Southern blot analysis (figure 4.35b). The sample in 
lane 9, demonstrates two bands on Southern blot analysis, one corresponding to the 
contaminating product and the other to the lkb product which is unique to this sample.
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Hybrid DNA sample Reported human chromosomal content
GM07299 1 + X
GM10826B 2
GM10253 3
HHW416 4
GM10114 5
MCP6BRA MCP6BRA 6p21-qter + Xq
CLONE21E 7
C4a 8
GM10611 9
7628a 10 + Y
J lc l4 11
laA9602+VE 12 + X + 21
289 13 + bits of 8, 11, 12
GM10479 14 + part of 16 (PCR=pl3.1-q22.1)
HORL1 15,1 lq, part of Xp and proximal long arm
2860H7 16
PCTBA1.8 17
DL18TS 18
GM10612 19
GM10478 Heterogeneous 4, 20, X
THYB1.3.3 21q + X
PGME25nu 22 + part of Xp
HORL9X X
853 Y
Table 4.2: Somatic cell hybrid DNA samples and their reported chromosomal content
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Figure 4.35: (a) 4% (w/v) agarose gel electrophoresis of PCR products from rodent- 
human hybrids (see key), (b) Southern blot analysis of (a) using the human cDNA probe 
(Phi-1-0).
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4.17.4. PCR analysis of chromosomal DNA hybrids containing fragments 
of chromosome 9
In order to further localise the (3-lyase gene to a specific region of chromosome 9, two DNA 
hybrid samples, CJ9q and SV340/BW (kindly provided by Dr. Sue Povey from the MRC, 
UCL), containing fragments of chromosome 9 were analysed as in 4.17.3. The human 
DNA content of these samples had been characterised by genetic markers. CJ9q is reported 
to contain the whole q arm of chromosome 9 and SV340/BW, the region 9Pter to 9q223.
Samples CJ9q and SV340/BW were analysed by PCR using the primers Phi and Ph2 as in 
4.17.3, along side GM10611, and human genomic DNA as positive controls. GM10611 
and human genomic DNA demonstrated the lkb fragment as above, however, CJ9q and 
SV340/BW were both negative (data not shown).
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4.18 DISCUSSION
The work presented in this chapter demonstrates the successful isolation of a full-length 
cDNA coding for human kidney cysteine conjugate (3-lyase. The (3-lyase cDNA was isolated 
using a combination of hybridisation screening with the rat cDNA as a probe, 5' RACE, 
using gene-specific oligonucleotide primers, and reverse transcriptase PCR of human 
kidney RNA.
Human kidney library (Cion tech, HL1123a) screening of lx  106 PFUs gave rise to two 
different cDNA clones phpl-1.0 and ph(3l-2.0. DNA sequencing of phpl-1.0 demonstrated 
that the cDNA was 1184 nucleotides in length. Nucleotides 1-647, and 1134-1165 
showed no homology with the rat (3-lyase cDNA p(31-2.0. Two coding regions, 648-1133 
and 1166-1184, were approximately 80% and 100% similar to the rat sequence, however, 
they were interrupted by nucleotides 1134-1165 which produced a frame shift in the 
second coding region. The presence of a GT sequence at the intron/exon boundary 
(nucleotides 646 and 647) and an AG sequence at the exon/intron boundary (nucleotides 
1164 and 1165) of the first coding region, strongly indicated that the non-coding regions 
were incompletely spliced introns. The nucleotide sequence of the two open reading 
frames, coded for 168 amino acids with approximately 82% similarity to the rat sequence.
ph(3l-2.0 contained a cDNA of 1441 nucleotides, with an additional poly A tail of 
approximately 100 nucleotides. An open reading frame of 738 nucleotides was present, 
preceded by 240 nucleotides of 5' non-coding region, and followed by approximately 560 
nucleotides of 3' non-coding region inclusive of the poly A tail. A poly adenylation 
sequence was present 20 nucleotides upstream of the poly A tail. As with ph(3l-1.0, the 
deduced amino acid sequence ph(3l-2.0 was approximately 83% similar to the rat sequence. 
Alignment analysis demonstrated that the first 240 nucleotides of ph(3l-2.0, originally 
thought to be non-coding, were in fact coding sequence which had somehow, during the 
library preparation, broken away and religated 3'-5'.
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The coding regions of phpl-1.0 and phpl-2.0, overlapped giving a combined sequence of 
355 amino acids. Comparison of the rat and human amino acid sequences demonstrates an 
overall sequence similarity of approximately 83%, and shows that the human sequence has 
one less amino acid than the rat, at the 3' terminus. The human pyridoxal phosphate 
binding site is highly conserved, with a single conservative serine/threonine amino acid 
change. The human 3' non-coding region demonstrates no similarity to the corresponding 
rat sequence. The combined human cDNAs of phpl-1.0 and phpl-2.0, code for 
approximately 84% of the complete p-lyase protein when compared to the rat sequence. As 
the full-length cDNA was required for expression in tissue culture cells library screening 
was resumed. However, due to the low number of positive clones, and the presence of 
intronic and 3'-5' sequences from the library HL1123a, a second human kidney library 
was chosen.
Subsequent screening of lxlO6 PFUs of a second human kidney library (Cion tech, 
HL3001b), using both the rat (ppl-1.0) and human (phpl-2.0) cDNAs as hybridisation 
probes, yielded no positives, therefore, 5' RACE was chosen as an alternative means of 
isolating the missing 5' sequence. 5' RACE using the homopolymeric tail procedure, gave 
rise to a 0.7kb p-lyase product, which was not visible on agarose gel electrophoresis, 
however, was detectable by Southern blotting using the rat and human cDNAs (ppl-2.0 and 
phpl-1.0) as hybridisation probes. Failure to amplify the product and to provide sufficient 
DNA for subcloning, was thought to be due to inadequate dC-tailing, which is required for 
successful primer annealing in the PCR amplification.
An alternative RACE procedure was used, in which a 5' anchor sequence was ligated to 
human kidney cDNA, as an alternative to the homopolymeric tail. A 377 nucleotide cDNA 
was isolated (phpl-3.1), which contained a single 348 nucleotide open reading frame 
initiated by an ATG codon, embedded in a translation start consensus sequence. The open 
reading frame demonstrated approximately 80% sequence similarity with the rat cDNA 
(ppl-2.0), and was preceded by 29 nucleotides of 5' non-coding region. 147 nucleotides
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(nucleotides 231-377) at the 3' end of phpl-3.1 were homologous to nucleotides 648-794 
of phpl-1.0. This overlap was present due to the position of the primers used in the 5' 
RACE procedure, and enabled confirmation that the 5' RACE product was part of the same 
cDNA as phpl-1.0. An overlap of 147 nucleotides with phpl-1.0, the presence of the start 
codon and a sequence similarity of approximately 80% compared with the rat cDNA, was 
conclusive evidence for the successful isolation of the remaining 5' p-lyase cDNA 
sequence.
A full-length p-lyase cDNA (phpl-4.0) was produced by ligation of the overlapping coding 
regions of phpl-1.0, phpl-2.0 and phpl-3.1. The ligated product was amplified by PCR, 
and expressed in COS-1 monkey kidney cells. The absence of both GTK and p-lyase 
activity in the cytosolic extracts of transfected cells, led to the full-length sequencing of the 
PCR product to determine if any PCR errors had occurred in the amplification reaction. Six 
nucleotide changes were demonstrated, four of which resulted in amino acid substitutions. 
The effect of these changes on protein conformation, and thus enzyme activity is discussed 
in chapter 5.
PCR errors arise because Taq DNA polymerase does not have the proof reading ability of 
other DNA polymerases. Normally PCR errors occur approximately once in every 900 
nucleotides, however, the 1.4kb PCR generated clone ppl-4.0 contained 6  nucleotide 
changes. The substantial increase in error seen here may have been due to two factors. The 
concentration of magnesium chloride in the reaction buffer required for optimal product 
varies, and is dependent on the DNA to be amplified and the primers used in the reaction. 
However, the higher the magnesium chloride concentration, the greater chance of 
nucleotide miss-incorporation (Innis et. al., 1990). The 5' RACE buffer, which contained 
2.5mM magnesium chloride (normal working range 0.5-2.5mM), may have contributed to 
the PCR errors. Alternatively, as the ligated cDNA was amplified directly from the PCR 
mixture, some of the reagents in the ligation buffer may have interfered with the PCR 
amplification.
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The full-length cDNA (phpl-5.0) was finally isolated by reverse transcriptase-PCR from 
human kidney RNA, using gene-specific oligonucleotide primers and a magnesium 
chloride concentration of 1.5mM. Comparison of the sequence of phpl-5.0 with the 
sequence derived from the overlapping clones phpl-1.0, phpl-2.0, and phpl-3.1, confirmed 
that the four amino acid substitutions in phpl-4.0, were PCR errors. However, two new 
substitutions were seen at amino acid residues 42 and 50 of phpl-5.0 (nucleotides 125 and 
150). These substitutions were also seen in a cDNA isolated from a separate PCR 
amplification. It was decided that the probability of the same two substitutions occurring 
twice out of 1328 nucleotides was very remote, and that the sequence of phpl-5.0 must be 
correct. This theory was re-enforced by the fact that the nucleotide changes in phpl-5.0 
result in amino acid changes to residues which are homologous to amino acids in the 
corresponding positions of the rat sequence, thereby increasing the overall similarity 
between the rat and human enzymes. However, it was possible that the differences between 
phpl-5.0 and phpl-3.1 were due to inter-individual variation, as the mRNA used for the 
cDNA synthesis was from different sources. Subsequent PCR amplification and 
sequencing of a full-length clone from the 5' RACE-Ready cDNA confirmed that the 
sequence of phpl-5.0 was correct and that the errors at nucleotides 125 and 150 had 
occurred in the original PCR amplification of phpl-3.1 from the 5' RACE-Ready cDNA.
phpl-5.0 was 1328 nucleotides in length, containing a single open reading frame of 1266 
nucleotides. The open reading frame codes for a protein of 422 amino acids, with an 
overall amino acid similarity of 82% with the rat kidney cytosolic p-lyase, and similarity of 
approximately 90% in the region spanning the putative pyridoxal phosphate binding site 
(residues 185-287). Of the 78 amino acid sequence differences between the rat and human 
orthologues of this protein, 23 are conservative. The deduced subunit molecular weight of 
the human kidney p-lyase protein is 47.9kDa, which compares well with the value of the 
purified protein (45kDa) reported by Lash et al., (1990).
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As with the rat cDNA residues 267 (lysine) and 216 (tyrosine), postulated to play a role in 
the mechanism of action of pyridoxal phosphate-dependent enzymes are conserved, 
however, residue 387, an arginine in the rat is substituted for valine in the human protein.
Expression of phpl-5.0 in COS-1 monkey kidney cells demonstrated significant GTK and 
p-lyase activities, using both TFEC and DCVC as substrates. Comparison of the enzyme 
activities in the cytosolic extracts from cells transfected with the rat and human cDNAs 
demonstrates that the human enzyme has significantly higher specific activity than the rat 
enzyme. This difference however, probably reflects the increased translation of the human 
cDNA, rather than the relative enzyme activities. The lower rat activity possibly due to 
negative modulation of expression, by the presence of the stem-loop structure, as discussed 
in chapter 3.
Due to the variability of the transfection procedure (as discussed in chapter 3) and the 
possible modulation effect of the rat stem-loop structure it is not possible to compare the rat 
and human enzymes by their specific activities in this expression system, therefore, the Km 
values of the rat and human enzymes for the substrates L-phenyl alanine and p-lyase were 
determined. As the Km is half the substrate concentration of Vmax, the factors of variability 
discussed above, are not taken into account. The Km of the human p-lyase enzyme 
expressed in COS-1 cells using TFEC as substrate was calculated by Hanes-Woolf analysis 
to be 6.5mM, which corresponded closely with the value of 5.2mM measured for the rat 
enzyme expressed in the same cells. Km values of 0.40mM and 0.85mM, using L-phenyl 
alanine as substrate, were calculated for the rat and human enzymes respectively.
As the activity of the rat enzyme using DCVC as substrate is very close to the levels of 
detection using this procedure, the margin for error in these measurements is relatively high 
compared to TFEC. In order to obtain more accurate measurements of rat p-lyase activity 
for further comparative studies between the rat and human enzymes and different p-lyase 
substrates, an assay with greater sensitivity such as an HPLC method will be required.
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However, if the removal of the stem-loop structure increases the rat p-lyase expression and 
thus enzyme activity, the requirement of a more sensitive and possibly more expensive 
assay may not be necessary.
The question of whether human kidney p-lyase is a member of a gene family has been 
investigated using Southern blot analysis. The results of this study indicate the presence of 
a single human p-lyase/GTK gene, with a maximum size of approximately 14kb. As with 
the rat Southern blot this would suggest that the human mitochondrial and cytosolic p- 
lyase/GTK enzymes are coded for by the same gene.
PCR analysis of genomic DNA from a panel of somatic cell hybrids, for the presence of 
human kidney p-lyase sequences, indicated that human kidney p-lyase was located on 
chromosome 9. Subsequent analysis of hybrid DNA samples containing fragments of 
chromosome 9, were negative. This result was unexpected as the DNA hybrid samples 
were thought to encompass the whole of chromosome 9. Although unlikely, it is possible 
that one of the hybrids has been wrongly characterised, this possibility is presently being 
investigated. An alternative answer to this problem, is to screen a chromosome 9 cosmid 
library to isolate a clone which can be screened by fluorescence in-situ hybridisation.
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CHAPTER 5
DISCUSSION
5.1 INTRODUCTION
Many drugs and xenobiotics are converted within the body to their corresponding 
mercapturic acids, via glutathione conjugation. The mercapturate, generally more soluble 
than the parent compound is excreted in the urine. The formation of glutathione S- 
conjugates and their processing to mercapturic acids is therefore considered to be a major 
route for the detoxification of drugs and xenobiotics. However, subsequent metabolic 
processing of the glutathione S-conjugate yields the cysteine S-conjugate of the original 
compound, which may then serve as a substrate for cysteine conjugate p-lyase. In rat and 
human kidney this activity is expressed by a specific form of p-lyase (glutamine 
transaminase K (GTK, EC 2.6.1.64). Exposure of rats to halogenated hydrocarbons, gives 
rise to the corresponding cysteine S-conjugate which is further metabolised by cysteine 
conjugate p-lyase to form metabolites which are toxic to the P3  segment of the kidney 
tubule (Lock etal., 1979; Ishmael et al., 1982). In man, however, no such nephrotoxicity 
has been reported, rather, exposure of man to the halogenated alkene trichloroethylene has 
produced neurotoxicity and neurodegeneration (Buxton and Hayward 1967; Schaumburg 
1992). The reasons for the species difference in toxicity between rat and man is not yet 
clear, but may simply reflect the lack of data and/or critical analysis of the nephrotoxicity of 
these compounds in man.
Recently rat kidney cysteine conjugate p-lyase/GTK has been shown to possess kynurenine 
aminotransferase activity (KAT) (Mosca etal., 1994), and to be identical to the brain form 
of p-lyase/GTK/KAT (Alberati-Giani et al., in press). KAT activity produces kynurenic 
acid from kynurenine, a tryptophan metabolite. Kynurenic acid acts as an antagonist at the 
co-agonist site of the ionotropic NMDA receptor, interfering with glutamate excitatory 
receptors in the brain. It may therefore be speculated that KAT activity plays a role in 
neurotransmission, via modulation of the NMDA receptor (Stone 1993).
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In order to further understand the toxicity of cysteine conjugates and to determine whether 
exposure to halogenated alkene compounds is a potential hazard for man, a number of 
studies of the structure and function of the rat and human kidney p-lyase enzymes have 
been persued (Stevens et al., 1988; Lash et al., 1990 and Buckberry et al., 1990 & 1994). 
However, kidney cysteine conjugate p-lyase can only be obtained in low yields from rat 
and human kidney tissue, the latter also being particularly difficult to obtain. Therefore, in 
order to gain a better understanding of the characteristics and mechanisms of action of 
cysteine conjugate p-lyase/GTK/KAT, it was decided that isolation of the cDNAs for the rat 
and human enzymes was necessary.
The aim of this investigation was to isolate the cDNAs for rat and human kidney cysteine 
conjugate p-lyase, for subsequent expression in tissue culture and/or bacterial cells, in order 
to provide large quantities of pure protein for characterisation and comparative kinetic, and 
toxicity studies with a number of cysteine S-conjugates.
5.2 CONCLUDING DISCUSSION
Presented in chapter 3 is the successful isolation of a full-length cDNA for rat kidney 
cytosolic cysteine conjugate p-lyase. The p-lyase cDNA was isolated from a rat kidney 
cDNA library in kgtlO, using a 641 nucleotide, truncated p-lyase cDNA probe, prepared 
from a cDNA previously isolated from a Wistar rat kidney expression library (Miles 
Schofield, PhD thesis, University of Surrey, 1993; Perry et al., 1993). The full-length 
1867 nucleotide cDNA contains an open reading frame of 1269 nucleotides, which code for 
a protein of 423 amino acids, with a predicted molecular weight of 47.8kDa. This is in 
good agreement with the literature value of 47.4kDa for the purified protein (Yamauchi et 
al., 1994). Analysis of the nucleotide sequence indicates that the 5' non-coding region of 
the mRNA may be involved in the regulation of p-lyase expression, via the formation of a 
secondary loop structure, that may effect ribosome progression.
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As p-lyase is a pyridoxal phosphate dependent enzyme, the predicted amino acid sequence 
was searched for the presence of a consensus pyridoxal phosphate binding site. A putative 
site was identified in the sequence, which compares well with the conserved pyridoxal 
phosphate binding site of other transaminases. Other conserved amino acids, such as lysine 
(residue 267), tyrosine (residue 216) and arginine (residue 387), that are postulated to play 
a role in the mechanism of action of pyridoxal phosphate dependent enzymes (Dr. David 
Lewis, personal communication), have been identified within the sequence. The amino acid 
composition, predicted from the cDNA sequence was compared with the predicted amino 
acid composition of the purified p-lyase/GTK enzyme (J. Commandeur and N. Vermeulen, 
personal communication), and gave a correlation coefficient of 0.98. This was the first 
strong evidence to indicate that the cDNA coded for p-lyase.
Final confirmation that the cDNA coded for p-lyase came from transfection studies in tissue 
culture cells. Transfection of the rat cDNA in COS-1 cells resulted in a significant increase 
in cytosolic GTK and p-lyase activities compared to control cells. This activity was 
inhibited by AOAA, an inhibitor of pyridoxal phosphate dependent enzymes. Although the 
level of enzyme activity was reproducible between assays of a single transfection, some 
variability between transfections was seen. This was probably due to factors effecting the 
transfection efficiency such as the condition of the cells, their confluency and the phase of 
cell growth at the time of transfection, as well as the harshness of the DMSO boost, which 
if prolonged, may damage cell membranes or result in cell death.
The level of rat enzyme activity detected in the cytosol of transfected COS-1 cells is similar 
to that observed in whole rat kidney cytosol. In view of the cell-type specificity of p-lyase 
expression in the kidney, that value is probably an underestimate of the intracellular level in 
the proximal tubule. This would indicate low level expression in transfected COS-1 cells 
relative to the in vivo situation. If, as speculated, the stem-loop structure slows ribosomal 
progression, thus modulating expression, removal of the stem loop would increase the 
level of p-lyase expression in the tissue culture system.
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The question of whether the rat kidney mitochondrial p-lyase is a separately coded 
isoenzyme or a modified version of the cytosolic form has yet to be resolved. However, the 
cryptic splice acceptor site suggests the possibility of alternative pre-mRNA splicing, 
whether this can result in the addition of extra coding sequence to the amino terminus of p- 
lyase remains to be determined. This modification could produce both mitochondrial 
targeting and the observed differences in substrate specificity. Southern blot analysis of rat 
genomic DNA indicates the presence of a single gene for rat kidney p-lyase, with a 
maximum size of approximately 9kb, thereby supporting the possibility of alternate 
splicing.
Lash et al., (1986a) reported that mitochondrial p-lyase activity was almost exclusively 
associated with the mitochondrial outer membrane, however, Stevens et al., (1988) 
reported that the p-lyase activity of GTK was present in the mitochondrial matrix. The 
conflicting localisation of mitochondrial p-lyase, may be due to differences in mitochondrial 
preparation, which result in differences in the retention of mitochondrial factors that 
support the p-lyase activity, eg., the availability of keto acids and pyridoxal phosphate 
(Stevens et al., 1988). These results demonstrate that the choice of preparation and 
optimisation of the experimental system are crucial in studies of this nature.
Stevens et al., (1988) also report that multiple p-lyases may exist in the mitochondria. This 
proposal arose from the observation that a-keto acids which are not substrates for the 
purified mitochondrial and cytosolic GTK, do stimulate p-lyase activity in the mitochondrial 
matrix fraction. The Southern blot analysis of rat genomic DNA (section 3. 6 ) indicates that 
such p-lyase enzymes if they really exist must be unrelated to the GTK/p-lyase form.
Stevens et al., (1988) have reported that the purified mitochondrial and cytosolic GTK/p- 
lyase enzymes are similar in several aspects. The pyridoxal phosphate dependent enzyme 
inhibitors, AOAA and hydroxyl amine, produced complete inhibition of enzyme activity 
and a 50% inhibition was seen with potassium cyanide. Both enzymes were markedly
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stimulated by the addition of hydrophobic, but not hydrophilic a-keto acids and by the 
addition of purified rat kidney amino acid oxidase. Finally, Ouchterlony double diffusion 
analysis, using an affinity purified antibody raised against cytosolic GTK/p-lyase 
demonstrated no difference between the two enzymes, which also could not be separated 
by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Km values for the 
mitochondrial and cytosolic enzyme activities using DCVC as substrate were similar, 
0.48mM and 0.30mM respectively, however, their Vmax values were quite different (4 and 
22 pmol/lOmin/mg respectively). The only other difference detected between the two 
enzymes was their separation by elution from hydroxylapatite at 3.4 and 4.3 mmho 
respectively.
The data reported by Stevens et al., (1988) suggested that the enzymes were closely 
related, although, not identical. However, the Southern blot in section 3.6 indicates the 
presence of a single gene for rat kidney GTK/p-lyase, suggesting that the cytosolic and 
mitochondrial forms are the same, or are derived from the same pre-mRNA. Other evidence 
to suggest that the mitochondrial and cytosolic forms may be one and the same comes from 
MacFarlane et al., (1989), who also showed that the antibody raised against cytosolic p- 
lyase, reacted with the mitochondrially associated enzyme. This again, is in agreement with 
the Southern blot data which suggests that only one gene for p-lyase is present in rat 
genomic DNA.
Recent transfection studies (Helen Harries, this laboratory) using the cDNA for rat kidney 
cytosolic p-lyase, have demonstrated that 1 -2 % of the expressed p-lyase protein becomes 
associated with mitochondrial fraction, and remains attached even after 3 washes prior to 
sonication and enzyme assay. The means of attachment to the mitochondria has yet to be 
resolved, however, molecular modelling (Dr. David Lewis, University of Surrey) using the 
putative p-lyase amino acid sequence and the crystal structure of aspartate aminotransferase, 
has predicted that the N-terminus of the protein forms a tail which does not associate with 
the remainder of the structure (figure 5.1). The amino acid sequence of the tail does not
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resemble a mitochondrial targeting sequence, or a membrane spanning region, however the 
possibility of its involvement in adherence to the mitochondrial membrane cannot be 
excluded. If this is the case, further investigation is required to determine whether this 
association also occurs in vivo or whether it is an artefact of the mitochondrial preparation.
As indicated above, the availability of keto acids, pyridoxal phosphate and other 
mitochondrial factors which support p-lyase activity, will vary from one mitochondrial 
preparation to another, thereby altering the observed enzyme activities and kinetics, making 
enzyme characterisation very difficult. Therefore, in order to establish conclusively 
whether or not the mitochondrial form is a close variant of the cytosolic form produced by 
alternate splicing, the cloning and characterisation of an alternatively spliced cDNA or 
isolation of a full-length genomic clone is necessary.
Reverse transcriptase PCR of rat brain using oligonucleotide primers to the 5' and 31 non­
coding regions of the rat kidney cDNA gave rise to two PCR products which hybridised to 
the rat kidney cDNA probe. The smaller and most intense hybridising band corresponds to 
the expected size (1380 nucleotides) for the oligonucleotide primers used in the PCR 
amplification reaction. The larger and less intense band is approximately 1700 nucleotides 
in length. Recent publication of the isolation of a cDNA for rat brain KAT (Alberati-Giani 
et al., in press.), reports that the cDNA sequence is identical to rat kidney GTK/p-lyase 
(Perry et al., 1993, work reported in this thesis). Although the brain cDNA isolated by 
reverse transcriptase PCR in the present investigation, has not yet been purified, subcloned 
and sequenced, it is possible that the smaller hybridising band of the Southern blot is the 
cytosolic p-lyase cDNA, equivalent to the kidney cytosolic form. Whether this is true, and 
the possibility that the larger cDNA is an alternatively spliced cDNA coding for a 
mitochondrially targeted form, has yet to be determined.
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Chapter 4 describes the successful isolation of a full-length human kidney p-lyase cDNA 
using a combination of hybridisation screening, 5' RACE technology and reverse 
transcriptase PCR. Library screening using the rat cDNA as a probe, yielded two 
overlapping cDNA clones phpl-1.0 and phpl-2.0. A composite sequence assembled from 
the overlapping clones, contains an open reading frame of 1065 nucleotides coding for 355 
amino acids, followed by a 3' non-coding region of 463 nucleotides. A polyadenosine tail 
of approximately 100 nucleotides is present after the 3' non-coding region.
The missing 5' end of the human p-lyase cDNA sequence was isolated using the 5' RACE 
procedure on human kidney 5' RACE-Ready cDNA. A 377 nucleotide cDNA was isolated 
(phpl-3.1), which overlapped phpl-1.0 by 147 nucleotides. A single 377 nucleotide open 
reading frame, initiated by an ATG codon embedded in a translation start consensus 
sequence was identified, which confirmed that the remainder of the coding region had been 
isolated.
Initially, isolation of a full-length cDNA was achieved by ligation of the overlapping coding 
regions of the cDNA sequences from phpl-3.1, phpl-1.0 and phpl-2.0. The full-length 
sequence phpl-4.0 was amplified from the ligation mixture by PCR, and subcloned into an 
expression vector for transfection experiments in COS-1 cells. Subsequent lack of p-lyase 
expression in COS-1 cells led to the discovery of PCR-introduced errors in the amplified 
sequence. Substitution of serine (residue 26), an uncharged, polar amino acid by glycine, a 
non-polar residue, may have an effect on the protein conformation as the hydrophobic 
glycine will prefer to cluster with other hydrophobic residues on the inside of the protein. A 
hydrophobic glycine at residue 152 was substituted by glutamate a very polar and therefore 
hydrophilic residue, which will want to move to the outside of the protein. The substitution 
of nonpolar valine (residue 209) for alanine, also nonpolar, will have little effect on polarity 
and therefore, protein conformation. A substitution of isoleucine to methionine (residue 
321), both nonpolar residues, will also have little effect on polarity. Changes in protein 
conformation may alter the active site and thus enzyme activity. It is not known which
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substitution or combination of substitutions is responsible for the inactivation of the 
enzyme, however, residue 152 is the most likely as it causes the greatest polarity change 
and is relatively close to the pyridoxal phosphate binding site and therefore the active site of 
this enzyme.
Gene-specific oligonucleotides, designed from the sequence information of phpl-3.1 and 
phpl-2.0, were subsequently used to isolate a full-length cDNA (phpl-5.0) using reverse 
transcriptase PCR. phpl-5.0 contains an open reading frame which codes for 422 amino 
acids. Comparison to the rat cDNA, which codes for 423 amino acids, demonstrates that 
the missing amino acid in the human sequence is from the carboxyl terminus of the 
protein. The overall amino acid sequence similarity between the rat and human enzymes is 
approximately 82%, however, the region spanning the pyridoxal phosphate binding site, 
(residues 185-287, coding for 34 amino acids) is approximately 90% similar. The predicted 
amino acid sequences of the rat and human enzymes demonstrate 78 amino acid 
differences, of which 23 are conservative. The deduced subunit molecular weight of the 
human kidney p-lyase protein is 47.9kDa, which is consistent with the literature value of 
45kDa (Lash et al., 1990).
Molecular modelling (Dr. David Lewis, University of Surrey) of the predicted amino acid 
sequence from the human p-lyase cDNA, using the crystal structure of aspartate 
aminotransferase as the template produced a structure (figure 5.2) which is very similar to 
the rat model (figure 5.1). The human model, as with the rat has predicted that the N- 
terminus of the protein forms a tail which does not associate with the remainder of the 
structure, whether this tail has a function, has yet to be determined.
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Figure 5.1: Molecular model of rat kidney cysteine conjugate p-lyase, constructed from 
the predicted amino acid sequence of the cDNA, using the crystal structure of aspartate 
aminotransferase as a template (Dr. David Lewis, University of Surrey).
F igure 5.2: Molecular model of human kidney cysteine conjugate p-lyase, constructed 
from the predicted amino acid sequence of the cDNA, using the crystal structure of 
aspartate aminotransferase as a template (Dr. David Lewis, University of Surrey).
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Significant GTK and p-lyase activities, using both TFEC and DCVC as substrates were 
seen in COS-1 monkey kidney cells transfected with pUSpl-5.0(+). When equimolar 
concentrations of the human pUSpl-5.0(+) and rat pUSpl-2.0(+) were transfected into 
COS-1 cells, significantly higher specific activities for both GTK and p-lyase were seen in 
the cytosolic extracts from cells transfected with the human cDNA, compared with the rat. 
This difference however, may reflect the more efficient translation of the human cDNA, 
rather than differences in enzyme activities, as the rat cDNA sequence contains 243 
nucleotides of 5' non-coding sequence, in which a 70 nucleotide inverted repeat is 
separated by 130 nucleotides. As speculated previously, the inverted repeat may form a 
stem loop structure, which could possibly effect ribosome progression. The increased 
activity in the cytosol of cells transfected with the human cDNA, which does not contain 5' 
non-coding sequence, may reflect the absence of this stem-loop structure. This may be 
investigated by removal of the stem-loop from the rat sequence and subsequent expression 
in COS-1 cells would demonstrate whether this structure is involved in the modulation of 
protein synthesis.
McCarthy et al., (1994), report that the ratios of p-lyase activity using TFEC and DCVC as 
substrates, are 3:1 and 1:1 for rat and human enzymes respectively. Although in this . 
investigation, rat p-lyase activity is also greater with TFEC than DCVC, the ratio is 
approximately 8:1. The difference observed here may be due to several factors, for 
example, as discussed earlier, the measurement of rat activity with DCVC was variable due 
to the low sensitivity of the assay system. Additionally the availability of factors, such as 
keto acids and pyridoxal phosphate required to support p-lyase activity, may differ in the 
cytosolic preparations from rat kidney tissue and the transfected COS-1 cells. The ratio of 
the human p-lyase activities with TFEC and DCVC, in this investigation are 3:1, which 
again differ from the results of McCarthy et al., (1994) who demonstrated equal activity 
with both substrates. This group report inter-individual variation of human p-lyase activity 
across a wide range of substrates, which may therefore account for the observed
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differences. Further investigation using purified enzymes is necessary so that the variability 
in enzyme activity, due to cytosolic factors, can be eliminated.
Measurement of the rat and human specific enzyme activities in COS-1 cells cannot be used 
for species comparison studies, as a number of factors effect the DNA transfection, even 
when attempts are made to ensure that the experimental conditions are equivalent. Also the 
efficiency of DNA uptake and replication may vary from one transfection experiment to 
another, and even within tissue culture flasks of the same experiment. Northern blot 
analysis would give an indication of whether the mRNA levels are comparable, however, 
the 5' stem-loop structure of the rat sequence may modulate the translation of the message, 
thus effecting enzyme protein levels. It is not, however, possible at present to determine the 
relative quantities of rat and human p-lyase protein as a human antibody is not yet available.
The kinetic properties and substrate specificity's of the rat and human enzymes could 
however, be determined by analysis of their Km and Vmax values for individual substrates. 
Km values of 0.40mM and 0.85mM, using L-phenyl alanine as substrates for the 
transaminase reaction, were calculated for the rat and human enzymes respectively. An 
initial estimate of the Km for the human p-lyase expressed in COS-1 cells using TFEC as 
substrate indicated that at 6.5mM it corresponded closely with that measured for the rat 
enzyme expressed in the same cells (5.2mM), and compares well with the value of 6.5mM, 
reported for human renal cytosolic (3-lyase (McCarthy et al., 1994). The Km value of 
5.2mM, obtained for the rat enzyme in this study, however, does not compare well with 
the rat renal cytosolic value of 1.4mM reported by McCarthy et al., (1994). The reasons for 
this discrepancy are not as yet known, however, the values obtained in this analysis are 
from a single set of duplicate reactions, and thus require further investigation and 
confirmation. If as the results of this study suggest, the rat and human Km values are 
similar, differences in the kidney toxicity and neurotoxicity between rat and man are not 
likely to be due to marked differences in (3-lyase enzyme kinetics or substrate specificity, 
but, may be due to differences in the absolute level of enzyme in the respective tissues,
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and/or other factors, such as the cellular uptake of cysteine conjugates. It is also 
conceivable that the precise molecular mechanisms of haloalkene nephrotoxicity are 
different in rat and man.
The question of whether human kidney (Tlyase is a member of a gene family has been 
investigated using Southern blot analysis. The results of this study indicate the presence of 
a single human p-lyase/GTK gene, with a maximum size of approximately 14kb. This 
suggests that the mitochondrial and cytosolic enzymes are coded for by the same gene and 
that alternate splicing may result in the addition of a mitochondrial targeting sequence which 
would direct the enzyme to the mitochondria.
Buckberry et al., (1990), reported the isolation of two isoenzymes for human (3-lyase, 
which have different relative molecular weights (values, not given), and different substrate 
specificity's. The results of the genomic Southern blot from this study suggests that the 
two forms are products of alternate splicing which may produce both differences in 
substrate specificity and molecular weight.
As discussed previously, two KAT enzymes, KAT I and KAT II have been isolated from 
human brain tissue, whereas, only one rat brain KAT enzyme has been identified, which is 
identical to the rat kidney (3-lyase enzyme (Mosca et al., 1994). KAT I and KAT II have 
been purified and characterised and are reported to be very different (Okuno et al., 1991). 
Whether, as in the rat one of these enzymes is identical to kidney GTK/(3-lyase has yet to be 
determined. It is known that KAT I has a molecular weight of approximately 60kDa, which 
does not correspond to the size of the human kidney, (3-lyase enzyme (48kDa, predicted 
from the cDNA, as reported in this investigation). Whether, KAT I corresponds to the 
human isoenzyme of kidney (3-lyase reported, by Buckberry et al., (1990) has yet to be 
investigated. The molecular weight of KAT II has not been reported, therefore, no 
comparison can be made with the human (3-lyase protein coded for by the cDNA isolated in 
this investigation.
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With regard to kynurenine aminotransferase activity and modulation of the NMD A 
receptor, it may be that upon exposure to halogenated alkenes there is an accumulation of 
toxic species in specific neurones, by localised (3-lyase activity. These toxic metabolites, 
may in turn be responsible for the modulation of neurotransmission by the alteration of 
KAT activity, a speculation that merits further investigation.
The enzyme glutamine transaminase K (and therefore (3-lyase) is widely spread throughout 
the rat brain, with its greatest activity in the choroid plexus. It has been suggested that the 
natural function of GTK in the brain is in ammonia metabolism (Cooper et al., 1993). The 
observation in man of neurotoxicity specific to the trigeminal nerve, suggests that factors 
other than the presence of glutathione S-transferase and (3-lyase/KAT, must be involved in 
this site specific toxicity. These may include the presence of specific uptake mechanisms in 
sensitive cells, for cysteine S-conjugates, and/or mercapturates and glutathione-S- 
conjugates, as well as the presence of the enzymes involved in their metabolism to the 
ultimate toxic species. The mechanism of neurotoxicity, and the possible interaction of both 
KAT and (3-lyase activities requires further investigation.
Preliminary analysis of genomic DNA from somatic cell hybrids for the presence of human 
kidney (3-lyase sequences by PCR, indicated that human kidney (3-lyase is located on human 
chromosome 9. Subsequent analysis of hybrid DNA samples containing fragments of 
chromosome 9, performed in order to map the gene locus was unsuccessful. However, an 
alternative method of localisation may be carried out in which a chromosome 9 cosmid or 
YAC library is screened in order to isolate a clone which can analysed by fluorescence in- 
situ hybridisation.
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5.3 CONCLUSIONS AND FUTURE WORK
Full-length rat and human (3-lyase cDNAs have been isolated, characterised and expressed. 
Preliminary kinetic investigations, using the cysteine S-conjugate TFEC as substrate, 
suggest that the human enzyme has a similar potential for toxic thiol production to that of 
the rat enzyme. The lack of nephrotoxicity in man is based on very little evidence, 
however, if the species difference in toxicity between rat and man really exists, the similar 
Km values for the rat and human enzymes, demonstrated in this investigation, suggest that 
the difference must be due to other factors. Such factors include, cellular uptake of cysteine 
conjugates, the level of enzymes in the kidney which are involved in mercapturic acid 
synthesis, as well as the level of (3-lyase/GTK/KAT.
The availability of cDNAs for rat and human (3-lyase will enable large quantities of enzyme 
to be produced by expression in bacterial cells. This will provide sufficient quantities of 
pure protein to enable, extensive studies on the kinetics of the rat and human enzymes, as 
well as for X-ray crystallography studies. Additionally site directed mutagenesis of the rat 
and human cDNAs, will enable the identification of the amino acid residues responsible for 
enzyme catalysis, from which it may be possible to assess substrate specificity and 
potential toxicity of cysteine conjugates. Together these studies will provide accurate 
information about the enzyme structure and active site, which will aid in the understanding 
of the mechanism of action and species differences between the rat and human enzymes. 
The availability of pure human (3-lyase protein will also enable the production of a specific 
antibody which will enable immunocytochemical investigation of human kidney and brain 
tissue. These experiments could be performed alongside, in-situ hybridisation analysis 
using a riboprobe transcribed from the human cDNA.
Although as discussed earlier, the level of (3-lyase activity (using TFEC as substrate) in 
COS-1 cells is relatively low compared to the in vivo situation, it is however, greater than 
that in pig kidney LLC-PKi cells, a cell line that has been investigated as a possible in vitro 
toxicity test system for cysteine conjugates (Stevens et al., 1986a). By transfecting LLC-
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PKi cells with the rat and human cDNAs it may be possible to increase their sensitivity to 
cysteine conjugate toxicity, providing a sensitive model for the toxicity studies of a number 
of halogenated alkene cysteine conjugates.
The inter-individual variation of human (3-lyase activities across a range of substrates 
(McCarthy et al., 1994), suggests that some individuals may be more susceptible than 
others to toxicity upon exposure to halogenated alkenes. This may be investigated by RFLP 
analysis of human genomic DNA, prepared from blood samples of a large number of 
individuals.
The availability of a cDNA for human kidney cysteine conjugate (3-lyase/GTK/KAT will 
assist further study on the (3-lyase mediated toxicity of halogenated alkenes in man and the 
role of KAT in the modulation of neurotransmission via the NMDA receptor.
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APPENDIX I:
SOLUTIONS, MEDIA AND BUFFERS
Ammediol buffer (0.2M):
10.5 lg 2-amino-2-methyl-l,3- propanediol-HCl
add 80ml of distilled water, adjust the pH to 9.0 with concentrated HC1 and add distilled 
water to 100ml. Sterilise by autoclaving.
Ampicillin stock solution:
lOOmg/ml in distilled water, sterilise by filtration.
Store at -20°C, use at 50pg/ml in growth media for selection of ampicillin resistant bacteria.
Chloroform/isoamyl alcohol (24:1):
24ml chloroform 
lml isoamyl alcohol
Chloroquine stock solution (40mM):
40mM in PBS (Ca2+, Mg2+ free).
CIAP (5X) buffer:
250mM Tris-HCl, pH 9.0 
5mM MgCl2  
0.5mM ZnCl2  
5mM spermidine
Cracking buffer (2X):
2ml 5M NaOH 
2.5ml 10% (w/v) SDS 
lOg sucrose
Add distilled water to 50ml
DEAE-Dextran (lOmg/ml):
0. lg DEAE-Dextran (Pharmacia, Mw 500,000)
Add PBS (Ca2+, Mg2+ free) to 10ml, sterilise by autoclaving.
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Deionised formamide:
lOg of ion exchange resin (Analytical grade mixed bed, 20-50 mesh, AG-501-XB, Biorad) 
500ml of formamide
Stir at 4°C for a minimum of 3 hours and filter into a light proof bottle. Aliquot into 50ml 
tubes and store at -20°C.
Denhardt’s solution (50X):
lOg Bovine Serum Albumen fraction V
lOg Ficoll 400,000
10 g Polyvinyl Pyrrolidone 40,000
Add distilled water to 11, sterilise by filtration, store at -20°C.
DEPC-treated water 0.1% (v/v): 
lml DEPC (diethyl pyrocarbonate)
Add distilled water to 11, stir vigorously for 1 hr and sterilise by autoclaving.
DNA denaturing solution:
(0.5M NaOH, 1.5M NaCl)
20g NaOH 
87.66g NaCl
Add distilled water to 11, sterilise by autoclaving 
DNA Dye:
10 % (w/v) bromophenol blue in 40% (w/v) sucrose solution.
DNA neutralising solution:
(0.5M Tris-HCl pH 7.5, 1.5M NaCl)
60.5g Tris-HCl 
87.66g NaCl
Add distilled water to 800ml, pH to 7.5, make up to 11 with distilled water, sterilise by 
autoclaving.
EDTA stock solution (0.5M):
186.1gEDTA 
20g of NaOH pellets.
Add 800ml of distilled water, adjust pH to 8.0, make up to 11 with distilled water.
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Ethidium bromide:
Stock solution of 3mg/ml in TAE
Use at 3pg/ml in IX TAE for staining DNA and RNA gels.
Genomic DNA isolation buffer:
lOmM Tris-HCl, pH 8.0 
lOOmM EDTA, pH 8.0 
0.5% (w/v) SDS 
sterilise by autoclaving.
Growth media for COS-1 cells:
365ml Milli Q water 
50ml 10XDMEM 
50ml foetal calf serum 
25ml sodium bicarbonate 
5ml glutamine (2mM)
5ml gentamicin (lOmg/ml)
pH to 7.4 with 3M NaOH and filter sterilise
GTK reagent:
500pi, 1M Ammediol (2-amino-2-methyl-1,3-propanediol HC1) 
250pi, lOOmM L-phenyl alanine (4.13mg/250pl)
125pl, lOOmM aKMB (2.125mg/125pl)
Store on ice prepare shortly before use.
Hybridisation/prehybridisation solution
20ml SSPE
20ml Denhardt’s (50X)
1.0ml 20% (w/v) SDS
2ml herring sperm DNA
Add sterile distilled water to 200ml
IPTG (0.1M stock solution):
0.24g diluted to 10ml distilled water (store at -20°C)
use 5ml/l of agar (58°C) to give a final concentration of 0.5mM.
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X bacteriophage lysis buffer:
(0.3M Tris-HCl/ 0 .15M EDTA/1.5% (w/v) SDS)
36.3g Tris-HCl
55.8g EDTA
75ml SDS (20% (w/v))
Add sterile distilled water to 11
LB-agar
15g agar (Oxoid N°l)/1 of LB medium, autoclave, cool to 58°C, and pour 16ml/petridish
LB (Luria-Bertaini) medium:
lOg tryptone 
lOg NaCl 
5g yeast extract
Add distilled water to 11, sterilise by autoclaving.
Lowry reagent-1:
A. 1% (w/v) CuS0 4 .5 H2 0 (2 g/2 0 0 ml)
B. 2% (w/v) KNa tartrate (4g/200ml)
C. 2% (w/v) Na2 C0 3  in 0.1M NaOH (4g/200ml)
Working solution is A:B:C in 1:1:100.
Lowry reagent-2:
A. 5% (w/v) CuS04 .5H20  (10g/200ml)
B. 1% (w/v) KNa tartrate (2g/200ml)
C. 10% (w/v) Na2 C0 3  in 0.1M NaOH (20g/200ml)
Working solution is A:B:C in 1:10:100.
M9 plates (for f' episome selection):
6.0g Na2 HP04  
3.0g KH2 P0 4  
0.5g NaCl 
l.Og NH4 .CI 
15g agarose
Add distilled water to approximately 11, autoclave, cool to 50°C. Add filtered:
2.0ml 1M MgS04  
0.1ml 1M CaCl2  
1 0 ml 2 0 % (w/v) glucose 
1.0ml 1M thiamine-HCl
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Nick column buffer:
lOmM Tris-HCl, pH 7.5
ImMEDTA
Sterilise by autoclaving
PBS for transfection experiments (Ca2+, Mg2 + free):
(Dulbecco 'A' tablets, Oxoid)
1 tablet dissolved in 1 0 0 ml of distilled water 
Sterilise by autoclaving.
PBS for Western blotting (10X):
80g NaCl 
2 g KH2 PO4  
29g Na2 HP0 4  
2g KC1
Add distilled water to 800ml pH to 7.4,
Add distilled water to 11, sterilise by autoclaving.
PBS-BT:
100ml PBS (10X)
2 ml triton X I0 0  
lgBSA
Add distilled water to 11
Phenol/chloroform (1:1):
50ml phenol pH 8.0 
50ml chloroform
Proteinase K (20mg/ml):
20mg Proteinase K
Add proteinase K buffer to 1ml.
Proteinase K buffer:
5.84g NaCl
10ml 1M Tris-HCl, pH 8.0
500ml 0.5M EDTA, pH 8.0
Add distilled water to 11, sterilise by autoclaving.
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Qiagen™ buffer PI:
lOOmg/ml RNase A in 50mM Tris-HCl 
lOmM EDTA, pH 8.0 
Store at 4°C.
Qiagen™ buffer P2:
200mM NaOH 
1% (w/v) SDS.
Qiagen™ buffer P3:
2.55M K acetate, pH 4.8.
Qiagen™ buffer QBT:
750mM NaCl 
50mM MOPS, pH 7.0 
15% (v/v) ethanol 
0.15% (v/v) Triton X-100.
Qiagen™ buffer QC:
1.0M NaCl
50mM MOPS, pH 7.0 
15% (v/v) ethanol.
Qiagen™ buffer QF:
1.25M NaCl 
50mM MOPS pH 8.2 
15% (v/v) ethanol
Restriction enzyme reaction buffers (IX concentrate): 
REact 2 (R2)
50mM Tris-HCl (pH 8.0) 
lOmMMgCh 
50mM NaCl
REact 3 (R3)
50mM Tris-HCl (pH 8.0) 
lOmM MgCl2  
lOOmM NaCl
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REact 4 (R4)
20mM Tris-HCl (pH 7.4)
5mMMgCl2  
50mM NaCl
Buffer G
50mM Tris-HCl (pH 8.2)
5mM MgCl2
RNA dye:
4% (w/v) bromophenol blue 
4% (w/v) xylene cyanol 
lOmMEDTA (pH 8.0)
50% (v/v) glycerol
RNA electrophoresis buffer (10X):
(0.2M MOPS, 0.05M sodium acetate, 0.01M EDTA)
41.8g MOPS
4. lg Sodium acetate
3.72gEDTA
Add DEPC water to 800ml, pH to 7.0, add DEPC water to 11 and sterilise by autoclaving.
SDS-PAGE electrophoresis buffer (2X):
12.12g Tris-HCl 
57.64g glycine 
40ml 10% (w/v) SDS 
Add distilled water to 41
SDS-PAGE sample buffer:
7.5ml glycerol
2.5ml p-mercaptoethanol
11.5ml 10% (w/v) SDS
0.5ml 0.1% (w/v) bromophenol blue
0.88g Tris-HCl
Add distilled water to 40ml, adjust pH to 6 . 8  and add distilled water to 50ml.
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SDS-PAGE separating gel buffer (1.5M Tris-HCl pH 8.8):
5ml SDS (20% w/v)
46.7g Tris-HCl
Add distilled water to 200ml, adjust pH to 8 . 8  and add distilled water to 250ml.
SDS-PAGE stacking gel buffer (0.5M Tris-HCl pH 6.8):
10ml SDS (20% w/v)
30.5g Tris-HCl
Add distilled water to 450ml, adjust pH to 6 . 8  and add distilled water to 500ml.
SDS-PAGE separating gel (10% w/v):
8.1ml Acrylagel (30% (w/v) acrylamide)
3.4ml Bisacrylagel (2% (w/v) N,N-methylene-bis-acrylamide)
6.25ml separating gel buffer (1.5M tris-HCl pH 8 .8 , 0.4% (w/v) SDS)
7.14ml distilled H2 O
SDS-PAGE stacking gel (3% w/v):
lml Acrylagel (30% (w/v) acrylamide)
0.4ml Bisacrylagel (2% (w/v) N,N-methylene-bis-acrylamide)
2.5ml stacking gel buffer (0.5M tris-HCl pH 6 .8 , 0.4% (w/v) SDS)
6 ml distilled H2 O
SDS-PAGE transfer buffer:
7.26g Tris-HCl (20mM)
33.78g glycine (150mM)
600ml methanol (2 0 % v/v)
Add distilled water to 31.
Sequencing gel (6% (w/v) polyacrylamide):
15ml of 30% (w/v) acrylamide
11.25ml of 2% (w/v) bisacrylamide 
31.5g of urea 
7.5ml of 10XTBE
Add distilled water to 75ml, heat to 37°C to dissolve urea, place on ice to cool.
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Sequencing gel fixing solution:
( 1 0 % (v/v) methanol 1 0 % (v/v) acetic acid)
2 0 0 ml methanol 
2 0 0 ml acetic acid 
Add distilled water to 21
SOC media (TA vector kit):
2 0 g tryptone 
5g yeast extract 
0.6g NaCl 
3.6g glucose 
0.95g MgCl2  
0.19g KC1 
1 .2 g MgS0 4
Add distilled water to 11, sterilise by filtration (2p membrane)
Sodium phosphate buffer (p-lyase assay), (0.1M):
Solution A; 14. lg Na2 HPC>4 (0.1M) diluted to 11 with distilled water 
Solution B; 15.6g NaH2  PO4 .2H20 (0.1M) diluted to 11 with distilled water.
Adjust the pH of solution A to 7.4 by adding solution B.
Spermidine (40mM):
1.02g Spermidine Trihydrochloride
Add distilled water to 100ml, sterilise by filtration, store at -20°C.
SSC (20X) Saline-sodium citrate solution:
(3M NaCl, 0.3M Sodium Citrate, pH 7)
175.32g NaCl 
88.23g sodium citrate
Add distilled water to 11, sterilise by autoclaving.
SSPE (20X):
174g NaCl
27.6g NaH2 PC>4 . H20  
7.4gEDTA
Add distilled water to 800ml, adjust pH to 7.7, add distilled water to 11, sterilise by 
autoclaving
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SM buffer, (A-diluent):
5.8g NaCl
2 .0 g MgS04  7.H2 0)
50ml, 1M Tris-HCl, pH 7.5 
5ml 2% (w/v) gelatin
Add distilled water to 11, sterilise by autoclaving.
TAE electrophoresis buffer (10X):
(400mM Tris acetate, 20mM EDTA, pH 8.3)
48.4g Tris-HCl
40ml 0.5M EDTA pH 8.0
11.42ml glacial acetic acid
Add distilled water to 11, pH to 8.3
The buffer is diluted to IX prior to use.
TBE (10X) Tris-borate EDTA:
108g Tris-HCl
55g boric acid
40ml 0.5M EDTA, pH 8.0
Add distilled water to 11, sterilise by autoclaving.
TE-saturated phenol :
500ml, distilled phenol 
500ml, 1M Tris-HCl, pH 8.0 
0 . lg 8  hydroxy quinoline 
Stir overnight
Allow to separate, decant top buffer layer, Add:
500ml 0.5M Tris-HCl, pH 8.0, mix lhr, stand and aspirate buffer,
500ml 0.5M Tris-HCl, pH 8.0, mix lhr, stand and aspirate buffer,
500ml 0.1M Tris-HCl, pH 8.0, mix lhr, stand and aspirate buffer,
500ml lOmM Tris-HCl, pH 8.0, ImM EDTA, mix lhr, stand and aspirate buffer.
Test pH of phenol with indicator paper, if lower than 7.5, go to 0.5M Tris-HCl and repeat.
Top agarose:
7g/l of LB medium, Autoclaved and cooled to 48°C prior to use
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Tris-EDTA (TE):
(lOmM Tris-HCl, pH 8.0, ImM EDTA)
1.21g Tris-HCl
2ml of 0.5M EDTA pH 8.0
Add distilled water to 800ml, pH to 8.0 and make up to 11, sterilise by autoclaving.
Tris-HCl, 1M Stock Solution:
121. lg Tris-HCl in 800ml distilled water 
Add concentrated HC1 to the desired pH 
Add distilled water to 11, sterilise by autoclaving.
Trituration buffer:
lOOmM CaCl2 
70mM MgCl2
40mM sodium acetate, pH 5.5
Wizard mini/maxi preparation solutions:
Cell lysis solution;
0.2M NaOH 
1% (w/v) SDS
Column wash solution;
200mM NaCl
20mM Tris HClpH7.5
5mMEDTA
Add 125ml of wash solution to 170ml of 95% (v/v) ethanol prior to use.
Neutralising solution;
1.32M potassium acetate pH 4.8
Resuspension solution;
50mM Tris-HCl, pH 7.5 
lOmMEDTA 
lOOpg/ml RNase A
X-Gal:
40mg/lml of dimethyl formamide (DMF)
Prepare fresh and add to 11 of agar (58°C) to give a final concentration of 40pg/ml.
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M A T E R I A L  R E D A C T E D  A T  R E Q U E S T  O F  U N I V E R S I T Y
